HK40112974A - Annulated pyridazine compound - Google Patents

Annulated pyridazine compound Download PDF

Info

Publication number
HK40112974A
HK40112974A HK62024101205.8A HK62024101205A HK40112974A HK 40112974 A HK40112974 A HK 40112974A HK 62024101205 A HK62024101205 A HK 62024101205A HK 40112974 A HK40112974 A HK 40112974A
Authority
HK
Hong Kong
Prior art keywords
alkyl
compound
formula
amino
pyridazin
Prior art date
Application number
HK62024101205.8A
Other languages
Chinese (zh)
Inventor
Yusuke INAGAKI
Takuya Washio
Yuka KOIZUMI
Hiroki Toya
Yumi Yamashita
Ikumi Kuriwaki
Junko Maeda
Takanori Koike
Takashi Kamikubo
Susumu Yamaki
Kazuyuki Kuramoto
Kengo SABA
Hiroshi Tomiyama
Yoshinori Iwai
Akihiko Nakamura
Original Assignee
Nico Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nico Therapeutics, Inc. filed Critical Nico Therapeutics, Inc.
Publication of HK40112974A publication Critical patent/HK40112974A/en

Links

Abstract

The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the present invention conducted extensive studies to find a compound that has an inhibiting action on NLRP3 inflammasome activation, and found that an annulated pyridazine compound has an inhibiting action on NLRP3 inflammasome activation, leading to the achievement of the present invention. The annulated pyridazine compound according to the present invention is expected to serve as a drug for preventing and/or treating inflammatory diseases and/or a neurodegenerative diseases.

Description

Cyclopyridazine compounds
Technical Field
This invention relates to cyclopyridazine compounds or salts thereof that have NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Background Technology
Inflammasomes are collections of intracellular proteins triggered by intrinsic/extrinsic alarm molecules. They are mechanisms that exacerbate inflammatory responses induced by the cleavage of inflammatory cytokines IL-1β and IL-18, or by the induction of cell death, through caspase 1 activation. Several types of alarm molecules are known to recognize alarm molecules, including NLRP1, NLRP3, NLRC4, and AIM2. NLRP3 is activated upon recognizing extracellular ATP molecules, pathogen toxins, uric acid or cholesterol crystals, and abnormal protein aggregates, all of which trigger cellular stress.
As diseases caused by gain-of-function variations in NLRP3, Cryopyrin-associated periodic syndrome (CAPS) is known (Nature Genetics, Vol. 29, No. 3, pp. 301-305, 2001). Additionally, it has been reported in gout (Arthritis Research and Therapy, Vol. 12, No. 2, Article No. 206, 2010), non-alcoholic steatohepatitis (Journal of Molecular Medicine, Vol. 92, No. 10, pp. 1069-1082, 2014), inflammatory bowel disease (Gut, Vol. 59, No. 9, pp. 1192-1100, 2010), and Alzheimer's disease (Nature, Vol. 493, No. 7434, pp. 674-678). Increased activation or expression of the NLRP3 inflammasome is observed in a wide variety of diseases, including Parkinson's disease (PLoS ONE, Vol. 8, No. 1, Article No. e55375, 2013), amyotrophic lateral sclerosis (ALS, Vol. 41, No. 1, pp. 93-103, 2018), and multiple system atrophy (Journal of Neuropathology and Extrinsic Neurology, Vol. 77, No. 11, pp. 1055-1065, 2018).
In addition, NLRP3 is known to be activated by α-synuclein filaments to promote the production of IL-1β from microglia; and functional improvement has been observed by administration of NLRP3 inhibitors in a mouse model of α-synuclein filament-induced α-synucleinopathy (Science Translational Medicine, Vol. 10, Article No. eaah4066, 2018).
Patent document 1 describes a compound represented by the following formula that has inhibitory activity on the NLRP3 inflammasome pathway ( R3 and R4 are H, cyano, C1-4 alkyl, or halo- C1-4 alkyl. Other notations in the formula refer to this publication).
[Chemical Formula 1]
Patent document 2 published after the priority date of this application describes a compound represented by the following formula that has an inhibitory effect on NLRP3 inflammasome activation (the notation in the formula is based on that publication).
[Chemical Formula 2]
Patent document 3 published after the priority date of this application describes a compound represented by the following formula that has NLRP3 inhibitory effects (the notations in the formula refer to that publication).
[Chemical Formula 3]
Patent document 4 describes a compound represented by the following formula that has NLRP3 inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 4]
Patent document 5 describes a compound represented by the following formula that has an NLRP1/3 regulating effect (refer to the notation in the formula in this publication).
[Chemical Formula 5]
Patent document 6 describes a compound represented by the following formula that has inhibitory effects on NLRP3 inflammasomes (the notation in the formula is based on that publication).
[Chemical Formula 6]
Patent document 7 describes a compound represented by the following formula that has C5a receptor inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 7]
Patent document 8 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 8]
Patent document 9 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 9]
Patent document 10 describes a compound represented by the following formula that has muscarinic M4 receptor antagonistic activity (the notation in the formula is the same as that in the publication).
[Chemical Formula 10]
Existing technical documents
Patent documents
Patent Document 1: International Publication No. 2020/234715
Patent Document 2: International Publication No. 2021/193897
Patent Document 3: US Patent No. 11,319,319
Patent Document 4: International Publication No. 2019/008025
Patent Document 5: International Publication No. 2017/184604
Patent Document 6: International Publication No. 2018/015445
Patent Document 7: International Publication No. 2006/004589
Patent Document 8: International Publication No. 2014/191737
Patent Document 9: International Publication No. 2015/001348
Patent Document 10: International Publication No. 2021/067696
Summary of the Invention
The problem that the invention aims to solve
Compounds that provide NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions, particularly for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Methods for solving problems
The inventors conducted in-depth research on compounds with NLRP3 inflammasome activation inhibition activity and found that cyclopyridazine compounds have NLRP3 inflammasome activation inhibition activity, and are expected to be used as effective ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, thus completing the present invention.
That is, the present invention relates to compounds of formula (I) or salts thereof, and pharmaceutical compositions containing compounds of formula (I) or salts thereof and one or more excipients.
[Chemical Formula 11]
(in the formula,
Ring A is a C5-8 cycloalkenyl group, a 5-11 member partially unsaturated heterocyclic group, an aryl group, or a heteroaryl group;
R1 may be the same or different from each other, and may be OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, -C1-6 alkylene-aryl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halogenated C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -, -O -, or -CR 4 R 5 -;
R3 is H or C1-6 alkyl;
R4 and R5 are the same or different from each other, and are H or C1-6 alkyl;
R6 is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a -C1-6 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a -C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups;
R7 is -OR 12 , -NR 13 , R 14 , halogen, or cyano;
R8 and R10 are C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen , or cyano;
R9 and R11 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene -NR13R14, halogen, cyano, oxo, -C(O)-C1-6 alkyl , or -S (O) 2 - C1-6 alkyl;
R 12 is H or C 1-6 alkyl;
R13 and R14 may be the same or different from each other, and may be H, C1-6 alkyl or -C(O) -C1-6 alkyl;
n is an integer from 1 to 4, representing the number of R1s used as substituents;
m is an integer from 0 to 3, representing the number of R2 substituents;
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia).
[Chemical Formula 12]
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
k is an integer from 0 to 3, representing the number of R 1a substituents.
It should be noted that, unless otherwise specified, if a symbol used in one chemical formula in this specification is also used in other chemical formulas, the same symbol has the same meaning.
Furthermore, the present invention relates to pharmaceutical compositions containing a compound of formula (I) or a salt thereof and one or more pharmaceutically permissible excipients, particularly pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases. It should be noted that the pharmaceutical composition comprises a preventive and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases containing a compound of formula (I) or a salt thereof.
In addition, the present invention relates to compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation; compounds of formula (I) or salts thereof used as inhibitors of NLRP3 inflammasome activation; NLRP3 inflammasome activation inhibitors containing compounds of formula (I) or salts thereof; pharmaceutical compositions containing compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation and one or more pharmaceutically permissible excipients; use of compounds of formula (I) or salts thereof in the manufacture of medicaments or pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; use of compounds of formula (I) or salts thereof for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; compounds of formula (I) or salts thereof used in the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; and methods for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, including applying an effective amount of a compound of formula (I) or salts thereof to a subject. It should be noted that "object" refers to a person or other animal that needs the prevention and/or treatment, and in a certain way, it refers to a person who needs the prevention and/or treatment.
The effects of the invention
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and can be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Detailed Implementation
The present invention will now be described in detail.
In this specification, unless otherwise specified, the following terms have the meanings indicated below. The definitions below are for clarification and not for limitation. Here, where a term is not specifically defined, it is used in the sense commonly accepted by those skilled in the art.
In this specification, " C1-6 alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms (hereinafter abbreviated as C1-6 ), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,3-dimethylbutyl, 1-ethyl-2-methylpropyl, etc. Alternatively, it may be a straight-chain or branched C1-4 alkyl group; alternatively, it may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl; alternatively, it may be methyl, ethyl, n-propyl, n-butyl, or isobutyl; further alternatively, it may be n-propyl, n-butyl, or isobutyl. Alternatively, it is methyl, ethyl, n-propyl or isopropyl; in one way, it is methyl or ethyl; in another way, it is ethyl; further in another way, it is methyl.
" C1-6 alkylene" is a straight-chain or branched C1-6 divalent saturated hydrocarbon group, such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 2-methyltrimethylene, ethylethylene, 1,2-dimethylethylene, or 1,1,2,2-tetramethylethylene. In one form, it is C1-4 alkylene; in another form, it is methylene or ethylene; further in another form, it is ethylene; and in yet another form, it is methylene.
"C 3-8 cycloalkyl" refers to a C 3-8 saturated hydrocarbon cycloalloy that can be bridged or form a spirocyclic ring. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[3.3.0]octyl, bicyclo[2.2.2]octyl, spiro[2.2]pentyl, spiro[3.3]heptyl, or spiro[2.5]octyl. As one mode, it is a C3-6 saturated hydrocarbon cycloyl group; as another mode, it is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; further as another mode, it is cyclopropyl; as yet another mode, it is cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; as one mode, it is cyclobutyl, cyclopentyl, or cyclohexyl; further as another mode, it is cyclobutyl or cyclohexyl; further as yet another mode, it is cyclobutyl; as yet another mode, it is cyclopentyl; and further as yet another mode, it is cyclohexyl.
"C 5-8 cycloalkenyl" is a C 5-8 hydrocarbon cycloalkenyl group with a single double bond within the molecule, which can be bridged. Examples include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]heptenyl, and bicyclo[2.2.2]octenyl. As one form, it is cyclopentenyl, cyclohexenyl, cycloheptenyl, and bicyclo[2.2.2]octenyl; further as another form, it is cyclopentenyl, cyclohexenyl, and cycloheptenyl; further as yet another form, it is cyclopentenyl; another form, it is cyclohexenyl; and yet another form, it is cycloheptenyl.
When ring A is a C5-8 cycloalkenyl group, [Chemical Formula 13-1] is a partial structure of formulas (I) and (Ia).
(The wavy lines represent the bonding portions with the phenyl and L in formula (I), respectively. The same applies below.)
The C5-8 cycloalkenyl group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 13-2]
"4- to 7-membered saturated heterocyclic groups" refer to 4- to 7-membered saturated hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms, as ring constituent atoms. Examples include oxohexacyclobutyl, azirhexacyclobutyl, thiohexacyclobutyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiopheneyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopheneyl, oxoheptanyl, azirheptanyl, thioheptanyl, dioxoheptanyl, imidazoalkyl, pyrazolyl, dithioheptanyl, oxazolyl, isoxazolyl, thiazoalkyl, isothiazolyl, dioxohexyl, piperazine, dithiohexyl, morpholinyl, thiomorpholinyl, oxathioheptanyl, dioxathioheptanyl, diazirheptanyl, dithioheptanyl, oxaazonyl, thioazonyl, and oxathioheptanyl, but not limited to these. As one embodiment, it is oxetyl, tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, piperidinyl, or tetrahydrothiaranyl; as another embodiment, it is tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is tetrahydropyranyl or piperidinyl; as yet another embodiment, it is tetrahydrofuranyl or tetrahydropyranyl; as yet another embodiment, it is tetrahydrofuranyl; as yet another embodiment, it is tetrahydropyranyl. As another embodiment, it is pyrrolyl or piperidinyl; as yet another embodiment, it is pyrrolyl; as yet another embodiment, it is piperidinyl. As yet another embodiment, it is oxetyl.
"5- to 11-membered partially unsaturated heterocyclic groups" are 5- to 11-membered hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms as ring-forming atoms, and possessing a single double bond within the molecule. They can also exhibit bridging or form spirocyclic rings. Examples include dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydronitroheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydrooxoheptenyl, tetrahydrothioheptenyl, dioxopentenyl, dihydroimidazoyl, dihydropyrazolyl, dithioheptenyl, dihydrooxazolyl, dihydroisooxazolyl, dihydrothiazoyl, dihydroisothiazoyl, and dihydrodioxoheptenyl. Hexenyl, tetrahydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazocyclohexenyl, dihydrodioxazocycloheptenyl, tetrahydrodiazacycloheptenyl, dihydrodithiocycloheptenyl, tetrahydrooxazocycloheptenyl, tetrahydrothiazazacycloheptenyl, dihydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl, 2-oxaspiro[4.5]decenyl, 3-oxaspiro[5.5]undecenyl, but not limited thereto. As one embodiment, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, dihydrothiaranyl, tetrahydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl. In one manner, it is a 5- to 8-membered partially unsaturated heterocyclic group; in another manner, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydroazaheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydroazaheptenyl, tetrahydrothioheptenyl, dioxazol ... Dihydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl; as one embodiment, it is dihydropyrroleyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl; further as another embodiment, it is dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl. As another form, it is dihydrofuranyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxoheptenyl; as another form, it is dihydrofuranyl, dihydropyranyl, tetrahydrooxoheptenyl or 2-oxaspiro[3.5]nonenyl; as another form, it is dihydropyranyl; further as another form, it is tetrahydropyridyl; and as yet another form, it is tetrahydrooxoheptenyl.
When ring A is a 5- to 11-membered partially unsaturated heterocyclic group, as part of the structures of formulas (I) and (Ia)
[Chemical Formula 14-1]
middle,
The 5- to 11-membered partially unsaturated heterocyclic group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 14-2]
"Aryl" is a C6-14 monocyclic to tricyclic aromatic hydrocarbon cyclic group, including bicyclic to tricyclic aromatic hydrocarbon cyclic groups formed by the condensation of its double bond with a C5-8 cyclic alkene. Examples include phenyl, naphthyl, tetrahydronaphthyl, indene, fluorenyl, etc., with phenyl being one example.
When ring A is aryl, as part of the structure of formulas (I) and (Ia)
[Chemical Formula 15-1]
middle,
The aryl benzene ring condenses with the pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 15-2]
"Heteroaryl" refers to a 5- to 6-membered aromatic hydrocarbon cyclic group containing 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen. Examples include pyrrole, furanyl, thiophene, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and tetraazinyl. In one form, it is thiophene or pyridinyl; further, in another form, it is pyridinyl; and still another form, it is thiophene.
When ring A is a heteroaryl group, [Chemical Formula 16-1] is a partial structure of formulas (I) and (Ia).
middle,
The heteroaryl group condenses with a pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 16-2]
"Halogen" refers to F, Cl, Br, or I. In one sense, it is F or Cl; further, in another sense, it is F; in yet another sense, it is Cl.
"Halogenated C1-6 alkyl" refers to a straight-chain or branched C1-6 alkyl group substituted with one or more halogens. Examples include: trifluoromethyl, trifluoroethyl, trifluoropropyl, 2-fluoro-2-methylpropyl, difluoromethyl, difluoroethyl, fluoromethyl, or chloromethyl. In one manner, it is difluoroethyl, trifluoromethyl, or difluoromethyl; further, it is trifluoromethyl or difluoromethyl; in another manner, it is trifluoromethyl; and in yet another manner, it is difluoromethyl.
In this specification, "substitutable" means unsubstituted or "substituted by one or more substituents". The substitution can be at any position, as long as the hydrogen is normally present in the group.
Even if the combination is not specifically recorded, one or more methods can be combined with another method.
In this specification, "inflammatory disease and/or neurodegenerative disease" is, in one sense, an inflammatory disease and a neurodegenerative disease; further, it is an inflammatory disease; and in another sense, it is a neurodegenerative disease.
In this specification, "inflammatory disease" includes, but is not limited to, autoinflammatory diseases such as Cryopyrin-associated periodic fever syndrome (CAPS), gout, and pseudogout; and diseases such as non-alcoholic steatohepatitis (NASH). As one mode, it is an autoinflammatory disease; as another, it is CAPS; and further, it is gout. It should be noted that "Cryopyrin-associated periodic fever syndrome (CAPS)" is a disease group comprised of familial cold urticaria (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multi-organ system inflammatory diseases/infantile chronic neurocutaneous joint syndrome (NOMID/CINCA syndrome).
In this specification, "neurodegenerative diseases" refers to a group of diseases including, but not limited to, alpha-synucleinopathies such as Parkinson's disease, multiple system atrophy, and Lewy body type dementia; Alzheimer's disease; amyotrophic lateral sclerosis (ALS); and multiple sclerosis. One example is Alzheimer's disease, multiple sclerosis, and ALS; another example is multiple sclerosis. Another example is alpha-synucleinopathies; another example is Parkinson's disease; yet another example is multiple system atrophy; and yet another example is Lewy body type dementia.
In this specification, "treatment" includes both "treatment for therapeutic purposes" and "treatment for preventative purposes." "Treatment for therapeutic purposes" refers to alleviating symptoms, altering disease course, or prolonging lifespan, while "treatment for preventative purposes" refers to reducing the likelihood of developing the disease in subjects at risk. "Subjects at risk" refers to individuals with known risk factors who are more susceptible to the disease than the general population.
The compound of formula (I) or a salt thereof in this invention is shown in one of the following ways.
(1-1) Compounds of formula (I) or their salts (n and m represent the number of R1 and R2 as substituents, respectively. The same applies below).
[Chemical Formula 17]
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia) (k represents the number of R 1a as substituents. The same applies below).
[Chemical Formula 18]
(1-2) Compounds of formula (Ia) or their salts.
(1-3) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
[Chemical Formula 19]
(1-4) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
(1-5) Compounds of formula (Ib), (Ic), (Id), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iv), (Iw), (Ix) or (Iy) or their salts.
(1-6) Compounds of formula (Ic), (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-7) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq) or (Ir) or salts thereof.
(1-8) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or their salts.
(1-9) Compounds of formula (Ib), (Ic), (Id) or (Ie) or their salts.
Compounds of formula (Ib) (1-10) or their salts.
Compounds of formula (Ic) or their salts thereof.
Compounds of formula (Id) (1-12) or their salts.
(1-13) A compound of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or a salt thereof.
(1-14) Compounds of formula (If), (Ig), (Ih), (Ii) or (Ij) or their salts.
(1-15) Compounds of formula (Ig), (Ih) or (Ij) or their salts.
Compounds of formula (Ig) (1-16) or their salts.
Compounds of formula (Ih) or their salts thereof.
Compounds of formula (Ij) or their salts. (1-18)
(1-19) Compounds of formula (Ik), (Im) or (In) or their salts.
Compounds of formula (Ik) or their salts thereof.
Compounds of formula (Im) or their salts thereof.
(1-22) Compounds of formula (In) or their salts.
(1-23) Compounds of formula (Io), (Ip), (Iq) or (Ir) or their salts.
Compounds of formula (Io) or their salts thereof.
Compounds of formula (Ip) (1-25) or their salts.
Compounds of formula (Iq) (1-26) or their salts.
Compounds of formula (Ir) or their salts thereof.
(1-28) Compounds of formula (Ic), (Ig), (Ih), (Ij) or (Im) or their salts.
(1-29) Compounds of formula (Ic), (Ih), (Ij) or (Im) or their salts.
(1-30) Compounds of formula (Ic) or formula (Ih) or their salts.
Compounds of formula (Ix) or their salts thereof. (1-31)
Compounds of formula (Iy) or their salts. (1-32)
(1-33) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy).
(1-34) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iu), (Iv), (Iw) or (Iy).
(1-35) Compounds of formula (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-36) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iv), (Iw) or (Iy).
(2-1) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-2) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 8-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-3) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-8 partially unsaturated heterocyclic group.
(2-4) Compounds with ring A being C5-8 cycloalkenyl or their salts.
(2-5) Compounds or their salts in which ring A is a 5- to 8-membered partially unsaturated heterocyclic group.
(2-6) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl, and k is an integer from 0 to 2.
(2-7) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-11 partially unsaturated heterocyclic group.
(2-8) Compounds in which ring A is aryl or heteroaryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-9) Compounds in which ring A is aryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-10) Compounds in which ring A is a heteroaryl group or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-11) Compounds or their salts in which ring A is a partially unsaturated heterocyclic group of 5 to 11 members.
(3-1) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo -C1-6 alkyl, or -OC3-8 cycloalkyl.
(3-2) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halo- C1-6 alkyl.
(4-1) R 1a are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl.
(4-2) R 1a are the same or different from each other, and are compounds of C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl or salts thereof.
(4-3) R 1a are the same or different from each other, and are compounds of halo- C1-6 alkyl, halogen, or -O-halo- C1-6 alkyl or salts thereof.
(4-4) R 1a is a halo- C1-6 alkyl compound or a salt thereof.
(4-5) R 1a is a halogen compound or its salt.
(4-6)R 1a is a compound of -O-halogenated C1-6 alkyl or a salt thereof.
(4-7) R 1a is a compound of C 1-6 alkyl or a salt thereof.
(4-8)R 1a is a compound of C 3-8 cycloalkyl or a salt thereof.
(4-9) R 1a is a compound of -OC 1-6 alkyl or a salt thereof.
(5-1) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-2) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-3) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-4) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C 1-6 alkylene-aryl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-5) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-6) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-7) R2 is a compound of C1-6 alkyl groups or a salt thereof.
(5-8)R 2 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(5-9)R 2 is a compound of -S(O) 2 -C 1-6 alkyl or a salt thereof.
(5-10) R2 is an oxolated compound or its salt.
(6-1)L is a compound of -NR 3- , -O- or -CR 4R 5- or a salt thereof.
(6-2)L is a compound of -NR 3- or -O- or its salt.
(6-3)L is a compound of -NR 3- or its salt.
(6-4)L is a compound of -O- or its salt.
(6-5)L is a compound of -CR4R5- or its salt.
(7-1) R 3 is a compound of H or C 1-6 alkyl or a salt thereof.
(7-2) R 3 is a compound of H or its salt.
(7-3) R 3 is a C1-6 alkyl compound or a salt thereof.
(8-1) R4 and R5 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(8-2) R4 and R5 are both compounds of H or their salts.
(8-3) R4 and R5 are both C1-6 alkyl compounds or their salts.
(9-1) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a C1-6 alkylene group ( a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups.
(9-2) R6 is a compound or a salt thereof consisting of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups), -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups), a C3- to 8-membered cycloalkyl group that may be substituted by 1 to 4 identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R11 groups.
(9-3) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with one R7 , a -C1-6 alkylene group (a C3-8 cycloalkyl group that may be substituted with one R8 ), a -C1-6 alkylene group (a 4- to 7-membered saturated heterocyclic group), a C3-8 cycloalkyl group that may be substituted with one or two identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted with one or two identical or different R11 groups .
(9-4) R6 is a compound or a salt thereof that can be substituted by 1 to 4 identical or different R10s of a C3-8 cycloalkyl group or a 4- to 7-membered saturated heterocyclic group that can be substituted by 1 to 4 identical or different R11s .
(9-5) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 4 identical or different R7s .
(9-6) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 3 identical or different R7s .
(9-7) R6 is a compound of C1-6 alkyl group or a salt thereof that is substituted with 1 to 2 identical or different R7 groups .
(9-8) R6 is a compound of a C1-6 alkyl group substituted with one R7 or a salt thereof.
(9-9) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups ) or a salt thereof.
(9-10) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 3 identical or different R8 groups ) or a salt thereof.
(9-11) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 2 identical or different R8 groups ) or a salt thereof.
(9-12) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by one R8 ) or a salt thereof.
(9-13) R 6 is a compound of -C 1-6 alkylene-C 3-8 cycloalkyl or a salt thereof.
(9-14) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups ) or a salt thereof.
(9-15) R6 is a compound or a salt thereof of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 3 identical or different R9 groups).
(9-16) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 2 identical or different R9 groups ) or a salt thereof.
(9-17) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by one R9 ) or a salt thereof.
(9-18) R 6 is a compound of -C 1-6 alkylene-(4-7 membered saturated heterocyclic group) or a salt thereof.
(9-19) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R10s of C3-8 cycloalkyl groups.
(9-20) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R10s of C3-8 cycloalkyl groups.
(9-21) R6 is a compound or a salt thereof that can be substituted by one or two identical or different R10s of a C3-8 cycloalkyl group.
(9-22) R6 is a compound of C3-8 cycloalkyl group or a salt thereof that can be replaced by one R10 .
(9-23) R6 is a compound of C3-8 cycloalkyl or a salt thereof.
(9-24) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-25) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-26) R6 is a compound or a salt thereof that can be replaced by 1 to 2 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-27) R6 is a compound or a salt thereof that can be replaced by a 4- to 7-membered saturated heterocyclic group of one R11 .
(9-28) R6 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(9-29) R6 is a C1-6 alkyl group substituted with one R7 , a C3-8 cycloalkyl group substituted with one or two identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with one or two identical or different R11 groups, or a salt thereof.
(9-30) R6 is a compound or a salt thereof that can be substituted by 1 to 2 identical or different R10s , or by 1 to 2 identical or different R11s , of a C3-8 cycloalkyl group.
(9-31) R6 is a compound or a salt thereof that can be replaced by a C3-8 cycloalkyl group that is substituted by one R10 or by a 4-7 member saturated heterocyclic group that is substituted by one R11 .
(10-1) R 7 is a compound of -OR 12 , -NR 13 , R 14 , halogen or cyano, or a salt thereof.
(10-2) R 7 is a compound of -OR 12 or -NR 13 R 14 or a salt thereof.
(10-3)R 7 is a compound of -OR 12 or a salt thereof.
(10-4)R 7 is a compound of -NR 13 R 14 or a salt thereof.
(10-5)R 7 is a halogen compound or a salt thereof.
(10-6)R 7 is a cyano compound or a salt thereof.
(11-1) R8 is a C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen or cyano compound or salt thereof.
(11-2) R8 is a compound of -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 or a salt thereof.
(11-3) R8 is a compound of C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , halogen, or cyano, or a salt thereof .
(11-4) R8 is a compound of -OR12 , -C1-6 alkylene- OR12 or a salt thereof.
(11-5) R 8 is a compound of -OR 12 or a salt thereof.
(11-6)R 8 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(12-1) R 9 is a compound of C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl or a salt thereof.
(12-2) R 9 is a compound or a salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(13-1) R 10 is a compound of C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, or cyano, or a salt thereof.
(13-2) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , halogen or cyano, or a salt thereof.
(13-3) R 10 is a C 1-6 alkyl compound or a -OR 12 compound or a salt thereof.
(13-4) R 10 is a compound of C1-6 alkyl groups or a salt thereof.
(13-5) R 10 is a compound of -OR 12 or a salt thereof.
(13-6) R 10 is a compound of -NR 13 R 14 or a salt thereof.
(13-7) R 10 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(13-8) R 10 is a halogen compound or a salt thereof.
(13-9) R 10 is a cyano compound or a salt thereof.
(13-10)R 10 is a compound of C1-6 alkyl, -OR 12 , -NR 13 R 14 , or cyano groups or a salt thereof.
(13-11) R 10 is a compound of C 1-6 alkyl, -OR 12 , or cyano groups or a salt thereof.
(13-12) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , or cyano, or a salt thereof.
(14-1) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or a salt thereof.
(14-2) R 11 is a compound or salt thereof of C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O)-C 1-6 alkyl.
(14-3) R 11 is a compound of C1-6 alkyl groups or a salt thereof.
(14-4)R 11 is a compound of C3-8 cycloalkyl or a salt thereof.
(14-5) R 11 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(14-6) R 11 is a compound of -OR 12 or a salt thereof.
(14-7) R 11 is an oxolated compound or its salt.
(14-8)R 11 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(14-9) R 11 is a compound or salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 member saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(14-10) R 11 is a compound of C 1-6 alkyl or -OR 12 or a salt thereof.
(14-11) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, -OR 12 , or -C(O)-C 1-6 alkyl or a salt thereof.
(15-1) R 12 is a compound of H or C 1-6 alkyl or a salt thereof.
(15-2) R 12 is a compound of H or its salt.
(15-3) R 12 is a compound of C1-6 alkyl groups or a salt thereof.
(16-1) R13 and R14 are the same or different from each other, and are compounds of H, C1-6 alkyl or -C(O) -C1-6 alkyl or salts thereof.
(16-2) R13 and R14 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(16-3) R13 and R14 are both compounds of H or their salts.
(16-4) A compound in which both R13 and R14 are H or salts thereof, or a compound in which R13 is -C(O) -C1-6 alkyl and R14 is H or salts thereof.
(16-5) R 13 is a -C(O)-C 1-6 alkyl compound, R 14 is H, or a salt thereof.
(17-1) n is an integer from 1 to 4, or a salt thereof.
(17-2) n is an integer from 1 to 3, or a salt thereof.
(17-3) A compound or its salt in which n is 1 or 2.
(17-4) Compounds or their salts in which n is 2.
(17-5) Compounds or their salts in which n is 1.
(18-1) m is an integer from 0 to 3, or a salt thereof.
(18-2)m is an integer from 0 to 2, which is a compound or its salt.
(18-3)A compound or its salt in which m is 0 or 1.
(18-4) Compounds or their salts with m = 1.
(18-5) Compounds or their salts where m is 0.
(19-1)k is an integer from 0 to 3, which is a compound or its salt.
(19-2)k is an integer from 0 to 2, which is a compound or its salt.
(19-3) Compounds or their salts in which k is 0 or 1.
(19-4) Compounds or their salts in which k is 1.
(19-5) Compounds or their salts in which k is 0.
(19-6)k is a compound or its salt where k is 1 or 2.
(20) A compound or its salt that is a combination of two or more groups described in (1-1) to (19-6) above without contradiction. Examples of such combinations are as follows, but not limited thereto.
(20-1) Compounds or salts thereof that are combinations of (1-1), (2-2), (3-1), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (17-1), (18-1), and (19-1).
(20-2) Compounds or salts thereof that are combinations of (1-2), (2-2), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-3) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-4) Compounds or salts thereof that are combinations of (1-2), (2-6), (4-2), (5-5), (6-1), (7-2), (8-2), (9-3), (10-2), (11-3), (12-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-5) Compounds or salts thereof that are combinations of (1-2), (2-7), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-6) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-3), (5-7), (6-3), (7-2), (9-30), (13-3), (14-10), (15-2), (18-3), and (19-6).
(20-7) Compounds or salts thereof that are combinations of (1-2), (2-11), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-8) Compounds or salts thereof that are combinations of (1-34), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-10), (15-2), (16-4), (18-5), and (19-2).
(20-9) Compounds or salts thereof that are combinations of (1-17), (4-2), (6-3), (7-2), (9-29), (10-2), (13-11), (14-10), (15-2), (16-5), (18-5), and (19-2).
(20-10) Compounds or salts thereof that are combinations of (1-6), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-11) Compounds or salts thereof that are combinations of (1-35), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-12) Compounds or salts thereof that are combinations of (1-7), (4-2), (5-4), (6-1), (7-2), (8-2), (9-3), (10-2), (11-4), (13-2), (14-2), (15-2), (16-4), (18-3), and (19-2).
(20-13) Compounds or salts thereof that are combinations of (1-28), (4-3), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-3), and (19-4) above.
(20-14) Compounds or salts thereof that are combinations of (1-11), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-15) Compounds or salts thereof that are combinations of (1-17), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-16) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-17) Compounds or salts thereof that are combinations of (1-11), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-18) Compounds or salts thereof that are combinations of (1-21), (4-4), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-4), and (19-4) above.
(20-19) Compounds or salts thereof that are combinations of (1-18), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-20) Compounds or salts thereof that are combinations of (1-17), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-21) Compounds or salts thereof that are combinations of (1-16), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-22) Compounds or salts thereof that are combinations of (1-16), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-23) Compounds or salts thereof that are combinations of (1-16), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-24) Compounds or salts thereof that are combinations of (1-31), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-25) Compounds or salts thereof that are combinations of (1-32), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-26) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-27), (14-3), (18-5), and (19-4) above.
Examples of specific compounds included in this invention include compounds selected from the group consisting of compounds or salts thereof.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5)-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
Examples of specific compounds included in this invention include the following group of compounds.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
In addition, the following group of compounds can be listed as one example of specific compounds included in the present invention.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
Depending on the type of substituent, compounds of formula (I) may contain tautomers or geometric isomers. In this specification, compounds of formula (I) or their salts are sometimes described as only one form of isomer, but the present invention also includes other isomers, as well as substances obtained by isomer separation, or mixtures thereof.
Furthermore, in cases where the compound of formula (I) or its salt has an asymmetric center or axial asymmetry, enantiomers (optical isomers) based thereon may exist. The compound of formula (I) or its salt also includes any of the separated enantiomers such as (R) bodies, (S) bodies, etc., and mixtures thereof (including racemic or non-racemic mixtures). In one manner, the enantiomer is "stereochemically pure." "Stereochemically pure" means a purity that can be recognized by a person skilled in the art as substantially stereochemically pure. Alternatively, the enantiomer is a compound having a stereochemical purity of, for example, 90% ee (enantiomeric excess) or more, 95% ee or more, 98% ee or more, or 99% ee or more.
Furthermore, the present invention also includes pharmaceutically permissible prodrugs of compounds represented by formula (I). A pharmaceutically permissible prodrug is a compound having groups that can be converted to amino, hydroxyl, carboxyl, or other groups by solvent decomposition or under physiological conditions. Examples of groups forming prodrugs include those described in Prog. Med., 5, 2157-2161 (1985), or in "Development of Pharmaceuticals" (Hirokawa Shoten, 1990), Vol. 7, Molecular Design, pp. 163-198.
Furthermore, salts of compounds of formula (I) are pharmaceutically permissible salts of compounds of formula (I). Depending on the type of substituent, they may sometimes form acid addition salts or salts with bases. Specifically, examples include: acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; or with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, dibenzoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid; salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; and salts with organic bases such as methylamine, ethylamine, ethanolamine, lysine, and ornithine; and salts or ammonium salts with various amino acids and amino acid derivatives such as acetylleucine.
Furthermore, the present invention also includes various hydrates or solvates of compounds of formula (I) or salts thereof, as well as polymorphic substances.
Furthermore, this invention includes all pharmaceutically permissible compounds of formula (I) or salts thereof labeled with one or more radioactive or non-radioactive isotopes. Examples of suitable isotopes used in the isotopic labeling of the compounds of this invention include isotopes of hydrogen (e.g., 2H and 3H ), carbon (e.g., 11C , 13C , and 14C ), nitrogen (e.g., 13N and 15N ), oxygen (e.g., 15O , 17O , and 18O ), fluorine (e.g., 18F ), chlorine (e.g., 36Cl ), iodine (e.g., 123I and 125I ), phosphorus (e.g., 32P ), and sulfur (e.g., 35S ). The isotopically labeled compounds of this invention can be used for studies such as the tissue distribution of drugs and/or matrices. For example, radioactive isotopes such as tritium ( 3H ) and carbon-14 ( 14C ) are suitable for this purpose due to their ease of labeling and detection. Substitution with heavier isotopes, such as hydrogen replacing deuterium ( 2H ), can sometimes be therapeutically advantageous due to increased metabolic stability (e.g., increased in vivo half-life, reduced dosage, and fewer drug interactions). Substitution with positron-emitting isotopes ( ¹¹C , ¹⁸F , ¹⁵O , and ¹³N , etc.) can be used in positron emission tomography (PET) assays to test matrix receptor occupancy. The isotopically labeled compounds of the present invention can generally be manufactured by conventional methods known to those skilled in the art, or by using suitable isotopically labeled reagents instead of unlabeled reagents, and by employing the same preparation methods as in the examples or manufacturing examples. For example, by subjecting 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (the compound of manufacturing example 64) to a known [ 11 C] acetylation reaction (International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, Vol. 39, No. 4, pp. 287-290, 1988), a compound of example 81 in which the carbonyl carbon atom is substituted with 11 C can be obtained.
(Manufacturing method)
Compounds of formula (I) or their salts can be manufactured using various known synthetic methods based on their basic structure or the types of substituents. In this case, depending on the type of functional group, it is sometimes technically effective to replace that functional group with a suitable protecting group (a group that can be easily converted into that functional group) during the process from the starting material to the intermediate. Examples of such protecting groups include those described in "Greene's Protective Groups in Organic Synthesis" (4th edition, 2006) by Wuts (P.G.M. Wuts) and Greene (T.W. Greene), which can be appropriately selected based on their reaction conditions. In such methods, the desired compound can be obtained by introducing the protecting group, reacting, and then removing the protecting group as needed.
Furthermore, the prodrug of the compound of formula (I) can be manufactured by introducing specific groups during the process from the starting material to the intermediate, similar to the protecting group described above, or by further reacting the obtained compound of formula (I). The reaction can be carried out using methods known to those skilled in the art, such as conventional esterification, amidation, and dehydration.
The following describes representative methods for manufacturing compounds of formula (I). Each method can also be performed with reference to the appended references. It should be noted that the manufacturing methods of the present invention are not limited to the examples shown below.
The following abbreviations are sometimes used in this specification.
CN: Cyano, COMU: ({[(1-cyano-2-oxoethylidene)amino]oxy}-4-morpholinomethylene)dimethylammonium hexafluorophosphate, DMF: N,N-dimethylformamide, DMSO: dimethyl sulfoxide, DIPEA: N,N-diisopropylethylamine, EDC·HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide of hexafluorophosphate, HOBt: 1-hydroxybenzotriazole, NMP: 1-methylpyrrolidone-2-one, Me: Methyl, Oxone (registered trademark): potassium persulfate, Pd-118: [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloroisocyanurate, PdCl₂ ( PPh₃ ) ₂ PdCl₂ (dppf): [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, PdCl₂ (dppf)· CH₂Cl₂ : [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride·dichloromethane adduct, Pd₂ (dba) ₃ : (1E,4E)-1,5-diphenylpentan-1,4-dien-3-one/palladium (3:2), Pd( PPh₃ ) ₄ : tetrakis (triphenylphosphino)palladium, RuPhos Pd G₃: (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate, SPhos Pd G3: (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)methanesulfonic acid, TBS: tert-butyl(dimethyl)silyl, THF: tetrahydrofuran, Tf: trifluoromethanesulfonyl, TFA: trifluoroacetic acid, XPhos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, ODS: octadecylsilyl.
(First System)
[Chemical Formula 20]
( X1 is a halogen, Ra and Rb are both H, or Ra and Rb and the borate residues bonded to Ra and Rb form 4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane. The same applies below.)
(First step)
This step involves reacting a compound of formula (IIa) with compounds of formulas (IIIa) to (IIIc) to obtain a compound of formula (IV). The choice of steps 1 to 5 can be made depending on the type of L used as a linking group.
(Step 1-1)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIa) to obtain a compound of formula (IV) where L is -O-. In this reaction, equal amounts of the compound of formula (IIIa) and the compound of formula (IIIa), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0–190°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Examples of bases are not particularly limited and include sodium hydride, potassium tert-butoxide, sodium hydroxide, and potassium hydroxide. The presence of phase-transfer catalysts such as benzyltrimethylammonium chloride, tetrabutylammonium bromide, and 18-crown-6-ether can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-2)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in a solvent inert to the reaction or in the absence of a solvent, under cooling to reflux, preferably at 0°C to 220°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-3)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst, a ligand, and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, such as palladium acetate and Pd₂ (dba) ₃ . Examples of ligands are not particularly limited, such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, tri-tert-butylphosphine, and XPhos. Examples of bases are not particularly limited, such as tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, and potassium tert-butoxide. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
[literature]
Journal of the American Chemical Society, 127, pp4685-4696(2005)
(Step 1-4)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . This step consists of a first stage that converts a compound of formula (IIa) into a compound of formula (IIb), and a second stage that converts a compound of formula (IIb) into a compound of formula (IV).
(Phase 1)
In this reaction, the compound of formula (IIa) is reacted in hydroiodic acid in the presence of a metal iodide, under cooling to reflux, preferably at room temperature to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of the metal iodide used herein are not particularly limited, and include sodium iodide, potassium iodide, etc.
(Phase Two)
In this reaction, equal amounts of compounds of formula (IIb) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 190°C. Examples of catalysts used herein are not particularly limited, including copper iodide (I), copper oxide (I), copper bromide (I), copper chloride (I), and copper 2-thiophenecarboxylate (I). The presence of ligands such as proline and ethylenediamine is sometimes advantageous for facilitating the reaction. Examples of bases are not particularly limited, including tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, and N,N-diisopropylethylamine. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-5)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIc) to obtain a compound of formula (IV) where L is -CR4R5- . In this reaction, equal amounts of the compounds of formula (IIa) and ( IIIc ), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include copper iodide (I) and iron acetylacetone (III). Examples of solvents are not particularly limited, but include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Alternatively, this reaction can be carried out under microwave irradiation.
(Second Step)
This step involves reacting a compound of formula (IV) with a compound of formula (V) to obtain a compound of formula (I). In this reaction, equal amounts of the compounds of formula (IV) and (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 (dba) 3 , RuPhos Pd G3, SPhos Pd G3, Pd-118, etc. Examples of bases are not particularly limited and can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, potassium acetate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are also not particularly limited and can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation.
(Second system)
[Chemical Formula 21]
(R 6a is a C1-5 alkyl group substituted with 1 to 4 identical or different R 7 groups, a -C1-5 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R 8 groups), or a -C1-5 alkylene group (a 4- to 7-membered saturated heterocyclic group substituted with 1 to 4 identical or different R 9 groups). The same applies below.
This method is for preparing the following compound (Iz): in the compound of formula (I), L is -CR4R5- , R4 and R5 are both H, R6 is -CH2- (a C1-5 alkyl group substituted by 1 to 4 identical or different R7 groups), -CH2 - C1-5 alkylene- (a C3-8 cycloalkyl group substituted by 1 to 4 identical or different R8 groups), or -CH2 - C1-5 alkylene- (a 4- to 7-membered saturated heterocyclic group substituted by 1 to 4 identical or different R9 groups).
(First step)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIId) to obtain a compound of formula (VI). In this reaction, equal amounts of the compound of formula (IIa) and the compound of formula (IIId), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base, preferably a copper salt, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3 , etc. Examples of bases are not particularly limited, but can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, triethylamine, N,N-diisopropylethylamine, diisopropylamine, pyrrolidine, etc. Examples of copper salts include copper iodide (I). Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation. It should be noted that this reaction can also be carried out after the compound of formula (IIa) has been converted to the compound of formula (IIb) through the first stage reaction in the first step-4 described in the first preparation method.
[literature]
Chemical Reviews, 107, pp874-922(2007)
(Second Step)
This step involves the reduction of a compound of formula (VI) to obtain a compound of formula (IVa). In this reaction, the compound of formula (VI) is reacted in the presence of a catalyst, under a hydrogen atmosphere, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 50°C, typically with stirring for 0.1 hours to 5 days. Examples of catalysts used herein are not particularly limited, but include palladium supported on carbon, palladium hydroxide, platinum oxide, etc. Examples of solvents are not particularly limited, but include alcohols such as methanol, ethanol, and 2-propanol; water, ethyl acetate, acetic acid, and mixtures thereof.
(Step 3)
This step is the same as the second step of the first preparation method, involving the reaction of the compound of formula (IVa) with the compound of formula (V) to obtain the compound of formula (Iz).
(Third System)
[Chemical Formula 22]
( Rc represents a C1-6 alkyl group, and X2 represents a halogen or -OTf. The same applies below.)
This method is for preparing a compound (Iaa) in which L is -NR 3- in the compound of formula (I).
(First step)
This step involves the cyanidation reaction of the compound of formula (VII) to obtain the compound of formula (VIII). In this reaction, equal amounts of the compound of formula (VII) and a cyanide metal, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of cyanide metals used herein are not particularly limited and include zinc cyanide, copper cyanide, sodium cyanide, potassium cyanide, etc. Examples of catalysts are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 ( dba ) 3 , etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Second Step)
This step involves the reaction of the compound of formula (VIII) with ammonia to obtain the compound of formula (IX). In this reaction, the compound of formula (VIII) and ammonia are reacted in an inert solvent under cooling to reflux, preferably at 0°C to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited, and alcohols such as methanol, ethanol, and 2-propanol can be listed. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 3)
This step involves the reaction of a compound of formula (IX) with a compound of formula (IIIb) to obtain a compound of formula (X). In this reaction, equal amounts of the compounds of formula (IX) and (IIIb), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes be advantageous for facilitating the reaction. Alternatively, this reaction can also be carried out under microwave irradiation.
(Fourth step)
This step involves the reaction of a compound of formula (X) with hydrazine monohydrate to obtain compounds of formula (XIa) and/or formula (XIb). In this reaction, equal amounts of the compound of formula (X) and hydrazine monohydrate, or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 100°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include alcohols such as methanol, ethanol, and 2-propanol; acetonitrile, etc. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 5)
This step is the process of obtaining a compound of formula (IVb) from a compound of formula (XIa) or formula (XIb). The choice of steps 1 through 3 may be made depending on the starting material and the type of X2 .
(Step 5-1)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is -OTf. In this reaction, the compound of formula (XIa) and a trifluoromethanesulfonating agent are reacted in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of trifluoromethanesulfonating agents used herein are not particularly limited, and may include trifluoromethanesulfonic anhydride, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide, etc. Examples of bases are not particularly limited, and may include sodium hydride, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, etc. Examples of solvents, without particular limitation, include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof.
(Step 5-2)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is a halogen. In this reaction, the compound of formula (XIa) and the halogenating agent are placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 150°C, typically for 0.1 hours to 5 days. Examples of halogenating agents used herein are not particularly limited and include phosphorus oxychloride, phosphorus tribromooxychloride, thionyl chloride, etc. Examples of solvents are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; NMP, DMF, and mixtures thereof.
(Step 5-3)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIb) where X2 is a halogen. In this reaction, the compound of formula (XIb) and a diazotizing agent are reacted in the presence of a copper halide in a solvent inert to the reaction, under cooling to reflux, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of diazotizing agents used herein are not particularly limited, and include sodium nitrite, tert-butyl nitrite, etc. Examples of copper halides are not particularly limited, and include copper chloride (I), copper bromide (I), copper iodide (I), etc. Examples of solvents are not particularly limited, and include halogenated hydrocarbons such as dichloromethane and chloroform; acetonitrile, NMP, DMF, and mixtures thereof. The presence of hydrogen halides such as hydrochloric acid, hydrobromic acid, and hydroiodic acid can sometimes be advantageous in facilitating the reaction.
(Step Six)
This step involves reacting a compound of formula (IVb) with a compound of formula (V) to obtain a compound of formula (Iaa). In this reaction, equal amounts of the compound of formula (IVb) and the compound of formula (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3, RuPhosPdG3, etc. Examples of bases are not particularly limited, but include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Raw Material Synthesis-1)
[Chemical Formula 23]
( Rd represents tris( C1-6 )silyloxy or pyrrolidine-1-yl. The same applies below.)
This method involves reacting a compound of formula (XIII) with a compound of formula (XIV) to obtain a compound of formula (IIa) in which ring A is a C5-8 cycloalkenyl group or a partially unsaturated heterocyclic group of 5 to 11 members. In this reaction, equal amounts of the compounds of formula (XIII) and (XIV), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. The solvent used in this reaction is not particularly limited, and examples include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane and chloroform; and mixtures thereof.
(Raw Material Synthesis-2)
[Chemical Formula 24]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XV).
(First step)
This step involves the reaction of a compound of formula (XV) with hydrazine monohydrate to obtain a compound of formula (XVI). In this reaction, an excess of hydrazine monohydrate is used, and the mixture of hydrazine monohydrate and the compound of formula (XV) is stirred for 0.1 hours to 5 days in a solvent-free or solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 200°C. The solvent used in this reaction is not particularly limited, and examples include alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; acetonitrile, DMF, NMP, DMSO, and mixtures thereof.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XVI). In this reaction, the compound of formula (XVI) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, and hydrochloric acid, sulfuric acid, acetic acid, etc. are also included. Examples of solvents used in this reaction are not particularly limited, and alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol are also included; water, acetonitrile, DMF, NMP, DMSO, etc., and mixtures thereof are also included.
(Step 3)
This step involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa). In this reaction, an excess of chlorinating agent is used, and the mixture of the chlorinating agent and the compound of formula (XVII) is stirred for 0.1 hours to 5 days under cooling to reflux, preferably at room temperature to 200°C. Examples of chlorinating agents used herein are not particularly limited, and include phosphorus oxychloride, thionyl chloride, etc. The addition of a small amount of DMF is sometimes advantageous in facilitating the reaction.
(Raw Material Synthesis-3)
[Chemical Formula 25]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XVIII).
(First step)
This step involves the reaction of a compound of formula (XVIII) with tert-butyl hydrazine carbamate to obtain a compound of formula (XIX). In this reaction, equal amounts of the compound of formula (XVIII) and tert-butyl hydrazine carbamate, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a condensing agent and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of condensing agents used herein are not particularly limited and include HATU, EDC·HCl, COMU, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Solvents used in this reaction are not particularly limited and include ethers such as THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; acetonitrile, NMP, DMF, DMSO, etc., and mixtures thereof. The presence of HOBt can sometimes be advantageous in ensuring the smooth progress of a reaction.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XIX). In this reaction, the compound of formula (XIX) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, such as hydrochloric acid and sulfuric acid. Examples of solvents used in this reaction are not particularly limited, such as water, ethyl acetate, and 1,4-dioxane.
(Step 3)
This step is the same as the third step in the synthesis of raw materials -2, which involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa).
(Other manufacturing methods)
By using the compound of formula (I) obtained by the above method as a raw material, further chemical modification reactions commonly used by those skilled in the art, such as alkylation, benzylation, esterification, amidation, acylation, sulfonation, oxidation, protection, and deprotection, can be carried out to obtain another compound of formula (I).
Compounds of formula (I) are separated and purified as free compounds, their salts, hydrates, solvates, or polymorphs. Salts of compounds of formula (I) can also be prepared by conventional salt-forming reactions. Separation and purification can be performed using common chemical operations such as extraction, fractional crystallization, and various fractional chromatography. Various isomers can be prepared by selecting appropriate starting material compounds, or they can be separated by utilizing the differences in physicochemical properties between isomers. For example, optical isomers can be obtained by general optical resolution of racemates (e.g., fractional crystallization of diastereomeric salts formed with optically active bases or acids, chromatography using chiral columns, etc.), or they can be prepared from appropriate optically active starting material compounds.
The pharmacological activity of the compound of formula (I) can be confirmed by the following tests. It should be noted that the pharmacological activity can also be confirmed by well-known modified tests.
Experimental Example 1: Inhibition of THP-1IL-1β Production
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) and ATP (Adenosine triphosphate, SIGMA, A2383) were added at final concentrations of 50 ng/mL and 5 mM, respectively, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of IL-1β was determined using ELISA (DuoSet ELISA human IL-1β, R&D Systems, DY201). IL-1β concentrations were plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoidEmax model nonlinear regression analysis.
The results are shown in Table 1. It can be confirmed that the compounds in the examples inhibit the activation of the NLRP3 inflammasome and inhibit the production of IL-1β.
[Table 1-1]
Table 1
[Table 1-2]
Table 1 (continued)
Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]>
100 4.9 108(2) 3.0 118 4.8 128 3.3
101(1) 2.0 109 1.5 119 6.0 129 86
101(2) 8.6 110 1.4 120 1.0 130 twenty two
102 5.1 111 2.9 121 8.5 131(1) 3.0
103 4.4 112 1.3 122 8.4 131(2) 79
104 3.5 113 1.2 123 47 132 95
105 8.9 114 15 I24 0.62 133 1.3
106 4.8 115 11 125 1.5 134 4.6
107 3.6 116 4.4 126 7.1 135 2.9
108(1) 27 117 130 127 5.6 136 2.2
Experimental Example 2: TNF-α Production Inhibition Test
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) was added at a final concentration of 50 ng/mL, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of TNF-α was determined by ELISA (DuoSetELISA human TNF-α, R&D Systems, DY210). The TNF-α concentration was plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoid Emax model nonlinear regression analysis.
It can be confirmed that Examples 1, 2(1), 3(1), 4(1), 5, 70, 73, 83, 88, 99, 111, 124 and 125, which are compounds of formula (I), showed IC50 values of more than 10 μM in this test.
Experiment 3: Rat Central Nervous System IL-1β Production Test
In male Wistar rats aged 10–14 weeks, 12.5 μg/5 μL of LPS (SIGMA, L2880) was administered intracerebrospinally under isoflurane anesthesia. Two hours later, the test compound was administered orally. One hour later, 50 μg/5 μL of BzATP (2’(3’)-O-(4-benzoylbenzoyl)adenosine 5’-triphosphate triethylammonium salt, SIGMA, B6396) was administered intracerebrospinally. Cerebrospinal fluid was recovered after 30 minutes. IL-1β p17 levels in the cerebrospinal fluid were quantified by Western blotting using an anti-IL-1β antibody (Millipore, AB1832P), and the inhibition rate relative to the solvent-administered group was calculated.
The IL-1βp17 inhibition rates relative to the solvent-administered group for Examples 1, 2 (1), 3 (1), and 124, which are compounds of formula (I), are shown in the table below. It should be noted that in the table, Dose represents the dosage of each tested compound, Ex1, Ex2 (1), Ex3 (1), and Ex124 represent Examples 1, 2 (1), 3 (1), and 124, respectively, and cases not measured are represented as NT. It can be confirmed that these compounds exhibit IL-1β inhibition.
[Table 2]
Dose Ex1 Ex2(1) Ex3(1) Ex124
0.1 mg/kg NT NT NT 55%
0.3 mg/kg -12% 81% 75% 49%
1mg/kg 74% 75% 82% 96%
3mg/kg 84% 88% 72% NT
Example 4: Evaluation of motor function in a mouse model of α-synuclein fibrils-induced neuroinflammation
In male C57BL/6J mice, 8 μg of mouse α-synuclein fibrillation protein (StressMarq Biosciences Inc., SPR-324) was administered to the left striatum. After 14–15 weeks, the test compound, suspended in 0.5% methylcellulose solution, was administered orally once daily. For the negative control group, 0.5% methylcellulose solution was administered. Motor function was evaluated using a suspension test 4 weeks after the start of administration. Mice were allowed to grasp a horizontally taut wire, fall, and then grasp again, repeating this process for 3 minutes, recording the number of falls. In this experiment, it was confirmed that specific compounds of formula (I) or their salts exhibited a beneficial effect on motor dysfunction.
Experimental Example 5: In Vitro (ex vivo) IL-1β Production Assay in Mice
Male C57BL/6J mice were administered the compound, suspended in 0.5% methylcellulose, orally once or multiple times at arbitrary doses, and blood was collected at any time afterward. LPS was added to the blood at a final concentration of 50 ng/mL, and the mice were incubated at 37°C for 3 hours. Then, ATP was added at a final concentration of 5 mM, and the mice were incubated at 37°C for 30 minutes. After centrifugation to remove blood cells, the concentration of IL-1β was determined using an ELISA method (DuoSet ELISA mouse IL-1β, R&D Systems, DY401).
Test Example 6: In Vitro Phototoxicity Test
The in vitro phototoxicity test was evaluated according to ICH S10: Guidelines for the evaluation of photosensitivity of pharmaceuticals (Drug and Food Inspection Certificate No. 0521-1) and the methods described in the OECD guideline for testing of chemicals 432: Invitro 3T3 NRU phototoxicity test, 2019. In this test, it was confirmed that the compounds of Example 1, Example 2(1), Example 3(1) and Example 124 did not have phototoxic effects.
Experimental Example 7: Safety Pharmacology Test
As a safety pharmacology study, the inhibitory effect on human Ether-a-go-go Related Gene (hereinafter referred to as hERG) channels was evaluated. The evaluation of hERG channel inhibition was performed using a modified method described in Combinatorial Chemistry & High Throughput Screening, 12, 1, 78-95 (2009). In this study, the compounds of Examples 1, 2(1), 3(1), and 124 showed IC50 values greater than 10 μM.
Based on the above results, it is expected that compounds of formula (I) or their salts may be used as highly safe pharmaceutical products for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
The compounds of formula (I) or their salts shown in Table 1 were demonstrated to inhibit IL-1β production in Example 1. Furthermore, the compounds of Examples 1, 2(1), 3(1), and 124 were also shown to inhibit IL-1β production in the central nervous system in Example 3. In addition, specific compounds of formula (I) or their salts showed improved motor function in a mouse model of α-synucleinosis induced by α-synuclein fibers, as described in Example 4. Based on these results, it is strongly expected that compounds of formula (I) or their salts can be used for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, particularly α-synucleinosis including Parkinson's disease, multiple system atrophy, and Lewy body dementia.
Furthermore, the results of Examples 6 and 7 show that the compounds of Examples 1, 2(1), 3(1), and 124 do not exhibit phototoxicity and have weak hERG channel inhibition. Based on these results, it is strongly expected that the compounds of Examples 1, 2(1), 3(1), and 124 will become highly safe pharmaceutical products.
Pharmaceutical compositions containing one or more compounds of formula (I) or their salts as active ingredients can be prepared using excipients commonly used in the art (i.e., pharmaceutical excipients or pharmaceutical carriers, etc.) and by commonly used methods.
Administration can be administered orally using tablets, pills, capsules, granules, powders, liquid preparations, etc., or via any of the following methods: intra-articular, intravenous, intramuscular, or intra-intra-articular injections, suppositories, eye drops, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalants, etc.
As a solid composition for oral administration, tablets, powders, granules, etc., can be used. In such a solid composition, one or more active ingredients may be mixed with at least one inert excipient. The composition may contain inert additives, such as lubricants or disintegrants, stabilizers, and solubilizers, according to conventional methods. Tablets, powders, granules, or pills may be coated with wax, sugar coating, or films of gastric-soluble or enteric-soluble substances as needed.
Liquid compositions intended for oral administration contain pharmaceutically permissible emulsifiers, solutions, suspensions, syrups, or elixirs, and commonly used inert diluents such as purified water or ethanol. In addition to inert diluents, the liquid composition may also contain excipients such as solubilizers, humectants, suspending agents, sweeteners, flavorings, aromatizers, and preservatives.
Injectable formulations intended for non-oral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Aqueous solvents include, for example, distilled water for injection or physiological saline. Non-aqueous solvents include, for example, alcohols such as ethanol. Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizers. They are sterilized, for example, by filtration through a bacterial trap, by combination with a bactericide, or by irradiation. Alternatively, they can be prepared as sterile solid compositions and dissolved or suspended in sterile water or sterile solvents for injection before use.
As external agents, they include ointments, plasters, creams, gels, pastes, sprays, lotions, eye drops, and eye ointments. They contain commonly used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, etc.
Inhalers or nasal inhalers, or other mucosal preparations, can be in solid, liquid, or semi-solid form and manufactured according to conventionally known methods. Known excipients may be added as appropriate, or further appropriate pH adjusters, preservatives, surfactants, lubricants, stabilizers, or thickeners may be added. Administration can be performed using a suitable inhalation or blowing device. For example, known devices or nebulizers, such as metered-dose inhalers, can be used to administer the compound alone or as a formulated mixture powder, or in combination with a pharmaceutically permissible carrier in the form of a solution or suspension. Dry powder inhalers, etc., can be used for single or multiple administration and can use dry powder or capsules containing powder. Alternatively, pressurized aerosol sprays, etc., can be used, employing a suitable propellant, such as a suitable gas like chlorofluorocarbons or carbon dioxide.
When administered orally, a daily dose of approximately 0.001 to 100 mg/kg of body weight is appropriate, preferably 0.1 to 30 mg/kg, and more preferably 0.1 to 10 mg/kg, and this dose is administered once or divided into 2 to 4 doses. When administered intravenously, a daily dose of approximately 0.0001 to 10 mg/kg of body weight is appropriate, and this dose is administered once daily or divided into multiple doses. Additionally, as a mucosal agent, approximately 0.001 to 100 mg/kg of body weight is administered once daily or divided into multiple doses. The dosage should be appropriately determined based on individual circumstances, taking into account symptoms, age, and sex.
Although the dosage form, administration site, type of excipient or additive may vary, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, or in some manner 0.01 to 50% by weight, one or more of a compound of formula (I) or a salt thereof as an active ingredient.
The compound of formula (I) can be used in combination with various therapeutic or preventative agents for diseases for which the compound of formula (I) is believed to be effective. When used in combination, the compounds can be administered simultaneously, separately and continuously, or at desired time intervals. Simultaneously administered formulations can be combination formulations or formulations prepared separately.
Example
Hereinafter, based on examples, a method for manufacturing compounds of formula (I) will be described in further detail. It should be noted that the present invention is not limited to the compounds described in the following examples. Furthermore, the manufacturing examples show a method for preparing the starting material compounds. Additionally, the method for manufacturing compounds of formula (I) is not limited to the manufacturing methods of the specific examples shown below; compounds of formula (I) can also be manufactured by combinations of these manufacturing methods or by methods obvious to those skilled in the art.
It should be noted that the starting temperatures of the DSC curves obtained under the following conditions are recorded in the table below. The DSC measurements were performed using a DSC Q2000 (manufactured by TA Instruments) at a temperature range of 25–300 °C, a heating rate of 10 °C/min, and a nitrogen flow rate of 50 mL/min. An aluminum sample pan was used, and measurements were performed without covering the sample pan. The starting temperatures of the DSC curves may vary slightly depending on the measurement conditions and should not be interpreted strictly.
Powder X-ray diffraction (XRD) was performed using an Empyrean (PANalytical) spectrometer under the following conditions: Cu bulb, 40 mA tube current, 45 kV tube voltage, 0.013° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). Alternatively, it was performed using a SmartLab (Rigaku) spectrometer under the following conditions: Cu bulb, 200 mA tube current, 45 kV tube voltage, 0.005° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). It should be noted that, regarding the nature of the data, the lattice spacing or overall pattern of the powder XRD pattern is important in determining the identity of the crystals. The error range of the diffraction angle (2θ (°)) in powder XRD is typically ±0.2°, but the diffraction angle and intensity vary slightly depending on the direction of crystal growth, particle size, and measurement conditions, and therefore should not be interpreted strictly.
In addition, the following abbreviations are sometimes used in the embodiments, manufacturing examples and tables described below.
The following represent the following values: PEx: Manufacturing Example Number; Ex: Example Number; PSyn: Manufacturing Example Number manufactured using the same method; Syn: Example Number manufactured using the same method; Str: Chemical Structural Formula; DAT: Physicochemical Data; EI+: m/z value in mass analysis (Electron Ionization EI, [M]+ unless otherwise specified); ESI+: m/z value in mass analysis (Ionization ESI, [M+H]+ unless otherwise specified); FAB: m/z value in mass analysis (Ionization FAB, [M+H]+ unless otherwise specified); CI: m/z value in mass analysis (Ionization CI, [M+H]+ unless otherwise specified); 1H -NMR (400MHz, CDCl3 ): δ value (ppm) of the signal in 1H -NMR of CDCl3 ; 1H -NMR (500MHz, CDCl3 ): δ value (ppm ) of the signal in 1H-NMR of CDCl3 . δ value (ppm) of the signal in 1H-NMR, 1H -NMR (400MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , 1H -NMR (500MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , J: coupling constant, s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, br: broad peak (e.g., br s), m: multiplet, DSC 1 : temperature (initial temperature) at which the endothermic peak (decomposition point) was observed using DSC, DSC 2 : temperature (initial temperature) at which the endothermic peak (amorphous decomposition point) was observed using DSC, 2θ: diffraction angle of the peak in powder X-ray diffraction.
In the PSyn and Syn columns of the table described later, the hyphen (-) indicates that the manufacturing method is described in text form in the manufacturing example or embodiment.
In addition, for convenience, the concentration in mol/L is expressed as M. For example, 1M sodium hydroxide aqueous solution means a 1 mol/L sodium hydroxide aqueous solution.
Manufacturing Example 1
A mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (10.92 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (16.3 g), DIPEA (28 mL), and cyclopentanol (55 mL) was stirred at 160 °C for 2 days. After cooling the reaction mixture to room temperature, water/saturated sodium chloride aqueous solution (1/1) and chloroform/methanol (9/1) were added to separate the organic layer. The aqueous layer was extracted with chloroform/methanol (9/1), the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]cyclohexane-1-ol (8.24 g) as a solid.
Manufacturing Example 2
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.7 mL) were added, and the mixture was stirred at 160 °C for 44 hours. After cooling the reaction mixture to room temperature, chloroform and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, dried with anhydrous sodium sulfate, and then the solution was concentrated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 3
A mixture of 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine (1.145 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (890 mg), DIPEA (2.7 mL), and NMP (15 mL) was stirred at 160 °C for 24 hours. (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (420 mg) and DIPEA (1.3 mL) were added to the reaction mixture, and the mixture was stirred at 160 °C for 20 hours. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, the organic layers were combined, and the mixture was washed with a 1/1 water/saturated sodium chloride solution and a saturated sodium chloride solution, then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate). (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohex-1-ol (36.1 mg) was obtained as a solid from the low polarity fraction, and (1R,2R)-2-[(6-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)amino]cyclohex-1-ol (504.8 mg) was obtained as an oil from the high polarity fraction.
Manufacturing Example 4
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1S,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.68 mL) were added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, DIPEA (1 mL) was added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water/saturated sodium chloride aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated and dried over anhydrous sodium sulfate. After concentrating the solution, the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain a mixture (774 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 5
At room temperature, a mixture of 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine (502.7 mg) and cyclopentanol (3 mL) was mixed with (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (394 mg) and DIPEA (0.393 mL), and stirred at 160 °C for 2 days under an argon atmosphere. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and saturated sodium chloride/water aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (57.4 mg) as an oil.
Manufacturing Example 42
A mixture of 1 g of 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione and 20 mL of methanol was mixed with 0.6 mL of 12 M hydrochloric acid and 100 mg of platinum oxide, and stirred overnight at room temperature under a hydrogen atmosphere. 20 mL of methanol and 20 mL of DMF were added to the reaction mixture, and the mixture was stirred for 1 hour under an argon atmosphere. The reaction mixture was filtered through a Celite filter, and the filtrate was concentrated under reduced pressure. Toluene was added to the residue, and the mixture was concentrated under reduced pressure. Ethyl acetate was added to the solid, and the mixture was ground. The solid was filtered off and washed with ethyl acetate to give 1.19 g of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride.
Manufacturing Example 43
A mixture of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride (800 mg) and dichloromethane (16 mL) was mixed with DIPEA (0.250 mL), benzaldehyde (0.500 mL), and sodium triacetoxyborohydride (1.1 g) and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with chloroform/methanol (5/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione (515 mg) as a solid.
Manufacturing Example 44
A mixture of 100 mg 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione and 2 mL phosphoryl chloride was stirred at 120 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, and toluene was added, followed by further concentration under reduced pressure. Chloroform (3 mL) was added to the resulting residue, and DIPEA (1 mL) was added under ice-cold conditions. Water was added to the reaction mixture, and extraction with chloroform was performed. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 87 mg 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine as an oil.
Manufacturing Example 45
Under a nitrogen atmosphere, sodium hydride (55%, liquid paraffin dispersion, 190 mg) was added to a mixture of 1,4-dichlorophthalazine (720 mg), 4 -hydroxy-1λ6-thiocyclohexane-1,1-dione (540 mg), and THF (14 mL) while the mixture was ice-cold. The mixture was stirred at the same temperature for 30 minutes, then heated to room temperature and stirred for 3 days. Water and ethyl acetate were added to the reaction mixture, the solid was filtered off, and washed with water and ethyl acetate to give 4-[(4-chlorophthalazine-1-yl)oxy] -1λ6 -thiocyclohexane-1,1-dione (681 mg) in solid form.
Manufacturing Example 47
In a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (100 mg) and 1,4-dioxane (3.2 mL), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane-pentaborane (350 mg), RuPhos Pd G3 (45 mg), potassium carbonate (147 mg), and water (0.64 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform and water were added, and the organic layer was separated. After concentrating the solution, the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (1R,2R)-2-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazine-1-yl}amino)cyclohexyl-1-ol (106 mg) in solid form.
Manufacturing Example 48
Under an argon atmosphere, a mixture of (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (34 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (38 mg), RuPhos Pd G3 (3 mg), potassium carbonate (38 mg), 1,4-dioxane (1 mL), and water (0.100 mL) was stirred at 130 °C for 60 minutes under microwave irradiation. Water and chloroform were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with chloroform, and the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15.6 mg) in solid form.
Manufacturing Example 63
A mixture of tert-butyl [4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]carbamate (1.38 g), dichloromethane (14 mL), and triethylamine (1.21 mL) was added to acetic anhydride (0.330 mL) and 4-dimethylaminopyridine (71 mg), and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate), and the solid was washed with hexane/ethyl acetate (4/1) to give 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl acetate (1.24 g) in solid form.
Manufacturing Example 64
Trifluoroacetic acid (1.83 mL) was added to a mixture of 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl ester (1.24 g) and dichloromethane (13 mL), and the mixture was stirred overnight at room temperature. A 1 M aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol/ammonia). The residue was mixed with chloroform and methanol and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the solid was washed with hexane/ethyl acetate (4/1) to give 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (607 mg) in solid form.
Manufacturing Example 65
A mixture of 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (403 mg), acetyl chloride (0.075 mL), DIPEA (0.495 mL), and dichloromethane (4 mL) was stirred at room temperature for 1 hour. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. DIPEA (0.495 mL) and acetyl chloride (0.075 mL) were added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 4 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-(4-acetaminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl acetate (401 mg) as a solid.
Manufacturing Example 67
Under an argon atmosphere, in a mixture of 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (500 mg), (2R)-but-3-yn-2-ol (0.150 mL), and THF (8 mL), PdCl₂ ( PPh₃ ) ₂ (126 mg), copper iodide (I) (17 mg), and diisopropylamine (0.755 mL) were added under ice-cold conditions, followed by heating to room temperature and stirring for 5 hours. Water and a saturated aqueous solution of ammonium chloride were added to the reaction mixture, and the mixture was extracted with chloroform. The aqueous layer was extracted with chloroform, the organic layers were combined, dried with anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) as an oil.
Manufacturing Example 69
Platinum oxide (67 mg) was added to a mixture of (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) and ethanol (6 mL), and the mixture was stirred at room temperature for 1.5 hours under a hydrogen atmosphere. Celite (registered trademark) was added to the reaction mixture and stirred. The mixture was then filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-2-ol (260 mg) as an oil.
Manufacturing Example 70
Under an argon atmosphere, a mixture of 1,4-dichloro-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.50 g), sodium iodide (3.1 g), and 57% hydroiodic acid (9 mL) was stirred at 100 °C for 30 min under microwave irradiation. The reaction mixture was cooled to room temperature, water was added, and extraction was performed with ethyl acetate. The organic layer was washed with saturated aqueous solutions of sodium bicarbonate, sodium thiosulfate, and sodium chloride, and then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.9 g) as a solid.
Manufacturing Example 72
Under an argon atmosphere, a mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (100 mg), (3-aminobicyclo[1.1.1]pentan-1-yl)methanol-hydrochloride (95 mg), palladium acetate (22 mg), (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (90 mg), cesium carbonate (385 mg), and 1,4-dioxane (2 mL) was stirred at 100 °C for 24 hours. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give {3-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]bicyclo[1.1.1]pentan-1-yl}methanol (46.2 mg) in solid form.
Manufacturing Example 73
Under ice-cold conditions, 1 g of 3,6-dichloro-1,2,4,5-tetraazine was added to a mixture of tert-butyl[(3,6-dihydro-2H-pyran-4-yl)oxy]di(methyl)silane (1.42 g) and toluene (20 mL). The mixture was stirred at room temperature for 0.5 h and then at 120 °C for 16 h. After cooling the reaction mixture to room temperature, it was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1.08 g) in solid form.
Manufacturing Example 74
Under an argon atmosphere, toluene (121 mL) and 3,6-dichloro-1,2,4,5-tetrahydrooxetrazine (6.61 g) were added to a mixture (11.67 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetrazine-4-yl)oxy]silane, and the mixture was stirred at 120 °C for 24 hours. The reaction mixture was cooled to room temperature and filtered through methanol and chloroform. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepten[4,5-d]pyridazine (502.7 mg) in solid form.
Manufacturing Example 76
Hydrochloric acid (12M, 15.8 mL) was added to a mixture of 2-amino-5-cyclopropylphenol (3.50 g) and ethanol (50 mL) at -15 °C, and the mixture was stirred for 10 minutes at the same temperature. Amyl nitrite (9.6 mL) was added to the reaction mixture at -15 °C, and the mixture was stirred for 30 minutes at the same temperature. Then, a mixture of potassium iodide (50.6 g) and water (50 mL) was added dropwise at -15 °C, the mixture was heated to room temperature, and stirred for 20 hours. Ethyl acetate was added to the reaction mixture to separate the organic layer. The organic layer was washed with saturated aqueous sodium thiosulfate solution and saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-cyclopropyl-2-iodophenol (5 g) as an oil.
Manufacturing Example 77
In a mixture of 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) and 1,4-dioxane (9.2 mL), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (1.24 g), PdCl₂ (dppf) (238 mg), and potassium acetate (957 mg) were added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, PdCl₂ (dppf) (238 mg) was added, and the mixture was stirred at 100 °C for 2 hours. After cooling the reaction mixture to room temperature, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (620 mg) was added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, hexane was added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (1.98 g) as an oil.
Manufacturing Example 81
A mixture of 2.86 g of 4-bromo-3-hydroxybenzaldehyde and 30 mL of dichloromethane was added to DIPEA (2.93 mL) and 1.19 mL of chloromethyl methyl ether, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, the organic layer was separated, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde as an oil.
Manufacturing Example 83
Diethylaminosulfur trifluoride (2.2 mL) was added to a mixture of 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde and 20 mL of dichloromethane under ice-cold conditions. The mixture was stirred at the same temperature for 1 hour, then heated to room temperature and stirred for 3 hours. The reaction mixture was added to a mixture of ice water, sodium bicarbonate, and chloroform and stirred. The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.3 g of 1-bromo-4-(difluoromethyl)-2-(methoxymethoxy)benzene as an oil.
Manufacturing Example 84
A mixture of 4-bromo-3-(methoxymethoxy)phenol (1.86 g), sodium dichloro(fluoro)acetate (2.43 g), and DMF (11 mL) was added dropwise to a mixture of potassium carbonate (1.65 g) and DMF (7.4 mL) at 95 °C for 1 hour, and stirred at the same temperature for 15 minutes. After cooling the reaction mixture to room temperature, potassium carbonate (1.65 g) and sodium dichloro(fluoro)acetate (2.43 g) were added, and the mixture was stirred at 95 °C for 1 hour. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with water and a saturated sodium chloride aqueous solution, and then dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) as an oil.
Manufacturing Example 85
Under an argon atmosphere, a mixture of 1-chloro-4-iodo-5,6,7,8-tetrahydrophthalazine (500 mg), (1R,2R)-2-amino-1-methylcyclohexane-1-ol (270 mg), copper iodide (I) (30 mg), potassium phosphate (725 mg), ethylene glycol (0.100 mL), and 1-propanol (5 mL) was stirred at 90 °C for 24 hours. After cooling the reaction mixture to room temperature, chloroform and a saturated aqueous solution of ammonium chloride were added, and the organic layer was separated. The aqueous layer was extracted with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]-1-methylcyclohexane-1-ol (292 mg) in solid form.
Manufacturing Example 86
Under an argon atmosphere, a mixture of ethyl 1-benzyl-5-[(trifluoromethanesulfonyl)oxy]-1,2,3,6-tetrahydropyridine-4-carboxylate (3.37 g), zinc cyanide (1.5 g), Pd(PPh 3 ) 4 (1.2 g), and DMF (42 mL) was stirred at 100 °C for 1.5 h. After cooling to room temperature, water and ethyl acetate were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, washed with a 1/1 water/saturated sodium chloride aqueous solution and a saturated sodium chloride aqueous solution, and dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (2.04 g) as an oil.
Manufacturing Example 87
Under an argon atmosphere, a mixture of ethyl 5-[(trifluoromethanesulfonyl)oxy]-3,6-dihydro-2H-pyran-4-carboxylate (7.4 g), zinc cyanide (4.3 g), Pd(PPh 3 ) 4 (2.8 g), and DMF (74 mL) was stirred at 100 °C for 2 hours. After cooling to room temperature, ethyl acetate and water were added to the reaction mixture, and the mixture was filtered through Celite (registered trademark). After separating the two layers, the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with a 1/1 solution of water/saturated sodium chloride and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) as an oil.
Manufacturing Example 88
A mixture of ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (930 mg) and ammonia (7 M methanol solution, 8 mL) was stirred at ice temperature for 6 hours. The reaction mixture was allowed to stand in a refrigerator for 18 hours, then heated to room temperature and stirred for 10 minutes. The reaction mixture was concentrated under reduced pressure to give 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridine-1-one (828 mg) as a solid.
Manufacturing Example 89
Ammonia (7M methanol solution, 44 mL) was added to ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) under ice-cold conditions, and the mixture was stirred at 0 °C for 3 days. The reaction mixture was concentrated under reduced pressure to give 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.261 g) as a solid.
Manufacturing Example 90
A mixture of 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (825 mg), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (530 mg), DIPEA (0.7 mL), and acetonitrile (20 mL) was stirred at 70 °C for 19 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (1.12 g) as a solid.
Manufacturing Example 91
A mixture of 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.26 g), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (3.4 g), DIPEA (5.5 mL), and acetonitrile (70 mL) was stirred at 70 °C for 18 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (5.63 g) in solid form.
Manufacturing Example 92
A mixture of 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (560 mg) and ethanol (10 mL) was mixed with hydrazine monohydrate (0.16 mL) and stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (201 mg) in solid form.
Manufacturing Example 93
Under an argon atmosphere, sodium hydride (55%, liquid paraffin dispersion, 12 mg) was added to a mixture of 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (90 mg) and THF (3 mL) under ice-cold conditions, and the mixture was stirred for 20 minutes at the same temperature. 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide (108 mg) was added to the reaction mixture, and the mixture was stirred for 1 hour under ice-cold conditions. Water and chloroform were added to the reaction mixture, and the organic layer was separated. After extraction of the aqueous layer with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then chloroform/ethyl acetate) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine-1-yl ester (40 mg) in solid form.
Manufacturing Example 94
Sodium hydroxide (0.596 g) and benzyltriethylammonium chloride (0.922 g) were added to a mixture of (3R)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (2 g) and dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes. 1,4-Dichlorophthalazine (2.37 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 24 hours. Water and dichloromethane were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (3R)-3-[(4-chlorophthalazine-1-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester (0.960 g) as a solid.
Manufacturing Example 96
A mixture of (3R)-3-[(3R)-piperidin-1-carboxylic acid tert-butyl ester (960 mg) and dichloromethane (10 mL) was mixed with a solution of 1,4-dioxane hydrogen chloride (4 M, 10 mL) and stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and then diethyl ether was added to the resulting solid and the mixture was ground. The solid was filtered off to give 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine monohydrochloride (850 mg) in solid form.
Manufacturing Example 97
Triethylamine (0.26 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (100 mg) and dichloromethane (2 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.04 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated sodium chloride aqueous solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture A). Triethylamine (0.70 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (300 mg) and dichloromethane (10 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.10 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-{(3R)-3-[(4-chlorophthalazin-1-yl)oxy]piperidin-1-yl}aceto-1-one (280 mg).
Manufacturing Example 98
Triethylamine (6.3 mL) was added to a mixture of oxetane (5 g) and diethyl ether (50 mL) under ice-cold conditions, followed by tert-butyldi(methyl)silane trifluoromethanesulfonate (12.3 mL), and the mixture was stirred for 10 minutes at the same temperature. Triethylamine (1.4 mL) was added to the reaction mixture, and the mixture was stirred under ice-cold conditions for 1.5 hours. Hexane and water were added to the reaction mixture, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated to give a mixture (11.7 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetane-heptene-4-yl)oxy]silane as an oil.
Manufacturing Example 99
A mixture of 500 mg of 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrolo-1(4H)-one and 2-propanol (20 mL) was mixed with 0.300 mL of hydrazine monohydrate and stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (200 mg) in solid form.
Manufacturing Example 100
Under an argon atmosphere, sodium nitrite (80 mg) was added to a mixture of (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (198 mg), copper chloride (I) (75 mg), and hydrochloric acid (12 M, 2.5 mL) under ice-cold conditions, and the mixture was stirred for 1 hour at the same temperature. Dichloromethane (10 mL), water, and triethylamine (4.2 mL) were added to the reaction mixture under ice-cold conditions and stirred. The reaction mixture was filtered through a Celite filter and washed with dichloromethane/methanol (10/1). The organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (170 mg) in solid form.
Manufacturing Example 101
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (131.6 mg), 10% palladium-supported carbon (containing 51% water, 84.5 mg), and methanol (3 mL) was stirred at room temperature for 4 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite filter. The filtrate was then concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (89.3 mg) as a solid.
Manufacturing Example 102
[(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.524 g) and sodium triacetoxyborohydride (2.416 g) were added to a mixture of cyclobutanone (0.640 g) and dichloromethane (25 mL) at room temperature, and the mixture was stirred for 5 hours at room temperature. The reaction mixture was injected into a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to give [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.940 g) as a solid.
Manufacturing Example 103
A solution of 1,4-dioxane hydrogen chloride (4M, 1.8 mL) was added to a mixture of [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (225 mg) and dichloromethane (1.8 mL) with stirring at room temperature, and the mixture was stirred for 3 hours at room temperature. The reaction mixture was concentrated under reduced pressure to give (3R)-1-cyclobutylpiperidin-3-amine dihydrochloride (250 mg) as a solid.
Manufacturing Example 104
A mixture ( 393 mg ) of (1R,2R)-N1-(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)cyclohexyl-1,2-diamine and (1R,2R) -N1- (4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)cyclohexyl-1,2-diamine was added to dichloromethane (14 mL), triethylamine (0.23 mL), and di-tert-butyl dicarbonate (0.34 mL), and the mixture was stirred at room temperature for 1.5 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (352 mg) of {(1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl}carbamate tert-butyl ester and {(1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl}carbamate tert-butyl ester in solid form.
Manufacturing Example 105
A solution of 1,4-dichloro-6-(triphenylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine (1.569 g) and dichloromethane (18 mL) was added to a solution of 1,4-dioxane hydrogen chloride (4 M, 6 mL), and the mixture was stirred at room temperature for 18.5 hours. The reaction mixture was filtered, the solid was washed with diethyl ether, and then dried under reduced pressure to give 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine hydrochloride (770 mg).
Manufacturing Example 106
Triethylamine (1.4 mL) and di-tert-butyl dicarbonate (1.2 mL) were added to a mixture of 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine monohydrochloride (765 mg) and dichloromethane (23 mL) under ice-cold stirring, and the mixture was stirred for 17 hours while being naturally heated to room temperature. The reaction mixture was injected into water and extracted with dichloromethane. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Diethyl ether was added to the resulting solid and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give tert-butyl 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid (788 mg) as a solid. The residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid tert-butyl ester (142 mg) in solid form.
Manufacturing Example 114
A mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (700 mg) and (3R)-3-aminopiperidine-1-carboxylic acid tert-butyl ester (1.4 g) was stirred at 120 °C for 24 hours. After cooling to room temperature, the mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (481 mg) of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester in solid form.
Manufacturing Example 116
A mixture of 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (384 mg), (1R,2R)-2-aminocyclohexyl-1-ol (426 mg), DIPEA (0.77 mL), and cyclopentanol (7.4 mL) was stirred at 145–155 °C for 18.5 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and then water and a saturated sodium chloride aqueous solution were added. Extraction was performed with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (236 mg) in solid form.
Manufacturing Example 120
A mixture of 1,4-dichloro-5,7-dihydrofurano[3,4-d]pyridazine (500 mg), (1S,3R)-3-aminocyclohexyl-1-ol monohydrochloride (795 mg), DIPEA (1.8 mL), and cyclopentanol (5 mL) was stirred at 120–130 °C for 22 hours. The reaction mixture was cooled to room temperature, injected into water, and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (556 mg) as a solid.
Manufacturing Example 122
A mixture of 2,3,5,7-tetrahydrothieno[3,4-d]pyridazine-1,4-dione (78 mg) and phosphorus oxychloride (1 mL) was stirred at 98–100 °C for 2.5 h. The reaction mixture was cooled to room temperature and then poured into ice water for washing with ice water and dichloromethane. A saturated sodium bicarbonate solution was added dropwise to adjust the pH to approximately 8 while stirring at room temperature, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (92 mg) as a solid.
Manufacturing Example 128
A mixture of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester (478 mg), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (680 mg), RuPhos Pd G3 (163 mg), potassium carbonate (450 mg), 1,4-dioxane (10 mL), and water (2 mL) was stirred at 100 °C for 4 hours. After cooling to room temperature, water was added to the mixture, and extraction was performed with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution and then dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and (3R)-3-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (200 mg) in solid form.
Manufacturing Example 134
Under an argon atmosphere, a mixture of (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (155 mg), 2-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (361 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 94 mg), potassium carbonate (159 mg), 1,4-dioxane (6 mL), and water (1.4 mL) was stirred at 90–110 °C for 20 hours. The reaction mixture was cooled to room temperature, injected into water, and then filtered through a Celite (trademark) filter. The filtrate was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-({4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (128 mg) in solid form.
Manufacturing Example 144
By the same reaction as in Manufacturing Example 74, 1,4-dichloro-5,7,8,9-tetrahydrooxetanehepten[3,4-d]pyridazine was obtained as a byproduct in solid form.
Manufacturing Example 152
Under ice-cold conditions, trifluoromethanesulfonic anhydride (0.17 mL) was added to a mixture of 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-ol (261 mg), 2,6-rutidine (0.16 mL), and dichloromethane (6 mL), and the mixture was stirred at the same temperature for 1.5 hours. Dichloromethane and water were added to the reaction mixture and stirred, and then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl ester (311 mg) in solid form.
Manufacturing Example 154
Under an argon atmosphere and with stirring at -30°C, trifluoromethanesulfonic anhydride (14.1 mL) was added dropwise to a mixture of ethyl 5,5-dimethyl-4-oxothiacyclopentane-3-carboxylate (16.169 g), DIPEA (15.3 mL), and dichloromethane (80 mL). The reaction mixture was then stirred at -45 to -15°C for 1 hour. Water was added to the reaction mixture, and the mixture was heated to room temperature and then extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (17.559 g) as an oil.
Manufacturing Example 159
Under ice-cold conditions, tert-butyl dimethyl silane trifluoromethanesulfonate (1.2 mL) was added to a mixture of (1S,2R)-2-aminocyclohexane-1-ol monohydrochloride (608 mg), dichloromethane (8 mL), and 2,6-rutidine (1.1 mL), and the mixture was stirred for 1 hour at the same temperature, followed by stirring at room temperature for 3 hours. 2,6-rutidine (0.16 mL) and tert-butyl dimethyl silane trifluoromethanesulfonate (0.3 mL) were added to the resulting mixture at room temperature, and the mixture was stirred for 20 hours at the same temperature. Dichloromethane and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture and stirred, then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexane-1-amine (445 mg) as an oil.
Manufacturing Example 160
At room temperature, hydrochloric acid (12M, 0.5 mL) was added to a mixture of (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and methanol (3 mL), and the mixture was stirred at 60 °C for 1 hour. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. Chloroform/methanol (9/1) and basic silica gel were added to the residue, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (alkaline silica, chloroform/methanol) to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (102 mg) in solid form.
Manufacturing Example 162
A mixture (113 mg) of (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol was purified by reversed-phase preparative HPLC (ODS column, 0.1% formic acid/methanol) to give (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (62.4 mg) as an oil.
Manufacturing Example 163
Potassium carbonate (197.99 mg) and methyl iodide (58.10 mg) were added to a mixture of 1-chloro-N-[(3R)-piperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine dihydrochloride (110 mg) and DMF (6 mL) at 25 °C, and the mixture was stirred for 16 hours at the same temperature. The reaction mixture was added to water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure to give 1-chloro-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (110 mg) as an oil.
Manufacturing Example 164
N-bromosuccinimide (23.88 g) was added to a mixture of 3-cyclopropylphenol (20 g) and chloroform (200 mL) at 0 °C, and the mixture was stirred at 15 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether) to give 2-bromo-5-cyclopropylphenol (7.7 g) as an oil.
Manufacturing Example 165
A mixture of 2,5-dihydrothiophene-3,4-dicarboxylhydrazide (127 mg) and 10% sulfuric acid (8 mL) was stirred at 115–120 °C for 1 hour. The reaction mixture was cooled to room temperature and then filtered. The filtered solid was washed with water and dried to give 2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione (94 mg) in solid form.
Manufacturing Example 166
A mixture of 308 mg of 4,6-dihydro-1H,3H-thieno[3,4-c]furan-1,3-dione, 0.96 mL of hydrazine monohydrate, and 20 mL of 2-propanol was heated to reflux at 100 °C and stirred for 14.5 h. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with 2-propanol and dried to give 2,5-dihydrothiophene-3,4-dicarboxyhydrazide (246 mg) as a solid.
Manufacturing Example 167
A mixture of 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazine-1-carboxylic acid, 9.1 mL of 1,4-dioxane hydrochloride solution, and 90 mL of ethyl acetate was stirred at 60–67 °C for 19 hours. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with ethyl acetate and dried to give 2.717 g of 5,5-dimethyl-2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione in solid form.
Manufacturing Example 168
A mixture of 5.095 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid, 3.509 g of tert-butyl hydrazinocarboxylate, 10.095 g of HATU, 7.73 mL of DIPEA, and 110 mL of DMF was stirred at room temperature for 2.5 hours. Water was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazino-1-carboxylic acid as an oil.
Manufacturing Example 169
Under an argon atmosphere, a mixture of ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (15.556 g), sodium formate (9.493 g), acetic anhydride (8.8 mL), DIPEA (16.3 mL), lithium chloride (5.917 g), palladium acetate (1.045 g), and DMF (230 mL) was stirred at room temperature for 17 hours. The reaction mixture was filtered, and 10% hydrochloric acid was added to the filtrate to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol). A saturated aqueous sodium bicarbonate solution was added to the purified product, and the mixture was stirred at room temperature to adjust the pH to approximately 8, followed by washing with ethyl acetate. Under stirring at room temperature, 10% hydrochloric acid was added to the aqueous layer to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dried with anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain 9.659 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid as an oil.
Example 1
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (4.4 g), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (4.5 g), RuPhos Pd G3 (1.3 g), potassium carbonate (5.4 g), 1,4-dioxane (40 mL), and water (8 mL) was stirred at 100 °C for 2 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 3 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 19 hours. After cooling the reaction mixture to room temperature, water and chloroform were added to separate the organic layer. The aqueous layer was extracted with chloroform, and the combined organic layers were washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (basic and neutral silica gel, chloroform/methanol). Ethyl acetate (10 mL) and hexane (50 mL) were added to the purified product, and the mixture was stirred at room temperature for 18 hours. The solid was filtered off to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol (3.97 g) in solid form.
Example 2
In a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (562 mg), RuPhos PdG3 (171 mg), potassium carbonate (563 mg), and water (2.5 mL) were added, and the mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (3 mL) and hexane (12 mL) were added to the two purified products, respectively, and the mixture was stirred for 15 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (108 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (172 mg) was obtained from the high-polarity fraction.
Example 3
In a mixture (440 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (14 mL), [2-hydroxy-4-(trifluoromethoxy)phenyl]boronic acid (690 mg), RuPhosPd G3 (195 mg), potassium carbonate (643 mg), and water (2.9 mL) were added. The mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (8 mL) were added to the two purified products, respectively, and the mixture was stirred for 30 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (124 mg) was obtained from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethoxy)phenol (242 mg) was obtained from the high-polarity fraction.
Example 4
In a mixture (380 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12.2 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (553 mg), RuPhosPd G3 (168 mg), potassium carbonate (555 mg), and water (2.4 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (6 mL) were added to the two purified products, respectively, and the mixture was stirred for 1 hour. The solids were filtered off, and 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (93 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (103 mg) was obtained from the high-polarity fraction.
Example 5
Under an argon atmosphere, RuPhos Pd G3 (17 mg) was added to a mixture of (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetane-hepteno[4,5-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (57.4 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (59.8 mg), potassium carbonate (80 mg), 1,4-dioxane (2.4 mL), and water (0.600 mL), and the mixture was stirred at 100 °C for 3 hours. RuPhos Pd G3 (16 mg) was then added to the reaction mixture, and the mixture was stirred at 100 °C for 1 hour. Subsequently, RuPhos Pd G3 (17.7 mg), 1,4-dioxane (0.800 mL), and water (0.200 mL) were added, and the mixture was stirred at 100 °C for 6 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1), saturated sodium chloride aqueous solution, and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxocyclohepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (9.1 mg) in solid form.
Example 70
Under an argon atmosphere, a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (150 mg), (4-chloro-2-hydroxyphenyl)boronic acid (120 mg), RuPhos Pd G3 (46 mg), potassium carbonate (150 mg), 1,4-dioxane (4 mL), and water (0.5 mL) was stirred at 100 °C for 5 hours. Then, (4-chloro-2-hydroxyphenyl)boronic acid (120 mg) and RuPhos Pd G3 (22 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 8 hours. After cooling the reaction mixture to room temperature, basic silica gel was added, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol) to obtain a solid. Hexane/ethyl acetate (10/1) was added to the obtained solid, and the solid was filtered off to obtain 5-chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (25.2 mg) in solid form.
Example 73
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (14 mg), formaldehyde (37% aqueous solution, 0.020 mL), 10% palladium-supported carbon (50% water content, 10 mg), and methanol (1 mL) was stirred at room temperature for 24 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite (trademark) filter. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (5.6 mg) as a solid.
Example 79
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and acetyl chloride (6 mg) under ice-cold conditions and stirred at the same temperature for 2 hours. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-{1-[2,4-bis(trifluoromethyl)phenyl]-4-{[(2R)-2-hydroxypropyl]amino}-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl}ethyl-1-one (18 mg) in solid form.
Example 80
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and methanesulfonyl chloride (8 mg) under ice-cold conditions and stirred at the same temperature for 30 minutes. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (2R)-1-({1-[2,4-bis(trifluoromethyl)phenyl]-6-(methanesulfonyl)-5,6,7,8-tetrahydropyridino[3,4-d]pyridazin-4-yl}amino)prop-2-ol (15 mg) in solid form.
Example 81
A mixture of 2-[4-(4-acetamidobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl ester acetate (398 mg) and methanol (8 mL) was mixed with an aqueous solution of sodium hydroxide (1 M, 1.73 mL) and stirred at room temperature for 3 hours. Hydrochloric acid (1 M, 1.73 mL) and water were added to the reaction mixture, and extraction was performed with chloroform/2-propanol (4/1). The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting solid was washed with ethyl acetate to give N-[4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]acetamide (309 mg) in solid form.
Example 82
A solution of 1,4-dioxane hydrogen chloride (4M, 4mL) was added to a mixture of [(1R,2R)-2-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}amino)cyclohexyl]tert-butyl carbamate (0.440 g) and 1,4-dioxane (10 mL) at 0 °C, and the mixture was heated to room temperature and stirred for 4 hours. A solution of 1,4-dioxane hydrogen chloride (4M, 4 mL) was added to the reaction mixture at 5 °C, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting solid was washed with diethyl ether to give 2-(4-{[(1R,2R)-2-aminocyclohexyl]amino}phthalazin-1-yl)-5-(trifluoromethyl)phenol dihydrochloride (0.375 g) in solid form.
Example 83
Hydrochloric acid (12 M, 0.060 mL) was added to a mixture of (1R,2R)-2-({4-[-4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)cyclohexane-1-ol (106 mg) and methanol (1.1 mL), and the mixture was stirred at 60 °C for 10 hours. Ethyl acetate and a saturated aqueous sodium bicarbonate solution were added to the reaction mixture to separate the organic layer, which was then extracted with ethyl acetate. The combined organic layers were washed with water and a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solution was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (1 mL) and hexane (3 mL) were added to the obtained solid, and the mixture was stirred for 15 minutes. The solid was then filtered off, thus obtaining 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol (62 mg) in solid form.
Example 88
Under an argon atmosphere, potassium carbonate (159 mg), 2-[4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5,5-tetramethyl-1,3,2-dioxane (564 mg), and RuPhos Pd G3 (49.3 mg) were added to a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (162 mg), 1,4-dioxane (2 mL), and water (0.500 mL), and the mixture was stirred at 100 °C for 1.5 h. The reaction mixture was cooled to room temperature, and methanol (2 mL) and hydrochloric acid (12 M, 0.590 mL) were added. The mixture was stirred at 60 °C for 2 h. After cooling the reaction mixture to room temperature, basic silica gel was added and the mixture was concentrated. The obtained residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol). Ethyl acetate and diisopropyl ether were added to the obtained residue, and after sonication, the solid was filtered off, thus yielding 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (46.3 mg) in solid form.
Example 90
Under ice-cold conditions, a solution of 1,4-dioxane hydrogen chloride (4M, 0.84 mL) was added to a mixture of 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazin-6(5H)-carboxylic acid tert-butyl ester (171 mg) and dichloromethane (2.6 mL), and the mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5(trifluoromethyl)phenol dihydrochloride (162 mg) as a solid.
Example 92
Under an argon atmosphere, acetyl chloride (0.041 mL) and pyridine (0.010 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (46.7 mg), dichloromethane (2 mL), and THF (1 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was then heated to room temperature, and an aqueous solution of sodium hydroxide (1 M, 1 mL) was added, and the mixture was stirred at the same temperature for 7 hours. The reaction mixture was then chilled, and hydrochloric acid (1 M, 1 mL) was added. The mixture was then heated to room temperature, and chloroform was added, and the mixture was stirred at the same temperature for 10 minutes. The organic layer was separated and concentrated. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl]ethyl-1-one (17.2 mg) in solid form.
Example 93
Under an argon atmosphere, methanesulfonyl chloride (0.004 mL) and DIPEA (0.039 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (18.5 mg) and dichloromethane (2 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture A). Under an argon atmosphere, methanesulfonyl chloride (0.005 mL) and DIPEA (0.048 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (22.9 mg) and dichloromethane (3 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-(methanesulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl]-5-(trifluoromethyl)phenol (13.8 mg) in solid form.
Example 94
Under an argon atmosphere and with ice-cold stirring, boron tribromide (17% dichloromethane solution, 2.5 mL) was added dropwise to a mixture of (1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]thiopheno[2,3-d]pyridazin-7-yl}amino)cyclohexyl-1-ol (210 mg) and dichloromethane (2.5 mL), and the mixture was stirred at 0 °C for 2 hours. A saturated aqueous solution of sodium bicarbonate and methanol were added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate), and dichloromethane was added to the purified product, followed by grinding. The precipitated solid was filtered, washed with dichloromethane, and dried under reduced pressure to obtain 2-(7-{[(1R,2R)-2-hydroxycyclohexyl]amino}thieno[2,3-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (75 mg) in solid form.
Example 95
Under ice-cold stirring, boron tribromide (0.7 mL of 17% dichloromethane solution) was added to a mixture of [(1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)cyclohexyl]carbamate tert-butyl ester (73 mg) and dichloromethane (1 mL), and the mixture was naturally heated to room temperature while stirring for 5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) to give 2-(1-{[(1R,2R)-2-aminocyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (44 mg) in solid form.
Example 96
A mixture of (3R)-3-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (194 mg), dichloromethane (4 mL), and trifluoroacetic acid (0.66 mL) was stirred at room temperature for 5.5 hours. Water was added to the reaction mixture, and the aqueous layer was washed with dichloromethane. The organic layer was extracted with 10% hydrochloric acid, and the aqueous layers were combined. Potassium carbonate and saturated sodium bicarbonate solution were added to make the mixture alkaline. The aqueous layer was extracted with dichloromethane/methanol. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Dichloromethane and hexane were added to the resulting residue, and the mixture was ground. The precipitated solid was filtered and dried under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (80 mg) in solid form. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg) in solid form.
Example 97
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg), dichloromethane (1 mL), methanol (0.1 mL), 3-oxetane (19.9 μL), and sodium triacetoxyborohydride (68 mg) was stirred at room temperature for 5 hours. 3-oxetane (39.9 μL) and sodium triacetoxyborohydride (136 mg) were added to the reaction mixture, and the mixture was stirred at room temperature for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to obtain 2-(4-{[(3R)-1-(oxecyclobut-3-yl)piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (45 mg) in solid form.
Example 98
A mixture of 264 mg of 1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-carboxylic acid tert-butyl ester, dichloromethane (5 mL), and trifluoroacetic acid (0.9 mL) was stirred at room temperature for 5 hours. Under ice-cold stirring, a saturated aqueous solution of sodium bicarbonate, dichloromethane, and methanol were added to the reaction mixture. Extraction was performed with dichloromethane, and the mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Ethyl acetate was added to the resulting residue, and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give 72 mg of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol as a solid. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (21 mg) in solid form.
Example 99
Sodium triacetoxyborohydride (75 mg) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (70 mg), methanol (1.8 mL), and 37% formaldehyde aqueous solution (20 μL) under stirring at room temperature, and the mixture was stirred for 4 hours at room temperature. A saturated sodium bicarbonate aqueous solution was added to the reaction mixture, and the precipitated solid was filtered off and washed with water. The filtered solid was dried, and hexane/ethyl acetate was added and the mixture was ground. The precipitated solid was filtered off, washed with hexane, and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (35 mg) in solid form.
Example 111
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (236 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (342 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 68 mg), potassium carbonate (229 mg), 1,4-dioxane (8 mL), and water (2 mL) was stirred at 107–112 °C for 14 hours. After cooling the reaction mixture to room temperature, [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (171 mg) and PdCl₂ (dppf)· CH₂Cl₂ (68 mg ) were added, and the mixture was further stirred at 110–120 °C for 2 hours. The reaction mixture was then injected into a mixture of water and a saturated sodium chloride aqueous solution and extracted with ethyl acetate. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate). The purified product was dissolved in a small amount of dichloromethane, hexane was added, the precipitated solid was filtered off and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (39 mg) in solid form.
Example 112
A solution of ethyl hydrochloride (4M, 4 mL) was added to a mixture of 1-[4-cyclopropyl-2-(methoxymethoxy)phenyl]-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (250 mg) and ethyl acetate (5 mL) at 25 °C, and the mixture was stirred for 1 hour at the same temperature. After adding water and a saturated aqueous sodium bicarbonate solution to the reaction mixture, extraction was performed with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. After the solution was concentrated under reduced pressure, the residue was purified by reversed-phase preparative HPLC (ODS column, ammonia + ammonium bicarbonate aqueous solution/acetonitrile) to obtain 5-cyclopropyl-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (29.3 mg) in solid form.
Example 114
A mixture of (1S,3R)-3-({4-[4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (122 mg), trifluoroacetic acid (0.48 mL), and dichloromethane (2 mL) was stirred at room temperature for 5 hours. While stirring the reaction mixture under ice-cold conditions, a saturated aqueous solution of sodium bicarbonate was added until the foaming subsided, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol (58 mg) as a solid.
Example 117
In a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (62 mg), DIPEA (33 μL), and dichloromethane (1.6 mL), acetic anhydride (18 μL) was added while stirring under ice-cold conditions, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered, the filtered solid was washed with dichloromethane, and dried to give 1-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-yl)ethyl-1-one (58 mg) in solid form.
Example 124
At room temperature, a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and THF (4 mL) was added to (1H-benzotriazol-1-yl)methanol (86 mg) and sodium acetate (55 mg), and stirred for 10 minutes at the same temperature. Sodium triacetoxyborohydride (125 mg) was added to the resulting mixture, and the mixture was stirred for 1 hour at room temperature. Water and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, followed by extraction with chloroform/methanol (9/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product, and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (72 mg) in solid form.
Example 126
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (71 mg), [(1-ethoxycyclopropyl)oxy]tri(methyl)silane (72 μL), sodium cyanoborohydride (17 mg), acetic acid (16 μL), THF (1 mL), and methanol (1 mL) was stirred at 49–54 °C for 15.5 hours. The reaction mixture was cooled to room temperature, and 10% sodium hydroxide solution was added. The solution was prepared to a pH of approximately 7–8, and then extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol) to give 2-(4-{[(3R)-1-cyclopropylpiperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15 mg) in solid form.
Example 127
Hydrochloric acid (12M, 0.5mL) was added to a mixture of 2-(4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (60mg) and methanol (2mL) at room temperature, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was chilled, and an aqueous solution of sodium hydroxide (1M, 6mL) was added, followed by extraction with chloroform and chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (25.7 mg) in solid form.
Example 128
TFA (0.5 mL) was added to a mixture of (3R)-3-({1-[2-hydroxy-4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (29 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and THF (4 mL), sodium acetate (15 mg), and (1H-benzotriazol-1-yl)methanol (25 mg) were added to the residue, and the mixture was stirred for 10 minutes at room temperature. Sodium triacetoxyborohydride (36 mg) was added to the resulting mixture, and the mixture was stirred for 2 hours at room temperature. A saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride were added to the reaction mixture, and the mixture was extracted with chloroform/methanol (9/1). After neutralization with 1 M hydrochloric acid in the aqueous layer, the mixture was extracted with chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to give 2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (14.3 mg) in solid form.
Example 129
Oxone (registered trademark) (1.3 g) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-thiaro[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (300 mg), acetonitrile (5 mL), and water (5 mL) at 25 °C, and the mixture was stirred for 2 hours at the same temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. Acetonitrile and water were added to the residue, and the mixture was freeze-dried to give 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydro- 6λ6 -thiaro[3,4-d]pyridazin-6,6(5H)-dione (185 mg) as a solid.
Example 132
A mixture of 2-(7,7-dimethyl-4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (50 mg), 2,2-difluoroethyl trifluoromethanesulfonate (19 μL), triethylamine (49 μL), and ethanol (1.2 mL) was stirred at 54–62 °C for 17 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and then extracted with dichloromethane after adding water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then dichloromethane/methanol). The purified product was dissolved in toluene and extracted with 5% aqueous sodium hydroxide solution, water, and saturated aqueous sodium chloride solution. The aqueous layer was washed with toluene, 10% hydrochloric acid was added, and then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/hexane/methanol, then hexane/ethyl acetate) to give 2-(4-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]amino}-7,7-dimethyl-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (6 mg) in solid form.
Example 133
A solution of 1,4-dioxane hydrogen chloride (4M, 0.11 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (150 mg) and dichloromethane (1.5 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (3 mL) was added, and the mixture was stirred at 50 °C for 48 hours. After cooling to room temperature, the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (149 mg) in crystalline form.
Example 134
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.074 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (103 mg) as a solid.
Example 135
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.071 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5-(trifluoromethoxy)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride (95 mg) in crystalline form.
Example 136
A solution of 1,4-dioxane hydrogen chloride (4M, 0.147 mL) was added to a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred for 120 hours at room temperature. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride (122 mg) as a solid.
The compounds of the manufacturing examples and embodiments shown in the table below were manufactured in the same manner as those of the manufacturing examples or embodiments described above.
[Table 3-1]
[Table 3-2]
[Table 3-3]
[Table 3-4]
[Table 3-5]
[Table 3-6]
[Table 3-7]
[Table 3-8]
[Table 3-9]
[Table 3-10]
[Table 4-1]
[Table 4-2]
[Table 4-3]
[Table 4-4]
[Table 4-5]
[Table 4-6]
[Table 4-7]
[Table 4-8]
[Table 5-1]
PEx PSyn DAT
1 - ESI+; 282.2, 284.2
2 - ESI+; 284.2, 286.1
3(1) - ESI+; 373.2, 375.2
3(2) - ES1+; 373.2, 376.2
4 - ESI+; 284.1, 286.1
5 - ESI+; 298.1, 300.2
6 1 FAB; 242.2
7 1 ESI+; 228.1, 230.1
8 1 ESI+; 333.2, 335.2
9 1 ESI+; 284.3, 286.3
10 1 ESI+; 264.3, 266.3
11 1 ESI+; 264.2, 266.2
12 1 ESI+; 264.3, 266.3
13 1 ESI+; 278.3, 280.3
14 1 ESI+; 239.1, 241.1
15 1 ESI+; 242.1, 244.0
16 1 ESI+; 228.1, 230.1
17 1 ESI+; 268.2, 270.2
18 1 ESI+; 242.2, 244.2
19 1 FAB; 377.1
20 1 FAB; 319.0
twenty one 1 FAB; 268.0
twenty two 1 ESI+; 268.1, 270.1
twenty three 1 ESI+; 296.1, 298.2
twenty four 1 ESI+; 284.2, 286.1
25(1) 1 ESI+; 284.1, 286.1
25(2) 1 ESI+; 284.I, 286.1
26 1 ESI+; 298.1, 300.1
27 1 ESI+; 282.2, 284.2
28 1 ESI+; 267.1, 269.1
29 1 ESI+; 270.1, 272.1
30 1 FAB; 254.0
31 1 FAB; 270.0
32 1 ESI+; 383.2, 385.2
33 1 FAB; 305.0
[Table 5-2]
PEx PSyn DAT
34 1 FAB; 277.0
35 1 ESI+; 284.1, 286.1
36 1 ESI+; 284.2, 286.2
37 1 ESI+; 321.3, 323.3
38 1 ESI+; 283.2, 285.2
39 1 ESI+; 293.0, 295.0
40 1 ESI+; 367.2, 369.2
41 1 ESI+; 369.3, 371.4
42 - ESI+; 168.3
43 - ESI+; 258.3
44 - ESI+; 294.3, 296.3, 298.3
45 - ESI+; 313.2
46 45 ESI+; 352.4
47 - ESI+; 450.3
48 - ESI+; 499.3
49 47 ESI+; 478.4
50 47 FAB; 503.6
51 47 ESI+; 434.3
52 47 ESI+; 470.3
53 47 ESI+; 499.2
54(1) 47 ESI+; 509.2
54(2) 47 ESI+; 509.2
55 47 ESI+; 515.2
56 47 ESI+; 445.3
57 47 ESI+; 472.3
58 47 ESI+; 436.3
59 47 ESI+; 424.4
60 47 ESI+; 523.3
61 47 ESI+; 493.5
62 47 ESI+; 495.5
63 - ESI+; 520.4
64 - ESI+; 378.2
65 - ESI+; 462.3
66 67 FAB; 236.9
67 - ESI+; 223.1, 225.1
[Table 5-3]
PEx PSyn DAT
68 69 FAB; 241.0
69 - ESI+; 227.1, 229.1
70 - ESI+; 281.0
71 70 ESI+; 295.0
72 - ESI+; 280.1, 282.1
73 - ESI+; 205.0, 207.0
74 - ESI+; 219.0, 221.0
75 73 ESI+; 304.1
76 - ESI - 259.0
77 - ESI+; 353.2 [M+Na]+
78 77 EI; 314.2
79 77 EI; 350.1
80 77 ESI+; 283.2 [M+Na]+
81 - ESI+; 245.0
82 81 EI; 302.0
83 - EI: 266.0
84 - CI; 282.9
85 - ESI+; 296.2, 298.2
86 - ESI+; 271.2
87 - ESI+; 182.1
88 - ESI+; 242.1
89 - ESI+; 153.0
90 - ESI+; 340.2
91 - ESI+; 251.2
92 - ESI+; 355.2
93 - ESI+; 487.2
94 - FAB; 364.1
95 94 FAB; 278.0
96 - FAB; 264.0
97 - FAB; 306.0
98 - CI; 229.1
99 - ESI+; 255.2
100 - ESI+; 284.1, 286.0
101 - ESI+; 409.3
102 - ESI+; 255.2
[Table 5-4]
[Table 5-5]
PEx PSyn DAT
107 72 ESI+; 281.1
108 1 ESI+; 286.1
109(1) 1 ESI+; 300.1, 302.1
109(2) 1 ESI+; 300.1, 302.1
110 1 ESI+; 324.2
111 1 ESI+; 357.0
112 1 ESI+; 369.2, 371.2
113 1 ESI+; 298.2, 300.2
114 - ESI+; 369.3
115 1 ESI+; 369.0
116 - ESI+; 286.1, 288.0
117 1 ESI+; 371.2, 373.3
118 1 <![CDATA[ESI+;377.3,379.3[M+Na]<sup>+</sup>]]>
119 1 ESI+; 270.1, 272.1
120 - ESI+; 270.1, 272.0
121 1 <![CDATA[ESI+;421.3, 423, 3[M+Na]<sup>+</sup>]]>
122 - <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm4.40(4H, s)]]>
123 44 <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm1.88(6H, s)4.25(2H, s)]]>
124 47 ESI+; 540.5
125 47 ESI+; 511.4
126 47 ESI+; 483.3
127 47 ESI+; 495.3
128(1) - ESI+; 537.4
128(2) - ESI+; 537.4
129 47 ESI+; 425.2
130 47 ESI+; 435.2
131 47 ESI+; 497.3
132 47 ESI+; 481.4
133 47 ESI+; 422.3
134 - ESI+; 422.3
135 47 ESI+; 525.1
136 64 -
137 64 ESI+; 395.2
138 64 ESI+; 397.2
139 64 ESI+; 381.3
[Table 5-6]
[Table 5-7]
[Table 6-1]
[Table 6-2]
Ex Syn DAT
6 1 ESI+; 298.1
7 1 FAB; 314.3
8 1 ESI+; 406.3
9 1 ESI+; 511.2
10 1 ESI+; 439.3
11 1 ESI+; 410.3
12 1 ESI+; 390.3
13 1 ESI+; 390.4
14 1 ESI+; 390.3
15 1 ESI+; 404.2
16(1) 1 FAB; 365.1
16(2) 1 FAB; 365.0
17 1 ESI+; 368.1
18 1 ESI+; 354.2
19 1 ESI+; 394.3
20 1 FAB; 367.2
twenty one 1 ESI+; 368.2
twenty two 1 ESI+; 353.2
twenty three 1 FAB; 445.2
twenty four 1 FAB; 394.2
25 1 ESI+; 374.2, 376.1
26 1 ESI+; 354.2
27 1 ESI+; 424.2
28 1 ESI+; 370.3
29 1 ESI+; 394.2
30 1 ESI+; 360.2, 362.1
31 1 ESI+; 340.2
32 1 ESI+; 410.2
33 1 ESI+; 356.2
34 1 ESI+; 422.3
35 1 ESI+; 410.2
36 I ESI+; 356.2
[Table 6-3]
Ex Syn DAT
37 1 ESI+; 426.2
38 1 ESI+; 372.2
39 1 ESI+; 376.2, 378.2
40 1 ESI+; 406.3
41 1 ESI+; 410.3
42 1 ESI+; 410.2
43 1 ESI+; 438.3
44 1 ESI+; 424.2
45 1 ESI+; 440.2
46 1 ESI+; 370.3
47 1 ESI+; 384.3
48 1 ESI+; 408.2
49 1 ESI+; 386.3
50 1 ESI+; 393.2
51 1 ESI+; 380.3
52(1) 1 ESI+; 382.3
52(2) 1 ESI+; 382.3
53 1 ESI+; 422.3
54 1 ESI+; 438.2
55 1 ESI+; 368.3
56(1) 1 ESI+; 396.2
56(2) 1 ESI+; 396.2
57(1) 1 ESI+; 412.2
57(2) 1 ESI+; 412.2
58 1 ESI+; 384.3
59 1 FAB; 380.4
60 1 ESI+; 395.8
61 1 ESI+; 342.2
[Table 6-4]
[Table 6-5]
[Table 6-6]
[Table 6-7]
[Table 6-8]
Industrial applicability
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and are expected to be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Cyclopyridazine compounds
Technical Field
This invention relates to cyclopyridazine compounds or salts thereof that have NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Background Technology
Inflammasomes are collections of intracellular proteins triggered by intrinsic/extrinsic alarm molecules. They are mechanisms that exacerbate inflammatory responses induced by the cleavage of inflammatory cytokines IL-1β and IL-18, or by the induction of cell death, through caspase 1 activation. Several types of alarm molecules are known to recognize alarm molecules, including NLRP1, NLRP3, NLRC4, and AIM2. NLRP3 is activated upon recognizing extracellular ATP molecules, pathogen toxins, uric acid or cholesterol crystals, and abnormal protein aggregates, all of which trigger cellular stress.
As diseases caused by gain-of-function variations in NLRP3, Cryopyrin-associated periodic syndrome (CAPS) is known (Nature Genetics, Vol. 29, No. 3, pp. 301-305, 2001). Additionally, it has been reported in gout (Arthritis Research and Therapy, Vol. 12, No. 2, Article No. 206, 2010), non-alcoholic steatohepatitis (Journal of Molecular Medicine, Vol. 92, No. 10, pp. 1069-1082, 2014), inflammatory bowel disease (Gut, Vol. 59, No. 9, pp. 1192-1100, 2010), and Alzheimer's disease (Nature, Vol. 493, No. 7434, pp. 674-678). Increased activation or expression of the NLRP3 inflammasome is observed in a wide variety of diseases, including Parkinson's disease (PLoS ONE, Vol. 8, No. 1, Article No. e55375, 2013), amyotrophic lateral sclerosis (ALS, Vol. 41, No. 1, pp. 93-103, 2018), and multiple system atrophy (Journal of Neuropathology and Extrinsic Neurology, Vol. 77, No. 11, pp. 1055-1065, 2018).
In addition, NLRP3 is known to be activated by α-synuclein filaments to promote the production of IL-1β from microglia; and functional improvement has been observed by administration of NLRP3 inhibitors in a mouse model of α-synuclein filament-induced α-synucleinopathy (Science Translational Medicine, Vol. 10, Article No. eaah4066, 2018).
Patent document 1 describes a compound represented by the following formula that has inhibitory activity on the NLRP3 inflammasome pathway ( R3 and R4 are H, cyano, C1-4 alkyl, or halo- C1-4 alkyl. Other notations in the formula refer to this publication).
[Chemical Formula 1]
Patent document 2 published after the priority date of this application describes a compound represented by the following formula that has an inhibitory effect on NLRP3 inflammasome activation (the notation in the formula is based on that publication).
[Chemical Formula 2]
Patent document 3 published after the priority date of this application describes a compound represented by the following formula that has NLRP3 inhibitory effects (the notations in the formula refer to that publication).
[Chemical Formula 3]
Patent document 4 describes a compound represented by the following formula that has NLRP3 inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 4]
Patent document 5 describes a compound represented by the following formula that has an NLRP1/3 regulating effect (refer to the notation in the formula in this publication).
[Chemical Formula 5]
Patent document 6 describes a compound represented by the following formula that has inhibitory effects on NLRP3 inflammasomes (the notation in the formula is based on that publication).
[Chemical Formula 6]
Patent document 7 describes a compound represented by the following formula that has C5a receptor inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 7]
Patent document 8 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 8]
Patent document 9 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 9]
Patent document 10 describes a compound represented by the following formula that has muscarinic M4 receptor antagonistic activity (the notation in the formula is the same as that in the publication).
[Chemical Formula 10]
Existing technical documents
Patent documents
Patent Document 1: International Publication No. 2020/234715
Patent Document 2: International Publication No. 2021/193897
Patent Document 3: US Patent No. 11,319,319
Patent Document 4: International Publication No. 2019/008025
Patent Document 5: International Publication No. 2017/184604
Patent Document 6: International Publication No. 2018/015445
Patent Document 7: International Publication No. 2006/004589
Patent Document 8: International Publication No. 2014/191737
Patent Document 9: International Publication No. 2015/001348
Patent Document 10: International Publication No. 2021/067696
Summary of the Invention
The problem that the invention aims to solve
Compounds that provide NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions, particularly for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Methods for solving problems
The inventors conducted in-depth research on compounds with NLRP3 inflammasome activation inhibition activity and found that cyclopyridazine compounds have NLRP3 inflammasome activation inhibition activity, and are expected to be used as effective ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, thus completing the present invention.
That is, the present invention relates to compounds of formula (I) or salts thereof, and pharmaceutical compositions containing compounds of formula (I) or salts thereof and one or more excipients.
[Chemical Formula 11]
(in the formula,
Ring A is a C5-8 cycloalkenyl group, a 5-11 member partially unsaturated heterocyclic group, an aryl group, or a heteroaryl group;
R1 may be the same or different from each other, and may be OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, -C1-6 alkylene-aryl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halogenated C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -, -O -, or -CR 4 R 5 -;
R3 is H or C1-6 alkyl;
R4 and R5 are the same or different from each other, and are H or C1-6 alkyl;
R6 is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a -C1-6 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a -C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups;
R7 is -OR 12 , -NR 13 , R 14 , halogen, or cyano;
R8 and R10 are C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen , or cyano;
R9 and R11 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene -NR13R14, halogen, cyano, oxo, -C(O)-C1-6 alkyl , or -S (O) 2 - C1-6 alkyl;
R 12 is H or C 1-6 alkyl;
R13 and R14 may be the same or different from each other, and may be H, C1-6 alkyl or -C(O) -C1-6 alkyl;
n is an integer from 1 to 4, representing the number of R1s used as substituents;
m is an integer from 0 to 3, representing the number of R2 substituents;
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia).
[Chemical Formula 12]
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
k is an integer from 0 to 3, representing the number of R 1a substituents.
It should be noted that, unless otherwise specified, if a symbol used in one chemical formula in this specification is also used in other chemical formulas, the same symbol has the same meaning.
Furthermore, the present invention relates to pharmaceutical compositions containing a compound of formula (I) or a salt thereof and one or more pharmaceutically permissible excipients, particularly pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases. It should be noted that the pharmaceutical composition comprises a preventive and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases containing a compound of formula (I) or a salt thereof.
In addition, the present invention relates to compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation; compounds of formula (I) or salts thereof used as inhibitors of NLRP3 inflammasome activation; NLRP3 inflammasome activation inhibitors containing compounds of formula (I) or salts thereof; pharmaceutical compositions containing compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation and one or more pharmaceutically permissible excipients; use of compounds of formula (I) or salts thereof in the manufacture of medicaments or pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; use of compounds of formula (I) or salts thereof for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; compounds of formula (I) or salts thereof used in the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; and methods for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, including applying an effective amount of a compound of formula (I) or salts thereof to a subject. It should be noted that "object" refers to a person or other animal that needs the prevention and/or treatment, and in a certain way, it refers to a person who needs the prevention and/or treatment.
The effects of the invention
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and can be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Detailed Implementation
The present invention will now be described in detail.
In this specification, unless otherwise specified, the following terms have the meanings indicated below. The definitions below are for clarification and not for limitation. Here, where a term is not specifically defined, it is used in the sense commonly accepted by those skilled in the art.
In this specification, " C1-6 alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms (hereinafter abbreviated as C1-6 ), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,3-dimethylbutyl, 1-ethyl-2-methylpropyl, etc. Alternatively, it may be a straight-chain or branched C1-4 alkyl group; alternatively, it may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl; alternatively, it may be methyl, ethyl, n-propyl, n-butyl, or isobutyl; further alternatively, it may be n-propyl, n-butyl, or isobutyl. Alternatively, it is methyl, ethyl, n-propyl or isopropyl; in one way, it is methyl or ethyl; in another way, it is ethyl; further in another way, it is methyl.
" C1-6 alkylene" is a straight-chain or branched C1-6 divalent saturated hydrocarbon group, such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 2-methyltrimethylene, ethylethylene, 1,2-dimethylethylene, or 1,1,2,2-tetramethylethylene. In one form, it is C1-4 alkylene; in another form, it is methylene or ethylene; further in another form, it is ethylene; and in yet another form, it is methylene.
"C 3-8 cycloalkyl" refers to a C 3-8 saturated hydrocarbon cycloalloy that can be bridged or form a spirocyclic ring. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[3.3.0]octyl, bicyclo[2.2.2]octyl, spiro[2.2]pentyl, spiro[3.3]heptyl, or spiro[2.5]octyl. As one mode, it is a C3-6 saturated hydrocarbon cycloyl group; as another mode, it is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; further as another mode, it is cyclopropyl; as yet another mode, it is cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; as one mode, it is cyclobutyl, cyclopentyl, or cyclohexyl; further as another mode, it is cyclobutyl or cyclohexyl; further as yet another mode, it is cyclobutyl; as yet another mode, it is cyclopentyl; and further as yet another mode, it is cyclohexyl.
"C 5-8 cycloalkenyl" is a C 5-8 hydrocarbon cycloalkenyl group with a single double bond within the molecule, which can be bridged. Examples include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]heptenyl, and bicyclo[2.2.2]octenyl. As one form, it is cyclopentenyl, cyclohexenyl, cycloheptenyl, and bicyclo[2.2.2]octenyl; further as another form, it is cyclopentenyl, cyclohexenyl, and cycloheptenyl; further as yet another form, it is cyclopentenyl; another form, it is cyclohexenyl; and yet another form, it is cycloheptenyl.
When ring A is a C5-8 cycloalkenyl group, [Chemical Formula 13-1] is a partial structure of formulas (I) and (Ia).
(The wavy lines represent the bonding portions with the phenyl and L in formula (I), respectively. The same applies below.)
The C5-8 cycloalkenyl group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 13-2]
"4- to 7-membered saturated heterocyclic groups" refer to 4- to 7-membered saturated hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms, as ring constituent atoms. Examples include oxohexacyclobutyl, azirhexacyclobutyl, thiohexacyclobutyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiopheneyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopheneyl, oxoheptanyl, azirheptanyl, thioheptanyl, dioxoheptanyl, imidazoalkyl, pyrazolyl, dithioheptanyl, oxazolyl, isoxazolyl, thiazoalkyl, isothiazolyl, dioxohexyl, piperazine, dithiohexyl, morpholinyl, thiomorpholinyl, oxathioheptanyl, dioxathioheptanyl, diazirheptanyl, dithioheptanyl, oxaazonyl, thioazonyl, and oxathioheptanyl, but not limited to these. As one embodiment, it is oxetyl, tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, piperidinyl, or tetrahydrothiaranyl; as another embodiment, it is tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is tetrahydropyranyl or piperidinyl; as yet another embodiment, it is tetrahydrofuranyl or tetrahydropyranyl; as yet another embodiment, it is tetrahydrofuranyl; as yet another embodiment, it is tetrahydropyranyl. As another embodiment, it is pyrrolyl or piperidinyl; as yet another embodiment, it is pyrrolyl; as yet another embodiment, it is piperidinyl. As yet another embodiment, it is oxetyl.
"5- to 11-membered partially unsaturated heterocyclic groups" are 5- to 11-membered hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms as ring-forming atoms, and possessing a single double bond within the molecule. They can also exhibit bridging or form spirocyclic rings. Examples include dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydronitroheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydrooxoheptenyl, tetrahydrothioheptenyl, dioxopentenyl, dihydroimidazoyl, dihydropyrazolyl, dithioheptenyl, dihydrooxazolyl, dihydroisooxazolyl, dihydrothiazoyl, dihydroisothiazoyl, and dihydrodioxoheptenyl. Hexenyl, tetrahydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazocyclohexenyl, dihydrodioxazocycloheptenyl, tetrahydrodiazacycloheptenyl, dihydrodithiocycloheptenyl, tetrahydrooxazocycloheptenyl, tetrahydrothiazazacycloheptenyl, dihydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl, 2-oxaspiro[4.5]decenyl, 3-oxaspiro[5.5]undecenyl, but not limited thereto. As one embodiment, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, dihydrothiaranyl, tetrahydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl. In one manner, it is a 5- to 8-membered partially unsaturated heterocyclic group; in another manner, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydroazaheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydroazaheptenyl, tetrahydrothioheptenyl, dioxazol ... Dihydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl; as one embodiment, it is dihydropyrroleyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl; further as another embodiment, it is dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl. As another form, it is dihydrofuranyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxoheptenyl; as another form, it is dihydrofuranyl, dihydropyranyl, tetrahydrooxoheptenyl or 2-oxaspiro[3.5]nonenyl; as another form, it is dihydropyranyl; further as another form, it is tetrahydropyridyl; and as yet another form, it is tetrahydrooxoheptenyl.
When ring A is a 5- to 11-membered partially unsaturated heterocyclic group, as part of the structures of formulas (I) and (Ia)
[Chemical Formula 14-1]
middle,
The 5- to 11-membered partially unsaturated heterocyclic group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 14-2]
"Aryl" is a C6-14 monocyclic to tricyclic aromatic hydrocarbon cyclic group, including bicyclic to tricyclic aromatic hydrocarbon cyclic groups formed by the condensation of its double bond with a C5-8 cyclic alkene. Examples include phenyl, naphthyl, tetrahydronaphthyl, indene, fluorenyl, etc., with phenyl being one example.
When ring A is aryl, as part of the structure of formulas (I) and (Ia)
[Chemical Formula 15-1]
middle,
The aryl benzene ring condenses with the pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 15-2]
"Heteroaryl" refers to a 5- to 6-membered aromatic hydrocarbon cyclic group containing 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen. Examples include pyrrole, furanyl, thiophene, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and tetraazinyl. In one form, it is thiophene or pyridinyl; further, in another form, it is pyridinyl; and still another form, it is thiophene.
When ring A is a heteroaryl group, [Chemical Formula 16-1] is a partial structure of formulas (I) and (Ia).
middle,
The heteroaryl group condenses with a pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 16-2]
"Halogen" refers to F, Cl, Br, or I. In one sense, it is F or Cl; further, in another sense, it is F; in yet another sense, it is Cl.
"Halogenated C1-6 alkyl" refers to a straight-chain or branched C1-6 alkyl group substituted with one or more halogens. Examples include: trifluoromethyl, trifluoroethyl, trifluoropropyl, 2-fluoro-2-methylpropyl, difluoromethyl, difluoroethyl, fluoromethyl, or chloromethyl. In one manner, it is difluoroethyl, trifluoromethyl, or difluoromethyl; further, it is trifluoromethyl or difluoromethyl; in another manner, it is trifluoromethyl; and in yet another manner, it is difluoromethyl.
In this specification, "substitutable" means unsubstituted or "substituted by one or more substituents". The substitution can be at any position, as long as the hydrogen is normally present in the group.
Even if the combination is not specifically recorded, one or more methods can be combined with another method.
In this specification, "inflammatory disease and/or neurodegenerative disease" is, in one sense, an inflammatory disease and a neurodegenerative disease; further, it is an inflammatory disease; and in another sense, it is a neurodegenerative disease.
In this specification, "inflammatory disease" includes, but is not limited to, autoinflammatory diseases such as Cryopyrin-associated periodic fever syndrome (CAPS), gout, and pseudogout; and diseases such as non-alcoholic steatohepatitis (NASH). As one mode, it is an autoinflammatory disease; as another, it is CAPS; and further, it is gout. It should be noted that "Cryopyrin-associated periodic fever syndrome (CAPS)" is a disease group comprised of familial cold urticaria (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multi-organ system inflammatory diseases/infantile chronic neurocutaneous joint syndrome (NOMID/CINCA syndrome).
In this specification, "neurodegenerative diseases" refers to a group of diseases including, but not limited to, alpha-synucleinopathies such as Parkinson's disease, multiple system atrophy, and Lewy body type dementia; Alzheimer's disease; amyotrophic lateral sclerosis (ALS); and multiple sclerosis. One example is Alzheimer's disease, multiple sclerosis, and ALS; another example is multiple sclerosis. Another example is alpha-synucleinopathies; another example is Parkinson's disease; yet another example is multiple system atrophy; and yet another example is Lewy body type dementia.
In this specification, "treatment" includes both "treatment for therapeutic purposes" and "treatment for preventative purposes." "Treatment for therapeutic purposes" refers to alleviating symptoms, altering disease course, or prolonging lifespan, while "treatment for preventative purposes" refers to reducing the likelihood of developing the disease in subjects at risk. "Subjects at risk" refers to individuals with known risk factors who are more susceptible to the disease than the general population.
The compound of formula (I) or a salt thereof in this invention is shown in one of the following ways.
(1-1) Compounds of formula (I) or their salts (n and m represent the number of R1 and R2 as substituents, respectively. The same applies below).
[Chemical Formula 17]
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia) (k represents the number of R 1a as substituents. The same applies below).
[Chemical Formula 18]
(1-2) Compounds of formula (Ia) or their salts.
(1-3) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
[Chemical Formula 19]
(1-4) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
(1-5) Compounds of formula (Ib), (Ic), (Id), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iv), (Iw), (Ix) or (Iy) or their salts.
(1-6) Compounds of formula (Ic), (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-7) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq) or (Ir) or salts thereof.
(1-8) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or their salts.
(1-9) Compounds of formula (Ib), (Ic), (Id) or (Ie) or their salts.
Compounds of formula (Ib) (1-10) or their salts.
Compounds of formula (Ic) or their salts thereof.
Compounds of formula (Id) (1-12) or their salts.
(1-13) A compound of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or a salt thereof.
(1-14) Compounds of formula (If), (Ig), (Ih), (Ii) or (Ij) or their salts.
(1-15) Compounds of formula (Ig), (Ih) or (Ij) or their salts.
Compounds of formula (Ig) (1-16) or their salts.
Compounds of formula (Ih) or their salts thereof.
Compounds of formula (Ij) or their salts. (1-18)
(1-19) Compounds of formula (Ik), (Im) or (In) or their salts.
Compounds of formula (Ik) or their salts thereof.
Compounds of formula (Im) or their salts thereof.
(1-22) Compounds of formula (In) or their salts.
(1-23) Compounds of formula (Io), (Ip), (Iq) or (Ir) or their salts.
Compounds of formula (Io) or their salts thereof.
Compounds of formula (Ip) (1-25) or their salts.
Compounds of formula (Iq) (1-26) or their salts.
Compounds of formula (Ir) or their salts thereof.
(1-28) Compounds of formula (Ic), (Ig), (Ih), (Ij) or (Im) or their salts.
(1-29) Compounds of formula (Ic), (Ih), (Ij) or (Im) or their salts.
(1-30) Compounds of formula (Ic) or formula (Ih) or their salts.
Compounds of formula (Ix) or their salts thereof. (1-31)
Compounds of formula (Iy) or their salts. (1-32)
(1-33) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy).
(1-34) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iu), (Iv), (Iw) or (Iy).
(1-35) Compounds of formula (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-36) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iv), (Iw) or (Iy).
(2-1) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-2) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 8-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-3) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-8 partially unsaturated heterocyclic group.
(2-4) Compounds with ring A being C5-8 cycloalkenyl or their salts.
(2-5) Compounds or their salts in which ring A is a 5- to 8-membered partially unsaturated heterocyclic group.
(2-6) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl, and k is an integer from 0 to 2.
(2-7) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-11 partially unsaturated heterocyclic group.
(2-8) Compounds in which ring A is aryl or heteroaryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-9) Compounds in which ring A is aryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-10) Compounds in which ring A is a heteroaryl group or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-11) Compounds or their salts in which ring A is a partially unsaturated heterocyclic group of 5 to 11 members.
(3-1) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo -C1-6 alkyl, or -OC3-8 cycloalkyl.
(3-2) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halo- C1-6 alkyl.
(4-1) R 1a are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl.
(4-2) R 1a are the same or different from each other, and are compounds of C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl or salts thereof.
(4-3) R 1a are the same or different from each other, and are compounds of halo- C1-6 alkyl, halogen, or -O-halo- C1-6 alkyl or salts thereof.
(4-4) R 1a is a halo- C1-6 alkyl compound or a salt thereof.
(4-5) R 1a is a halogen compound or its salt.
(4-6)R 1a is a compound of -O-halogenated C1-6 alkyl or a salt thereof.
(4-7) R 1a is a compound of C 1-6 alkyl or a salt thereof.
(4-8)R 1a is a compound of C 3-8 cycloalkyl or a salt thereof.
(4-9) R 1a is a compound of -OC 1-6 alkyl or a salt thereof.
(5-1) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-2) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-3) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-4) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C 1-6 alkylene-aryl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-5) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-6) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-7) R2 is a compound of C1-6 alkyl groups or a salt thereof.
(5-8)R 2 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(5-9)R 2 is a compound of -S(O) 2 -C 1-6 alkyl or a salt thereof.
(5-10) R2 is an oxolated compound or its salt.
(6-1)L is a compound of -NR 3- , -O- or -CR 4R 5- or a salt thereof.
(6-2)L is a compound of -NR 3- or -O- or its salt.
(6-3)L is a compound of -NR 3- or its salt.
(6-4)L is a compound of -O- or its salt.
(6-5)L is a compound of -CR4R5- or its salt.
(7-1) R 3 is a compound of H or C 1-6 alkyl or a salt thereof.
(7-2) R 3 is a compound of H or its salt.
(7-3) R 3 is a C1-6 alkyl compound or a salt thereof.
(8-1) R4 and R5 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(8-2) R4 and R5 are both compounds of H or their salts.
(8-3) R4 and R5 are both C1-6 alkyl compounds or their salts.
(9-1) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a C1-6 alkylene group ( a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups.
(9-2) R6 is a compound or a salt thereof consisting of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups), -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups), a C3- to 8-membered cycloalkyl group that may be substituted by 1 to 4 identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R11 groups.
(9-3) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with one R7 , a -C1-6 alkylene group (a C3-8 cycloalkyl group that may be substituted with one R8 ), a -C1-6 alkylene group (a 4- to 7-membered saturated heterocyclic group), a C3-8 cycloalkyl group that may be substituted with one or two identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted with one or two identical or different R11 groups .
(9-4) R6 is a compound or a salt thereof that can be substituted by 1 to 4 identical or different R10s of a C3-8 cycloalkyl group or a 4- to 7-membered saturated heterocyclic group that can be substituted by 1 to 4 identical or different R11s .
(9-5) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 4 identical or different R7s .
(9-6) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 3 identical or different R7s .
(9-7) R6 is a compound of C1-6 alkyl group or a salt thereof that is substituted with 1 to 2 identical or different R7 groups .
(9-8) R6 is a compound of a C1-6 alkyl group substituted with one R7 or a salt thereof.
(9-9) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups ) or a salt thereof.
(9-10) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 3 identical or different R8 groups ) or a salt thereof.
(9-11) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 2 identical or different R8 groups ) or a salt thereof.
(9-12) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by one R8 ) or a salt thereof.
(9-13) R 6 is a compound of -C 1-6 alkylene-C 3-8 cycloalkyl or a salt thereof.
(9-14) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups ) or a salt thereof.
(9-15) R6 is a compound or a salt thereof of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 3 identical or different R9 groups).
(9-16) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 2 identical or different R9 groups ) or a salt thereof.
(9-17) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by one R9 ) or a salt thereof.
(9-18) R 6 is a compound of -C 1-6 alkylene-(4-7 membered saturated heterocyclic group) or a salt thereof.
(9-19) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R10s of C3-8 cycloalkyl groups.
(9-20) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R10s of C3-8 cycloalkyl groups.
(9-21) R6 is a compound or a salt thereof that can be substituted by one or two identical or different R10s of a C3-8 cycloalkyl group.
(9-22) R6 is a compound of C3-8 cycloalkyl group or a salt thereof that can be replaced by one R10 .
(9-23) R6 is a compound of C3-8 cycloalkyl or a salt thereof.
(9-24) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-25) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-26) R6 is a compound or a salt thereof that can be replaced by 1 to 2 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-27) R6 is a compound or a salt thereof that can be replaced by a 4- to 7-membered saturated heterocyclic group of one R11 .
(9-28) R6 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(9-29) R6 is a C1-6 alkyl group substituted with one R7 , a C3-8 cycloalkyl group substituted with one or two identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with one or two identical or different R11 groups, or a salt thereof.
(9-30) R6 is a compound or a salt thereof that can be substituted by 1 to 2 identical or different R10s , or by 1 to 2 identical or different R11s , of a C3-8 cycloalkyl group.
(9-31) R6 is a compound or a salt thereof that can be replaced by a C3-8 cycloalkyl group that is substituted by one R10 or by a 4-7 member saturated heterocyclic group that is substituted by one R11 .
(10-1) R 7 is a compound of -OR 12 , -NR 13 , R 14 , halogen or cyano, or a salt thereof.
(10-2) R 7 is a compound of -OR 12 or -NR 13 R 14 or a salt thereof.
(10-3)R 7 is a compound of -OR 12 or a salt thereof.
(10-4)R 7 is a compound of -NR 13 R 14 or a salt thereof.
(10-5)R 7 is a halogen compound or a salt thereof.
(10-6)R 7 is a cyano compound or a salt thereof.
(11-1) R8 is a C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen or cyano compound or salt thereof.
(11-2) R8 is a compound of -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 or a salt thereof.
(11-3) R8 is a compound of C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , halogen, or cyano, or a salt thereof .
(11-4) R8 is a compound of -OR12 , -C1-6 alkylene- OR12 or a salt thereof.
(11-5) R 8 is a compound of -OR 12 or a salt thereof.
(11-6)R 8 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(12-1) R 9 is a compound of C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl or a salt thereof.
(12-2) R 9 is a compound or a salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(13-1) R 10 is a compound of C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, or cyano, or a salt thereof.
(13-2) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , halogen or cyano, or a salt thereof.
(13-3) R 10 is a C 1-6 alkyl compound or a -OR 12 compound or a salt thereof.
(13-4) R 10 is a compound of C1-6 alkyl groups or a salt thereof.
(13-5) R 10 is a compound of -OR 12 or a salt thereof.
(13-6) R 10 is a compound of -NR 13 R 14 or a salt thereof.
(13-7) R 10 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(13-8) R 10 is a halogen compound or a salt thereof.
(13-9) R 10 is a cyano compound or a salt thereof.
(13-10)R 10 is a compound of C1-6 alkyl, -OR 12 , -NR 13 R 14 , or cyano groups or a salt thereof.
(13-11) R 10 is a compound of C 1-6 alkyl, -OR 12 , or cyano groups or a salt thereof.
(13-12) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , or cyano, or a salt thereof.
(14-1) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or a salt thereof.
(14-2) R 11 is a compound or salt thereof of C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O)-C 1-6 alkyl.
(14-3) R 11 is a compound of C1-6 alkyl groups or a salt thereof.
(14-4)R 11 is a compound of C3-8 cycloalkyl or a salt thereof.
(14-5) R 11 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(14-6) R 11 is a compound of -OR 12 or a salt thereof.
(14-7) R 11 is an oxolated compound or its salt.
(14-8)R 11 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(14-9) R 11 is a compound or salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 member saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(14-10) R 11 is a compound of C 1-6 alkyl or -OR 12 or a salt thereof.
(14-11) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, -OR 12 , or -C(O)-C 1-6 alkyl or a salt thereof.
(15-1) R 12 is a compound of H or C 1-6 alkyl or a salt thereof.
(15-2) R 12 is a compound of H or its salt.
(15-3) R 12 is a compound of C1-6 alkyl groups or a salt thereof.
(16-1) R13 and R14 are the same or different from each other, and are compounds of H, C1-6 alkyl or -C(O) -C1-6 alkyl or salts thereof.
(16-2) R13 and R14 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(16-3) R13 and R14 are both compounds of H or their salts.
(16-4) A compound in which both R13 and R14 are H or salts thereof, or a compound in which R13 is -C(O) -C1-6 alkyl and R14 is H or salts thereof.
(16-5) R 13 is a -C(O)-C 1-6 alkyl compound, R 14 is H, or a salt thereof.
(17-1) n is an integer from 1 to 4, or a salt thereof.
(17-2) n is an integer from 1 to 3, or a salt thereof.
(17-3) A compound or its salt in which n is 1 or 2.
(17-4) Compounds or their salts in which n is 2.
(17-5) Compounds or their salts in which n is 1.
(18-1) m is an integer from 0 to 3, or a salt thereof.
(18-2)m is an integer from 0 to 2, which is a compound or its salt.
(18-3)A compound or its salt in which m is 0 or 1.
(18-4) Compounds or their salts with m = 1.
(18-5) Compounds or their salts where m is 0.
(19-1)k is an integer from 0 to 3, which is a compound or its salt.
(19-2)k is an integer from 0 to 2, which is a compound or its salt.
(19-3) Compounds or their salts in which k is 0 or 1.
(19-4) Compounds or their salts in which k is 1.
(19-5) Compounds or their salts in which k is 0.
(19-6)k is a compound or its salt where k is 1 or 2.
(20) A compound or its salt that is a combination of two or more groups described in (1-1) to (19-6) above without contradiction. Examples of such combinations are as follows, but not limited thereto.
(20-1) Compounds or salts thereof that are combinations of (1-1), (2-2), (3-1), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (17-1), (18-1), and (19-1).
(20-2) Compounds or salts thereof that are combinations of (1-2), (2-2), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-3) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-4) Compounds or salts thereof that are combinations of (1-2), (2-6), (4-2), (5-5), (6-1), (7-2), (8-2), (9-3), (10-2), (11-3), (12-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-5) Compounds or salts thereof that are combinations of (1-2), (2-7), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-6) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-3), (5-7), (6-3), (7-2), (9-30), (13-3), (14-10), (15-2), (18-3), and (19-6).
(20-7) Compounds or salts thereof that are combinations of (1-2), (2-11), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-8) Compounds or salts thereof that are combinations of (1-34), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-10), (15-2), (16-4), (18-5), and (19-2).
(20-9) Compounds or salts thereof that are combinations of (1-17), (4-2), (6-3), (7-2), (9-29), (10-2), (13-11), (14-10), (15-2), (16-5), (18-5), and (19-2).
(20-10) Compounds or salts thereof that are combinations of (1-6), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-11) Compounds or salts thereof that are combinations of (1-35), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-12) Compounds or salts thereof that are combinations of (1-7), (4-2), (5-4), (6-1), (7-2), (8-2), (9-3), (10-2), (11-4), (13-2), (14-2), (15-2), (16-4), (18-3), and (19-2).
(20-13) Compounds or salts thereof that are combinations of (1-28), (4-3), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-3), and (19-4) above.
(20-14) Compounds or salts thereof that are combinations of (1-11), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-15) Compounds or salts thereof that are combinations of (1-17), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-16) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-17) Compounds or salts thereof that are combinations of (1-11), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-18) Compounds or salts thereof that are combinations of (1-21), (4-4), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-4), and (19-4) above.
(20-19) Compounds or salts thereof that are combinations of (1-18), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-20) Compounds or salts thereof that are combinations of (1-17), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-21) Compounds or salts thereof that are combinations of (1-16), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-22) Compounds or salts thereof that are combinations of (1-16), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-23) Compounds or salts thereof that are combinations of (1-16), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-24) Compounds or salts thereof that are combinations of (1-31), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-25) Compounds or salts thereof that are combinations of (1-32), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-26) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-27), (14-3), (18-5), and (19-4) above.
Examples of specific compounds included in this invention include compounds selected from the group consisting of compounds or salts thereof.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5)-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
Examples of specific compounds included in this invention include the following group of compounds.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
In addition, the following group of compounds can be listed as one example of specific compounds included in the present invention.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
Depending on the type of substituent, compounds of formula (I) may contain tautomers or geometric isomers. In this specification, compounds of formula (I) or their salts are sometimes described as only one form of isomer, but the present invention also includes other isomers, as well as substances obtained by isomer separation, or mixtures thereof.
Furthermore, in cases where the compound of formula (I) or its salt has an asymmetric center or axial asymmetry, enantiomers (optical isomers) based thereon may exist. The compound of formula (I) or its salt also includes any of the separated enantiomers such as (R) bodies, (S) bodies, etc., and mixtures thereof (including racemic or non-racemic mixtures). In one manner, the enantiomer is "stereochemically pure." "Stereochemically pure" means a purity that can be recognized by a person skilled in the art as substantially stereochemically pure. Alternatively, the enantiomer is a compound having a stereochemical purity of, for example, 90% ee (enantiomeric excess) or more, 95% ee or more, 98% ee or more, or 99% ee or more.
Furthermore, the present invention also includes pharmaceutically permissible prodrugs of compounds represented by formula (I). A pharmaceutically permissible prodrug is a compound having groups that can be converted to amino, hydroxyl, carboxyl, or other groups by solvent decomposition or under physiological conditions. Examples of groups forming prodrugs include those described in Prog. Med., 5, 2157-2161 (1985), or in "Development of Pharmaceuticals" (Hirokawa Shoten, 1990), Vol. 7, Molecular Design, pp. 163-198.
Furthermore, salts of compounds of formula (I) are pharmaceutically permissible salts of compounds of formula (I). Depending on the type of substituent, they may sometimes form acid addition salts or salts with bases. Specifically, examples include: acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; or with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, dibenzoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid; salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; and salts with organic bases such as methylamine, ethylamine, ethanolamine, lysine, and ornithine; and salts or ammonium salts with various amino acids and amino acid derivatives such as acetylleucine.
Furthermore, the present invention also includes various hydrates or solvates of compounds of formula (I) or salts thereof, as well as polymorphic substances.
Furthermore, this invention includes all pharmaceutically permissible compounds of formula (I) or salts thereof labeled with one or more radioactive or non-radioactive isotopes. Examples of suitable isotopes used in the isotopic labeling of the compounds of this invention include isotopes of hydrogen (e.g., 2H and 3H ), carbon (e.g., 11C , 13C , and 14C ), nitrogen (e.g., 13N and 15N ), oxygen (e.g., 15O , 17O , and 18O ), fluorine (e.g., 18F ), chlorine (e.g., 36Cl ), iodine (e.g., 123I and 125I ), phosphorus (e.g., 32P ), and sulfur (e.g., 35S ). The isotopically labeled compounds of this invention can be used for studies such as the tissue distribution of drugs and/or matrices. For example, radioactive isotopes such as tritium ( 3H ) and carbon-14 ( 14C ) are suitable for this purpose due to their ease of labeling and detection. Substitution with heavier isotopes, such as hydrogen replacing deuterium ( 2H ), can sometimes be therapeutically advantageous due to increased metabolic stability (e.g., increased in vivo half-life, reduced dosage, and fewer drug interactions). Substitution with positron-emitting isotopes ( ¹¹C , ¹⁸F , ¹⁵O , and ¹³N , etc.) can be used in positron emission tomography (PET) assays to test matrix receptor occupancy. The isotopically labeled compounds of the present invention can generally be manufactured by conventional methods known to those skilled in the art, or by using suitable isotopically labeled reagents instead of unlabeled reagents, and by employing the same preparation methods as in the examples or manufacturing examples. For example, by subjecting 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (the compound of manufacturing example 64) to a known [ 11 C] acetylation reaction (International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, Vol. 39, No. 4, pp. 287-290, 1988), a compound of example 81 in which the carbonyl carbon atom is substituted with 11 C can be obtained.
(Manufacturing method)
Compounds of formula (I) or their salts can be manufactured using various known synthetic methods based on their basic structure or the types of substituents. In this case, depending on the type of functional group, it is sometimes technically effective to replace that functional group with a suitable protecting group (a group that can be easily converted into that functional group) during the process from the starting material to the intermediate. Examples of such protecting groups include those described in "Greene's Protective Groups in Organic Synthesis" (4th edition, 2006) by Wuts (P.G.M. Wuts) and Greene (T.W. Greene), which can be appropriately selected based on their reaction conditions. In such methods, the desired compound can be obtained by introducing the protecting group, reacting, and then removing the protecting group as needed.
Furthermore, the prodrug of the compound of formula (I) can be manufactured by introducing specific groups during the process from the starting material to the intermediate, similar to the protecting group described above, or by further reacting the obtained compound of formula (I). The reaction can be carried out using methods known to those skilled in the art, such as conventional esterification, amidation, and dehydration.
The following describes representative methods for manufacturing compounds of formula (I). Each method can also be performed with reference to the appended references. It should be noted that the manufacturing methods of the present invention are not limited to the examples shown below.
The following abbreviations are sometimes used in this specification.
CN: Cyano, COMU: ({[(1-cyano-2-oxoethylidene)amino]oxy}-4-morpholinomethylene)dimethylammonium hexafluorophosphate, DMF: N,N-dimethylformamide, DMSO: dimethyl sulfoxide, DIPEA: N,N-diisopropylethylamine, EDC·HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide of hexafluorophosphate, HOBt: 1-hydroxybenzotriazole, NMP: 1-methylpyrrolidone-2-one, Me: Methyl, Oxone (registered trademark): potassium persulfate, Pd-118: [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloroisocyanurate, PdCl₂ ( PPh₃ ) ₂ PdCl₂ (dppf): [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, PdCl₂ (dppf)· CH₂Cl₂ : [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride·dichloromethane adduct, Pd₂ (dba) ₃ : (1E,4E)-1,5-diphenylpentan-1,4-dien-3-one/palladium (3:2), Pd( PPh₃ ) ₄ : tetrakis (triphenylphosphino)palladium, RuPhos Pd G₃: (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate, SPhos Pd G3: (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)methanesulfonic acid, TBS: tert-butyl(dimethyl)silyl, THF: tetrahydrofuran, Tf: trifluoromethanesulfonyl, TFA: trifluoroacetic acid, XPhos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, ODS: octadecylsilyl.
(First System)
[Chemical Formula 20]
( X1 is a halogen, Ra and Rb are both H, or Ra and Rb and the borate residues bonded to Ra and Rb form 4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane. The same applies below.)
(First step)
This step involves reacting a compound of formula (IIa) with compounds of formulas (IIIa) to (IIIc) to obtain a compound of formula (IV). The choice of steps 1 to 5 can be made depending on the type of L used as a linking group.
(Step 1-1)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIa) to obtain a compound of formula (IV) where L is -O-. In this reaction, equal amounts of the compound of formula (IIIa) and the compound of formula (IIIa), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0–190°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Examples of bases are not particularly limited and include sodium hydride, potassium tert-butoxide, sodium hydroxide, and potassium hydroxide. The presence of phase-transfer catalysts such as benzyltrimethylammonium chloride, tetrabutylammonium bromide, and 18-crown-6-ether can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-2)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in a solvent inert to the reaction or in the absence of a solvent, under cooling to reflux, preferably at 0°C to 220°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-3)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst, a ligand, and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, such as palladium acetate and Pd₂ (dba) ₃ . Examples of ligands are not particularly limited, such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, tri-tert-butylphosphine, and XPhos. Examples of bases are not particularly limited, such as tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, and potassium tert-butoxide. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
[literature]
Journal of the American Chemical Society, 127, pp4685-4696(2005)
(Step 1-4)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . This step consists of a first stage that converts a compound of formula (IIa) into a compound of formula (IIb), and a second stage that converts a compound of formula (IIb) into a compound of formula (IV).
(Phase 1)
In this reaction, the compound of formula (IIa) is reacted in hydroiodic acid in the presence of a metal iodide, under cooling to reflux, preferably at room temperature to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of the metal iodide used herein are not particularly limited, and include sodium iodide, potassium iodide, etc.
(Phase Two)
In this reaction, equal amounts of compounds of formula (IIb) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 190°C. Examples of catalysts used herein are not particularly limited, including copper iodide (I), copper oxide (I), copper bromide (I), copper chloride (I), and copper 2-thiophenecarboxylate (I). The presence of ligands such as proline and ethylenediamine is sometimes advantageous for facilitating the reaction. Examples of bases are not particularly limited, including tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, and N,N-diisopropylethylamine. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-5)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIc) to obtain a compound of formula (IV) where L is -CR4R5- . In this reaction, equal amounts of the compounds of formula (IIa) and ( IIIc ), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include copper iodide (I) and iron acetylacetone (III). Examples of solvents are not particularly limited, but include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Alternatively, this reaction can be carried out under microwave irradiation.
(Second Step)
This step involves reacting a compound of formula (IV) with a compound of formula (V) to obtain a compound of formula (I). In this reaction, equal amounts of the compounds of formula (IV) and (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 (dba) 3 , RuPhos Pd G3, SPhos Pd G3, Pd-118, etc. Examples of bases are not particularly limited and can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, potassium acetate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are also not particularly limited and can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation.
(Second system)
[Chemical Formula 21]
(R 6a is a C1-5 alkyl group substituted with 1 to 4 identical or different R 7 groups, a -C1-5 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R 8 groups), or a -C1-5 alkylene group (a 4- to 7-membered saturated heterocyclic group substituted with 1 to 4 identical or different R 9 groups). The same applies below.
This method is for preparing the following compound (Iz): in the compound of formula (I), L is -CR4R5- , R4 and R5 are both H, R6 is -CH2- (a C1-5 alkyl group substituted by 1 to 4 identical or different R7 groups), -CH2 - C1-5 alkylene- (a C3-8 cycloalkyl group substituted by 1 to 4 identical or different R8 groups), or -CH2 - C1-5 alkylene- (a 4- to 7-membered saturated heterocyclic group substituted by 1 to 4 identical or different R9 groups).
(First step)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIId) to obtain a compound of formula (VI). In this reaction, equal amounts of the compound of formula (IIa) and the compound of formula (IIId), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base, preferably a copper salt, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3 , etc. Examples of bases are not particularly limited, but can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, triethylamine, N,N-diisopropylethylamine, diisopropylamine, pyrrolidine, etc. Examples of copper salts include copper iodide (I). Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation. It should be noted that this reaction can also be carried out after the compound of formula (IIa) has been converted to the compound of formula (IIb) through the first stage reaction in the first step-4 described in the first preparation method.
[literature]
Chemical Reviews, 107, pp874-922(2007)
(Second Step)
This step involves the reduction of a compound of formula (VI) to obtain a compound of formula (IVa). In this reaction, the compound of formula (VI) is reacted in the presence of a catalyst, under a hydrogen atmosphere, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 50°C, typically with stirring for 0.1 hours to 5 days. Examples of catalysts used herein are not particularly limited, but include palladium supported on carbon, palladium hydroxide, platinum oxide, etc. Examples of solvents are not particularly limited, but include alcohols such as methanol, ethanol, and 2-propanol; water, ethyl acetate, acetic acid, and mixtures thereof.
(Step 3)
This step is the same as the second step of the first preparation method, involving the reaction of the compound of formula (IVa) with the compound of formula (V) to obtain the compound of formula (Iz).
(Third System)
[Chemical Formula 22]
( Rc represents a C1-6 alkyl group, and X2 represents a halogen or -OTf. The same applies below.)
This method is for preparing a compound (Iaa) in which L is -NR 3- in the compound of formula (I).
(First step)
This step involves the cyanidation reaction of the compound of formula (VII) to obtain the compound of formula (VIII). In this reaction, equal amounts of the compound of formula (VII) and a cyanide metal, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of cyanide metals used herein are not particularly limited and include zinc cyanide, copper cyanide, sodium cyanide, potassium cyanide, etc. Examples of catalysts are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 ( dba ) 3 , etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Second Step)
This step involves the reaction of the compound of formula (VIII) with ammonia to obtain the compound of formula (IX). In this reaction, the compound of formula (VIII) and ammonia are reacted in an inert solvent under cooling to reflux, preferably at 0°C to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited, and alcohols such as methanol, ethanol, and 2-propanol can be listed. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 3)
This step involves the reaction of a compound of formula (IX) with a compound of formula (IIIb) to obtain a compound of formula (X). In this reaction, equal amounts of the compounds of formula (IX) and (IIIb), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes be advantageous for facilitating the reaction. Alternatively, this reaction can also be carried out under microwave irradiation.
(Fourth step)
This step involves the reaction of a compound of formula (X) with hydrazine monohydrate to obtain compounds of formula (XIa) and/or formula (XIb). In this reaction, equal amounts of the compound of formula (X) and hydrazine monohydrate, or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 100°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include alcohols such as methanol, ethanol, and 2-propanol; acetonitrile, etc. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 5)
This step is the process of obtaining a compound of formula (IVb) from a compound of formula (XIa) or formula (XIb). The choice of steps 1 through 3 may be made depending on the starting material and the type of X2 .
(Step 5-1)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is -OTf. In this reaction, the compound of formula (XIa) and a trifluoromethanesulfonating agent are reacted in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of trifluoromethanesulfonating agents used herein are not particularly limited, and may include trifluoromethanesulfonic anhydride, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide, etc. Examples of bases are not particularly limited, and may include sodium hydride, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, etc. Examples of solvents, without particular limitation, include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof.
(Step 5-2)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is a halogen. In this reaction, the compound of formula (XIa) and the halogenating agent are placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 150°C, typically for 0.1 hours to 5 days. Examples of halogenating agents used herein are not particularly limited and include phosphorus oxychloride, phosphorus tribromooxychloride, thionyl chloride, etc. Examples of solvents are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; NMP, DMF, and mixtures thereof.
(Step 5-3)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIb) where X2 is a halogen. In this reaction, the compound of formula (XIb) and a diazotizing agent are reacted in the presence of a copper halide in a solvent inert to the reaction, under cooling to reflux, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of diazotizing agents used herein are not particularly limited, and include sodium nitrite, tert-butyl nitrite, etc. Examples of copper halides are not particularly limited, and include copper chloride (I), copper bromide (I), copper iodide (I), etc. Examples of solvents are not particularly limited, and include halogenated hydrocarbons such as dichloromethane and chloroform; acetonitrile, NMP, DMF, and mixtures thereof. The presence of hydrogen halides such as hydrochloric acid, hydrobromic acid, and hydroiodic acid can sometimes be advantageous in facilitating the reaction.
(Step Six)
This step involves reacting a compound of formula (IVb) with a compound of formula (V) to obtain a compound of formula (Iaa). In this reaction, equal amounts of the compound of formula (IVb) and the compound of formula (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3, RuPhosPdG3, etc. Examples of bases are not particularly limited, but include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Raw Material Synthesis-1)
[Chemical Formula 23]
( Rd represents tris( C1-6 )silyloxy or pyrrolidine-1-yl. The same applies below.)
This method involves reacting a compound of formula (XIII) with a compound of formula (XIV) to obtain a compound of formula (IIa) in which ring A is a C5-8 cycloalkenyl group or a partially unsaturated heterocyclic group of 5 to 11 members. In this reaction, equal amounts of the compounds of formula (XIII) and (XIV), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. The solvent used in this reaction is not particularly limited, and examples include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane and chloroform; and mixtures thereof.
(Raw Material Synthesis-2)
[Chemical Formula 24]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XV).
(First step)
This step involves the reaction of a compound of formula (XV) with hydrazine monohydrate to obtain a compound of formula (XVI). In this reaction, an excess of hydrazine monohydrate is used, and the mixture of hydrazine monohydrate and the compound of formula (XV) is stirred for 0.1 hours to 5 days in a solvent-free or solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 200°C. The solvent used in this reaction is not particularly limited, and examples include alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; acetonitrile, DMF, NMP, DMSO, and mixtures thereof.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XVI). In this reaction, the compound of formula (XVI) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, and hydrochloric acid, sulfuric acid, acetic acid, etc. are also included. Examples of solvents used in this reaction are not particularly limited, and alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol are also included; water, acetonitrile, DMF, NMP, DMSO, etc., and mixtures thereof are also included.
(Step 3)
This step involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa). In this reaction, an excess of chlorinating agent is used, and the mixture of the chlorinating agent and the compound of formula (XVII) is stirred for 0.1 hours to 5 days under cooling to reflux, preferably at room temperature to 200°C. Examples of chlorinating agents used herein are not particularly limited, and include phosphorus oxychloride, thionyl chloride, etc. The addition of a small amount of DMF is sometimes advantageous in facilitating the reaction.
(Raw Material Synthesis-3)
[Chemical Formula 25]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XVIII).
(First step)
This step involves the reaction of a compound of formula (XVIII) with tert-butyl hydrazine carbamate to obtain a compound of formula (XIX). In this reaction, equal amounts of the compound of formula (XVIII) and tert-butyl hydrazine carbamate, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a condensing agent and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of condensing agents used herein are not particularly limited and include HATU, EDC·HCl, COMU, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Solvents used in this reaction are not particularly limited and include ethers such as THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; acetonitrile, NMP, DMF, DMSO, etc., and mixtures thereof. The presence of HOBt can sometimes be advantageous in ensuring the smooth progress of a reaction.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XIX). In this reaction, the compound of formula (XIX) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, such as hydrochloric acid and sulfuric acid. Examples of solvents used in this reaction are not particularly limited, such as water, ethyl acetate, and 1,4-dioxane.
(Step 3)
This step is the same as the third step in the synthesis of raw materials -2, which involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa).
(Other manufacturing methods)
By using the compound of formula (I) obtained by the above method as a raw material, further chemical modification reactions commonly used by those skilled in the art, such as alkylation, benzylation, esterification, amidation, acylation, sulfonation, oxidation, protection, and deprotection, can be carried out to obtain another compound of formula (I).
Compounds of formula (I) are separated and purified as free compounds, their salts, hydrates, solvates, or polymorphs. Salts of compounds of formula (I) can also be prepared by conventional salt-forming reactions. Separation and purification can be performed using common chemical operations such as extraction, fractional crystallization, and various fractional chromatography. Various isomers can be prepared by selecting appropriate starting material compounds, or they can be separated by utilizing the differences in physicochemical properties between isomers. For example, optical isomers can be obtained by general optical resolution of racemates (e.g., fractional crystallization of diastereomeric salts formed with optically active bases or acids, chromatography using chiral columns, etc.), or they can be prepared from appropriate optically active starting material compounds.
The pharmacological activity of the compound of formula (I) can be confirmed by the following tests. It should be noted that the pharmacological activity can also be confirmed by well-known modified tests.
Experimental Example 1: Inhibition of THP-1IL-1β Production
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) and ATP (Adenosine triphosphate, SIGMA, A2383) were added at final concentrations of 50 ng/mL and 5 mM, respectively, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of IL-1β was determined using ELISA (DuoSet ELISA human IL-1β, R&D Systems, DY201). IL-1β concentrations were plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoidEmax model nonlinear regression analysis.
The results are shown in Table 1. It can be confirmed that the compounds in the examples inhibit the activation of the NLRP3 inflammasome and inhibit the production of IL-1β.
[Table 1-1]
Table 1
[Table 1-2]
Table 1 (continued)
Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]>
100 4.9 108(2) 3.0 118 4.8 128 3.3
101(1) 2.0 109 1.5 119 6.0 129 86
101(2) 8.6 110 1.4 120 1.0 130 twenty two
102 5.1 111 2.9 121 8.5 131(1) 3.0
103 4.4 112 1.3 122 8.4 131(2) 79
104 3.5 113 1.2 123 47 132 95
105 8.9 114 15 I24 0.62 133 1.3
106 4.8 115 11 125 1.5 134 4.6
107 3.6 116 4.4 126 7.1 135 2.9
108(1) 27 117 130 127 5.6 136 2.2
Experimental Example 2: TNF-α Production Inhibition Test
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) was added at a final concentration of 50 ng/mL, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of TNF-α was determined by ELISA (DuoSetELISA human TNF-α, R&D Systems, DY210). The TNF-α concentration was plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoid Emax model nonlinear regression analysis.
It can be confirmed that Examples 1, 2(1), 3(1), 4(1), 5, 70, 73, 83, 88, 99, 111, 124 and 125, which are compounds of formula (I), showed IC50 values of more than 10 μM in this test.
Experiment 3: Rat Central Nervous System IL-1β Production Test
In male Wistar rats aged 10–14 weeks, 12.5 μg/5 μL of LPS (SIGMA, L2880) was administered intracerebrospinally under isoflurane anesthesia. Two hours later, the test compound was administered orally. One hour later, 50 μg/5 μL of BzATP (2’(3’)-O-(4-benzoylbenzoyl)adenosine 5’-triphosphate triethylammonium salt, SIGMA, B6396) was administered intracerebrospinally. Cerebrospinal fluid was recovered after 30 minutes. IL-1β p17 levels in the cerebrospinal fluid were quantified by Western blotting using an anti-IL-1β antibody (Millipore, AB1832P), and the inhibition rate relative to the solvent-administered group was calculated.
The IL-1βp17 inhibition rates relative to the solvent-administered group for Examples 1, 2 (1), 3 (1), and 124, which are compounds of formula (I), are shown in the table below. It should be noted that in the table, Dose represents the dosage of each tested compound, Ex1, Ex2 (1), Ex3 (1), and Ex124 represent Examples 1, 2 (1), 3 (1), and 124, respectively, and cases not measured are represented as NT. It can be confirmed that these compounds exhibit IL-1β inhibition.
[Table 2]
Dose Ex1 Ex2(1) Ex3(1) Ex124
0.1 mg/kg NT NT NT 55%
0.3 mg/kg -12% 81% 75% 49%
1mg/kg 74% 75% 82% 96%
3mg/kg 84% 88% 72% NT
Example 4: Evaluation of motor function in a mouse model of α-synuclein fibrils-induced neuroinflammation
In male C57BL/6J mice, 8 μg of mouse α-synuclein fibrillation protein (StressMarq Biosciences Inc., SPR-324) was administered to the left striatum. After 14–15 weeks, the test compound, suspended in 0.5% methylcellulose solution, was administered orally once daily. For the negative control group, 0.5% methylcellulose solution was administered. Motor function was evaluated using a suspension test 4 weeks after the start of administration. Mice were allowed to grasp a horizontally taut wire, fall, and then grasp again, repeating this process for 3 minutes, recording the number of falls. In this experiment, it was confirmed that specific compounds of formula (I) or their salts exhibited a beneficial effect on motor dysfunction.
Experimental Example 5: In Vitro (ex vivo) IL-1β Production Assay in Mice
Male C57BL/6J mice were administered the compound, suspended in 0.5% methylcellulose, orally once or multiple times at arbitrary doses, and blood was collected at any time afterward. LPS was added to the blood at a final concentration of 50 ng/mL, and the mice were incubated at 37°C for 3 hours. Then, ATP was added at a final concentration of 5 mM, and the mice were incubated at 37°C for 30 minutes. After centrifugation to remove blood cells, the concentration of IL-1β was determined using an ELISA method (DuoSet ELISA mouse IL-1β, R&D Systems, DY401).
Test Example 6: In Vitro Phototoxicity Test
The in vitro phototoxicity test was evaluated according to ICH S10: Guidelines for the evaluation of photosensitivity of pharmaceuticals (Drug and Food Inspection Certificate No. 0521-1) and the methods described in the OECD guideline for testing of chemicals 432: Invitro 3T3 NRU phototoxicity test, 2019. In this test, it was confirmed that the compounds of Example 1, Example 2(1), Example 3(1) and Example 124 did not have phototoxic effects.
Experimental Example 7: Safety Pharmacology Test
As a safety pharmacology study, the inhibitory effect on human Ether-a-go-go Related Gene (hereinafter referred to as hERG) channels was evaluated. The evaluation of hERG channel inhibition was performed using a modified method described in Combinatorial Chemistry & High Throughput Screening, 12, 1, 78-95 (2009). In this study, the compounds of Examples 1, 2(1), 3(1), and 124 showed IC50 values greater than 10 μM.
Based on the above results, it is expected that compounds of formula (I) or their salts may be used as highly safe pharmaceutical products for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
The compounds of formula (I) or their salts shown in Table 1 were demonstrated to inhibit IL-1β production in Example 1. Furthermore, the compounds of Examples 1, 2(1), 3(1), and 124 were also shown to inhibit IL-1β production in the central nervous system in Example 3. In addition, specific compounds of formula (I) or their salts showed improved motor function in a mouse model of α-synucleinosis induced by α-synuclein fibers, as described in Example 4. Based on these results, it is strongly expected that compounds of formula (I) or their salts can be used for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, particularly α-synucleinosis including Parkinson's disease, multiple system atrophy, and Lewy body dementia.
Furthermore, the results of Examples 6 and 7 show that the compounds of Examples 1, 2(1), 3(1), and 124 do not exhibit phototoxicity and have weak hERG channel inhibition. Based on these results, it is strongly expected that the compounds of Examples 1, 2(1), 3(1), and 124 will become highly safe pharmaceutical products.
Pharmaceutical compositions containing one or more compounds of formula (I) or their salts as active ingredients can be prepared using excipients commonly used in the art (i.e., pharmaceutical excipients or pharmaceutical carriers, etc.) and by commonly used methods.
Administration can be administered orally using tablets, pills, capsules, granules, powders, liquid preparations, etc., or via any of the following methods: intra-articular, intravenous, intramuscular, or intra-intra-articular injections, suppositories, eye drops, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalants, etc.
As a solid composition for oral administration, tablets, powders, granules, etc., can be used. In such a solid composition, one or more active ingredients may be mixed with at least one inert excipient. The composition may contain inert additives, such as lubricants or disintegrants, stabilizers, and solubilizers, according to conventional methods. Tablets, powders, granules, or pills may be coated with wax, sugar coating, or films of gastric-soluble or enteric-soluble substances as needed.
Liquid compositions intended for oral administration contain pharmaceutically permissible emulsifiers, solutions, suspensions, syrups, or elixirs, and commonly used inert diluents such as purified water or ethanol. In addition to inert diluents, the liquid composition may also contain excipients such as solubilizers, humectants, suspending agents, sweeteners, flavorings, aromatizers, and preservatives.
Injectable formulations intended for non-oral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Aqueous solvents include, for example, distilled water for injection or physiological saline. Non-aqueous solvents include, for example, alcohols such as ethanol. Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizers. They are sterilized, for example, by filtration through a bacterial trap, by combination with a bactericide, or by irradiation. Alternatively, they can be prepared as sterile solid compositions and dissolved or suspended in sterile water or sterile solvents for injection before use.
As external agents, they include ointments, plasters, creams, gels, pastes, sprays, lotions, eye drops, and eye ointments. They contain commonly used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, etc.
Inhalers or nasal inhalers, or other mucosal preparations, can be in solid, liquid, or semi-solid form and manufactured according to conventionally known methods. Known excipients may be added as appropriate, or further appropriate pH adjusters, preservatives, surfactants, lubricants, stabilizers, or thickeners may be added. Administration can be performed using a suitable inhalation or blowing device. For example, known devices or nebulizers, such as metered-dose inhalers, can be used to administer the compound alone or as a formulated mixture powder, or in combination with a pharmaceutically permissible carrier in the form of a solution or suspension. Dry powder inhalers, etc., can be used for single or multiple administration and can use dry powder or capsules containing powder. Alternatively, pressurized aerosol sprays, etc., can be used, employing a suitable propellant, such as a suitable gas like chlorofluorocarbons or carbon dioxide.
When administered orally, a daily dose of approximately 0.001 to 100 mg/kg of body weight is appropriate, preferably 0.1 to 30 mg/kg, and more preferably 0.1 to 10 mg/kg, and this dose is administered once or divided into 2 to 4 doses. When administered intravenously, a daily dose of approximately 0.0001 to 10 mg/kg of body weight is appropriate, and this dose is administered once daily or divided into multiple doses. Additionally, as a mucosal agent, approximately 0.001 to 100 mg/kg of body weight is administered once daily or divided into multiple doses. The dosage should be appropriately determined based on individual circumstances, taking into account symptoms, age, and sex.
Although the dosage form, administration site, type of excipient or additive may vary, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, or in some manner 0.01 to 50% by weight, one or more of a compound of formula (I) or a salt thereof as an active ingredient.
The compound of formula (I) can be used in combination with various therapeutic or preventative agents for diseases for which the compound of formula (I) is believed to be effective. When used in combination, the compounds can be administered simultaneously, separately and continuously, or at desired time intervals. Simultaneously administered formulations can be combination formulations or formulations prepared separately.
Example
Hereinafter, based on examples, a method for manufacturing compounds of formula (I) will be described in further detail. It should be noted that the present invention is not limited to the compounds described in the following examples. Furthermore, the manufacturing examples show a method for preparing the starting material compounds. Additionally, the method for manufacturing compounds of formula (I) is not limited to the manufacturing methods of the specific examples shown below; compounds of formula (I) can also be manufactured by combinations of these manufacturing methods or by methods obvious to those skilled in the art.
It should be noted that the starting temperatures of the DSC curves obtained under the following conditions are recorded in the table below. The DSC measurements were performed using a DSC Q2000 (manufactured by TA Instruments) at a temperature range of 25–300 °C, a heating rate of 10 °C/min, and a nitrogen flow rate of 50 mL/min. An aluminum sample pan was used, and measurements were performed without covering the sample pan. The starting temperatures of the DSC curves may vary slightly depending on the measurement conditions and should not be interpreted strictly.
Powder X-ray diffraction (XRD) was performed using an Empyrean (PANalytical) spectrometer under the following conditions: Cu bulb, 40 mA tube current, 45 kV tube voltage, 0.013° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). Alternatively, it was performed using a SmartLab (Rigaku) spectrometer under the following conditions: Cu bulb, 200 mA tube current, 45 kV tube voltage, 0.005° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). It should be noted that, regarding the nature of the data, the lattice spacing or overall pattern of the powder XRD pattern is important in determining the identity of the crystals. The error range of the diffraction angle (2θ (°)) in powder XRD is typically ±0.2°, but the diffraction angle and intensity vary slightly depending on the direction of crystal growth, particle size, and measurement conditions, and therefore should not be interpreted strictly.
In addition, the following abbreviations are sometimes used in the embodiments, manufacturing examples and tables described below.
The following represent the following values: PEx: Manufacturing Example Number; Ex: Example Number; PSyn: Manufacturing Example Number manufactured using the same method; Syn: Example Number manufactured using the same method; Str: Chemical Structural Formula; DAT: Physicochemical Data; EI+: m/z value in mass analysis (Electron Ionization EI, [M]+ unless otherwise specified); ESI+: m/z value in mass analysis (Ionization ESI, [M+H]+ unless otherwise specified); FAB: m/z value in mass analysis (Ionization FAB, [M+H]+ unless otherwise specified); CI: m/z value in mass analysis (Ionization CI, [M+H]+ unless otherwise specified); 1H -NMR (400MHz, CDCl3 ): δ value (ppm) of the signal in 1H -NMR of CDCl3 ; 1H -NMR (500MHz, CDCl3 ): δ value (ppm ) of the signal in 1H-NMR of CDCl3 . δ value (ppm) of the signal in 1H-NMR, 1H -NMR (400MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , 1H -NMR (500MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , J: coupling constant, s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, br: broad peak (e.g., br s), m: multiplet, DSC 1 : temperature (initial temperature) at which the endothermic peak (decomposition point) was observed using DSC, DSC 2 : temperature (initial temperature) at which the endothermic peak (amorphous decomposition point) was observed using DSC, 2θ: diffraction angle of the peak in powder X-ray diffraction.
In the PSyn and Syn columns of the table described later, the hyphen (-) indicates that the manufacturing method is described in text form in the manufacturing example or embodiment.
In addition, for convenience, the concentration in mol/L is expressed as M. For example, 1M sodium hydroxide aqueous solution means a 1 mol/L sodium hydroxide aqueous solution.
Manufacturing Example 1
A mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (10.92 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (16.3 g), DIPEA (28 mL), and cyclopentanol (55 mL) was stirred at 160 °C for 2 days. After cooling the reaction mixture to room temperature, water/saturated sodium chloride aqueous solution (1/1) and chloroform/methanol (9/1) were added to separate the organic layer. The aqueous layer was extracted with chloroform/methanol (9/1), the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]cyclohexane-1-ol (8.24 g) as a solid.
Manufacturing Example 2
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.7 mL) were added, and the mixture was stirred at 160 °C for 44 hours. After cooling the reaction mixture to room temperature, chloroform and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, dried with anhydrous sodium sulfate, and then the solution was concentrated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 3
A mixture of 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine (1.145 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (890 mg), DIPEA (2.7 mL), and NMP (15 mL) was stirred at 160 °C for 24 hours. (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (420 mg) and DIPEA (1.3 mL) were added to the reaction mixture, and the mixture was stirred at 160 °C for 20 hours. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, the organic layers were combined, and the mixture was washed with a 1/1 water/saturated sodium chloride solution and a saturated sodium chloride solution, then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate). (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohex-1-ol (36.1 mg) was obtained as a solid from the low polarity fraction, and (1R,2R)-2-[(6-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)amino]cyclohex-1-ol (504.8 mg) was obtained as an oil from the high polarity fraction.
Manufacturing Example 4
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1S,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.68 mL) were added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, DIPEA (1 mL) was added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water/saturated sodium chloride aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated and dried over anhydrous sodium sulfate. After concentrating the solution, the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain a mixture (774 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 5
At room temperature, a mixture of 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine (502.7 mg) and cyclopentanol (3 mL) was mixed with (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (394 mg) and DIPEA (0.393 mL), and stirred at 160 °C for 2 days under an argon atmosphere. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and saturated sodium chloride/water aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (57.4 mg) as an oil.
Manufacturing Example 42
A mixture of 1 g of 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione and 20 mL of methanol was mixed with 0.6 mL of 12 M hydrochloric acid and 100 mg of platinum oxide, and stirred overnight at room temperature under a hydrogen atmosphere. 20 mL of methanol and 20 mL of DMF were added to the reaction mixture, and the mixture was stirred for 1 hour under an argon atmosphere. The reaction mixture was filtered through a Celite filter, and the filtrate was concentrated under reduced pressure. Toluene was added to the residue, and the mixture was concentrated under reduced pressure. Ethyl acetate was added to the solid, and the mixture was ground. The solid was filtered off and washed with ethyl acetate to give 1.19 g of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride.
Manufacturing Example 43
A mixture of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride (800 mg) and dichloromethane (16 mL) was mixed with DIPEA (0.250 mL), benzaldehyde (0.500 mL), and sodium triacetoxyborohydride (1.1 g) and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with chloroform/methanol (5/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione (515 mg) as a solid.
Manufacturing Example 44
A mixture of 100 mg 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione and 2 mL phosphoryl chloride was stirred at 120 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, and toluene was added, followed by further concentration under reduced pressure. Chloroform (3 mL) was added to the resulting residue, and DIPEA (1 mL) was added under ice-cold conditions. Water was added to the reaction mixture, and extraction with chloroform was performed. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 87 mg 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine as an oil.
Manufacturing Example 45
Under a nitrogen atmosphere, sodium hydride (55%, liquid paraffin dispersion, 190 mg) was added to a mixture of 1,4-dichlorophthalazine (720 mg), 4 -hydroxy-1λ6-thiocyclohexane-1,1-dione (540 mg), and THF (14 mL) while the mixture was ice-cold. The mixture was stirred at the same temperature for 30 minutes, then heated to room temperature and stirred for 3 days. Water and ethyl acetate were added to the reaction mixture, the solid was filtered off, and washed with water and ethyl acetate to give 4-[(4-chlorophthalazine-1-yl)oxy] -1λ6 -thiocyclohexane-1,1-dione (681 mg) in solid form.
Manufacturing Example 47
In a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (100 mg) and 1,4-dioxane (3.2 mL), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane-pentaborane (350 mg), RuPhos Pd G3 (45 mg), potassium carbonate (147 mg), and water (0.64 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform and water were added, and the organic layer was separated. After concentrating the solution, the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (1R,2R)-2-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazine-1-yl}amino)cyclohexyl-1-ol (106 mg) in solid form.
Manufacturing Example 48
Under an argon atmosphere, a mixture of (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (34 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (38 mg), RuPhos Pd G3 (3 mg), potassium carbonate (38 mg), 1,4-dioxane (1 mL), and water (0.100 mL) was stirred at 130 °C for 60 minutes under microwave irradiation. Water and chloroform were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with chloroform, and the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15.6 mg) in solid form.
Manufacturing Example 63
A mixture of tert-butyl [4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]carbamate (1.38 g), dichloromethane (14 mL), and triethylamine (1.21 mL) was added to acetic anhydride (0.330 mL) and 4-dimethylaminopyridine (71 mg), and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate), and the solid was washed with hexane/ethyl acetate (4/1) to give 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl acetate (1.24 g) in solid form.
Manufacturing Example 64
Trifluoroacetic acid (1.83 mL) was added to a mixture of 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl ester (1.24 g) and dichloromethane (13 mL), and the mixture was stirred overnight at room temperature. A 1 M aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol/ammonia). The residue was mixed with chloroform and methanol and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the solid was washed with hexane/ethyl acetate (4/1) to give 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (607 mg) in solid form.
Manufacturing Example 65
A mixture of 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (403 mg), acetyl chloride (0.075 mL), DIPEA (0.495 mL), and dichloromethane (4 mL) was stirred at room temperature for 1 hour. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. DIPEA (0.495 mL) and acetyl chloride (0.075 mL) were added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 4 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-(4-acetaminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl acetate (401 mg) as a solid.
Manufacturing Example 67
Under an argon atmosphere, in a mixture of 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (500 mg), (2R)-but-3-yn-2-ol (0.150 mL), and THF (8 mL), PdCl₂ ( PPh₃ ) ₂ (126 mg), copper iodide (I) (17 mg), and diisopropylamine (0.755 mL) were added under ice-cold conditions, followed by heating to room temperature and stirring for 5 hours. Water and a saturated aqueous solution of ammonium chloride were added to the reaction mixture, and the mixture was extracted with chloroform. The aqueous layer was extracted with chloroform, the organic layers were combined, dried with anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) as an oil.
Manufacturing Example 69
Platinum oxide (67 mg) was added to a mixture of (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) and ethanol (6 mL), and the mixture was stirred at room temperature for 1.5 hours under a hydrogen atmosphere. Celite (registered trademark) was added to the reaction mixture and stirred. The mixture was then filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-2-ol (260 mg) as an oil.
Manufacturing Example 70
Under an argon atmosphere, a mixture of 1,4-dichloro-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.50 g), sodium iodide (3.1 g), and 57% hydroiodic acid (9 mL) was stirred at 100 °C for 30 min under microwave irradiation. The reaction mixture was cooled to room temperature, water was added, and extraction was performed with ethyl acetate. The organic layer was washed with saturated aqueous solutions of sodium bicarbonate, sodium thiosulfate, and sodium chloride, and then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.9 g) as a solid.
Manufacturing Example 72
Under an argon atmosphere, a mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (100 mg), (3-aminobicyclo[1.1.1]pentan-1-yl)methanol-hydrochloride (95 mg), palladium acetate (22 mg), (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (90 mg), cesium carbonate (385 mg), and 1,4-dioxane (2 mL) was stirred at 100 °C for 24 hours. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give {3-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]bicyclo[1.1.1]pentan-1-yl}methanol (46.2 mg) in solid form.
Manufacturing Example 73
Under ice-cold conditions, 1 g of 3,6-dichloro-1,2,4,5-tetraazine was added to a mixture of tert-butyl[(3,6-dihydro-2H-pyran-4-yl)oxy]di(methyl)silane (1.42 g) and toluene (20 mL). The mixture was stirred at room temperature for 0.5 h and then at 120 °C for 16 h. After cooling the reaction mixture to room temperature, it was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1.08 g) in solid form.
Manufacturing Example 74
Under an argon atmosphere, toluene (121 mL) and 3,6-dichloro-1,2,4,5-tetrahydrooxetrazine (6.61 g) were added to a mixture (11.67 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetrazine-4-yl)oxy]silane, and the mixture was stirred at 120 °C for 24 hours. The reaction mixture was cooled to room temperature and filtered through methanol and chloroform. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepten[4,5-d]pyridazine (502.7 mg) in solid form.
Manufacturing Example 76
Hydrochloric acid (12M, 15.8 mL) was added to a mixture of 2-amino-5-cyclopropylphenol (3.50 g) and ethanol (50 mL) at -15 °C, and the mixture was stirred for 10 minutes at the same temperature. Amyl nitrite (9.6 mL) was added to the reaction mixture at -15 °C, and the mixture was stirred for 30 minutes at the same temperature. Then, a mixture of potassium iodide (50.6 g) and water (50 mL) was added dropwise at -15 °C, the mixture was heated to room temperature, and stirred for 20 hours. Ethyl acetate was added to the reaction mixture to separate the organic layer. The organic layer was washed with saturated aqueous sodium thiosulfate solution and saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-cyclopropyl-2-iodophenol (5 g) as an oil.
Manufacturing Example 77
In a mixture of 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) and 1,4-dioxane (9.2 mL), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (1.24 g), PdCl₂ (dppf) (238 mg), and potassium acetate (957 mg) were added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, PdCl₂ (dppf) (238 mg) was added, and the mixture was stirred at 100 °C for 2 hours. After cooling the reaction mixture to room temperature, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (620 mg) was added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, hexane was added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (1.98 g) as an oil.
Manufacturing Example 81
A mixture of 2.86 g of 4-bromo-3-hydroxybenzaldehyde and 30 mL of dichloromethane was added to DIPEA (2.93 mL) and 1.19 mL of chloromethyl methyl ether, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, the organic layer was separated, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde as an oil.
Manufacturing Example 83
Diethylaminosulfur trifluoride (2.2 mL) was added to a mixture of 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde and 20 mL of dichloromethane under ice-cold conditions. The mixture was stirred at the same temperature for 1 hour, then heated to room temperature and stirred for 3 hours. The reaction mixture was added to a mixture of ice water, sodium bicarbonate, and chloroform and stirred. The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.3 g of 1-bromo-4-(difluoromethyl)-2-(methoxymethoxy)benzene as an oil.
Manufacturing Example 84
A mixture of 4-bromo-3-(methoxymethoxy)phenol (1.86 g), sodium dichloro(fluoro)acetate (2.43 g), and DMF (11 mL) was added dropwise to a mixture of potassium carbonate (1.65 g) and DMF (7.4 mL) at 95 °C for 1 hour, and stirred at the same temperature for 15 minutes. After cooling the reaction mixture to room temperature, potassium carbonate (1.65 g) and sodium dichloro(fluoro)acetate (2.43 g) were added, and the mixture was stirred at 95 °C for 1 hour. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with water and a saturated sodium chloride aqueous solution, and then dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) as an oil.
Manufacturing Example 85
Under an argon atmosphere, a mixture of 1-chloro-4-iodo-5,6,7,8-tetrahydrophthalazine (500 mg), (1R,2R)-2-amino-1-methylcyclohexane-1-ol (270 mg), copper iodide (I) (30 mg), potassium phosphate (725 mg), ethylene glycol (0.100 mL), and 1-propanol (5 mL) was stirred at 90 °C for 24 hours. After cooling the reaction mixture to room temperature, chloroform and a saturated aqueous solution of ammonium chloride were added, and the organic layer was separated. The aqueous layer was extracted with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]-1-methylcyclohexane-1-ol (292 mg) in solid form.
Manufacturing Example 86
Under an argon atmosphere, a mixture of ethyl 1-benzyl-5-[(trifluoromethanesulfonyl)oxy]-1,2,3,6-tetrahydropyridine-4-carboxylate (3.37 g), zinc cyanide (1.5 g), Pd(PPh 3 ) 4 (1.2 g), and DMF (42 mL) was stirred at 100 °C for 1.5 h. After cooling to room temperature, water and ethyl acetate were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, washed with a 1/1 water/saturated sodium chloride aqueous solution and a saturated sodium chloride aqueous solution, and dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (2.04 g) as an oil.
Manufacturing Example 87
Under an argon atmosphere, a mixture of ethyl 5-[(trifluoromethanesulfonyl)oxy]-3,6-dihydro-2H-pyran-4-carboxylate (7.4 g), zinc cyanide (4.3 g), Pd(PPh 3 ) 4 (2.8 g), and DMF (74 mL) was stirred at 100 °C for 2 hours. After cooling to room temperature, ethyl acetate and water were added to the reaction mixture, and the mixture was filtered through Celite (registered trademark). After separating the two layers, the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with a 1/1 solution of water/saturated sodium chloride and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) as an oil.
Manufacturing Example 88
A mixture of ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (930 mg) and ammonia (7 M methanol solution, 8 mL) was stirred at ice temperature for 6 hours. The reaction mixture was allowed to stand in a refrigerator for 18 hours, then heated to room temperature and stirred for 10 minutes. The reaction mixture was concentrated under reduced pressure to give 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridine-1-one (828 mg) as a solid.
Manufacturing Example 89
Ammonia (7M methanol solution, 44 mL) was added to ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) under ice-cold conditions, and the mixture was stirred at 0 °C for 3 days. The reaction mixture was concentrated under reduced pressure to give 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.261 g) as a solid.
Manufacturing Example 90
A mixture of 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (825 mg), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (530 mg), DIPEA (0.7 mL), and acetonitrile (20 mL) was stirred at 70 °C for 19 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (1.12 g) as a solid.
Manufacturing Example 91
A mixture of 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.26 g), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (3.4 g), DIPEA (5.5 mL), and acetonitrile (70 mL) was stirred at 70 °C for 18 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (5.63 g) in solid form.
Manufacturing Example 92
A mixture of 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (560 mg) and ethanol (10 mL) was mixed with hydrazine monohydrate (0.16 mL) and stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (201 mg) in solid form.
Manufacturing Example 93
Under an argon atmosphere, sodium hydride (55%, liquid paraffin dispersion, 12 mg) was added to a mixture of 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (90 mg) and THF (3 mL) under ice-cold conditions, and the mixture was stirred for 20 minutes at the same temperature. 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide (108 mg) was added to the reaction mixture, and the mixture was stirred for 1 hour under ice-cold conditions. Water and chloroform were added to the reaction mixture, and the organic layer was separated. After extraction of the aqueous layer with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then chloroform/ethyl acetate) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine-1-yl ester (40 mg) in solid form.
Manufacturing Example 94
Sodium hydroxide (0.596 g) and benzyltriethylammonium chloride (0.922 g) were added to a mixture of (3R)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (2 g) and dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes. 1,4-Dichlorophthalazine (2.37 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 24 hours. Water and dichloromethane were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (3R)-3-[(4-chlorophthalazine-1-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester (0.960 g) as a solid.
Manufacturing Example 96
A mixture of (3R)-3-[(3R)-piperidin-1-carboxylic acid tert-butyl ester (960 mg) and dichloromethane (10 mL) was mixed with a solution of 1,4-dioxane hydrogen chloride (4 M, 10 mL) and stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and then diethyl ether was added to the resulting solid and the mixture was ground. The solid was filtered off to give 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine monohydrochloride (850 mg) in solid form.
Manufacturing Example 97
Triethylamine (0.26 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (100 mg) and dichloromethane (2 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.04 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated sodium chloride aqueous solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture A). Triethylamine (0.70 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (300 mg) and dichloromethane (10 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.10 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-{(3R)-3-[(4-chlorophthalazin-1-yl)oxy]piperidin-1-yl}aceto-1-one (280 mg).
Manufacturing Example 98
Triethylamine (6.3 mL) was added to a mixture of oxetane (5 g) and diethyl ether (50 mL) under ice-cold conditions, followed by tert-butyldi(methyl)silane trifluoromethanesulfonate (12.3 mL), and the mixture was stirred for 10 minutes at the same temperature. Triethylamine (1.4 mL) was added to the reaction mixture, and the mixture was stirred under ice-cold conditions for 1.5 hours. Hexane and water were added to the reaction mixture, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated to give a mixture (11.7 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetane-heptene-4-yl)oxy]silane as an oil.
Manufacturing Example 99
A mixture of 500 mg of 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrolo-1(4H)-one and 2-propanol (20 mL) was mixed with 0.300 mL of hydrazine monohydrate and stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (200 mg) in solid form.
Manufacturing Example 100
Under an argon atmosphere, sodium nitrite (80 mg) was added to a mixture of (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (198 mg), copper chloride (I) (75 mg), and hydrochloric acid (12 M, 2.5 mL) under ice-cold conditions, and the mixture was stirred for 1 hour at the same temperature. Dichloromethane (10 mL), water, and triethylamine (4.2 mL) were added to the reaction mixture under ice-cold conditions and stirred. The reaction mixture was filtered through a Celite filter and washed with dichloromethane/methanol (10/1). The organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (170 mg) in solid form.
Manufacturing Example 101
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (131.6 mg), 10% palladium-supported carbon (containing 51% water, 84.5 mg), and methanol (3 mL) was stirred at room temperature for 4 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite filter. The filtrate was then concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (89.3 mg) as a solid.
Manufacturing Example 102
[(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.524 g) and sodium triacetoxyborohydride (2.416 g) were added to a mixture of cyclobutanone (0.640 g) and dichloromethane (25 mL) at room temperature, and the mixture was stirred for 5 hours at room temperature. The reaction mixture was injected into a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to give [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.940 g) as a solid.
Manufacturing Example 103
A solution of 1,4-dioxane hydrogen chloride (4M, 1.8 mL) was added to a mixture of [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (225 mg) and dichloromethane (1.8 mL) with stirring at room temperature, and the mixture was stirred for 3 hours at room temperature. The reaction mixture was concentrated under reduced pressure to give (3R)-1-cyclobutylpiperidin-3-amine dihydrochloride (250 mg) as a solid.
Manufacturing Example 104
A mixture ( 393 mg ) of (1R,2R)-N1-(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)cyclohexyl-1,2-diamine and (1R,2R) -N1- (4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)cyclohexyl-1,2-diamine was added to dichloromethane (14 mL), triethylamine (0.23 mL), and di-tert-butyl dicarbonate (0.34 mL), and the mixture was stirred at room temperature for 1.5 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (352 mg) of {(1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl}carbamate tert-butyl ester and {(1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl}carbamate tert-butyl ester in solid form.
Manufacturing Example 105
A solution of 1,4-dichloro-6-(triphenylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine (1.569 g) and dichloromethane (18 mL) was added to a solution of 1,4-dioxane hydrogen chloride (4 M, 6 mL), and the mixture was stirred at room temperature for 18.5 hours. The reaction mixture was filtered, the solid was washed with diethyl ether, and then dried under reduced pressure to give 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine hydrochloride (770 mg).
Manufacturing Example 106
Triethylamine (1.4 mL) and di-tert-butyl dicarbonate (1.2 mL) were added to a mixture of 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine monohydrochloride (765 mg) and dichloromethane (23 mL) under ice-cold stirring, and the mixture was stirred for 17 hours while being naturally heated to room temperature. The reaction mixture was injected into water and extracted with dichloromethane. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Diethyl ether was added to the resulting solid and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give tert-butyl 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid (788 mg) as a solid. The residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid tert-butyl ester (142 mg) in solid form.
Manufacturing Example 114
A mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (700 mg) and (3R)-3-aminopiperidine-1-carboxylic acid tert-butyl ester (1.4 g) was stirred at 120 °C for 24 hours. After cooling to room temperature, the mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (481 mg) of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester in solid form.
Manufacturing Example 116
A mixture of 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (384 mg), (1R,2R)-2-aminocyclohexyl-1-ol (426 mg), DIPEA (0.77 mL), and cyclopentanol (7.4 mL) was stirred at 145–155 °C for 18.5 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and then water and a saturated sodium chloride aqueous solution were added. Extraction was performed with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (236 mg) in solid form.
Manufacturing Example 120
A mixture of 1,4-dichloro-5,7-dihydrofurano[3,4-d]pyridazine (500 mg), (1S,3R)-3-aminocyclohexyl-1-ol monohydrochloride (795 mg), DIPEA (1.8 mL), and cyclopentanol (5 mL) was stirred at 120–130 °C for 22 hours. The reaction mixture was cooled to room temperature, injected into water, and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (556 mg) as a solid.
Manufacturing Example 122
A mixture of 2,3,5,7-tetrahydrothieno[3,4-d]pyridazine-1,4-dione (78 mg) and phosphorus oxychloride (1 mL) was stirred at 98–100 °C for 2.5 h. The reaction mixture was cooled to room temperature and then poured into ice water for washing with ice water and dichloromethane. A saturated sodium bicarbonate solution was added dropwise to adjust the pH to approximately 8 while stirring at room temperature, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (92 mg) as a solid.
Manufacturing Example 128
A mixture of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester (478 mg), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (680 mg), RuPhos Pd G3 (163 mg), potassium carbonate (450 mg), 1,4-dioxane (10 mL), and water (2 mL) was stirred at 100 °C for 4 hours. After cooling to room temperature, water was added to the mixture, and extraction was performed with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution and then dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and (3R)-3-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (200 mg) in solid form.
Manufacturing Example 134
Under an argon atmosphere, a mixture of (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (155 mg), 2-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (361 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 94 mg), potassium carbonate (159 mg), 1,4-dioxane (6 mL), and water (1.4 mL) was stirred at 90–110 °C for 20 hours. The reaction mixture was cooled to room temperature, injected into water, and then filtered through a Celite (trademark) filter. The filtrate was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-({4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (128 mg) in solid form.
Manufacturing Example 144
By the same reaction as in Manufacturing Example 74, 1,4-dichloro-5,7,8,9-tetrahydrooxetanehepten[3,4-d]pyridazine was obtained as a byproduct in solid form.
Manufacturing Example 152
Under ice-cold conditions, trifluoromethanesulfonic anhydride (0.17 mL) was added to a mixture of 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-ol (261 mg), 2,6-rutidine (0.16 mL), and dichloromethane (6 mL), and the mixture was stirred at the same temperature for 1.5 hours. Dichloromethane and water were added to the reaction mixture and stirred, and then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl ester (311 mg) in solid form.
Manufacturing Example 154
Under an argon atmosphere and with stirring at -30°C, trifluoromethanesulfonic anhydride (14.1 mL) was added dropwise to a mixture of ethyl 5,5-dimethyl-4-oxothiacyclopentane-3-carboxylate (16.169 g), DIPEA (15.3 mL), and dichloromethane (80 mL). The reaction mixture was then stirred at -45 to -15°C for 1 hour. Water was added to the reaction mixture, and the mixture was heated to room temperature and then extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (17.559 g) as an oil.
Manufacturing Example 159
Under ice-cold conditions, tert-butyl dimethyl silane trifluoromethanesulfonate (1.2 mL) was added to a mixture of (1S,2R)-2-aminocyclohexane-1-ol monohydrochloride (608 mg), dichloromethane (8 mL), and 2,6-rutidine (1.1 mL), and the mixture was stirred for 1 hour at the same temperature, followed by stirring at room temperature for 3 hours. 2,6-rutidine (0.16 mL) and tert-butyl dimethyl silane trifluoromethanesulfonate (0.3 mL) were added to the resulting mixture at room temperature, and the mixture was stirred for 20 hours at the same temperature. Dichloromethane and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture and stirred, then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexane-1-amine (445 mg) as an oil.
Manufacturing Example 160
At room temperature, hydrochloric acid (12M, 0.5 mL) was added to a mixture of (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and methanol (3 mL), and the mixture was stirred at 60 °C for 1 hour. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. Chloroform/methanol (9/1) and basic silica gel were added to the residue, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (alkaline silica, chloroform/methanol) to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (102 mg) in solid form.
Manufacturing Example 162
A mixture (113 mg) of (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol was purified by reversed-phase preparative HPLC (ODS column, 0.1% formic acid/methanol) to give (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (62.4 mg) as an oil.
Manufacturing Example 163
Potassium carbonate (197.99 mg) and methyl iodide (58.10 mg) were added to a mixture of 1-chloro-N-[(3R)-piperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine dihydrochloride (110 mg) and DMF (6 mL) at 25 °C, and the mixture was stirred for 16 hours at the same temperature. The reaction mixture was added to water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure to give 1-chloro-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (110 mg) as an oil.
Manufacturing Example 164
N-bromosuccinimide (23.88 g) was added to a mixture of 3-cyclopropylphenol (20 g) and chloroform (200 mL) at 0 °C, and the mixture was stirred at 15 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether) to give 2-bromo-5-cyclopropylphenol (7.7 g) as an oil.
Manufacturing Example 165
A mixture of 2,5-dihydrothiophene-3,4-dicarboxylhydrazide (127 mg) and 10% sulfuric acid (8 mL) was stirred at 115–120 °C for 1 hour. The reaction mixture was cooled to room temperature and then filtered. The filtered solid was washed with water and dried to give 2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione (94 mg) in solid form.
Manufacturing Example 166
A mixture of 308 mg of 4,6-dihydro-1H,3H-thieno[3,4-c]furan-1,3-dione, 0.96 mL of hydrazine monohydrate, and 20 mL of 2-propanol was heated to reflux at 100 °C and stirred for 14.5 h. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with 2-propanol and dried to give 2,5-dihydrothiophene-3,4-dicarboxyhydrazide (246 mg) as a solid.
Manufacturing Example 167
A mixture of 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazine-1-carboxylic acid, 9.1 mL of 1,4-dioxane hydrochloride solution, and 90 mL of ethyl acetate was stirred at 60–67 °C for 19 hours. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with ethyl acetate and dried to give 2.717 g of 5,5-dimethyl-2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione in solid form.
Manufacturing Example 168
A mixture of 5.095 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid, 3.509 g of tert-butyl hydrazinocarboxylate, 10.095 g of HATU, 7.73 mL of DIPEA, and 110 mL of DMF was stirred at room temperature for 2.5 hours. Water was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazino-1-carboxylic acid as an oil.
Manufacturing Example 169
Under an argon atmosphere, a mixture of ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (15.556 g), sodium formate (9.493 g), acetic anhydride (8.8 mL), DIPEA (16.3 mL), lithium chloride (5.917 g), palladium acetate (1.045 g), and DMF (230 mL) was stirred at room temperature for 17 hours. The reaction mixture was filtered, and 10% hydrochloric acid was added to the filtrate to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol). A saturated aqueous sodium bicarbonate solution was added to the purified product, and the mixture was stirred at room temperature to adjust the pH to approximately 8, followed by washing with ethyl acetate. Under stirring at room temperature, 10% hydrochloric acid was added to the aqueous layer to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dried with anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain 9.659 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid as an oil.
Example 1
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (4.4 g), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (4.5 g), RuPhos Pd G3 (1.3 g), potassium carbonate (5.4 g), 1,4-dioxane (40 mL), and water (8 mL) was stirred at 100 °C for 2 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 3 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 19 hours. After cooling the reaction mixture to room temperature, water and chloroform were added to separate the organic layer. The aqueous layer was extracted with chloroform, and the combined organic layers were washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (basic and neutral silica gel, chloroform/methanol). Ethyl acetate (10 mL) and hexane (50 mL) were added to the purified product, and the mixture was stirred at room temperature for 18 hours. The solid was filtered off to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol (3.97 g) in solid form.
Example 2
In a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (562 mg), RuPhos PdG3 (171 mg), potassium carbonate (563 mg), and water (2.5 mL) were added, and the mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (3 mL) and hexane (12 mL) were added to the two purified products, respectively, and the mixture was stirred for 15 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (108 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (172 mg) was obtained from the high-polarity fraction.
Example 3
In a mixture (440 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (14 mL), [2-hydroxy-4-(trifluoromethoxy)phenyl]boronic acid (690 mg), RuPhosPd G3 (195 mg), potassium carbonate (643 mg), and water (2.9 mL) were added. The mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (8 mL) were added to the two purified products, respectively, and the mixture was stirred for 30 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (124 mg) was obtained from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethoxy)phenol (242 mg) was obtained from the high-polarity fraction.
Example 4
In a mixture (380 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12.2 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (553 mg), RuPhosPd G3 (168 mg), potassium carbonate (555 mg), and water (2.4 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (6 mL) were added to the two purified products, respectively, and the mixture was stirred for 1 hour. The solids were filtered off, and 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (93 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (103 mg) was obtained from the high-polarity fraction.
Example 5
Under an argon atmosphere, RuPhos Pd G3 (17 mg) was added to a mixture of (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetane-hepteno[4,5-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (57.4 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (59.8 mg), potassium carbonate (80 mg), 1,4-dioxane (2.4 mL), and water (0.600 mL), and the mixture was stirred at 100 °C for 3 hours. RuPhos Pd G3 (16 mg) was then added to the reaction mixture, and the mixture was stirred at 100 °C for 1 hour. Subsequently, RuPhos Pd G3 (17.7 mg), 1,4-dioxane (0.800 mL), and water (0.200 mL) were added, and the mixture was stirred at 100 °C for 6 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1), saturated sodium chloride aqueous solution, and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxocyclohepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (9.1 mg) in solid form.
Example 70
Under an argon atmosphere, a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (150 mg), (4-chloro-2-hydroxyphenyl)boronic acid (120 mg), RuPhos Pd G3 (46 mg), potassium carbonate (150 mg), 1,4-dioxane (4 mL), and water (0.5 mL) was stirred at 100 °C for 5 hours. Then, (4-chloro-2-hydroxyphenyl)boronic acid (120 mg) and RuPhos Pd G3 (22 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 8 hours. After cooling the reaction mixture to room temperature, basic silica gel was added, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol) to obtain a solid. Hexane/ethyl acetate (10/1) was added to the obtained solid, and the solid was filtered off to obtain 5-chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (25.2 mg) in solid form.
Example 73
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (14 mg), formaldehyde (37% aqueous solution, 0.020 mL), 10% palladium-supported carbon (50% water content, 10 mg), and methanol (1 mL) was stirred at room temperature for 24 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite (trademark) filter. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (5.6 mg) as a solid.
Example 79
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and acetyl chloride (6 mg) under ice-cold conditions and stirred at the same temperature for 2 hours. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-{1-[2,4-bis(trifluoromethyl)phenyl]-4-{[(2R)-2-hydroxypropyl]amino}-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl}ethyl-1-one (18 mg) in solid form.
Example 80
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and methanesulfonyl chloride (8 mg) under ice-cold conditions and stirred at the same temperature for 30 minutes. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (2R)-1-({1-[2,4-bis(trifluoromethyl)phenyl]-6-(methanesulfonyl)-5,6,7,8-tetrahydropyridino[3,4-d]pyridazin-4-yl}amino)prop-2-ol (15 mg) in solid form.
Example 81
A mixture of 2-[4-(4-acetamidobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl ester acetate (398 mg) and methanol (8 mL) was mixed with an aqueous solution of sodium hydroxide (1 M, 1.73 mL) and stirred at room temperature for 3 hours. Hydrochloric acid (1 M, 1.73 mL) and water were added to the reaction mixture, and extraction was performed with chloroform/2-propanol (4/1). The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting solid was washed with ethyl acetate to give N-[4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]acetamide (309 mg) in solid form.
Example 82
A solution of 1,4-dioxane hydrogen chloride (4M, 4mL) was added to a mixture of [(1R,2R)-2-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}amino)cyclohexyl]tert-butyl carbamate (0.440 g) and 1,4-dioxane (10 mL) at 0 °C, and the mixture was heated to room temperature and stirred for 4 hours. A solution of 1,4-dioxane hydrogen chloride (4M, 4 mL) was added to the reaction mixture at 5 °C, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting solid was washed with diethyl ether to give 2-(4-{[(1R,2R)-2-aminocyclohexyl]amino}phthalazin-1-yl)-5-(trifluoromethyl)phenol dihydrochloride (0.375 g) in solid form.
Example 83
Hydrochloric acid (12 M, 0.060 mL) was added to a mixture of (1R,2R)-2-({4-[-4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)cyclohexane-1-ol (106 mg) and methanol (1.1 mL), and the mixture was stirred at 60 °C for 10 hours. Ethyl acetate and a saturated aqueous sodium bicarbonate solution were added to the reaction mixture to separate the organic layer, which was then extracted with ethyl acetate. The combined organic layers were washed with water and a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solution was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (1 mL) and hexane (3 mL) were added to the obtained solid, and the mixture was stirred for 15 minutes. The solid was then filtered off, thus obtaining 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol (62 mg) in solid form.
Example 88
Under an argon atmosphere, potassium carbonate (159 mg), 2-[4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5,5-tetramethyl-1,3,2-dioxane (564 mg), and RuPhos Pd G3 (49.3 mg) were added to a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (162 mg), 1,4-dioxane (2 mL), and water (0.500 mL), and the mixture was stirred at 100 °C for 1.5 h. The reaction mixture was cooled to room temperature, and methanol (2 mL) and hydrochloric acid (12 M, 0.590 mL) were added. The mixture was stirred at 60 °C for 2 h. After cooling the reaction mixture to room temperature, basic silica gel was added and the mixture was concentrated. The obtained residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol). Ethyl acetate and diisopropyl ether were added to the obtained residue, and after sonication, the solid was filtered off, thus yielding 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (46.3 mg) in solid form.
Example 90
Under ice-cold conditions, a solution of 1,4-dioxane hydrogen chloride (4M, 0.84 mL) was added to a mixture of 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazin-6(5H)-carboxylic acid tert-butyl ester (171 mg) and dichloromethane (2.6 mL), and the mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5(trifluoromethyl)phenol dihydrochloride (162 mg) as a solid.
Example 92
Under an argon atmosphere, acetyl chloride (0.041 mL) and pyridine (0.010 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (46.7 mg), dichloromethane (2 mL), and THF (1 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was then heated to room temperature, and an aqueous solution of sodium hydroxide (1 M, 1 mL) was added, and the mixture was stirred at the same temperature for 7 hours. The reaction mixture was then chilled, and hydrochloric acid (1 M, 1 mL) was added. The mixture was then heated to room temperature, and chloroform was added, and the mixture was stirred at the same temperature for 10 minutes. The organic layer was separated and concentrated. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl]ethyl-1-one (17.2 mg) in solid form.
Example 93
Under an argon atmosphere, methanesulfonyl chloride (0.004 mL) and DIPEA (0.039 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (18.5 mg) and dichloromethane (2 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture A). Under an argon atmosphere, methanesulfonyl chloride (0.005 mL) and DIPEA (0.048 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (22.9 mg) and dichloromethane (3 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-(methanesulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl]-5-(trifluoromethyl)phenol (13.8 mg) in solid form.
Example 94
Under an argon atmosphere and with ice-cold stirring, boron tribromide (17% dichloromethane solution, 2.5 mL) was added dropwise to a mixture of (1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]thiopheno[2,3-d]pyridazin-7-yl}amino)cyclohexyl-1-ol (210 mg) and dichloromethane (2.5 mL), and the mixture was stirred at 0 °C for 2 hours. A saturated aqueous solution of sodium bicarbonate and methanol were added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate), and dichloromethane was added to the purified product, followed by grinding. The precipitated solid was filtered, washed with dichloromethane, and dried under reduced pressure to obtain 2-(7-{[(1R,2R)-2-hydroxycyclohexyl]amino}thieno[2,3-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (75 mg) in solid form.
Example 95
Under ice-cold stirring, boron tribromide (0.7 mL of 17% dichloromethane solution) was added to a mixture of [(1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)cyclohexyl]carbamate tert-butyl ester (73 mg) and dichloromethane (1 mL), and the mixture was naturally heated to room temperature while stirring for 5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) to give 2-(1-{[(1R,2R)-2-aminocyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (44 mg) in solid form.
Example 96
A mixture of (3R)-3-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (194 mg), dichloromethane (4 mL), and trifluoroacetic acid (0.66 mL) was stirred at room temperature for 5.5 hours. Water was added to the reaction mixture, and the aqueous layer was washed with dichloromethane. The organic layer was extracted with 10% hydrochloric acid, and the aqueous layers were combined. Potassium carbonate and saturated sodium bicarbonate solution were added to make the mixture alkaline. The aqueous layer was extracted with dichloromethane/methanol. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Dichloromethane and hexane were added to the resulting residue, and the mixture was ground. The precipitated solid was filtered and dried under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (80 mg) in solid form. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg) in solid form.
Example 97
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg), dichloromethane (1 mL), methanol (0.1 mL), 3-oxetane (19.9 μL), and sodium triacetoxyborohydride (68 mg) was stirred at room temperature for 5 hours. 3-oxetane (39.9 μL) and sodium triacetoxyborohydride (136 mg) were added to the reaction mixture, and the mixture was stirred at room temperature for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to obtain 2-(4-{[(3R)-1-(oxecyclobut-3-yl)piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (45 mg) in solid form.
Example 98
A mixture of 264 mg of 1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-carboxylic acid tert-butyl ester, dichloromethane (5 mL), and trifluoroacetic acid (0.9 mL) was stirred at room temperature for 5 hours. Under ice-cold stirring, a saturated aqueous solution of sodium bicarbonate, dichloromethane, and methanol were added to the reaction mixture. Extraction was performed with dichloromethane, and the mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Ethyl acetate was added to the resulting residue, and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give 72 mg of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol as a solid. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (21 mg) in solid form.
Example 99
Sodium triacetoxyborohydride (75 mg) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (70 mg), methanol (1.8 mL), and 37% formaldehyde aqueous solution (20 μL) under stirring at room temperature, and the mixture was stirred for 4 hours at room temperature. A saturated sodium bicarbonate aqueous solution was added to the reaction mixture, and the precipitated solid was filtered off and washed with water. The filtered solid was dried, and hexane/ethyl acetate was added and the mixture was ground. The precipitated solid was filtered off, washed with hexane, and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (35 mg) in solid form.
Example 111
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (236 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (342 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 68 mg), potassium carbonate (229 mg), 1,4-dioxane (8 mL), and water (2 mL) was stirred at 107–112 °C for 14 hours. After cooling the reaction mixture to room temperature, [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (171 mg) and PdCl₂ (dppf)· CH₂Cl₂ (68 mg ) were added, and the mixture was further stirred at 110–120 °C for 2 hours. The reaction mixture was then injected into a mixture of water and a saturated sodium chloride aqueous solution and extracted with ethyl acetate. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate). The purified product was dissolved in a small amount of dichloromethane, hexane was added, the precipitated solid was filtered off and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (39 mg) in solid form.
Example 112
A solution of ethyl hydrochloride (4M, 4 mL) was added to a mixture of 1-[4-cyclopropyl-2-(methoxymethoxy)phenyl]-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (250 mg) and ethyl acetate (5 mL) at 25 °C, and the mixture was stirred for 1 hour at the same temperature. After adding water and a saturated aqueous sodium bicarbonate solution to the reaction mixture, extraction was performed with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. After the solution was concentrated under reduced pressure, the residue was purified by reversed-phase preparative HPLC (ODS column, ammonia + ammonium bicarbonate aqueous solution/acetonitrile) to obtain 5-cyclopropyl-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (29.3 mg) in solid form.
Example 114
A mixture of (1S,3R)-3-({4-[4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (122 mg), trifluoroacetic acid (0.48 mL), and dichloromethane (2 mL) was stirred at room temperature for 5 hours. While stirring the reaction mixture under ice-cold conditions, a saturated aqueous solution of sodium bicarbonate was added until the foaming subsided, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol (58 mg) as a solid.
Example 117
In a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (62 mg), DIPEA (33 μL), and dichloromethane (1.6 mL), acetic anhydride (18 μL) was added while stirring under ice-cold conditions, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered, the filtered solid was washed with dichloromethane, and dried to give 1-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-yl)ethyl-1-one (58 mg) in solid form.
Example 124
At room temperature, a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and THF (4 mL) was added to (1H-benzotriazol-1-yl)methanol (86 mg) and sodium acetate (55 mg), and stirred for 10 minutes at the same temperature. Sodium triacetoxyborohydride (125 mg) was added to the resulting mixture, and the mixture was stirred for 1 hour at room temperature. Water and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, followed by extraction with chloroform/methanol (9/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product, and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (72 mg) in solid form.
Example 126
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (71 mg), [(1-ethoxycyclopropyl)oxy]tri(methyl)silane (72 μL), sodium cyanoborohydride (17 mg), acetic acid (16 μL), THF (1 mL), and methanol (1 mL) was stirred at 49–54 °C for 15.5 hours. The reaction mixture was cooled to room temperature, and 10% sodium hydroxide solution was added. The solution was prepared to a pH of approximately 7–8, and then extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol) to give 2-(4-{[(3R)-1-cyclopropylpiperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15 mg) in solid form.
Example 127
Hydrochloric acid (12M, 0.5mL) was added to a mixture of 2-(4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (60mg) and methanol (2mL) at room temperature, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was chilled, and an aqueous solution of sodium hydroxide (1M, 6mL) was added, followed by extraction with chloroform and chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (25.7 mg) in solid form.
Example 128
TFA (0.5 mL) was added to a mixture of (3R)-3-({1-[2-hydroxy-4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (29 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and THF (4 mL), sodium acetate (15 mg), and (1H-benzotriazol-1-yl)methanol (25 mg) were added to the residue, and the mixture was stirred for 10 minutes at room temperature. Sodium triacetoxyborohydride (36 mg) was added to the resulting mixture, and the mixture was stirred for 2 hours at room temperature. A saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride were added to the reaction mixture, and the mixture was extracted with chloroform/methanol (9/1). After neutralization with 1 M hydrochloric acid in the aqueous layer, the mixture was extracted with chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to give 2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (14.3 mg) in solid form.
Example 129
Oxone (registered trademark) (1.3 g) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-thiaro[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (300 mg), acetonitrile (5 mL), and water (5 mL) at 25 °C, and the mixture was stirred for 2 hours at the same temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. Acetonitrile and water were added to the residue, and the mixture was freeze-dried to give 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydro- 6λ6 -thiaro[3,4-d]pyridazin-6,6(5H)-dione (185 mg) as a solid.
Example 132
A mixture of 2-(7,7-dimethyl-4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (50 mg), 2,2-difluoroethyl trifluoromethanesulfonate (19 μL), triethylamine (49 μL), and ethanol (1.2 mL) was stirred at 54–62 °C for 17 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and then extracted with dichloromethane after adding water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then dichloromethane/methanol). The purified product was dissolved in toluene and extracted with 5% aqueous sodium hydroxide solution, water, and saturated aqueous sodium chloride solution. The aqueous layer was washed with toluene, 10% hydrochloric acid was added, and then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/hexane/methanol, then hexane/ethyl acetate) to give 2-(4-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]amino}-7,7-dimethyl-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (6 mg) in solid form.
Example 133
A solution of 1,4-dioxane hydrogen chloride (4M, 0.11 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (150 mg) and dichloromethane (1.5 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (3 mL) was added, and the mixture was stirred at 50 °C for 48 hours. After cooling to room temperature, the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (149 mg) in crystalline form.
Example 134
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.074 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (103 mg) as a solid.
Example 135
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.071 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5-(trifluoromethoxy)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride (95 mg) in crystalline form.
Example 136
A solution of 1,4-dioxane hydrogen chloride (4M, 0.147 mL) was added to a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred for 120 hours at room temperature. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride (122 mg) as a solid.
The compounds of the manufacturing examples and embodiments shown in the table below were manufactured in the same manner as those of the manufacturing examples or embodiments described above.
[Table 3-1]
[Table 3-2]
[Table 3-3]
[Table 3-4]
[Table 3-5]
[Table 3-6]
[Table 3-7]
[Table 3-8]
[Table 3-9]
[Table 3-10]
[Table 4-1]
[Table 4-2]
[Table 4-3]
[Table 4-4]
[Table 4-5]
[Table 4-6]
[Table 4-7]
[Table 4-8]
[Table 5-1]
PEx PSyn DAT
1 - ESI+; 282.2, 284.2
2 - ESI+; 284.2, 286.1
3(1) - ESI+; 373.2, 375.2
3(2) - ES1+; 373.2, 376.2
4 - ESI+; 284.1, 286.1
5 - ESI+; 298.1, 300.2
6 1 FAB; 242.2
7 1 ESI+; 228.1, 230.1
8 1 ESI+; 333.2, 335.2
9 1 ESI+; 284.3, 286.3
10 1 ESI+; 264.3, 266.3
11 1 ESI+; 264.2, 266.2
12 1 ESI+; 264.3, 266.3
13 1 ESI+; 278.3, 280.3
14 1 ESI+; 239.1, 241.1
15 1 ESI+; 242.1, 244.0
16 1 ESI+; 228.1, 230.1
17 1 ESI+; 268.2, 270.2
18 1 ESI+; 242.2, 244.2
19 1 FAB; 377.1
20 1 FAB; 319.0
twenty one 1 FAB; 268.0
twenty two 1 ESI+; 268.1, 270.1
twenty three 1 ESI+; 296.1, 298.2
twenty four 1 ESI+; 284.2, 286.1
25(1) 1 ESI+; 284.1, 286.1
25(2) 1 ESI+; 284.I, 286.1
26 1 ESI+; 298.1, 300.1
27 1 ESI+; 282.2, 284.2
28 1 ESI+; 267.1, 269.1
29 1 ESI+; 270.1, 272.1
30 1 FAB; 254.0
31 1 FAB; 270.0
32 1 ESI+; 383.2, 385.2
33 1 FAB; 305.0
[Table 5-2]
PEx PSyn DAT
34 1 FAB; 277.0
35 1 ESI+; 284.1, 286.1
36 1 ESI+; 284.2, 286.2
37 1 ESI+; 321.3, 323.3
38 1 ESI+; 283.2, 285.2
39 1 ESI+; 293.0, 295.0
40 1 ESI+; 367.2, 369.2
41 1 ESI+; 369.3, 371.4
42 - ESI+; 168.3
43 - ESI+; 258.3
44 - ESI+; 294.3, 296.3, 298.3
45 - ESI+; 313.2
46 45 ESI+; 352.4
47 - ESI+; 450.3
48 - ESI+; 499.3
49 47 ESI+; 478.4
50 47 FAB; 503.6
51 47 ESI+; 434.3
52 47 ESI+; 470.3
53 47 ESI+; 499.2
54(1) 47 ESI+; 509.2
54(2) 47 ESI+; 509.2
55 47 ESI+; 515.2
56 47 ESI+; 445.3
57 47 ESI+; 472.3
58 47 ESI+; 436.3
59 47 ESI+; 424.4
60 47 ESI+; 523.3
61 47 ESI+; 493.5
62 47 ESI+; 495.5
63 - ESI+; 520.4
64 - ESI+; 378.2
65 - ESI+; 462.3
66 67 FAB; 236.9
67 - ESI+; 223.1, 225.1
[Table 5-3]
PEx PSyn DAT
68 69 FAB; 241.0
69 - ESI+; 227.1, 229.1
70 - ESI+; 281.0
71 70 ESI+; 295.0
72 - ESI+; 280.1, 282.1
73 - ESI+; 205.0, 207.0
74 - ESI+; 219.0, 221.0
75 73 ESI+; 304.1
76 - ESI - 259.0
77 - ESI+; 353.2 [M+Na]+
78 77 EI; 314.2
79 77 EI; 350.1
80 77 ESI+; 283.2 [M+Na]+
81 - ESI+; 245.0
82 81 EI; 302.0
83 - EI: 266.0
84 - CI; 282.9
85 - ESI+; 296.2, 298.2
86 - ESI+; 271.2
87 - ESI+; 182.1
88 - ESI+; 242.1
89 - ESI+; 153.0
90 - ESI+; 340.2
91 - ESI+; 251.2
92 - ESI+; 355.2
93 - ESI+; 487.2
94 - FAB; 364.1
95 94 FAB; 278.0
96 - FAB; 264.0
97 - FAB; 306.0
98 - CI; 229.1
99 - ESI+; 255.2
100 - ESI+; 284.1, 286.0
101 - ESI+; 409.3
102 - ESI+; 255.2
[Table 5-4]
[Table 5-5]
PEx PSyn DAT
107 72 ESI+; 281.1
108 1 ESI+; 286.1
109(1) 1 ESI+; 300.1, 302.1
109(2) 1 ESI+; 300.1, 302.1
110 1 ESI+; 324.2
111 1 ESI+; 357.0
112 1 ESI+; 369.2, 371.2
113 1 ESI+; 298.2, 300.2
114 - ESI+; 369.3
115 1 ESI+; 369.0
116 - ESI+; 286.1, 288.0
117 1 ESI+; 371.2, 373.3
118 1 <![CDATA[ESI+;377.3,379.3[M+Na]<sup>+</sup>]]>
119 1 ESI+; 270.1, 272.1
120 - ESI+; 270.1, 272.0
121 1 <![CDATA[ESI+;421.3, 423, 3[M+Na]<sup>+</sup>]]>
122 - <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm4.40(4H, s)]]>
123 44 <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm1.88(6H, s)4.25(2H, s)]]>
124 47 ESI+; 540.5
125 47 ESI+; 511.4
126 47 ESI+; 483.3
127 47 ESI+; 495.3
128(1) - ESI+; 537.4
128(2) - ESI+; 537.4
129 47 ESI+; 425.2
130 47 ESI+; 435.2
131 47 ESI+; 497.3
132 47 ESI+; 481.4
133 47 ESI+; 422.3
134 - ESI+; 422.3
135 47 ESI+; 525.1
136 64 -
137 64 ESI+; 395.2
138 64 ESI+; 397.2
139 64 ESI+; 381.3
[Table 5-6]
[Table 5-7]
[Table 6-1]
[Table 6-2]
Ex Syn DAT
6 1 ESI+; 298.1
7 1 FAB; 314.3
8 1 ESI+; 406.3
9 1 ESI+; 511.2
10 1 ESI+; 439.3
11 1 ESI+; 410.3
12 1 ESI+; 390.3
13 1 ESI+; 390.4
14 1 ESI+; 390.3
15 1 ESI+; 404.2
16(1) 1 FAB; 365.1
16(2) 1 FAB; 365.0
17 1 ESI+; 368.1
18 1 ESI+; 354.2
19 1 ESI+; 394.3
20 1 FAB; 367.2
twenty one 1 ESI+; 368.2
twenty two 1 ESI+; 353.2
twenty three 1 FAB; 445.2
twenty four 1 FAB; 394.2
25 1 ESI+; 374.2, 376.1
26 1 ESI+; 354.2
27 1 ESI+; 424.2
28 1 ESI+; 370.3
29 1 ESI+; 394.2
30 1 ESI+; 360.2, 362.1
31 1 ESI+; 340.2
32 1 ESI+; 410.2
33 1 ESI+; 356.2
34 1 ESI+; 422.3
35 1 ESI+; 410.2
36 I ESI+; 356.2
[Table 6-3]
Ex Syn DAT
37 1 ESI+; 426.2
38 1 ESI+; 372.2
39 1 ESI+; 376.2, 378.2
40 1 ESI+; 406.3
41 1 ESI+; 410.3
42 1 ESI+; 410.2
43 1 ESI+; 438.3
44 1 ESI+; 424.2
45 1 ESI+; 440.2
46 1 ESI+; 370.3
47 1 ESI+; 384.3
48 1 ESI+; 408.2
49 1 ESI+; 386.3
50 1 ESI+; 393.2
51 1 ESI+; 380.3
52(1) 1 ESI+; 382.3
52(2) 1 ESI+; 382.3
53 1 ESI+; 422.3
54 1 ESI+; 438.2
55 1 ESI+; 368.3
56(1) 1 ESI+; 396.2
56(2) 1 ESI+; 396.2
57(1) 1 ESI+; 412.2
57(2) 1 ESI+; 412.2
58 1 ESI+; 384.3
59 1 FAB; 380.4
60 1 ESI+; 395.8
61 1 ESI+; 342.2
[Table 6-4]
[Table 6-5]
[Table 6-6]
[Table 6-7]
[Table 6-8]
Industrial applicability
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and are expected to be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Technical Field
This invention relates to cyclopyridazine compounds or salts thereof that have NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Background Technology
Inflammasomes are collections of intracellular proteins triggered by intrinsic/extrinsic alarm molecules. They are mechanisms that exacerbate inflammatory responses induced by the cleavage of inflammatory cytokines IL-1β and IL-18, or by the induction of cell death, through caspase 1 activation. Several types of alarm molecules are known to recognize alarm molecules, including NLRP1, NLRP3, NLRC4, and AIM2. NLRP3 is activated upon recognizing extracellular ATP molecules, pathogen toxins, uric acid or cholesterol crystals, and abnormal protein aggregates, all of which trigger cellular stress.
As diseases caused by gain-of-function variations in NLRP3, Cryopyrin-associated periodic syndrome (CAPS) is known (Nature Genetics, Vol. 29, No. 3, pp. 301-305, 2001). Additionally, it has been reported in gout (Arthritis Research and Therapy, Vol. 12, No. 2, Article No. 206, 2010), non-alcoholic steatohepatitis (Journal of Molecular Medicine, Vol. 92, No. 10, pp. 1069-1082, 2014), inflammatory bowel disease (Gut, Vol. 59, No. 9, pp. 1192-1100, 2010), and Alzheimer's disease (Nature, Vol. 493, No. 7434, pp. 674-678). Increased activation or expression of the NLRP3 inflammasome is observed in a wide variety of diseases, including Parkinson's disease (PLoS ONE, Vol. 8, No. 1, Article No. e55375, 2013), amyotrophic lateral sclerosis (ALS, Vol. 41, No. 1, pp. 93-103, 2018), and multiple system atrophy (Journal of Neuropathology and Extrinsic Neurology, Vol. 77, No. 11, pp. 1055-1065, 2018).
In addition, NLRP3 is known to be activated by α-synuclein filaments to promote the production of IL-1β from microglia; and functional improvement has been observed by administration of NLRP3 inhibitors in a mouse model of α-synuclein filament-induced α-synucleinopathy (Science Translational Medicine, Vol. 10, Article No. eaah4066, 2018).
Patent document 1 describes a compound represented by the following formula that has inhibitory activity on the NLRP3 inflammasome pathway ( R3 and R4 are H, cyano, C1-4 alkyl, or halo- C1-4 alkyl. Other notations in the formula refer to this publication).
[Chemical Formula 1]
Patent document 2 published after the priority date of this application describes a compound represented by the following formula that has an inhibitory effect on NLRP3 inflammasome activation (the notation in the formula is based on that publication).
[Chemical Formula 2]
Patent document 3 published after the priority date of this application describes a compound represented by the following formula that has NLRP3 inhibitory effects (the notations in the formula refer to that publication).
[Chemical Formula 3]
Patent document 4 describes a compound represented by the following formula that has NLRP3 inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 4]
Patent document 5 describes a compound represented by the following formula that has an NLRP1/3 regulating effect (refer to the notation in the formula in this publication).
[Chemical Formula 5]
Patent document 6 describes a compound represented by the following formula that has inhibitory effects on NLRP3 inflammasomes (the notation in the formula is based on that publication).
[Chemical Formula 6]
Patent document 7 describes a compound represented by the following formula that has C5a receptor inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 7]
Patent document 8 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 8]
Patent document 9 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 9]
Patent document 10 describes a compound represented by the following formula that has muscarinic M4 receptor antagonistic activity (the notation in the formula is the same as that in the publication).
[Chemical Formula 10]
Existing technical documents
Patent documents
Patent Document 1: International Publication No. 2020/234715
Patent Document 2: International Publication No. 2021/193897
Patent Document 3: US Patent No. 11,319,319
Patent Document 4: International Publication No. 2019/008025
Patent Document 5: International Publication No. 2017/184604
Patent Document 6: International Publication No. 2018/015445
Patent Document 7: International Publication No. 2006/004589
Patent Document 8: International Publication No. 2014/191737
Patent Document 9: International Publication No. 2015/001348
Patent Document 10: International Publication No. 2021/067696
Summary of the Invention
The problem that the invention aims to solve
Compounds that provide NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions, particularly for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Methods for solving problems
The inventors conducted in-depth research on compounds with NLRP3 inflammasome activation inhibition activity and found that cyclopyridazine compounds have NLRP3 inflammasome activation inhibition activity, and are expected to be used as effective ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, thus completing the present invention.
That is, the present invention relates to compounds of formula (I) or salts thereof, and pharmaceutical compositions containing compounds of formula (I) or salts thereof and one or more excipients.
[Chemical Formula 11]
(in the formula,
Ring A is a C5-8 cycloalkenyl group, a 5-11 member partially unsaturated heterocyclic group, an aryl group, or a heteroaryl group;
R1 may be the same or different from each other, and may be OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, -C1-6 alkylene-aryl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halogenated C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -, -O -, or -CR 4 R 5 -;
R3 is H or C1-6 alkyl;
R4 and R5 are the same or different from each other, and are H or C1-6 alkyl;
R6 is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a -C1-6 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a -C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups;
R7 is -OR 12 , -NR 13 , R 14 , halogen, or cyano;
R8 and R10 are C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen , or cyano;
R9 and R11 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene -NR13R14, halogen, cyano, oxo, -C(O)-C1-6 alkyl , or -S (O) 2 - C1-6 alkyl;
R 12 is H or C 1-6 alkyl;
R13 and R14 may be the same or different from each other, and may be H, C1-6 alkyl or -C(O) -C1-6 alkyl;
n is an integer from 1 to 4, representing the number of R1s used as substituents;
m is an integer from 0 to 3, representing the number of R2 substituents;
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia).
[Chemical Formula 12]
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
k is an integer from 0 to 3, representing the number of R 1a substituents.
It should be noted that, unless otherwise specified, if a symbol used in one chemical formula in this specification is also used in other chemical formulas, the same symbol has the same meaning.
Furthermore, the present invention relates to pharmaceutical compositions containing a compound of formula (I) or a salt thereof and one or more pharmaceutically permissible excipients, particularly pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases. It should be noted that the pharmaceutical composition comprises a preventive and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases containing a compound of formula (I) or a salt thereof.
In addition, the present invention relates to compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation; compounds of formula (I) or salts thereof used as inhibitors of NLRP3 inflammasome activation; NLRP3 inflammasome activation inhibitors containing compounds of formula (I) or salts thereof; pharmaceutical compositions containing compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation and one or more pharmaceutically permissible excipients; use of compounds of formula (I) or salts thereof in the manufacture of medicaments or pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; use of compounds of formula (I) or salts thereof for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; compounds of formula (I) or salts thereof used in the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; and methods for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, including applying an effective amount of a compound of formula (I) or salts thereof to a subject. It should be noted that "object" refers to a person or other animal that needs the prevention and/or treatment, and in a certain way, it refers to a person who needs the prevention and/or treatment.
The effects of the invention
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and can be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Detailed Implementation
The present invention will now be described in detail.
In this specification, unless otherwise specified, the following terms have the meanings indicated below. The definitions below are for clarification and not for limitation. Here, where a term is not specifically defined, it is used in the sense commonly accepted by those skilled in the art.
In this specification, " C1-6 alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms (hereinafter abbreviated as C1-6 ), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,3-dimethylbutyl, 1-ethyl-2-methylpropyl, etc. Alternatively, it may be a straight-chain or branched C1-4 alkyl group; alternatively, it may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl; alternatively, it may be methyl, ethyl, n-propyl, n-butyl, or isobutyl; further alternatively, it may be n-propyl, n-butyl, or isobutyl. Alternatively, it is methyl, ethyl, n-propyl or isopropyl; in one way, it is methyl or ethyl; in another way, it is ethyl; further in another way, it is methyl.
" C1-6 alkylene" is a straight-chain or branched C1-6 divalent saturated hydrocarbon group, such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 2-methyltrimethylene, ethylethylene, 1,2-dimethylethylene, or 1,1,2,2-tetramethylethylene. In one form, it is C1-4 alkylene; in another form, it is methylene or ethylene; further in another form, it is ethylene; and in yet another form, it is methylene.
"C 3-8 cycloalkyl" refers to a C 3-8 saturated hydrocarbon cycloalloy that can be bridged or form a spirocyclic ring. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[3.3.0]octyl, bicyclo[2.2.2]octyl, spiro[2.2]pentyl, spiro[3.3]heptyl, or spiro[2.5]octyl. As one mode, it is a C3-6 saturated hydrocarbon cycloyl group; as another mode, it is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; further as another mode, it is cyclopropyl; as yet another mode, it is cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; as one mode, it is cyclobutyl, cyclopentyl, or cyclohexyl; further as another mode, it is cyclobutyl or cyclohexyl; further as yet another mode, it is cyclobutyl; as yet another mode, it is cyclopentyl; and further as yet another mode, it is cyclohexyl.
"C 5-8 cycloalkenyl" is a C 5-8 hydrocarbon cycloalkenyl group with a single double bond within the molecule, which can be bridged. Examples include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]heptenyl, and bicyclo[2.2.2]octenyl. As one form, it is cyclopentenyl, cyclohexenyl, cycloheptenyl, and bicyclo[2.2.2]octenyl; further as another form, it is cyclopentenyl, cyclohexenyl, and cycloheptenyl; further as yet another form, it is cyclopentenyl; another form, it is cyclohexenyl; and yet another form, it is cycloheptenyl.
When ring A is a C5-8 cycloalkenyl group, [Chemical Formula 13-1] is a partial structure of formulas (I) and (Ia).
(The wavy lines represent the bonding portions with the phenyl and L in formula (I), respectively. The same applies below.)
The C5-8 cycloalkenyl group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 13-2]
"4- to 7-membered saturated heterocyclic groups" refer to 4- to 7-membered saturated hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms, as ring constituent atoms. Examples include oxohexacyclobutyl, azirhexacyclobutyl, thiohexacyclobutyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiopheneyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopheneyl, oxoheptanyl, azirheptanyl, thioheptanyl, dioxoheptanyl, imidazoalkyl, pyrazolyl, dithioheptanyl, oxazolyl, isoxazolyl, thiazoalkyl, isothiazolyl, dioxohexyl, piperazine, dithiohexyl, morpholinyl, thiomorpholinyl, oxathioheptanyl, dioxathioheptanyl, diazirheptanyl, dithioheptanyl, oxaazonyl, thioazonyl, and oxathioheptanyl, but not limited to these. As one embodiment, it is oxetyl, tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, piperidinyl, or tetrahydrothiaranyl; as another embodiment, it is tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is tetrahydropyranyl or piperidinyl; as yet another embodiment, it is tetrahydrofuranyl or tetrahydropyranyl; as yet another embodiment, it is tetrahydrofuranyl; as yet another embodiment, it is tetrahydropyranyl. As another embodiment, it is pyrrolyl or piperidinyl; as yet another embodiment, it is pyrrolyl; as yet another embodiment, it is piperidinyl. As yet another embodiment, it is oxetyl.
"5- to 11-membered partially unsaturated heterocyclic groups" are 5- to 11-membered hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms as ring-forming atoms, and possessing a single double bond within the molecule. They can also exhibit bridging or form spirocyclic rings. Examples include dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydronitroheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydrooxoheptenyl, tetrahydrothioheptenyl, dioxopentenyl, dihydroimidazoyl, dihydropyrazolyl, dithioheptenyl, dihydrooxazolyl, dihydroisooxazolyl, dihydrothiazoyl, dihydroisothiazoyl, and dihydrodioxoheptenyl. Hexenyl, tetrahydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazocyclohexenyl, dihydrodioxazocycloheptenyl, tetrahydrodiazacycloheptenyl, dihydrodithiocycloheptenyl, tetrahydrooxazocycloheptenyl, tetrahydrothiazazacycloheptenyl, dihydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl, 2-oxaspiro[4.5]decenyl, 3-oxaspiro[5.5]undecenyl, but not limited thereto. As one embodiment, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, dihydrothiaranyl, tetrahydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl. In one manner, it is a 5- to 8-membered partially unsaturated heterocyclic group; in another manner, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydroazaheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydroazaheptenyl, tetrahydrothioheptenyl, dioxazol ... Dihydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl; as one embodiment, it is dihydropyrroleyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl; further as another embodiment, it is dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl. As another form, it is dihydrofuranyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxoheptenyl; as another form, it is dihydrofuranyl, dihydropyranyl, tetrahydrooxoheptenyl or 2-oxaspiro[3.5]nonenyl; as another form, it is dihydropyranyl; further as another form, it is tetrahydropyridyl; and as yet another form, it is tetrahydrooxoheptenyl.
When ring A is a 5- to 11-membered partially unsaturated heterocyclic group, as part of the structures of formulas (I) and (Ia)
[Chemical Formula 14-1]
middle,
The 5- to 11-membered partially unsaturated heterocyclic group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 14-2]
"Aryl" is a C6-14 monocyclic to tricyclic aromatic hydrocarbon cyclic group, including bicyclic to tricyclic aromatic hydrocarbon cyclic groups formed by the condensation of its double bond with a C5-8 cyclic alkene. Examples include phenyl, naphthyl, tetrahydronaphthyl, indene, fluorenyl, etc., with phenyl being one example.
When ring A is aryl, as part of the structure of formulas (I) and (Ia)
[Chemical Formula 15-1]
middle,
The aryl benzene ring condenses with the pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 15-2]
"Heteroaryl" refers to a 5- to 6-membered aromatic hydrocarbon cyclic group containing 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen. Examples include pyrrole, furanyl, thiophene, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and tetraazinyl. In one form, it is thiophene or pyridinyl; further, in another form, it is pyridinyl; and still another form, it is thiophene.
When ring A is a heteroaryl group, [Chemical Formula 16-1] is a partial structure of formulas (I) and (Ia).
middle,
The heteroaryl group condenses with a pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 16-2]
"Halogen" refers to F, Cl, Br, or I. In one sense, it is F or Cl; further, in another sense, it is F; in yet another sense, it is Cl.
"Halogenated C1-6 alkyl" refers to a straight-chain or branched C1-6 alkyl group substituted with one or more halogens. Examples include: trifluoromethyl, trifluoroethyl, trifluoropropyl, 2-fluoro-2-methylpropyl, difluoromethyl, difluoroethyl, fluoromethyl, or chloromethyl. In one manner, it is difluoroethyl, trifluoromethyl, or difluoromethyl; further, it is trifluoromethyl or difluoromethyl; in another manner, it is trifluoromethyl; and in yet another manner, it is difluoromethyl.
In this specification, "substitutable" means unsubstituted or "substituted by one or more substituents". The substitution can be at any position, as long as the hydrogen is normally present in the group.
Even if the combination is not specifically recorded, one or more methods can be combined with another method.
In this specification, "inflammatory disease and/or neurodegenerative disease" is, in one sense, an inflammatory disease and a neurodegenerative disease; further, it is an inflammatory disease; and in another sense, it is a neurodegenerative disease.
In this specification, "inflammatory disease" includes, but is not limited to, autoinflammatory diseases such as Cryopyrin-associated periodic fever syndrome (CAPS), gout, and pseudogout; and diseases such as non-alcoholic steatohepatitis (NASH). As one mode, it is an autoinflammatory disease; as another, it is CAPS; and further, it is gout. It should be noted that "Cryopyrin-associated periodic fever syndrome (CAPS)" is a disease group comprised of familial cold urticaria (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multi-organ system inflammatory diseases/infantile chronic neurocutaneous joint syndrome (NOMID/CINCA syndrome).
In this specification, "neurodegenerative diseases" refers to a group of diseases including, but not limited to, alpha-synucleinopathies such as Parkinson's disease, multiple system atrophy, and Lewy body type dementia; Alzheimer's disease; amyotrophic lateral sclerosis (ALS); and multiple sclerosis. One example is Alzheimer's disease, multiple sclerosis, and ALS; another example is multiple sclerosis. Another example is alpha-synucleinopathies; another example is Parkinson's disease; yet another example is multiple system atrophy; and yet another example is Lewy body type dementia.
In this specification, "treatment" includes both "treatment for therapeutic purposes" and "treatment for preventative purposes." "Treatment for therapeutic purposes" refers to alleviating symptoms, altering disease course, or prolonging lifespan, while "treatment for preventative purposes" refers to reducing the likelihood of developing the disease in subjects at risk. "Subjects at risk" refers to individuals with known risk factors who are more susceptible to the disease than the general population.
The compound of formula (I) or a salt thereof in this invention is shown in one of the following ways.
(1-1) Compounds of formula (I) or their salts (n and m represent the number of R1 and R2 as substituents, respectively. The same applies below).
[Chemical Formula 17]
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia) (k represents the number of R 1a as substituents. The same applies below).
[Chemical Formula 18]
(1-2) Compounds of formula (Ia) or their salts.
(1-3) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
[Chemical Formula 19]
(1-4) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
(1-5) Compounds of formula (Ib), (Ic), (Id), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iv), (Iw), (Ix) or (Iy) or their salts.
(1-6) Compounds of formula (Ic), (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-7) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq) or (Ir) or salts thereof.
(1-8) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or their salts.
(1-9) Compounds of formula (Ib), (Ic), (Id) or (Ie) or their salts.
Compounds of formula (Ib) (1-10) or their salts.
Compounds of formula (Ic) or their salts thereof.
Compounds of formula (Id) (1-12) or their salts.
(1-13) A compound of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or a salt thereof.
(1-14) Compounds of formula (If), (Ig), (Ih), (Ii) or (Ij) or their salts.
(1-15) Compounds of formula (Ig), (Ih) or (Ij) or their salts.
Compounds of formula (Ig) (1-16) or their salts.
Compounds of formula (Ih) or their salts thereof.
Compounds of formula (Ij) or their salts. (1-18)
(1-19) Compounds of formula (Ik), (Im) or (In) or their salts.
Compounds of formula (Ik) or their salts thereof.
Compounds of formula (Im) or their salts thereof.
(1-22) Compounds of formula (In) or their salts.
(1-23) Compounds of formula (Io), (Ip), (Iq) or (Ir) or their salts.
Compounds of formula (Io) or their salts thereof.
Compounds of formula (Ip) (1-25) or their salts.
Compounds of formula (Iq) (1-26) or their salts.
Compounds of formula (Ir) or their salts thereof.
(1-28) Compounds of formula (Ic), (Ig), (Ih), (Ij) or (Im) or their salts.
(1-29) Compounds of formula (Ic), (Ih), (Ij) or (Im) or their salts.
(1-30) Compounds of formula (Ic) or formula (Ih) or their salts.
Compounds of formula (Ix) or their salts thereof. (1-31)
Compounds of formula (Iy) or their salts. (1-32)
(1-33) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy).
(1-34) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iu), (Iv), (Iw) or (Iy).
(1-35) Compounds of formula (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-36) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iv), (Iw) or (Iy).
(2-1) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-2) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 8-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-3) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-8 partially unsaturated heterocyclic group.
(2-4) Compounds with ring A being C5-8 cycloalkenyl or their salts.
(2-5) Compounds or their salts in which ring A is a 5- to 8-membered partially unsaturated heterocyclic group.
(2-6) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl, and k is an integer from 0 to 2.
(2-7) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-11 partially unsaturated heterocyclic group.
(2-8) Compounds in which ring A is aryl or heteroaryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-9) Compounds in which ring A is aryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-10) Compounds in which ring A is a heteroaryl group or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-11) Compounds or their salts in which ring A is a partially unsaturated heterocyclic group of 5 to 11 members.
(3-1) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo -C1-6 alkyl, or -OC3-8 cycloalkyl.
(3-2) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halo- C1-6 alkyl.
(4-1) R 1a are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl.
(4-2) R 1a are the same or different from each other, and are compounds of C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl or salts thereof.
(4-3) R 1a are the same or different from each other, and are compounds of halo- C1-6 alkyl, halogen, or -O-halo- C1-6 alkyl or salts thereof.
(4-4) R 1a is a halo- C1-6 alkyl compound or a salt thereof.
(4-5) R 1a is a halogen compound or its salt.
(4-6)R 1a is a compound of -O-halogenated C1-6 alkyl or a salt thereof.
(4-7) R 1a is a compound of C 1-6 alkyl or a salt thereof.
(4-8)R 1a is a compound of C 3-8 cycloalkyl or a salt thereof.
(4-9) R 1a is a compound of -OC 1-6 alkyl or a salt thereof.
(5-1) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-2) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-3) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-4) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C 1-6 alkylene-aryl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-5) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-6) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-7) R2 is a compound of C1-6 alkyl groups or a salt thereof.
(5-8)R 2 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(5-9)R 2 is a compound of -S(O) 2 -C 1-6 alkyl or a salt thereof.
(5-10) R2 is an oxolated compound or its salt.
(6-1)L is a compound of -NR 3- , -O- or -CR 4R 5- or a salt thereof.
(6-2)L is a compound of -NR 3- or -O- or its salt.
(6-3)L is a compound of -NR 3- or its salt.
(6-4)L is a compound of -O- or its salt.
(6-5)L is a compound of -CR4R5- or its salt.
(7-1) R 3 is a compound of H or C 1-6 alkyl or a salt thereof.
(7-2) R 3 is a compound of H or its salt.
(7-3) R 3 is a C1-6 alkyl compound or a salt thereof.
(8-1) R4 and R5 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(8-2) R4 and R5 are both compounds of H or their salts.
(8-3) R4 and R5 are both C1-6 alkyl compounds or their salts.
(9-1) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a C1-6 alkylene group ( a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups.
(9-2) R6 is a compound or a salt thereof consisting of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups), -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups), a C3- to 8-membered cycloalkyl group that may be substituted by 1 to 4 identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R11 groups.
(9-3) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with one R7 , a -C1-6 alkylene group (a C3-8 cycloalkyl group that may be substituted with one R8 ), a -C1-6 alkylene group (a 4- to 7-membered saturated heterocyclic group), a C3-8 cycloalkyl group that may be substituted with one or two identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted with one or two identical or different R11 groups .
(9-4) R6 is a compound or a salt thereof that can be substituted by 1 to 4 identical or different R10s of a C3-8 cycloalkyl group or a 4- to 7-membered saturated heterocyclic group that can be substituted by 1 to 4 identical or different R11s .
(9-5) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 4 identical or different R7s .
(9-6) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 3 identical or different R7s .
(9-7) R6 is a compound of C1-6 alkyl group or a salt thereof that is substituted with 1 to 2 identical or different R7 groups .
(9-8) R6 is a compound of a C1-6 alkyl group substituted with one R7 or a salt thereof.
(9-9) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups ) or a salt thereof.
(9-10) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 3 identical or different R8 groups ) or a salt thereof.
(9-11) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 2 identical or different R8 groups ) or a salt thereof.
(9-12) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by one R8 ) or a salt thereof.
(9-13) R 6 is a compound of -C 1-6 alkylene-C 3-8 cycloalkyl or a salt thereof.
(9-14) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups ) or a salt thereof.
(9-15) R6 is a compound or a salt thereof of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 3 identical or different R9 groups).
(9-16) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 2 identical or different R9 groups ) or a salt thereof.
(9-17) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by one R9 ) or a salt thereof.
(9-18) R 6 is a compound of -C 1-6 alkylene-(4-7 membered saturated heterocyclic group) or a salt thereof.
(9-19) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R10s of C3-8 cycloalkyl groups.
(9-20) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R10s of C3-8 cycloalkyl groups.
(9-21) R6 is a compound or a salt thereof that can be substituted by one or two identical or different R10s of a C3-8 cycloalkyl group.
(9-22) R6 is a compound of C3-8 cycloalkyl group or a salt thereof that can be replaced by one R10 .
(9-23) R6 is a compound of C3-8 cycloalkyl or a salt thereof.
(9-24) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-25) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-26) R6 is a compound or a salt thereof that can be replaced by 1 to 2 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-27) R6 is a compound or a salt thereof that can be replaced by a 4- to 7-membered saturated heterocyclic group of one R11 .
(9-28) R6 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(9-29) R6 is a C1-6 alkyl group substituted with one R7 , a C3-8 cycloalkyl group substituted with one or two identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with one or two identical or different R11 groups, or a salt thereof.
(9-30) R6 is a compound or a salt thereof that can be substituted by 1 to 2 identical or different R10s , or by 1 to 2 identical or different R11s , of a C3-8 cycloalkyl group.
(9-31) R6 is a compound or a salt thereof that can be replaced by a C3-8 cycloalkyl group that is substituted by one R10 or by a 4-7 member saturated heterocyclic group that is substituted by one R11 .
(10-1) R 7 is a compound of -OR 12 , -NR 13 , R 14 , halogen or cyano, or a salt thereof.
(10-2) R 7 is a compound of -OR 12 or -NR 13 R 14 or a salt thereof.
(10-3)R 7 is a compound of -OR 12 or a salt thereof.
(10-4)R 7 is a compound of -NR 13 R 14 or a salt thereof.
(10-5)R 7 is a halogen compound or a salt thereof.
(10-6)R 7 is a cyano compound or a salt thereof.
(11-1) R8 is a C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen or cyano compound or salt thereof.
(11-2) R8 is a compound of -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 or a salt thereof.
(11-3) R8 is a compound of C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , halogen, or cyano, or a salt thereof .
(11-4) R8 is a compound of -OR12 , -C1-6 alkylene- OR12 or a salt thereof.
(11-5) R 8 is a compound of -OR 12 or a salt thereof.
(11-6)R 8 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(12-1) R 9 is a compound of C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl or a salt thereof.
(12-2) R 9 is a compound or a salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(13-1) R 10 is a compound of C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, or cyano, or a salt thereof.
(13-2) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , halogen or cyano, or a salt thereof.
(13-3) R 10 is a C 1-6 alkyl compound or a -OR 12 compound or a salt thereof.
(13-4) R 10 is a compound of C1-6 alkyl groups or a salt thereof.
(13-5) R 10 is a compound of -OR 12 or a salt thereof.
(13-6) R 10 is a compound of -NR 13 R 14 or a salt thereof.
(13-7) R 10 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(13-8) R 10 is a halogen compound or a salt thereof.
(13-9) R 10 is a cyano compound or a salt thereof.
(13-10)R 10 is a compound of C1-6 alkyl, -OR 12 , -NR 13 R 14 , or cyano groups or a salt thereof.
(13-11) R 10 is a compound of C 1-6 alkyl, -OR 12 , or cyano groups or a salt thereof.
(13-12) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , or cyano, or a salt thereof.
(14-1) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or a salt thereof.
(14-2) R 11 is a compound or salt thereof of C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O)-C 1-6 alkyl.
(14-3) R 11 is a compound of C1-6 alkyl groups or a salt thereof.
(14-4)R 11 is a compound of C3-8 cycloalkyl or a salt thereof.
(14-5) R 11 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(14-6) R 11 is a compound of -OR 12 or a salt thereof.
(14-7) R 11 is an oxolated compound or its salt.
(14-8)R 11 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(14-9) R 11 is a compound or salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 member saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(14-10) R 11 is a compound of C 1-6 alkyl or -OR 12 or a salt thereof.
(14-11) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, -OR 12 , or -C(O)-C 1-6 alkyl or a salt thereof.
(15-1) R 12 is a compound of H or C 1-6 alkyl or a salt thereof.
(15-2) R 12 is a compound of H or its salt.
(15-3) R 12 is a compound of C1-6 alkyl groups or a salt thereof.
(16-1) R13 and R14 are the same or different from each other, and are compounds of H, C1-6 alkyl or -C(O) -C1-6 alkyl or salts thereof.
(16-2) R13 and R14 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(16-3) R13 and R14 are both compounds of H or their salts.
(16-4) A compound in which both R13 and R14 are H or salts thereof, or a compound in which R13 is -C(O) -C1-6 alkyl and R14 is H or salts thereof.
(16-5) R 13 is a -C(O)-C 1-6 alkyl compound, R 14 is H, or a salt thereof.
(17-1) n is an integer from 1 to 4, or a salt thereof.
(17-2) n is an integer from 1 to 3, or a salt thereof.
(17-3) A compound or its salt in which n is 1 or 2.
(17-4) Compounds or their salts in which n is 2.
(17-5) Compounds or their salts in which n is 1.
(18-1) m is an integer from 0 to 3, or a salt thereof.
(18-2)m is an integer from 0 to 2, which is a compound or its salt.
(18-3)A compound or its salt in which m is 0 or 1.
(18-4) Compounds or their salts with m = 1.
(18-5) Compounds or their salts where m is 0.
(19-1)k is an integer from 0 to 3, which is a compound or its salt.
(19-2)k is an integer from 0 to 2, which is a compound or its salt.
(19-3) Compounds or their salts in which k is 0 or 1.
(19-4) Compounds or their salts in which k is 1.
(19-5) Compounds or their salts in which k is 0.
(19-6)k is a compound or its salt where k is 1 or 2.
(20) A compound or its salt that is a combination of two or more groups described in (1-1) to (19-6) above without contradiction. Examples of such combinations are as follows, but not limited thereto.
(20-1) Compounds or salts thereof that are combinations of (1-1), (2-2), (3-1), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (17-1), (18-1), and (19-1).
(20-2) Compounds or salts thereof that are combinations of (1-2), (2-2), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-3) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-4) Compounds or salts thereof that are combinations of (1-2), (2-6), (4-2), (5-5), (6-1), (7-2), (8-2), (9-3), (10-2), (11-3), (12-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-5) Compounds or salts thereof that are combinations of (1-2), (2-7), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-6) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-3), (5-7), (6-3), (7-2), (9-30), (13-3), (14-10), (15-2), (18-3), and (19-6).
(20-7) Compounds or salts thereof that are combinations of (1-2), (2-11), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-8) Compounds or salts thereof that are combinations of (1-34), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-10), (15-2), (16-4), (18-5), and (19-2).
(20-9) Compounds or salts thereof that are combinations of (1-17), (4-2), (6-3), (7-2), (9-29), (10-2), (13-11), (14-10), (15-2), (16-5), (18-5), and (19-2).
(20-10) Compounds or salts thereof that are combinations of (1-6), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-11) Compounds or salts thereof that are combinations of (1-35), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-12) Compounds or salts thereof that are combinations of (1-7), (4-2), (5-4), (6-1), (7-2), (8-2), (9-3), (10-2), (11-4), (13-2), (14-2), (15-2), (16-4), (18-3), and (19-2).
(20-13) Compounds or salts thereof that are combinations of (1-28), (4-3), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-3), and (19-4) above.
(20-14) Compounds or salts thereof that are combinations of (1-11), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-15) Compounds or salts thereof that are combinations of (1-17), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-16) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-17) Compounds or salts thereof that are combinations of (1-11), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-18) Compounds or salts thereof that are combinations of (1-21), (4-4), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-4), and (19-4) above.
(20-19) Compounds or salts thereof that are combinations of (1-18), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-20) Compounds or salts thereof that are combinations of (1-17), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-21) Compounds or salts thereof that are combinations of (1-16), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-22) Compounds or salts thereof that are combinations of (1-16), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-23) Compounds or salts thereof that are combinations of (1-16), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-24) Compounds or salts thereof that are combinations of (1-31), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-25) Compounds or salts thereof that are combinations of (1-32), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-26) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-27), (14-3), (18-5), and (19-4) above.
Examples of specific compounds included in this invention include compounds selected from the group consisting of compounds or salts thereof.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5)-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
Examples of specific compounds included in this invention include the following group of compounds.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
In addition, the following group of compounds can be listed as one example of specific compounds included in the present invention.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
Depending on the type of substituent, compounds of formula (I) may contain tautomers or geometric isomers. In this specification, compounds of formula (I) or their salts are sometimes described as only one form of isomer, but the present invention also includes other isomers, as well as substances obtained by isomer separation, or mixtures thereof.
Furthermore, in cases where the compound of formula (I) or its salt has an asymmetric center or axial asymmetry, enantiomers (optical isomers) based thereon may exist. The compound of formula (I) or its salt also includes any of the separated enantiomers such as (R) bodies, (S) bodies, etc., and mixtures thereof (including racemic or non-racemic mixtures). In one manner, the enantiomer is "stereochemically pure." "Stereochemically pure" means a purity that can be recognized by a person skilled in the art as substantially stereochemically pure. Alternatively, the enantiomer is a compound having a stereochemical purity of, for example, 90% ee (enantiomeric excess) or more, 95% ee or more, 98% ee or more, or 99% ee or more.
Furthermore, the present invention also includes pharmaceutically permissible prodrugs of compounds represented by formula (I). A pharmaceutically permissible prodrug is a compound having groups that can be converted to amino, hydroxyl, carboxyl, or other groups by solvent decomposition or under physiological conditions. Examples of groups forming prodrugs include those described in Prog. Med., 5, 2157-2161 (1985), or in "Development of Pharmaceuticals" (Hirokawa Shoten, 1990), Vol. 7, Molecular Design, pp. 163-198.
Furthermore, salts of compounds of formula (I) are pharmaceutically permissible salts of compounds of formula (I). Depending on the type of substituent, they may sometimes form acid addition salts or salts with bases. Specifically, examples include: acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; or with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, dibenzoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid; salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; and salts with organic bases such as methylamine, ethylamine, ethanolamine, lysine, and ornithine; and salts or ammonium salts with various amino acids and amino acid derivatives such as acetylleucine.
Furthermore, the present invention also includes various hydrates or solvates of compounds of formula (I) or salts thereof, as well as polymorphic substances.
Furthermore, this invention includes all pharmaceutically permissible compounds of formula (I) or salts thereof labeled with one or more radioactive or non-radioactive isotopes. Examples of suitable isotopes used in the isotopic labeling of the compounds of this invention include isotopes of hydrogen (e.g., 2H and 3H ), carbon (e.g., 11C , 13C , and 14C ), nitrogen (e.g., 13N and 15N ), oxygen (e.g., 15O , 17O , and 18O ), fluorine (e.g., 18F ), chlorine (e.g., 36Cl ), iodine (e.g., 123I and 125I ), phosphorus (e.g., 32P ), and sulfur (e.g., 35S ). The isotopically labeled compounds of this invention can be used for studies such as the tissue distribution of drugs and/or matrices. For example, radioactive isotopes such as tritium ( 3H ) and carbon-14 ( 14C ) are suitable for this purpose due to their ease of labeling and detection. Substitution with heavier isotopes, such as hydrogen replacing deuterium ( 2H ), can sometimes be therapeutically advantageous due to increased metabolic stability (e.g., increased in vivo half-life, reduced dosage, and fewer drug interactions). Substitution with positron-emitting isotopes ( ¹¹C , ¹⁸F , ¹⁵O , and ¹³N , etc.) can be used in positron emission tomography (PET) assays to test matrix receptor occupancy. The isotopically labeled compounds of the present invention can generally be manufactured by conventional methods known to those skilled in the art, or by using suitable isotopically labeled reagents instead of unlabeled reagents, and by employing the same preparation methods as in the examples or manufacturing examples. For example, by subjecting 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (the compound of manufacturing example 64) to a known [ 11 C] acetylation reaction (International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, Vol. 39, No. 4, pp. 287-290, 1988), a compound of example 81 in which the carbonyl carbon atom is substituted with 11 C can be obtained.
(Manufacturing method)
Compounds of formula (I) or their salts can be manufactured using various known synthetic methods based on their basic structure or the types of substituents. In this case, depending on the type of functional group, it is sometimes technically effective to replace that functional group with a suitable protecting group (a group that can be easily converted into that functional group) during the process from the starting material to the intermediate. Examples of such protecting groups include those described in "Greene's Protective Groups in Organic Synthesis" (4th edition, 2006) by Wuts (P.G.M. Wuts) and Greene (T.W. Greene), which can be appropriately selected based on their reaction conditions. In such methods, the desired compound can be obtained by introducing the protecting group, reacting, and then removing the protecting group as needed.
Furthermore, the prodrug of the compound of formula (I) can be manufactured by introducing specific groups during the process from the starting material to the intermediate, similar to the protecting group described above, or by further reacting the obtained compound of formula (I). The reaction can be carried out using methods known to those skilled in the art, such as conventional esterification, amidation, and dehydration.
The following describes representative methods for manufacturing compounds of formula (I). Each method can also be performed with reference to the appended references. It should be noted that the manufacturing methods of the present invention are not limited to the examples shown below.
The following abbreviations are sometimes used in this specification.
CN: Cyano, COMU: ({[(1-cyano-2-oxoethylidene)amino]oxy}-4-morpholinomethylene)dimethylammonium hexafluorophosphate, DMF: N,N-dimethylformamide, DMSO: dimethyl sulfoxide, DIPEA: N,N-diisopropylethylamine, EDC·HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide of hexafluorophosphate, HOBt: 1-hydroxybenzotriazole, NMP: 1-methylpyrrolidone-2-one, Me: Methyl, Oxone (registered trademark): potassium persulfate, Pd-118: [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloroisocyanurate, PdCl₂ ( PPh₃ ) ₂ PdCl₂ (dppf): [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, PdCl₂ (dppf)· CH₂Cl₂ : [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride·dichloromethane adduct, Pd₂ (dba) ₃ : (1E,4E)-1,5-diphenylpentan-1,4-dien-3-one/palladium (3:2), Pd( PPh₃ ) ₄ : tetrakis (triphenylphosphino)palladium, RuPhos Pd G₃: (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate, SPhos Pd G3: (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)methanesulfonic acid, TBS: tert-butyl(dimethyl)silyl, THF: tetrahydrofuran, Tf: trifluoromethanesulfonyl, TFA: trifluoroacetic acid, XPhos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, ODS: octadecylsilyl.
(First System)
[Chemical Formula 20]
( X1 is a halogen, Ra and Rb are both H, or Ra and Rb and the borate residues bonded to Ra and Rb form 4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane. The same applies below.)
(First step)
This step involves reacting a compound of formula (IIa) with compounds of formulas (IIIa) to (IIIc) to obtain a compound of formula (IV). The choice of steps 1 to 5 can be made depending on the type of L used as a linking group.
(Step 1-1)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIa) to obtain a compound of formula (IV) where L is -O-. In this reaction, equal amounts of the compound of formula (IIIa) and the compound of formula (IIIa), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0–190°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Examples of bases are not particularly limited and include sodium hydride, potassium tert-butoxide, sodium hydroxide, and potassium hydroxide. The presence of phase-transfer catalysts such as benzyltrimethylammonium chloride, tetrabutylammonium bromide, and 18-crown-6-ether can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-2)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in a solvent inert to the reaction or in the absence of a solvent, under cooling to reflux, preferably at 0°C to 220°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-3)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst, a ligand, and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, such as palladium acetate and Pd₂ (dba) ₃ . Examples of ligands are not particularly limited, such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, tri-tert-butylphosphine, and XPhos. Examples of bases are not particularly limited, such as tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, and potassium tert-butoxide. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
[literature]
Journal of the American Chemical Society, 127, pp4685-4696(2005)
(Step 1-4)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . This step consists of a first stage that converts a compound of formula (IIa) into a compound of formula (IIb), and a second stage that converts a compound of formula (IIb) into a compound of formula (IV).
(Phase 1)
In this reaction, the compound of formula (IIa) is reacted in hydroiodic acid in the presence of a metal iodide, under cooling to reflux, preferably at room temperature to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of the metal iodide used herein are not particularly limited, and include sodium iodide, potassium iodide, etc.
(Phase Two)
In this reaction, equal amounts of compounds of formula (IIb) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 190°C. Examples of catalysts used herein are not particularly limited, including copper iodide (I), copper oxide (I), copper bromide (I), copper chloride (I), and copper 2-thiophenecarboxylate (I). The presence of ligands such as proline and ethylenediamine is sometimes advantageous for facilitating the reaction. Examples of bases are not particularly limited, including tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, and N,N-diisopropylethylamine. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-5)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIc) to obtain a compound of formula (IV) where L is -CR4R5- . In this reaction, equal amounts of the compounds of formula (IIa) and ( IIIc ), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include copper iodide (I) and iron acetylacetone (III). Examples of solvents are not particularly limited, but include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Alternatively, this reaction can be carried out under microwave irradiation.
(Second Step)
This step involves reacting a compound of formula (IV) with a compound of formula (V) to obtain a compound of formula (I). In this reaction, equal amounts of the compounds of formula (IV) and (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 (dba) 3 , RuPhos Pd G3, SPhos Pd G3, Pd-118, etc. Examples of bases are not particularly limited and can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, potassium acetate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are also not particularly limited and can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation.
(Second system)
[Chemical Formula 21]
(R 6a is a C1-5 alkyl group substituted with 1 to 4 identical or different R 7 groups, a -C1-5 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R 8 groups), or a -C1-5 alkylene group (a 4- to 7-membered saturated heterocyclic group substituted with 1 to 4 identical or different R 9 groups). The same applies below.
This method is for preparing the following compound (Iz): in the compound of formula (I), L is -CR4R5- , R4 and R5 are both H, R6 is -CH2- (a C1-5 alkyl group substituted by 1 to 4 identical or different R7 groups), -CH2 - C1-5 alkylene- (a C3-8 cycloalkyl group substituted by 1 to 4 identical or different R8 groups), or -CH2 - C1-5 alkylene- (a 4- to 7-membered saturated heterocyclic group substituted by 1 to 4 identical or different R9 groups).
(First step)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIId) to obtain a compound of formula (VI). In this reaction, equal amounts of the compound of formula (IIa) and the compound of formula (IIId), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base, preferably a copper salt, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3 , etc. Examples of bases are not particularly limited, but can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, triethylamine, N,N-diisopropylethylamine, diisopropylamine, pyrrolidine, etc. Examples of copper salts include copper iodide (I). Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation. It should be noted that this reaction can also be carried out after the compound of formula (IIa) has been converted to the compound of formula (IIb) through the first stage reaction in the first step-4 described in the first preparation method.
[literature]
Chemical Reviews, 107, pp874-922(2007)
(Second Step)
This step involves the reduction of a compound of formula (VI) to obtain a compound of formula (IVa). In this reaction, the compound of formula (VI) is reacted in the presence of a catalyst, under a hydrogen atmosphere, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 50°C, typically with stirring for 0.1 hours to 5 days. Examples of catalysts used herein are not particularly limited, but include palladium supported on carbon, palladium hydroxide, platinum oxide, etc. Examples of solvents are not particularly limited, but include alcohols such as methanol, ethanol, and 2-propanol; water, ethyl acetate, acetic acid, and mixtures thereof.
(Step 3)
This step is the same as the second step of the first preparation method, involving the reaction of the compound of formula (IVa) with the compound of formula (V) to obtain the compound of formula (Iz).
(Third System)
[Chemical Formula 22]
( Rc represents a C1-6 alkyl group, and X2 represents a halogen or -OTf. The same applies below.)
This method is for preparing a compound (Iaa) in which L is -NR 3- in the compound of formula (I).
(First step)
This step involves the cyanidation reaction of the compound of formula (VII) to obtain the compound of formula (VIII). In this reaction, equal amounts of the compound of formula (VII) and a cyanide metal, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of cyanide metals used herein are not particularly limited and include zinc cyanide, copper cyanide, sodium cyanide, potassium cyanide, etc. Examples of catalysts are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 ( dba ) 3 , etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Second Step)
This step involves the reaction of the compound of formula (VIII) with ammonia to obtain the compound of formula (IX). In this reaction, the compound of formula (VIII) and ammonia are reacted in an inert solvent under cooling to reflux, preferably at 0°C to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited, and alcohols such as methanol, ethanol, and 2-propanol can be listed. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 3)
This step involves the reaction of a compound of formula (IX) with a compound of formula (IIIb) to obtain a compound of formula (X). In this reaction, equal amounts of the compounds of formula (IX) and (IIIb), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes be advantageous for facilitating the reaction. Alternatively, this reaction can also be carried out under microwave irradiation.
(Fourth step)
This step involves the reaction of a compound of formula (X) with hydrazine monohydrate to obtain compounds of formula (XIa) and/or formula (XIb). In this reaction, equal amounts of the compound of formula (X) and hydrazine monohydrate, or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 100°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include alcohols such as methanol, ethanol, and 2-propanol; acetonitrile, etc. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 5)
This step is the process of obtaining a compound of formula (IVb) from a compound of formula (XIa) or formula (XIb). The choice of steps 1 through 3 may be made depending on the starting material and the type of X2 .
(Step 5-1)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is -OTf. In this reaction, the compound of formula (XIa) and a trifluoromethanesulfonating agent are reacted in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of trifluoromethanesulfonating agents used herein are not particularly limited, and may include trifluoromethanesulfonic anhydride, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide, etc. Examples of bases are not particularly limited, and may include sodium hydride, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, etc. Examples of solvents, without particular limitation, include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof.
(Step 5-2)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is a halogen. In this reaction, the compound of formula (XIa) and the halogenating agent are placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 150°C, typically for 0.1 hours to 5 days. Examples of halogenating agents used herein are not particularly limited and include phosphorus oxychloride, phosphorus tribromooxychloride, thionyl chloride, etc. Examples of solvents are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; NMP, DMF, and mixtures thereof.
(Step 5-3)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIb) where X2 is a halogen. In this reaction, the compound of formula (XIb) and a diazotizing agent are reacted in the presence of a copper halide in a solvent inert to the reaction, under cooling to reflux, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of diazotizing agents used herein are not particularly limited, and include sodium nitrite, tert-butyl nitrite, etc. Examples of copper halides are not particularly limited, and include copper chloride (I), copper bromide (I), copper iodide (I), etc. Examples of solvents are not particularly limited, and include halogenated hydrocarbons such as dichloromethane and chloroform; acetonitrile, NMP, DMF, and mixtures thereof. The presence of hydrogen halides such as hydrochloric acid, hydrobromic acid, and hydroiodic acid can sometimes be advantageous in facilitating the reaction.
(Step Six)
This step involves reacting a compound of formula (IVb) with a compound of formula (V) to obtain a compound of formula (Iaa). In this reaction, equal amounts of the compound of formula (IVb) and the compound of formula (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3, RuPhosPdG3, etc. Examples of bases are not particularly limited, but include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Raw Material Synthesis-1)
[Chemical Formula 23]
( Rd represents tris( C1-6 )silyloxy or pyrrolidine-1-yl. The same applies below.)
This method involves reacting a compound of formula (XIII) with a compound of formula (XIV) to obtain a compound of formula (IIa) in which ring A is a C5-8 cycloalkenyl group or a partially unsaturated heterocyclic group of 5 to 11 members. In this reaction, equal amounts of the compounds of formula (XIII) and (XIV), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. The solvent used in this reaction is not particularly limited, and examples include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane and chloroform; and mixtures thereof.
(Raw Material Synthesis-2)
[Chemical Formula 24]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XV).
(First step)
This step involves the reaction of a compound of formula (XV) with hydrazine monohydrate to obtain a compound of formula (XVI). In this reaction, an excess of hydrazine monohydrate is used, and the mixture of hydrazine monohydrate and the compound of formula (XV) is stirred for 0.1 hours to 5 days in a solvent-free or solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 200°C. The solvent used in this reaction is not particularly limited, and examples include alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; acetonitrile, DMF, NMP, DMSO, and mixtures thereof.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XVI). In this reaction, the compound of formula (XVI) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, and hydrochloric acid, sulfuric acid, acetic acid, etc. are also included. Examples of solvents used in this reaction are not particularly limited, and alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol are also included; water, acetonitrile, DMF, NMP, DMSO, etc., and mixtures thereof are also included.
(Step 3)
This step involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa). In this reaction, an excess of chlorinating agent is used, and the mixture of the chlorinating agent and the compound of formula (XVII) is stirred for 0.1 hours to 5 days under cooling to reflux, preferably at room temperature to 200°C. Examples of chlorinating agents used herein are not particularly limited, and include phosphorus oxychloride, thionyl chloride, etc. The addition of a small amount of DMF is sometimes advantageous in facilitating the reaction.
(Raw Material Synthesis-3)
[Chemical Formula 25]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XVIII).
(First step)
This step involves the reaction of a compound of formula (XVIII) with tert-butyl hydrazine carbamate to obtain a compound of formula (XIX). In this reaction, equal amounts of the compound of formula (XVIII) and tert-butyl hydrazine carbamate, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a condensing agent and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of condensing agents used herein are not particularly limited and include HATU, EDC·HCl, COMU, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Solvents used in this reaction are not particularly limited and include ethers such as THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; acetonitrile, NMP, DMF, DMSO, etc., and mixtures thereof. The presence of HOBt can sometimes be advantageous in ensuring the smooth progress of a reaction.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XIX). In this reaction, the compound of formula (XIX) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, such as hydrochloric acid and sulfuric acid. Examples of solvents used in this reaction are not particularly limited, such as water, ethyl acetate, and 1,4-dioxane.
(Step 3)
This step is the same as the third step in the synthesis of raw materials -2, which involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa).
(Other manufacturing methods)
By using the compound of formula (I) obtained by the above method as a raw material, further chemical modification reactions commonly used by those skilled in the art, such as alkylation, benzylation, esterification, amidation, acylation, sulfonation, oxidation, protection, and deprotection, can be carried out to obtain another compound of formula (I).
Compounds of formula (I) are separated and purified as free compounds, their salts, hydrates, solvates, or polymorphs. Salts of compounds of formula (I) can also be prepared by conventional salt-forming reactions. Separation and purification can be performed using common chemical operations such as extraction, fractional crystallization, and various fractional chromatography. Various isomers can be prepared by selecting appropriate starting material compounds, or they can be separated by utilizing the differences in physicochemical properties between isomers. For example, optical isomers can be obtained by general optical resolution of racemates (e.g., fractional crystallization of diastereomeric salts formed with optically active bases or acids, chromatography using chiral columns, etc.), or they can be prepared from appropriate optically active starting material compounds.
The pharmacological activity of the compound of formula (I) can be confirmed by the following tests. It should be noted that the pharmacological activity can also be confirmed by well-known modified tests.
Experimental Example 1: Inhibition of THP-1IL-1β Production
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) and ATP (Adenosine triphosphate, SIGMA, A2383) were added at final concentrations of 50 ng/mL and 5 mM, respectively, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of IL-1β was determined using ELISA (DuoSet ELISA human IL-1β, R&D Systems, DY201). IL-1β concentrations were plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoidEmax model nonlinear regression analysis.
The results are shown in Table 1. It can be confirmed that the compounds in the examples inhibit the activation of the NLRP3 inflammasome and inhibit the production of IL-1β.
[Table 1-1]
Table 1
[Table 1-2]
Table 1 (continued)
Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]>
100 4.9 108(2) 3.0 118 4.8 128 3.3
101(1) 2.0 109 1.5 119 6.0 129 86
101(2) 8.6 110 1.4 120 1.0 130 twenty two
102 5.1 111 2.9 121 8.5 131(1) 3.0
103 4.4 112 1.3 122 8.4 131(2) 79
104 3.5 113 1.2 123 47 132 95
105 8.9 114 15 I24 0.62 133 1.3
106 4.8 115 11 125 1.5 134 4.6
107 3.6 116 4.4 126 7.1 135 2.9
108(1) 27 117 130 127 5.6 136 2.2
Experimental Example 2: TNF-α Production Inhibition Test
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) was added at a final concentration of 50 ng/mL, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of TNF-α was determined by ELISA (DuoSetELISA human TNF-α, R&D Systems, DY210). The TNF-α concentration was plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoid Emax model nonlinear regression analysis.
It can be confirmed that Examples 1, 2(1), 3(1), 4(1), 5, 70, 73, 83, 88, 99, 111, 124 and 125, which are compounds of formula (I), showed IC50 values of more than 10 μM in this test.
Experiment 3: Rat Central Nervous System IL-1β Production Test
In male Wistar rats aged 10–14 weeks, 12.5 μg/5 μL of LPS (SIGMA, L2880) was administered intracerebrospinally under isoflurane anesthesia. Two hours later, the test compound was administered orally. One hour later, 50 μg/5 μL of BzATP (2’(3’)-O-(4-benzoylbenzoyl)adenosine 5’-triphosphate triethylammonium salt, SIGMA, B6396) was administered intracerebrospinally. Cerebrospinal fluid was recovered after 30 minutes. IL-1β p17 levels in the cerebrospinal fluid were quantified by Western blotting using an anti-IL-1β antibody (Millipore, AB1832P), and the inhibition rate relative to the solvent-administered group was calculated.
The IL-1βp17 inhibition rates relative to the solvent-administered group for Examples 1, 2 (1), 3 (1), and 124, which are compounds of formula (I), are shown in the table below. It should be noted that in the table, Dose represents the dosage of each tested compound, Ex1, Ex2 (1), Ex3 (1), and Ex124 represent Examples 1, 2 (1), 3 (1), and 124, respectively, and cases not measured are represented as NT. It can be confirmed that these compounds exhibit IL-1β inhibition.
[Table 2]
Dose Ex1 Ex2(1) Ex3(1) Ex124
0.1 mg/kg NT NT NT 55%
0.3 mg/kg -12% 81% 75% 49%
1mg/kg 74% 75% 82% 96%
3mg/kg 84% 88% 72% NT
Example 4: Evaluation of motor function in a mouse model of α-synuclein fibrils-induced neuroinflammation
In male C57BL/6J mice, 8 μg of mouse α-synuclein fibrillation protein (StressMarq Biosciences Inc., SPR-324) was administered to the left striatum. After 14–15 weeks, the test compound, suspended in 0.5% methylcellulose solution, was administered orally once daily. For the negative control group, 0.5% methylcellulose solution was administered. Motor function was evaluated using a suspension test 4 weeks after the start of administration. Mice were allowed to grasp a horizontally taut wire, fall, and then grasp again, repeating this process for 3 minutes, recording the number of falls. In this experiment, it was confirmed that specific compounds of formula (I) or their salts exhibited a beneficial effect on motor dysfunction.
Experimental Example 5: In Vitro (ex vivo) IL-1β Production Assay in Mice
Male C57BL/6J mice were administered the compound, suspended in 0.5% methylcellulose, orally once or multiple times at arbitrary doses, and blood was collected at any time afterward. LPS was added to the blood at a final concentration of 50 ng/mL, and the mice were incubated at 37°C for 3 hours. Then, ATP was added at a final concentration of 5 mM, and the mice were incubated at 37°C for 30 minutes. After centrifugation to remove blood cells, the concentration of IL-1β was determined using an ELISA method (DuoSet ELISA mouse IL-1β, R&D Systems, DY401).
Test Example 6: In Vitro Phototoxicity Test
The in vitro phototoxicity test was evaluated according to ICH S10: Guidelines for the evaluation of photosensitivity of pharmaceuticals (Drug and Food Inspection Certificate No. 0521-1) and the methods described in the OECD guideline for testing of chemicals 432: Invitro 3T3 NRU phototoxicity test, 2019. In this test, it was confirmed that the compounds of Example 1, Example 2(1), Example 3(1) and Example 124 did not have phototoxic effects.
Experimental Example 7: Safety Pharmacology Test
As a safety pharmacology study, the inhibitory effect on human Ether-a-go-go Related Gene (hereinafter referred to as hERG) channels was evaluated. The evaluation of hERG channel inhibition was performed using a modified method described in Combinatorial Chemistry & High Throughput Screening, 12, 1, 78-95 (2009). In this study, the compounds of Examples 1, 2(1), 3(1), and 124 showed IC50 values greater than 10 μM.
Based on the above results, it is expected that compounds of formula (I) or their salts may be used as highly safe pharmaceutical products for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
The compounds of formula (I) or their salts shown in Table 1 were demonstrated to inhibit IL-1β production in Example 1. Furthermore, the compounds of Examples 1, 2(1), 3(1), and 124 were also shown to inhibit IL-1β production in the central nervous system in Example 3. In addition, specific compounds of formula (I) or their salts showed improved motor function in a mouse model of α-synucleinosis induced by α-synuclein fibers, as described in Example 4. Based on these results, it is strongly expected that compounds of formula (I) or their salts can be used for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, particularly α-synucleinosis including Parkinson's disease, multiple system atrophy, and Lewy body dementia.
Furthermore, the results of Examples 6 and 7 show that the compounds of Examples 1, 2(1), 3(1), and 124 do not exhibit phototoxicity and have weak hERG channel inhibition. Based on these results, it is strongly expected that the compounds of Examples 1, 2(1), 3(1), and 124 will become highly safe pharmaceutical products.
Pharmaceutical compositions containing one or more compounds of formula (I) or their salts as active ingredients can be prepared using excipients commonly used in the art (i.e., pharmaceutical excipients or pharmaceutical carriers, etc.) and by commonly used methods.
Administration can be administered orally using tablets, pills, capsules, granules, powders, liquid preparations, etc., or via any of the following methods: intra-articular, intravenous, intramuscular, or intra-intra-articular injections, suppositories, eye drops, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalants, etc.
As a solid composition for oral administration, tablets, powders, granules, etc., can be used. In such a solid composition, one or more active ingredients may be mixed with at least one inert excipient. The composition may contain inert additives, such as lubricants or disintegrants, stabilizers, and solubilizers, according to conventional methods. Tablets, powders, granules, or pills may be coated with wax, sugar coating, or films of gastric-soluble or enteric-soluble substances as needed.
Liquid compositions intended for oral administration contain pharmaceutically permissible emulsifiers, solutions, suspensions, syrups, or elixirs, and commonly used inert diluents such as purified water or ethanol. In addition to inert diluents, the liquid composition may also contain excipients such as solubilizers, humectants, suspending agents, sweeteners, flavorings, aromatizers, and preservatives.
Injectable formulations intended for non-oral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Aqueous solvents include, for example, distilled water for injection or physiological saline. Non-aqueous solvents include, for example, alcohols such as ethanol. Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizers. They are sterilized, for example, by filtration through a bacterial trap, by combination with a bactericide, or by irradiation. Alternatively, they can be prepared as sterile solid compositions and dissolved or suspended in sterile water or sterile solvents for injection before use.
As external agents, they include ointments, plasters, creams, gels, pastes, sprays, lotions, eye drops, and eye ointments. They contain commonly used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, etc.
Inhalers or nasal inhalers, or other mucosal preparations, can be in solid, liquid, or semi-solid form and manufactured according to conventionally known methods. Known excipients may be added as appropriate, or further appropriate pH adjusters, preservatives, surfactants, lubricants, stabilizers, or thickeners may be added. Administration can be performed using a suitable inhalation or blowing device. For example, known devices or nebulizers, such as metered-dose inhalers, can be used to administer the compound alone or as a formulated mixture powder, or in combination with a pharmaceutically permissible carrier in the form of a solution or suspension. Dry powder inhalers, etc., can be used for single or multiple administration and can use dry powder or capsules containing powder. Alternatively, pressurized aerosol sprays, etc., can be used, employing a suitable propellant, such as a suitable gas like chlorofluorocarbons or carbon dioxide.
When administered orally, a daily dose of approximately 0.001 to 100 mg/kg of body weight is appropriate, preferably 0.1 to 30 mg/kg, and more preferably 0.1 to 10 mg/kg, and this dose is administered once or divided into 2 to 4 doses. When administered intravenously, a daily dose of approximately 0.0001 to 10 mg/kg of body weight is appropriate, and this dose is administered once daily or divided into multiple doses. Additionally, as a mucosal agent, approximately 0.001 to 100 mg/kg of body weight is administered once daily or divided into multiple doses. The dosage should be appropriately determined based on individual circumstances, taking into account symptoms, age, and sex.
Although the dosage form, administration site, type of excipient or additive may vary, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, or in some manner 0.01 to 50% by weight, one or more of a compound of formula (I) or a salt thereof as an active ingredient.
The compound of formula (I) can be used in combination with various therapeutic or preventative agents for diseases for which the compound of formula (I) is believed to be effective. When used in combination, the compounds can be administered simultaneously, separately and continuously, or at desired time intervals. Simultaneously administered formulations can be combination formulations or formulations prepared separately.
Example
Hereinafter, based on examples, a method for manufacturing compounds of formula (I) will be described in further detail. It should be noted that the present invention is not limited to the compounds described in the following examples. Furthermore, the manufacturing examples show a method for preparing the starting material compounds. Additionally, the method for manufacturing compounds of formula (I) is not limited to the manufacturing methods of the specific examples shown below; compounds of formula (I) can also be manufactured by combinations of these manufacturing methods or by methods obvious to those skilled in the art.
It should be noted that the starting temperatures of the DSC curves obtained under the following conditions are recorded in the table below. The DSC measurements were performed using a DSC Q2000 (manufactured by TA Instruments) at a temperature range of 25–300 °C, a heating rate of 10 °C/min, and a nitrogen flow rate of 50 mL/min. An aluminum sample pan was used, and measurements were performed without covering the sample pan. The starting temperatures of the DSC curves may vary slightly depending on the measurement conditions and should not be interpreted strictly.
Powder X-ray diffraction (XRD) was performed using an Empyrean (PANalytical) spectrometer under the following conditions: Cu bulb, 40 mA tube current, 45 kV tube voltage, 0.013° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). Alternatively, it was performed using a SmartLab (Rigaku) spectrometer under the following conditions: Cu bulb, 200 mA tube current, 45 kV tube voltage, 0.005° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). It should be noted that, regarding the nature of the data, the lattice spacing or overall pattern of the powder XRD pattern is important in determining the identity of the crystals. The error range of the diffraction angle (2θ (°)) in powder XRD is typically ±0.2°, but the diffraction angle and intensity vary slightly depending on the direction of crystal growth, particle size, and measurement conditions, and therefore should not be interpreted strictly.
In addition, the following abbreviations are sometimes used in the embodiments, manufacturing examples and tables described below.
The following represent the following values: PEx: Manufacturing Example Number; Ex: Example Number; PSyn: Manufacturing Example Number manufactured using the same method; Syn: Example Number manufactured using the same method; Str: Chemical Structural Formula; DAT: Physicochemical Data; EI+: m/z value in mass analysis (Electron Ionization EI, [M]+ unless otherwise specified); ESI+: m/z value in mass analysis (Ionization ESI, [M+H]+ unless otherwise specified); FAB: m/z value in mass analysis (Ionization FAB, [M+H]+ unless otherwise specified); CI: m/z value in mass analysis (Ionization CI, [M+H]+ unless otherwise specified); 1H -NMR (400MHz, CDCl3 ): δ value (ppm) of the signal in 1H -NMR of CDCl3 ; 1H -NMR (500MHz, CDCl3 ): δ value (ppm ) of the signal in 1H-NMR of CDCl3 . δ value (ppm) of the signal in 1H-NMR, 1H -NMR (400MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , 1H -NMR (500MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , J: coupling constant, s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, br: broad peak (e.g., br s), m: multiplet, DSC 1 : temperature (initial temperature) at which the endothermic peak (decomposition point) was observed using DSC, DSC 2 : temperature (initial temperature) at which the endothermic peak (amorphous decomposition point) was observed using DSC, 2θ: diffraction angle of the peak in powder X-ray diffraction.
In the PSyn and Syn columns of the table described later, the hyphen (-) indicates that the manufacturing method is described in text form in the manufacturing example or embodiment.
In addition, for convenience, the concentration in mol/L is expressed as M. For example, 1M sodium hydroxide aqueous solution means a 1 mol/L sodium hydroxide aqueous solution.
Manufacturing Example 1
A mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (10.92 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (16.3 g), DIPEA (28 mL), and cyclopentanol (55 mL) was stirred at 160 °C for 2 days. After cooling the reaction mixture to room temperature, water/saturated sodium chloride aqueous solution (1/1) and chloroform/methanol (9/1) were added to separate the organic layer. The aqueous layer was extracted with chloroform/methanol (9/1), the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]cyclohexane-1-ol (8.24 g) as a solid.
Manufacturing Example 2
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.7 mL) were added, and the mixture was stirred at 160 °C for 44 hours. After cooling the reaction mixture to room temperature, chloroform and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, dried with anhydrous sodium sulfate, and then the solution was concentrated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 3
A mixture of 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine (1.145 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (890 mg), DIPEA (2.7 mL), and NMP (15 mL) was stirred at 160 °C for 24 hours. (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (420 mg) and DIPEA (1.3 mL) were added to the reaction mixture, and the mixture was stirred at 160 °C for 20 hours. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, the organic layers were combined, and the mixture was washed with a 1/1 water/saturated sodium chloride solution and a saturated sodium chloride solution, then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate). (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohex-1-ol (36.1 mg) was obtained as a solid from the low polarity fraction, and (1R,2R)-2-[(6-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)amino]cyclohex-1-ol (504.8 mg) was obtained as an oil from the high polarity fraction.
Manufacturing Example 4
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1S,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.68 mL) were added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, DIPEA (1 mL) was added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water/saturated sodium chloride aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated and dried over anhydrous sodium sulfate. After concentrating the solution, the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain a mixture (774 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 5
At room temperature, a mixture of 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine (502.7 mg) and cyclopentanol (3 mL) was mixed with (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (394 mg) and DIPEA (0.393 mL), and stirred at 160 °C for 2 days under an argon atmosphere. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and saturated sodium chloride/water aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (57.4 mg) as an oil.
Manufacturing Example 42
A mixture of 1 g of 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione and 20 mL of methanol was mixed with 0.6 mL of 12 M hydrochloric acid and 100 mg of platinum oxide, and stirred overnight at room temperature under a hydrogen atmosphere. 20 mL of methanol and 20 mL of DMF were added to the reaction mixture, and the mixture was stirred for 1 hour under an argon atmosphere. The reaction mixture was filtered through a Celite filter, and the filtrate was concentrated under reduced pressure. Toluene was added to the residue, and the mixture was concentrated under reduced pressure. Ethyl acetate was added to the solid, and the mixture was ground. The solid was filtered off and washed with ethyl acetate to give 1.19 g of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride.
Manufacturing Example 43
A mixture of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride (800 mg) and dichloromethane (16 mL) was mixed with DIPEA (0.250 mL), benzaldehyde (0.500 mL), and sodium triacetoxyborohydride (1.1 g) and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with chloroform/methanol (5/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione (515 mg) as a solid.
Manufacturing Example 44
A mixture of 100 mg 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione and 2 mL phosphoryl chloride was stirred at 120 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, and toluene was added, followed by further concentration under reduced pressure. Chloroform (3 mL) was added to the resulting residue, and DIPEA (1 mL) was added under ice-cold conditions. Water was added to the reaction mixture, and extraction with chloroform was performed. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 87 mg 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine as an oil.
Manufacturing Example 45
Under a nitrogen atmosphere, sodium hydride (55%, liquid paraffin dispersion, 190 mg) was added to a mixture of 1,4-dichlorophthalazine (720 mg), 4 -hydroxy-1λ6-thiocyclohexane-1,1-dione (540 mg), and THF (14 mL) while the mixture was ice-cold. The mixture was stirred at the same temperature for 30 minutes, then heated to room temperature and stirred for 3 days. Water and ethyl acetate were added to the reaction mixture, the solid was filtered off, and washed with water and ethyl acetate to give 4-[(4-chlorophthalazine-1-yl)oxy] -1λ6 -thiocyclohexane-1,1-dione (681 mg) in solid form.
Manufacturing Example 47
In a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (100 mg) and 1,4-dioxane (3.2 mL), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane-pentaborane (350 mg), RuPhos Pd G3 (45 mg), potassium carbonate (147 mg), and water (0.64 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform and water were added, and the organic layer was separated. After concentrating the solution, the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (1R,2R)-2-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazine-1-yl}amino)cyclohexyl-1-ol (106 mg) in solid form.
Manufacturing Example 48
Under an argon atmosphere, a mixture of (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (34 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (38 mg), RuPhos Pd G3 (3 mg), potassium carbonate (38 mg), 1,4-dioxane (1 mL), and water (0.100 mL) was stirred at 130 °C for 60 minutes under microwave irradiation. Water and chloroform were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with chloroform, and the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15.6 mg) in solid form.
Manufacturing Example 63
A mixture of tert-butyl [4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]carbamate (1.38 g), dichloromethane (14 mL), and triethylamine (1.21 mL) was added to acetic anhydride (0.330 mL) and 4-dimethylaminopyridine (71 mg), and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate), and the solid was washed with hexane/ethyl acetate (4/1) to give 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl acetate (1.24 g) in solid form.
Manufacturing Example 64
Trifluoroacetic acid (1.83 mL) was added to a mixture of 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl ester (1.24 g) and dichloromethane (13 mL), and the mixture was stirred overnight at room temperature. A 1 M aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol/ammonia). The residue was mixed with chloroform and methanol and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the solid was washed with hexane/ethyl acetate (4/1) to give 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (607 mg) in solid form.
Manufacturing Example 65
A mixture of 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (403 mg), acetyl chloride (0.075 mL), DIPEA (0.495 mL), and dichloromethane (4 mL) was stirred at room temperature for 1 hour. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. DIPEA (0.495 mL) and acetyl chloride (0.075 mL) were added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 4 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-(4-acetaminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl acetate (401 mg) as a solid.
Manufacturing Example 67
Under an argon atmosphere, in a mixture of 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (500 mg), (2R)-but-3-yn-2-ol (0.150 mL), and THF (8 mL), PdCl₂ ( PPh₃ ) ₂ (126 mg), copper iodide (I) (17 mg), and diisopropylamine (0.755 mL) were added under ice-cold conditions, followed by heating to room temperature and stirring for 5 hours. Water and a saturated aqueous solution of ammonium chloride were added to the reaction mixture, and the mixture was extracted with chloroform. The aqueous layer was extracted with chloroform, the organic layers were combined, dried with anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) as an oil.
Manufacturing Example 69
Platinum oxide (67 mg) was added to a mixture of (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) and ethanol (6 mL), and the mixture was stirred at room temperature for 1.5 hours under a hydrogen atmosphere. Celite (registered trademark) was added to the reaction mixture and stirred. The mixture was then filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-2-ol (260 mg) as an oil.
Manufacturing Example 70
Under an argon atmosphere, a mixture of 1,4-dichloro-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.50 g), sodium iodide (3.1 g), and 57% hydroiodic acid (9 mL) was stirred at 100 °C for 30 min under microwave irradiation. The reaction mixture was cooled to room temperature, water was added, and extraction was performed with ethyl acetate. The organic layer was washed with saturated aqueous solutions of sodium bicarbonate, sodium thiosulfate, and sodium chloride, and then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.9 g) as a solid.
Manufacturing Example 72
Under an argon atmosphere, a mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (100 mg), (3-aminobicyclo[1.1.1]pentan-1-yl)methanol-hydrochloride (95 mg), palladium acetate (22 mg), (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (90 mg), cesium carbonate (385 mg), and 1,4-dioxane (2 mL) was stirred at 100 °C for 24 hours. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give {3-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]bicyclo[1.1.1]pentan-1-yl}methanol (46.2 mg) in solid form.
Manufacturing Example 73
Under ice-cold conditions, 1 g of 3,6-dichloro-1,2,4,5-tetraazine was added to a mixture of tert-butyl[(3,6-dihydro-2H-pyran-4-yl)oxy]di(methyl)silane (1.42 g) and toluene (20 mL). The mixture was stirred at room temperature for 0.5 h and then at 120 °C for 16 h. After cooling the reaction mixture to room temperature, it was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1.08 g) in solid form.
Manufacturing Example 74
Under an argon atmosphere, toluene (121 mL) and 3,6-dichloro-1,2,4,5-tetrahydrooxetrazine (6.61 g) were added to a mixture (11.67 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetrazine-4-yl)oxy]silane, and the mixture was stirred at 120 °C for 24 hours. The reaction mixture was cooled to room temperature and filtered through methanol and chloroform. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepten[4,5-d]pyridazine (502.7 mg) in solid form.
Manufacturing Example 76
Hydrochloric acid (12M, 15.8 mL) was added to a mixture of 2-amino-5-cyclopropylphenol (3.50 g) and ethanol (50 mL) at -15 °C, and the mixture was stirred for 10 minutes at the same temperature. Amyl nitrite (9.6 mL) was added to the reaction mixture at -15 °C, and the mixture was stirred for 30 minutes at the same temperature. Then, a mixture of potassium iodide (50.6 g) and water (50 mL) was added dropwise at -15 °C, the mixture was heated to room temperature, and stirred for 20 hours. Ethyl acetate was added to the reaction mixture to separate the organic layer. The organic layer was washed with saturated aqueous sodium thiosulfate solution and saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-cyclopropyl-2-iodophenol (5 g) as an oil.
Manufacturing Example 77
In a mixture of 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) and 1,4-dioxane (9.2 mL), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (1.24 g), PdCl₂ (dppf) (238 mg), and potassium acetate (957 mg) were added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, PdCl₂ (dppf) (238 mg) was added, and the mixture was stirred at 100 °C for 2 hours. After cooling the reaction mixture to room temperature, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (620 mg) was added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, hexane was added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (1.98 g) as an oil.
Manufacturing Example 81
A mixture of 2.86 g of 4-bromo-3-hydroxybenzaldehyde and 30 mL of dichloromethane was added to DIPEA (2.93 mL) and 1.19 mL of chloromethyl methyl ether, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, the organic layer was separated, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde as an oil.
Manufacturing Example 83
Diethylaminosulfur trifluoride (2.2 mL) was added to a mixture of 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde and 20 mL of dichloromethane under ice-cold conditions. The mixture was stirred at the same temperature for 1 hour, then heated to room temperature and stirred for 3 hours. The reaction mixture was added to a mixture of ice water, sodium bicarbonate, and chloroform and stirred. The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.3 g of 1-bromo-4-(difluoromethyl)-2-(methoxymethoxy)benzene as an oil.
Manufacturing Example 84
A mixture of 4-bromo-3-(methoxymethoxy)phenol (1.86 g), sodium dichloro(fluoro)acetate (2.43 g), and DMF (11 mL) was added dropwise to a mixture of potassium carbonate (1.65 g) and DMF (7.4 mL) at 95 °C for 1 hour, and stirred at the same temperature for 15 minutes. After cooling the reaction mixture to room temperature, potassium carbonate (1.65 g) and sodium dichloro(fluoro)acetate (2.43 g) were added, and the mixture was stirred at 95 °C for 1 hour. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with water and a saturated sodium chloride aqueous solution, and then dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) as an oil.
Manufacturing Example 85
Under an argon atmosphere, a mixture of 1-chloro-4-iodo-5,6,7,8-tetrahydrophthalazine (500 mg), (1R,2R)-2-amino-1-methylcyclohexane-1-ol (270 mg), copper iodide (I) (30 mg), potassium phosphate (725 mg), ethylene glycol (0.100 mL), and 1-propanol (5 mL) was stirred at 90 °C for 24 hours. After cooling the reaction mixture to room temperature, chloroform and a saturated aqueous solution of ammonium chloride were added, and the organic layer was separated. The aqueous layer was extracted with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]-1-methylcyclohexane-1-ol (292 mg) in solid form.
Manufacturing Example 86
Under an argon atmosphere, a mixture of ethyl 1-benzyl-5-[(trifluoromethanesulfonyl)oxy]-1,2,3,6-tetrahydropyridine-4-carboxylate (3.37 g), zinc cyanide (1.5 g), Pd(PPh 3 ) 4 (1.2 g), and DMF (42 mL) was stirred at 100 °C for 1.5 h. After cooling to room temperature, water and ethyl acetate were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, washed with a 1/1 water/saturated sodium chloride aqueous solution and a saturated sodium chloride aqueous solution, and dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (2.04 g) as an oil.
Manufacturing Example 87
Under an argon atmosphere, a mixture of ethyl 5-[(trifluoromethanesulfonyl)oxy]-3,6-dihydro-2H-pyran-4-carboxylate (7.4 g), zinc cyanide (4.3 g), Pd(PPh 3 ) 4 (2.8 g), and DMF (74 mL) was stirred at 100 °C for 2 hours. After cooling to room temperature, ethyl acetate and water were added to the reaction mixture, and the mixture was filtered through Celite (registered trademark). After separating the two layers, the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with a 1/1 solution of water/saturated sodium chloride and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) as an oil.
Manufacturing Example 88
A mixture of ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (930 mg) and ammonia (7 M methanol solution, 8 mL) was stirred at ice temperature for 6 hours. The reaction mixture was allowed to stand in a refrigerator for 18 hours, then heated to room temperature and stirred for 10 minutes. The reaction mixture was concentrated under reduced pressure to give 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridine-1-one (828 mg) as a solid.
Manufacturing Example 89
Ammonia (7M methanol solution, 44 mL) was added to ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) under ice-cold conditions, and the mixture was stirred at 0 °C for 3 days. The reaction mixture was concentrated under reduced pressure to give 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.261 g) as a solid.
Manufacturing Example 90
A mixture of 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (825 mg), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (530 mg), DIPEA (0.7 mL), and acetonitrile (20 mL) was stirred at 70 °C for 19 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (1.12 g) as a solid.
Manufacturing Example 91
A mixture of 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.26 g), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (3.4 g), DIPEA (5.5 mL), and acetonitrile (70 mL) was stirred at 70 °C for 18 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (5.63 g) in solid form.
Manufacturing Example 92
A mixture of 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (560 mg) and ethanol (10 mL) was mixed with hydrazine monohydrate (0.16 mL) and stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (201 mg) in solid form.
Manufacturing Example 93
Under an argon atmosphere, sodium hydride (55%, liquid paraffin dispersion, 12 mg) was added to a mixture of 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (90 mg) and THF (3 mL) under ice-cold conditions, and the mixture was stirred for 20 minutes at the same temperature. 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide (108 mg) was added to the reaction mixture, and the mixture was stirred for 1 hour under ice-cold conditions. Water and chloroform were added to the reaction mixture, and the organic layer was separated. After extraction of the aqueous layer with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then chloroform/ethyl acetate) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine-1-yl ester (40 mg) in solid form.
Manufacturing Example 94
Sodium hydroxide (0.596 g) and benzyltriethylammonium chloride (0.922 g) were added to a mixture of (3R)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (2 g) and dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes. 1,4-Dichlorophthalazine (2.37 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 24 hours. Water and dichloromethane were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (3R)-3-[(4-chlorophthalazine-1-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester (0.960 g) as a solid.
Manufacturing Example 96
A mixture of (3R)-3-[(3R)-piperidin-1-carboxylic acid tert-butyl ester (960 mg) and dichloromethane (10 mL) was mixed with a solution of 1,4-dioxane hydrogen chloride (4 M, 10 mL) and stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and then diethyl ether was added to the resulting solid and the mixture was ground. The solid was filtered off to give 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine monohydrochloride (850 mg) in solid form.
Manufacturing Example 97
Triethylamine (0.26 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (100 mg) and dichloromethane (2 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.04 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated sodium chloride aqueous solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture A). Triethylamine (0.70 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (300 mg) and dichloromethane (10 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.10 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-{(3R)-3-[(4-chlorophthalazin-1-yl)oxy]piperidin-1-yl}aceto-1-one (280 mg).
Manufacturing Example 98
Triethylamine (6.3 mL) was added to a mixture of oxetane (5 g) and diethyl ether (50 mL) under ice-cold conditions, followed by tert-butyldi(methyl)silane trifluoromethanesulfonate (12.3 mL), and the mixture was stirred for 10 minutes at the same temperature. Triethylamine (1.4 mL) was added to the reaction mixture, and the mixture was stirred under ice-cold conditions for 1.5 hours. Hexane and water were added to the reaction mixture, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated to give a mixture (11.7 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetane-heptene-4-yl)oxy]silane as an oil.
Manufacturing Example 99
A mixture of 500 mg of 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrolo-1(4H)-one and 2-propanol (20 mL) was mixed with 0.300 mL of hydrazine monohydrate and stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (200 mg) in solid form.
Manufacturing Example 100
Under an argon atmosphere, sodium nitrite (80 mg) was added to a mixture of (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (198 mg), copper chloride (I) (75 mg), and hydrochloric acid (12 M, 2.5 mL) under ice-cold conditions, and the mixture was stirred for 1 hour at the same temperature. Dichloromethane (10 mL), water, and triethylamine (4.2 mL) were added to the reaction mixture under ice-cold conditions and stirred. The reaction mixture was filtered through a Celite filter and washed with dichloromethane/methanol (10/1). The organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (170 mg) in solid form.
Manufacturing Example 101
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (131.6 mg), 10% palladium-supported carbon (containing 51% water, 84.5 mg), and methanol (3 mL) was stirred at room temperature for 4 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite filter. The filtrate was then concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (89.3 mg) as a solid.
Manufacturing Example 102
[(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.524 g) and sodium triacetoxyborohydride (2.416 g) were added to a mixture of cyclobutanone (0.640 g) and dichloromethane (25 mL) at room temperature, and the mixture was stirred for 5 hours at room temperature. The reaction mixture was injected into a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to give [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.940 g) as a solid.
Manufacturing Example 103
A solution of 1,4-dioxane hydrogen chloride (4M, 1.8 mL) was added to a mixture of [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (225 mg) and dichloromethane (1.8 mL) with stirring at room temperature, and the mixture was stirred for 3 hours at room temperature. The reaction mixture was concentrated under reduced pressure to give (3R)-1-cyclobutylpiperidin-3-amine dihydrochloride (250 mg) as a solid.
Manufacturing Example 104
A mixture ( 393 mg ) of (1R,2R)-N1-(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)cyclohexyl-1,2-diamine and (1R,2R) -N1- (4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)cyclohexyl-1,2-diamine was added to dichloromethane (14 mL), triethylamine (0.23 mL), and di-tert-butyl dicarbonate (0.34 mL), and the mixture was stirred at room temperature for 1.5 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (352 mg) of {(1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl}carbamate tert-butyl ester and {(1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl}carbamate tert-butyl ester in solid form.
Manufacturing Example 105
A solution of 1,4-dichloro-6-(triphenylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine (1.569 g) and dichloromethane (18 mL) was added to a solution of 1,4-dioxane hydrogen chloride (4 M, 6 mL), and the mixture was stirred at room temperature for 18.5 hours. The reaction mixture was filtered, the solid was washed with diethyl ether, and then dried under reduced pressure to give 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine hydrochloride (770 mg).
Manufacturing Example 106
Triethylamine (1.4 mL) and di-tert-butyl dicarbonate (1.2 mL) were added to a mixture of 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine monohydrochloride (765 mg) and dichloromethane (23 mL) under ice-cold stirring, and the mixture was stirred for 17 hours while being naturally heated to room temperature. The reaction mixture was injected into water and extracted with dichloromethane. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Diethyl ether was added to the resulting solid and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give tert-butyl 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid (788 mg) as a solid. The residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid tert-butyl ester (142 mg) in solid form.
Manufacturing Example 114
A mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (700 mg) and (3R)-3-aminopiperidine-1-carboxylic acid tert-butyl ester (1.4 g) was stirred at 120 °C for 24 hours. After cooling to room temperature, the mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (481 mg) of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester in solid form.
Manufacturing Example 116
A mixture of 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (384 mg), (1R,2R)-2-aminocyclohexyl-1-ol (426 mg), DIPEA (0.77 mL), and cyclopentanol (7.4 mL) was stirred at 145–155 °C for 18.5 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and then water and a saturated sodium chloride aqueous solution were added. Extraction was performed with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (236 mg) in solid form.
Manufacturing Example 120
A mixture of 1,4-dichloro-5,7-dihydrofurano[3,4-d]pyridazine (500 mg), (1S,3R)-3-aminocyclohexyl-1-ol monohydrochloride (795 mg), DIPEA (1.8 mL), and cyclopentanol (5 mL) was stirred at 120–130 °C for 22 hours. The reaction mixture was cooled to room temperature, injected into water, and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (556 mg) as a solid.
Manufacturing Example 122
A mixture of 2,3,5,7-tetrahydrothieno[3,4-d]pyridazine-1,4-dione (78 mg) and phosphorus oxychloride (1 mL) was stirred at 98–100 °C for 2.5 h. The reaction mixture was cooled to room temperature and then poured into ice water for washing with ice water and dichloromethane. A saturated sodium bicarbonate solution was added dropwise to adjust the pH to approximately 8 while stirring at room temperature, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (92 mg) as a solid.
Manufacturing Example 128
A mixture of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester (478 mg), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (680 mg), RuPhos Pd G3 (163 mg), potassium carbonate (450 mg), 1,4-dioxane (10 mL), and water (2 mL) was stirred at 100 °C for 4 hours. After cooling to room temperature, water was added to the mixture, and extraction was performed with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution and then dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and (3R)-3-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (200 mg) in solid form.
Manufacturing Example 134
Under an argon atmosphere, a mixture of (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (155 mg), 2-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (361 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 94 mg), potassium carbonate (159 mg), 1,4-dioxane (6 mL), and water (1.4 mL) was stirred at 90–110 °C for 20 hours. The reaction mixture was cooled to room temperature, injected into water, and then filtered through a Celite (trademark) filter. The filtrate was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-({4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (128 mg) in solid form.
Manufacturing Example 144
By the same reaction as in Manufacturing Example 74, 1,4-dichloro-5,7,8,9-tetrahydrooxetanehepten[3,4-d]pyridazine was obtained as a byproduct in solid form.
Manufacturing Example 152
Under ice-cold conditions, trifluoromethanesulfonic anhydride (0.17 mL) was added to a mixture of 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-ol (261 mg), 2,6-rutidine (0.16 mL), and dichloromethane (6 mL), and the mixture was stirred at the same temperature for 1.5 hours. Dichloromethane and water were added to the reaction mixture and stirred, and then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl ester (311 mg) in solid form.
Manufacturing Example 154
Under an argon atmosphere and with stirring at -30°C, trifluoromethanesulfonic anhydride (14.1 mL) was added dropwise to a mixture of ethyl 5,5-dimethyl-4-oxothiacyclopentane-3-carboxylate (16.169 g), DIPEA (15.3 mL), and dichloromethane (80 mL). The reaction mixture was then stirred at -45 to -15°C for 1 hour. Water was added to the reaction mixture, and the mixture was heated to room temperature and then extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (17.559 g) as an oil.
Manufacturing Example 159
Under ice-cold conditions, tert-butyl dimethyl silane trifluoromethanesulfonate (1.2 mL) was added to a mixture of (1S,2R)-2-aminocyclohexane-1-ol monohydrochloride (608 mg), dichloromethane (8 mL), and 2,6-rutidine (1.1 mL), and the mixture was stirred for 1 hour at the same temperature, followed by stirring at room temperature for 3 hours. 2,6-rutidine (0.16 mL) and tert-butyl dimethyl silane trifluoromethanesulfonate (0.3 mL) were added to the resulting mixture at room temperature, and the mixture was stirred for 20 hours at the same temperature. Dichloromethane and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture and stirred, then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexane-1-amine (445 mg) as an oil.
Manufacturing Example 160
At room temperature, hydrochloric acid (12M, 0.5 mL) was added to a mixture of (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and methanol (3 mL), and the mixture was stirred at 60 °C for 1 hour. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. Chloroform/methanol (9/1) and basic silica gel were added to the residue, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (alkaline silica, chloroform/methanol) to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (102 mg) in solid form.
Manufacturing Example 162
A mixture (113 mg) of (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol was purified by reversed-phase preparative HPLC (ODS column, 0.1% formic acid/methanol) to give (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (62.4 mg) as an oil.
Manufacturing Example 163
Potassium carbonate (197.99 mg) and methyl iodide (58.10 mg) were added to a mixture of 1-chloro-N-[(3R)-piperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine dihydrochloride (110 mg) and DMF (6 mL) at 25 °C, and the mixture was stirred for 16 hours at the same temperature. The reaction mixture was added to water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure to give 1-chloro-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (110 mg) as an oil.
Manufacturing Example 164
N-bromosuccinimide (23.88 g) was added to a mixture of 3-cyclopropylphenol (20 g) and chloroform (200 mL) at 0 °C, and the mixture was stirred at 15 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether) to give 2-bromo-5-cyclopropylphenol (7.7 g) as an oil.
Manufacturing Example 165
A mixture of 2,5-dihydrothiophene-3,4-dicarboxylhydrazide (127 mg) and 10% sulfuric acid (8 mL) was stirred at 115–120 °C for 1 hour. The reaction mixture was cooled to room temperature and then filtered. The filtered solid was washed with water and dried to give 2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione (94 mg) in solid form.
Manufacturing Example 166
A mixture of 308 mg of 4,6-dihydro-1H,3H-thieno[3,4-c]furan-1,3-dione, 0.96 mL of hydrazine monohydrate, and 20 mL of 2-propanol was heated to reflux at 100 °C and stirred for 14.5 h. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with 2-propanol and dried to give 2,5-dihydrothiophene-3,4-dicarboxyhydrazide (246 mg) as a solid.
Manufacturing Example 167
A mixture of 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazine-1-carboxylic acid, 9.1 mL of 1,4-dioxane hydrochloride solution, and 90 mL of ethyl acetate was stirred at 60–67 °C for 19 hours. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with ethyl acetate and dried to give 2.717 g of 5,5-dimethyl-2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione in solid form.
Manufacturing Example 168
A mixture of 5.095 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid, 3.509 g of tert-butyl hydrazinocarboxylate, 10.095 g of HATU, 7.73 mL of DIPEA, and 110 mL of DMF was stirred at room temperature for 2.5 hours. Water was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazino-1-carboxylic acid as an oil.
Manufacturing Example 169
Under an argon atmosphere, a mixture of ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (15.556 g), sodium formate (9.493 g), acetic anhydride (8.8 mL), DIPEA (16.3 mL), lithium chloride (5.917 g), palladium acetate (1.045 g), and DMF (230 mL) was stirred at room temperature for 17 hours. The reaction mixture was filtered, and 10% hydrochloric acid was added to the filtrate to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol). A saturated aqueous sodium bicarbonate solution was added to the purified product, and the mixture was stirred at room temperature to adjust the pH to approximately 8, followed by washing with ethyl acetate. Under stirring at room temperature, 10% hydrochloric acid was added to the aqueous layer to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dried with anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain 9.659 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid as an oil.
Example 1
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (4.4 g), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (4.5 g), RuPhos Pd G3 (1.3 g), potassium carbonate (5.4 g), 1,4-dioxane (40 mL), and water (8 mL) was stirred at 100 °C for 2 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 3 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 19 hours. After cooling the reaction mixture to room temperature, water and chloroform were added to separate the organic layer. The aqueous layer was extracted with chloroform, and the combined organic layers were washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (basic and neutral silica gel, chloroform/methanol). Ethyl acetate (10 mL) and hexane (50 mL) were added to the purified product, and the mixture was stirred at room temperature for 18 hours. The solid was filtered off to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol (3.97 g) in solid form.
Example 2
In a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (562 mg), RuPhos PdG3 (171 mg), potassium carbonate (563 mg), and water (2.5 mL) were added, and the mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (3 mL) and hexane (12 mL) were added to the two purified products, respectively, and the mixture was stirred for 15 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (108 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (172 mg) was obtained from the high-polarity fraction.
Example 3
In a mixture (440 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (14 mL), [2-hydroxy-4-(trifluoromethoxy)phenyl]boronic acid (690 mg), RuPhosPd G3 (195 mg), potassium carbonate (643 mg), and water (2.9 mL) were added. The mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (8 mL) were added to the two purified products, respectively, and the mixture was stirred for 30 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (124 mg) was obtained from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethoxy)phenol (242 mg) was obtained from the high-polarity fraction.
Example 4
In a mixture (380 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12.2 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (553 mg), RuPhosPd G3 (168 mg), potassium carbonate (555 mg), and water (2.4 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (6 mL) were added to the two purified products, respectively, and the mixture was stirred for 1 hour. The solids were filtered off, and 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (93 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (103 mg) was obtained from the high-polarity fraction.
Example 5
Under an argon atmosphere, RuPhos Pd G3 (17 mg) was added to a mixture of (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetane-hepteno[4,5-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (57.4 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (59.8 mg), potassium carbonate (80 mg), 1,4-dioxane (2.4 mL), and water (0.600 mL), and the mixture was stirred at 100 °C for 3 hours. RuPhos Pd G3 (16 mg) was then added to the reaction mixture, and the mixture was stirred at 100 °C for 1 hour. Subsequently, RuPhos Pd G3 (17.7 mg), 1,4-dioxane (0.800 mL), and water (0.200 mL) were added, and the mixture was stirred at 100 °C for 6 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1), saturated sodium chloride aqueous solution, and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxocyclohepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (9.1 mg) in solid form.
Example 70
Under an argon atmosphere, a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (150 mg), (4-chloro-2-hydroxyphenyl)boronic acid (120 mg), RuPhos Pd G3 (46 mg), potassium carbonate (150 mg), 1,4-dioxane (4 mL), and water (0.5 mL) was stirred at 100 °C for 5 hours. Then, (4-chloro-2-hydroxyphenyl)boronic acid (120 mg) and RuPhos Pd G3 (22 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 8 hours. After cooling the reaction mixture to room temperature, basic silica gel was added, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol) to obtain a solid. Hexane/ethyl acetate (10/1) was added to the obtained solid, and the solid was filtered off to obtain 5-chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (25.2 mg) in solid form.
Example 73
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (14 mg), formaldehyde (37% aqueous solution, 0.020 mL), 10% palladium-supported carbon (50% water content, 10 mg), and methanol (1 mL) was stirred at room temperature for 24 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite (trademark) filter. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (5.6 mg) as a solid.
Example 79
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and acetyl chloride (6 mg) under ice-cold conditions and stirred at the same temperature for 2 hours. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-{1-[2,4-bis(trifluoromethyl)phenyl]-4-{[(2R)-2-hydroxypropyl]amino}-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl}ethyl-1-one (18 mg) in solid form.
Example 80
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and methanesulfonyl chloride (8 mg) under ice-cold conditions and stirred at the same temperature for 30 minutes. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (2R)-1-({1-[2,4-bis(trifluoromethyl)phenyl]-6-(methanesulfonyl)-5,6,7,8-tetrahydropyridino[3,4-d]pyridazin-4-yl}amino)prop-2-ol (15 mg) in solid form.
Example 81
A mixture of 2-[4-(4-acetamidobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl ester acetate (398 mg) and methanol (8 mL) was mixed with an aqueous solution of sodium hydroxide (1 M, 1.73 mL) and stirred at room temperature for 3 hours. Hydrochloric acid (1 M, 1.73 mL) and water were added to the reaction mixture, and extraction was performed with chloroform/2-propanol (4/1). The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting solid was washed with ethyl acetate to give N-[4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]acetamide (309 mg) in solid form.
Example 82
A solution of 1,4-dioxane hydrogen chloride (4M, 4mL) was added to a mixture of [(1R,2R)-2-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}amino)cyclohexyl]tert-butyl carbamate (0.440 g) and 1,4-dioxane (10 mL) at 0 °C, and the mixture was heated to room temperature and stirred for 4 hours. A solution of 1,4-dioxane hydrogen chloride (4M, 4 mL) was added to the reaction mixture at 5 °C, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting solid was washed with diethyl ether to give 2-(4-{[(1R,2R)-2-aminocyclohexyl]amino}phthalazin-1-yl)-5-(trifluoromethyl)phenol dihydrochloride (0.375 g) in solid form.
Example 83
Hydrochloric acid (12 M, 0.060 mL) was added to a mixture of (1R,2R)-2-({4-[-4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)cyclohexane-1-ol (106 mg) and methanol (1.1 mL), and the mixture was stirred at 60 °C for 10 hours. Ethyl acetate and a saturated aqueous sodium bicarbonate solution were added to the reaction mixture to separate the organic layer, which was then extracted with ethyl acetate. The combined organic layers were washed with water and a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solution was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (1 mL) and hexane (3 mL) were added to the obtained solid, and the mixture was stirred for 15 minutes. The solid was then filtered off, thus obtaining 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol (62 mg) in solid form.
Example 88
Under an argon atmosphere, potassium carbonate (159 mg), 2-[4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5,5-tetramethyl-1,3,2-dioxane (564 mg), and RuPhos Pd G3 (49.3 mg) were added to a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (162 mg), 1,4-dioxane (2 mL), and water (0.500 mL), and the mixture was stirred at 100 °C for 1.5 h. The reaction mixture was cooled to room temperature, and methanol (2 mL) and hydrochloric acid (12 M, 0.590 mL) were added. The mixture was stirred at 60 °C for 2 h. After cooling the reaction mixture to room temperature, basic silica gel was added and the mixture was concentrated. The obtained residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol). Ethyl acetate and diisopropyl ether were added to the obtained residue, and after sonication, the solid was filtered off, thus yielding 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (46.3 mg) in solid form.
Example 90
Under ice-cold conditions, a solution of 1,4-dioxane hydrogen chloride (4M, 0.84 mL) was added to a mixture of 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazin-6(5H)-carboxylic acid tert-butyl ester (171 mg) and dichloromethane (2.6 mL), and the mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5(trifluoromethyl)phenol dihydrochloride (162 mg) as a solid.
Example 92
Under an argon atmosphere, acetyl chloride (0.041 mL) and pyridine (0.010 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (46.7 mg), dichloromethane (2 mL), and THF (1 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was then heated to room temperature, and an aqueous solution of sodium hydroxide (1 M, 1 mL) was added, and the mixture was stirred at the same temperature for 7 hours. The reaction mixture was then chilled, and hydrochloric acid (1 M, 1 mL) was added. The mixture was then heated to room temperature, and chloroform was added, and the mixture was stirred at the same temperature for 10 minutes. The organic layer was separated and concentrated. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl]ethyl-1-one (17.2 mg) in solid form.
Example 93
Under an argon atmosphere, methanesulfonyl chloride (0.004 mL) and DIPEA (0.039 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (18.5 mg) and dichloromethane (2 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture A). Under an argon atmosphere, methanesulfonyl chloride (0.005 mL) and DIPEA (0.048 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (22.9 mg) and dichloromethane (3 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-(methanesulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl]-5-(trifluoromethyl)phenol (13.8 mg) in solid form.
Example 94
Under an argon atmosphere and with ice-cold stirring, boron tribromide (17% dichloromethane solution, 2.5 mL) was added dropwise to a mixture of (1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]thiopheno[2,3-d]pyridazin-7-yl}amino)cyclohexyl-1-ol (210 mg) and dichloromethane (2.5 mL), and the mixture was stirred at 0 °C for 2 hours. A saturated aqueous solution of sodium bicarbonate and methanol were added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate), and dichloromethane was added to the purified product, followed by grinding. The precipitated solid was filtered, washed with dichloromethane, and dried under reduced pressure to obtain 2-(7-{[(1R,2R)-2-hydroxycyclohexyl]amino}thieno[2,3-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (75 mg) in solid form.
Example 95
Under ice-cold stirring, boron tribromide (0.7 mL of 17% dichloromethane solution) was added to a mixture of [(1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)cyclohexyl]carbamate tert-butyl ester (73 mg) and dichloromethane (1 mL), and the mixture was naturally heated to room temperature while stirring for 5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) to give 2-(1-{[(1R,2R)-2-aminocyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (44 mg) in solid form.
Example 96
A mixture of (3R)-3-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (194 mg), dichloromethane (4 mL), and trifluoroacetic acid (0.66 mL) was stirred at room temperature for 5.5 hours. Water was added to the reaction mixture, and the aqueous layer was washed with dichloromethane. The organic layer was extracted with 10% hydrochloric acid, and the aqueous layers were combined. Potassium carbonate and saturated sodium bicarbonate solution were added to make the mixture alkaline. The aqueous layer was extracted with dichloromethane/methanol. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Dichloromethane and hexane were added to the resulting residue, and the mixture was ground. The precipitated solid was filtered and dried under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (80 mg) in solid form. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg) in solid form.
Example 97
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg), dichloromethane (1 mL), methanol (0.1 mL), 3-oxetane (19.9 μL), and sodium triacetoxyborohydride (68 mg) was stirred at room temperature for 5 hours. 3-oxetane (39.9 μL) and sodium triacetoxyborohydride (136 mg) were added to the reaction mixture, and the mixture was stirred at room temperature for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to obtain 2-(4-{[(3R)-1-(oxecyclobut-3-yl)piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (45 mg) in solid form.
Example 98
A mixture of 264 mg of 1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-carboxylic acid tert-butyl ester, dichloromethane (5 mL), and trifluoroacetic acid (0.9 mL) was stirred at room temperature for 5 hours. Under ice-cold stirring, a saturated aqueous solution of sodium bicarbonate, dichloromethane, and methanol were added to the reaction mixture. Extraction was performed with dichloromethane, and the mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Ethyl acetate was added to the resulting residue, and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give 72 mg of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol as a solid. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (21 mg) in solid form.
Example 99
Sodium triacetoxyborohydride (75 mg) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (70 mg), methanol (1.8 mL), and 37% formaldehyde aqueous solution (20 μL) under stirring at room temperature, and the mixture was stirred for 4 hours at room temperature. A saturated sodium bicarbonate aqueous solution was added to the reaction mixture, and the precipitated solid was filtered off and washed with water. The filtered solid was dried, and hexane/ethyl acetate was added and the mixture was ground. The precipitated solid was filtered off, washed with hexane, and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (35 mg) in solid form.
Example 111
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (236 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (342 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 68 mg), potassium carbonate (229 mg), 1,4-dioxane (8 mL), and water (2 mL) was stirred at 107–112 °C for 14 hours. After cooling the reaction mixture to room temperature, [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (171 mg) and PdCl₂ (dppf)· CH₂Cl₂ (68 mg ) were added, and the mixture was further stirred at 110–120 °C for 2 hours. The reaction mixture was then injected into a mixture of water and a saturated sodium chloride aqueous solution and extracted with ethyl acetate. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate). The purified product was dissolved in a small amount of dichloromethane, hexane was added, the precipitated solid was filtered off and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (39 mg) in solid form.
Example 112
A solution of ethyl hydrochloride (4M, 4 mL) was added to a mixture of 1-[4-cyclopropyl-2-(methoxymethoxy)phenyl]-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (250 mg) and ethyl acetate (5 mL) at 25 °C, and the mixture was stirred for 1 hour at the same temperature. After adding water and a saturated aqueous sodium bicarbonate solution to the reaction mixture, extraction was performed with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. After the solution was concentrated under reduced pressure, the residue was purified by reversed-phase preparative HPLC (ODS column, ammonia + ammonium bicarbonate aqueous solution/acetonitrile) to obtain 5-cyclopropyl-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (29.3 mg) in solid form.
Example 114
A mixture of (1S,3R)-3-({4-[4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (122 mg), trifluoroacetic acid (0.48 mL), and dichloromethane (2 mL) was stirred at room temperature for 5 hours. While stirring the reaction mixture under ice-cold conditions, a saturated aqueous solution of sodium bicarbonate was added until the foaming subsided, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol (58 mg) as a solid.
Example 117
In a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (62 mg), DIPEA (33 μL), and dichloromethane (1.6 mL), acetic anhydride (18 μL) was added while stirring under ice-cold conditions, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered, the filtered solid was washed with dichloromethane, and dried to give 1-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-yl)ethyl-1-one (58 mg) in solid form.
Example 124
At room temperature, a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and THF (4 mL) was added to (1H-benzotriazol-1-yl)methanol (86 mg) and sodium acetate (55 mg), and stirred for 10 minutes at the same temperature. Sodium triacetoxyborohydride (125 mg) was added to the resulting mixture, and the mixture was stirred for 1 hour at room temperature. Water and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, followed by extraction with chloroform/methanol (9/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product, and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (72 mg) in solid form.
Example 126
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (71 mg), [(1-ethoxycyclopropyl)oxy]tri(methyl)silane (72 μL), sodium cyanoborohydride (17 mg), acetic acid (16 μL), THF (1 mL), and methanol (1 mL) was stirred at 49–54 °C for 15.5 hours. The reaction mixture was cooled to room temperature, and 10% sodium hydroxide solution was added. The solution was prepared to a pH of approximately 7–8, and then extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol) to give 2-(4-{[(3R)-1-cyclopropylpiperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15 mg) in solid form.
Example 127
Hydrochloric acid (12M, 0.5mL) was added to a mixture of 2-(4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (60mg) and methanol (2mL) at room temperature, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was chilled, and an aqueous solution of sodium hydroxide (1M, 6mL) was added, followed by extraction with chloroform and chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (25.7 mg) in solid form.
Example 128
TFA (0.5 mL) was added to a mixture of (3R)-3-({1-[2-hydroxy-4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (29 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and THF (4 mL), sodium acetate (15 mg), and (1H-benzotriazol-1-yl)methanol (25 mg) were added to the residue, and the mixture was stirred for 10 minutes at room temperature. Sodium triacetoxyborohydride (36 mg) was added to the resulting mixture, and the mixture was stirred for 2 hours at room temperature. A saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride were added to the reaction mixture, and the mixture was extracted with chloroform/methanol (9/1). After neutralization with 1 M hydrochloric acid in the aqueous layer, the mixture was extracted with chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to give 2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (14.3 mg) in solid form.
Example 129
Oxone (registered trademark) (1.3 g) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-thiaro[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (300 mg), acetonitrile (5 mL), and water (5 mL) at 25 °C, and the mixture was stirred for 2 hours at the same temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. Acetonitrile and water were added to the residue, and the mixture was freeze-dried to give 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydro- 6λ6 -thiaro[3,4-d]pyridazin-6,6(5H)-dione (185 mg) as a solid.
Example 132
A mixture of 2-(7,7-dimethyl-4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (50 mg), 2,2-difluoroethyl trifluoromethanesulfonate (19 μL), triethylamine (49 μL), and ethanol (1.2 mL) was stirred at 54–62 °C for 17 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and then extracted with dichloromethane after adding water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then dichloromethane/methanol). The purified product was dissolved in toluene and extracted with 5% aqueous sodium hydroxide solution, water, and saturated aqueous sodium chloride solution. The aqueous layer was washed with toluene, 10% hydrochloric acid was added, and then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/hexane/methanol, then hexane/ethyl acetate) to give 2-(4-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]amino}-7,7-dimethyl-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (6 mg) in solid form.
Example 133
A solution of 1,4-dioxane hydrogen chloride (4M, 0.11 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (150 mg) and dichloromethane (1.5 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (3 mL) was added, and the mixture was stirred at 50 °C for 48 hours. After cooling to room temperature, the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (149 mg) in crystalline form.
Example 134
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.074 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (103 mg) as a solid.
Example 135
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.071 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5-(trifluoromethoxy)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride (95 mg) in crystalline form.
Example 136
A solution of 1,4-dioxane hydrogen chloride (4M, 0.147 mL) was added to a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred for 120 hours at room temperature. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride (122 mg) as a solid.
The compounds of the manufacturing examples and embodiments shown in the table below were manufactured in the same manner as those of the manufacturing examples or embodiments described above.
[Table 3-1]
[Table 3-2]
[Table 3-3]
[Table 3-4]
[Table 3-5]
[Table 3-6]
[Table 3-7]
[Table 3-8]
[Table 3-9]
[Table 3-10]
[Table 4-1]
[Table 4-2]
[Table 4-3]
[Table 4-4]
[Table 4-5]
[Table 4-6]
[Table 4-7]
[Table 4-8]
[Table 5-1]
PEx PSyn DAT
1 - ESI+; 282.2, 284.2
2 - ESI+; 284.2, 286.1
3(1) - ESI+; 373.2, 375.2
3(2) - ES1+; 373.2, 376.2
4 - ESI+; 284.1, 286.1
5 - ESI+; 298.1, 300.2
6 1 FAB; 242.2
7 1 ESI+; 228.1, 230.1
8 1 ESI+; 333.2, 335.2
9 1 ESI+; 284.3, 286.3
10 1 ESI+; 264.3, 266.3
11 1 ESI+; 264.2, 266.2
12 1 ESI+; 264.3, 266.3
13 1 ESI+; 278.3, 280.3
14 1 ESI+; 239.1, 241.1
15 1 ESI+; 242.1, 244.0
16 1 ESI+; 228.1, 230.1
17 1 ESI+; 268.2, 270.2
18 1 ESI+; 242.2, 244.2
19 1 FAB; 377.1
20 1 FAB; 319.0
twenty one 1 FAB; 268.0
twenty two 1 ESI+; 268.1, 270.1
twenty three 1 ESI+; 296.1, 298.2
twenty four 1 ESI+; 284.2, 286.1
25(1) 1 ESI+; 284.1, 286.1
25(2) 1 ESI+; 284.I, 286.1
26 1 ESI+; 298.1, 300.1
27 1 ESI+; 282.2, 284.2
28 1 ESI+; 267.1, 269.1
29 1 ESI+; 270.1, 272.1
30 1 FAB; 254.0
31 1 FAB; 270.0
32 1 ESI+; 383.2, 385.2
33 1 FAB; 305.0
[Table 5-2]
PEx PSyn DAT
34 1 FAB; 277.0
35 1 ESI+; 284.1, 286.1
36 1 ESI+; 284.2, 286.2
37 1 ESI+; 321.3, 323.3
38 1 ESI+; 283.2, 285.2
39 1 ESI+; 293.0, 295.0
40 1 ESI+; 367.2, 369.2
41 1 ESI+; 369.3, 371.4
42 - ESI+; 168.3
43 - ESI+; 258.3
44 - ESI+; 294.3, 296.3, 298.3
45 - ESI+; 313.2
46 45 ESI+; 352.4
47 - ESI+; 450.3
48 - ESI+; 499.3
49 47 ESI+; 478.4
50 47 FAB; 503.6
51 47 ESI+; 434.3
52 47 ESI+; 470.3
53 47 ESI+; 499.2
54(1) 47 ESI+; 509.2
54(2) 47 ESI+; 509.2
55 47 ESI+; 515.2
56 47 ESI+; 445.3
57 47 ESI+; 472.3
58 47 ESI+; 436.3
59 47 ESI+; 424.4
60 47 ESI+; 523.3
61 47 ESI+; 493.5
62 47 ESI+; 495.5
63 - ESI+; 520.4
64 - ESI+; 378.2
65 - ESI+; 462.3
66 67 FAB; 236.9
67 - ESI+; 223.1, 225.1
[Table 5-3]
PEx PSyn DAT
68 69 FAB; 241.0
69 - ESI+; 227.1, 229.1
70 - ESI+; 281.0
71 70 ESI+; 295.0
72 - ESI+; 280.1, 282.1
73 - ESI+; 205.0, 207.0
74 - ESI+; 219.0, 221.0
75 73 ESI+; 304.1
76 - ESI - 259.0
77 - ESI+; 353.2 [M+Na]+
78 77 EI; 314.2
79 77 EI; 350.1
80 77 ESI+; 283.2 [M+Na]+
81 - ESI+; 245.0
82 81 EI; 302.0
83 - EI: 266.0
84 - CI; 282.9
85 - ESI+; 296.2, 298.2
86 - ESI+; 271.2
87 - ESI+; 182.1
88 - ESI+; 242.1
89 - ESI+; 153.0
90 - ESI+; 340.2
91 - ESI+; 251.2
92 - ESI+; 355.2
93 - ESI+; 487.2
94 - FAB; 364.1
95 94 FAB; 278.0
96 - FAB; 264.0
97 - FAB; 306.0
98 - CI; 229.1
99 - ESI+; 255.2
100 - ESI+; 284.1, 286.0
101 - ESI+; 409.3
102 - ESI+; 255.2
[Table 5-4]
[Table 5-5]
PEx PSyn DAT
107 72 ESI+; 281.1
108 1 ESI+; 286.1
109(1) 1 ESI+; 300.1, 302.1
109(2) 1 ESI+; 300.1, 302.1
110 1 ESI+; 324.2
111 1 ESI+; 357.0
112 1 ESI+; 369.2, 371.2
113 1 ESI+; 298.2, 300.2
114 - ESI+; 369.3
115 1 ESI+; 369.0
116 - ESI+; 286.1, 288.0
117 1 ESI+; 371.2, 373.3
118 1 <![CDATA[ESI+;377.3,379.3[M+Na]<sup>+</sup>]]>
119 1 ESI+; 270.1, 272.1
120 - ESI+; 270.1, 272.0
121 1 <![CDATA[ESI+;421.3, 423, 3[M+Na]<sup>+</sup>]]>
122 - <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm4.40(4H, s)]]>
123 44 <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm1.88(6H, s)4.25(2H, s)]]>
124 47 ESI+; 540.5
125 47 ESI+; 511.4
126 47 ESI+; 483.3
127 47 ESI+; 495.3
128(1) - ESI+; 537.4
128(2) - ESI+; 537.4
129 47 ESI+; 425.2
130 47 ESI+; 435.2
131 47 ESI+; 497.3
132 47 ESI+; 481.4
133 47 ESI+; 422.3
134 - ESI+; 422.3
135 47 ESI+; 525.1
136 64 -
137 64 ESI+; 395.2
138 64 ESI+; 397.2
139 64 ESI+; 381.3
[Table 5-6]
[Table 5-7]
[Table 6-1]
[Table 6-2]
Ex Syn DAT
6 1 ESI+; 298.1
7 1 FAB; 314.3
8 1 ESI+; 406.3
9 1 ESI+; 511.2
10 1 ESI+; 439.3
11 1 ESI+; 410.3
12 1 ESI+; 390.3
13 1 ESI+; 390.4
14 1 ESI+; 390.3
15 1 ESI+; 404.2
16(1) 1 FAB; 365.1
16(2) 1 FAB; 365.0
17 1 ESI+; 368.1
18 1 ESI+; 354.2
19 1 ESI+; 394.3
20 1 FAB; 367.2
twenty one 1 ESI+; 368.2
twenty two 1 ESI+; 353.2
twenty three 1 FAB; 445.2
twenty four 1 FAB; 394.2
25 1 ESI+; 374.2, 376.1
26 1 ESI+; 354.2
27 1 ESI+; 424.2
28 1 ESI+; 370.3
29 1 ESI+; 394.2
30 1 ESI+; 360.2, 362.1
31 1 ESI+; 340.2
32 1 ESI+; 410.2
33 1 ESI+; 356.2
34 1 ESI+; 422.3
35 1 ESI+; 410.2
36 I ESI+; 356.2
[Table 6-3]
Ex Syn DAT
37 1 ESI+; 426.2
38 1 ESI+; 372.2
39 1 ESI+; 376.2, 378.2
40 1 ESI+; 406.3
41 1 ESI+; 410.3
42 1 ESI+; 410.2
43 1 ESI+; 438.3
44 1 ESI+; 424.2
45 1 ESI+; 440.2
46 1 ESI+; 370.3
47 1 ESI+; 384.3
48 1 ESI+; 408.2
49 1 ESI+; 386.3
50 1 ESI+; 393.2
51 1 ESI+; 380.3
52(1) 1 ESI+; 382.3
52(2) 1 ESI+; 382.3
53 1 ESI+; 422.3
54 1 ESI+; 438.2
55 1 ESI+; 368.3
56(1) 1 ESI+; 396.2
56(2) 1 ESI+; 396.2
57(1) 1 ESI+; 412.2
57(2) 1 ESI+; 412.2
58 1 ESI+; 384.3
59 1 FAB; 380.4
60 1 ESI+; 395.8
61 1 ESI+; 342.2
[Table 6-4]
[Table 6-5]
[Table 6-6]
[Table 6-7]
[Table 6-8]
Industrial applicability
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and are expected to be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Technical Field
This invention relates to cyclopyridazine compounds or salts thereof that have NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Background Technology
Inflammasomes are collections of intracellular proteins triggered by intrinsic/extrinsic alarm molecules. They are mechanisms that exacerbate inflammatory responses induced by the cleavage of inflammatory cytokines IL-1β and IL-18, or by the induction of cell death, through caspase 1 activation. Several types of alarm molecules are known to recognize alarm molecules, including NLRP1, NLRP3, NLRC4, and AIM2. NLRP3 is activated upon recognizing extracellular ATP molecules, pathogen toxins, uric acid or cholesterol crystals, and abnormal protein aggregates, all of which trigger cellular stress.
As diseases caused by gain-of-function variations in NLRP3, Cryopyrin-associated periodic syndrome (CAPS) is known (Nature Genetics, Vol. 29, No. 3, pp. 301-305, 2001). Additionally, it has been reported in gout (Arthritis Research and Therapy, Vol. 12, No. 2, Article No. 206, 2010), non-alcoholic steatohepatitis (Journal of Molecular Medicine, Vol. 92, No. 10, pp. 1069-1082, 2014), inflammatory bowel disease (Gut, Vol. 59, No. 9, pp. 1192-1100, 2010), and Alzheimer's disease (Nature, Vol. 493, No. 7434, pp. 674-678). Increased activation or expression of the NLRP3 inflammasome is observed in a wide variety of diseases, including Parkinson's disease (PLoS ONE, Vol. 8, No. 1, Article No. e55375, 2013), amyotrophic lateral sclerosis (ALS, Vol. 41, No. 1, pp. 93-103, 2018), and multiple system atrophy (Journal of Neuropathology and Extrinsic Neurology, Vol. 77, No. 11, pp. 1055-1065, 2018).
In addition, NLRP3 is known to be activated by α-synuclein filaments to promote the production of IL-1β from microglia; and functional improvement has been observed by administration of NLRP3 inhibitors in a mouse model of α-synuclein filament-induced α-synucleinopathy (Science Translational Medicine, Vol. 10, Article No. eaah4066, 2018).
Patent document 1 describes a compound represented by the following formula that has inhibitory activity on the NLRP3 inflammasome pathway ( R3 and R4 are H, cyano, C1-4 alkyl, or halo- C1-4 alkyl. Other notations in the formula refer to this publication).
[Chemical Formula 1]
Patent document 2 published after the priority date of this application describes a compound represented by the following formula that has an inhibitory effect on NLRP3 inflammasome activation (the notation in the formula is based on that publication).
[Chemical Formula 2]
Patent document 3 published after the priority date of this application describes a compound represented by the following formula that has NLRP3 inhibitory effects (the notations in the formula refer to that publication).
[Chemical Formula 3]
Patent document 4 describes a compound represented by the following formula that has NLRP3 inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 4]
Patent document 5 describes a compound represented by the following formula that has an NLRP1/3 regulating effect (refer to the notation in the formula in this publication).
[Chemical Formula 5]
Patent document 6 describes a compound represented by the following formula that has inhibitory effects on NLRP3 inflammasomes (the notation in the formula is based on that publication).
[Chemical Formula 6]
Patent document 7 describes a compound represented by the following formula that has C5a receptor inhibitory activity (the notation in the formula is based on that publication).
[Chemical Formula 7]
Patent document 8 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 8]
Patent document 9 describes a compound represented by the following formula that has an inhibitory effect on the Hedgehog signaling pathway (the notation in the formula is the same as that in the publication).
[Chemical Formula 9]
Patent document 10 describes a compound represented by the following formula that has muscarinic M4 receptor antagonistic activity (the notation in the formula is the same as that in the publication).
[Chemical Formula 10]
Existing technical documents
Patent documents
Patent Document 1: International Publication No. 2020/234715
Patent Document 2: International Publication No. 2021/193897
Patent Document 3: US Patent No. 11,319,319
Patent Document 4: International Publication No. 2019/008025
Patent Document 5: International Publication No. 2017/184604
Patent Document 6: International Publication No. 2018/015445
Patent Document 7: International Publication No. 2006/004589
Patent Document 8: International Publication No. 2014/191737
Patent Document 9: International Publication No. 2015/001348
Patent Document 10: International Publication No. 2021/067696
Summary of the Invention
The problem that the invention aims to solve
Compounds that provide NLRP3 inflammasome activation inhibition activity and are expected to be used as active ingredients in pharmaceutical compositions, particularly for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
Methods for solving problems
The inventors conducted in-depth research on compounds with NLRP3 inflammasome activation inhibition activity and found that cyclopyridazine compounds have NLRP3 inflammasome activation inhibition activity, and are expected to be used as effective ingredients in pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, thus completing the present invention.
That is, the present invention relates to compounds of formula (I) or salts thereof, and pharmaceutical compositions containing compounds of formula (I) or salts thereof and one or more excipients.
[Chemical Formula 11]
(in the formula,
Ring A is a C5-8 cycloalkenyl group, a 5-11 member partially unsaturated heterocyclic group, an aryl group, or a heteroaryl group;
R1 may be the same or different from each other, and may be OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, -C1-6 alkylene-aryl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halogenated C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -, -O -, or -CR 4 R 5 -;
R3 is H or C1-6 alkyl;
R4 and R5 are the same or different from each other, and are H or C1-6 alkyl;
R6 is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a -C1-6 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a -C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups;
R7 is -OR 12 , -NR 13 , R 14 , halogen, or cyano;
R8 and R10 are C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen , or cyano;
R9 and R11 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene -NR13R14, halogen, cyano, oxo, -C(O)-C1-6 alkyl , or -S (O) 2 - C1-6 alkyl;
R 12 is H or C 1-6 alkyl;
R13 and R14 may be the same or different from each other, and may be H, C1-6 alkyl or -C(O) -C1-6 alkyl;
n is an integer from 1 to 4, representing the number of R1s used as substituents;
m is an integer from 0 to 3, representing the number of R2 substituents;
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia).
[Chemical Formula 12]
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
k is an integer from 0 to 3, representing the number of R 1a substituents.
It should be noted that, unless otherwise specified, if a symbol used in one chemical formula in this specification is also used in other chemical formulas, the same symbol has the same meaning.
Furthermore, the present invention relates to pharmaceutical compositions containing a compound of formula (I) or a salt thereof and one or more pharmaceutically permissible excipients, particularly pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases. It should be noted that the pharmaceutical composition comprises a preventive and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases containing a compound of formula (I) or a salt thereof.
In addition, the present invention relates to compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation; compounds of formula (I) or salts thereof used as inhibitors of NLRP3 inflammasome activation; NLRP3 inflammasome activation inhibitors containing compounds of formula (I) or salts thereof; pharmaceutical compositions containing compounds of formula (I) or salts thereof as inhibitors of NLRP3 inflammasome activation and one or more pharmaceutically permissible excipients; use of compounds of formula (I) or salts thereof in the manufacture of medicaments or pharmaceutical compositions for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; use of compounds of formula (I) or salts thereof for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; compounds of formula (I) or salts thereof used in the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases; and methods for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, including applying an effective amount of a compound of formula (I) or salts thereof to a subject. It should be noted that "object" refers to a person or other animal that needs the prevention and/or treatment, and in a certain way, it refers to a person who needs the prevention and/or treatment.
The effects of the invention
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and can be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.
Detailed Implementation
The present invention will now be described in detail.
In this specification, unless otherwise specified, the following terms have the meanings indicated below. The definitions below are for clarification and not for limitation. Here, where a term is not specifically defined, it is used in the sense commonly accepted by those skilled in the art.
In this specification, " C1-6 alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms (hereinafter abbreviated as C1-6 ), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,3-dimethylbutyl, 1-ethyl-2-methylpropyl, etc. Alternatively, it may be a straight-chain or branched C1-4 alkyl group; alternatively, it may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl; alternatively, it may be methyl, ethyl, n-propyl, n-butyl, or isobutyl; further alternatively, it may be n-propyl, n-butyl, or isobutyl. Alternatively, it is methyl, ethyl, n-propyl or isopropyl; in one way, it is methyl or ethyl; in another way, it is ethyl; further in another way, it is methyl.
" C1-6 alkylene" is a straight-chain or branched C1-6 divalent saturated hydrocarbon group, such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 2-methyltrimethylene, ethylethylene, 1,2-dimethylethylene, or 1,1,2,2-tetramethylethylene. In one form, it is C1-4 alkylene; in another form, it is methylene or ethylene; further in another form, it is ethylene; and in yet another form, it is methylene.
"C 3-8 cycloalkyl" refers to a C 3-8 saturated hydrocarbon cycloalloy that can be bridged or form a spirocyclic ring. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[3.3.0]octyl, bicyclo[2.2.2]octyl, spiro[2.2]pentyl, spiro[3.3]heptyl, or spiro[2.5]octyl. As one mode, it is a C3-6 saturated hydrocarbon cycloyl group; as another mode, it is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; further as another mode, it is cyclopropyl; as yet another mode, it is cyclobutyl, cyclopentyl, cyclohexyl, or bicyclo[1.1.1]pentyl; as one mode, it is cyclobutyl, cyclopentyl, or cyclohexyl; further as another mode, it is cyclobutyl or cyclohexyl; further as yet another mode, it is cyclobutyl; as yet another mode, it is cyclopentyl; and further as yet another mode, it is cyclohexyl.
"C 5-8 cycloalkenyl" is a C 5-8 hydrocarbon cycloalkenyl group with a single double bond within the molecule, which can be bridged. Examples include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]heptenyl, and bicyclo[2.2.2]octenyl. As one form, it is cyclopentenyl, cyclohexenyl, cycloheptenyl, and bicyclo[2.2.2]octenyl; further as another form, it is cyclopentenyl, cyclohexenyl, and cycloheptenyl; further as yet another form, it is cyclopentenyl; another form, it is cyclohexenyl; and yet another form, it is cycloheptenyl.
When ring A is a C5-8 cycloalkenyl group, [Chemical Formula 13-1] is a partial structure of formulas (I) and (Ia).
(The wavy lines represent the bonding portions with the phenyl and L in formula (I), respectively. The same applies below.)
The C5-8 cycloalkenyl group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 13-2]
"4- to 7-membered saturated heterocyclic groups" refer to 4- to 7-membered saturated hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms, as ring constituent atoms. Examples include oxohexacyclobutyl, azirhexacyclobutyl, thiohexacyclobutyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiopheneyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopheneyl, oxoheptanyl, azirheptanyl, thioheptanyl, dioxoheptanyl, imidazoalkyl, pyrazolyl, dithioheptanyl, oxazolyl, isoxazolyl, thiazoalkyl, isothiazolyl, dioxohexyl, piperazine, dithiohexyl, morpholinyl, thiomorpholinyl, oxathioheptanyl, dioxathioheptanyl, diazirheptanyl, dithioheptanyl, oxaazonyl, thioazonyl, and oxathioheptanyl, but not limited to these. As one embodiment, it is oxetyl, tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, piperidinyl, or tetrahydrothiaranyl; as another embodiment, it is tetrahydrofuranyl, pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is pyrrolyl, tetrahydropyranyl, or piperidinyl; as yet another embodiment, it is tetrahydropyranyl or piperidinyl; as yet another embodiment, it is tetrahydrofuranyl or tetrahydropyranyl; as yet another embodiment, it is tetrahydrofuranyl; as yet another embodiment, it is tetrahydropyranyl. As another embodiment, it is pyrrolyl or piperidinyl; as yet another embodiment, it is pyrrolyl; as yet another embodiment, it is piperidinyl. As yet another embodiment, it is oxetyl.
"5- to 11-membered partially unsaturated heterocyclic groups" are 5- to 11-membered hydrocarbon cyclic groups containing one or more heteroatoms, particularly oxygen, nitrogen, or sulfur atoms as ring-forming atoms, and possessing a single double bond within the molecule. They can also exhibit bridging or form spirocyclic rings. Examples include dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydronitroheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydrooxoheptenyl, tetrahydrothioheptenyl, dioxopentenyl, dihydroimidazoyl, dihydropyrazolyl, dithioheptenyl, dihydrooxazolyl, dihydroisooxazolyl, dihydrothiazoyl, dihydroisothiazoyl, and dihydrodioxoheptenyl. Hexenyl, tetrahydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazocyclohexenyl, dihydrodioxazocycloheptenyl, tetrahydrodiazacycloheptenyl, dihydrodithiocycloheptenyl, tetrahydrooxazocycloheptenyl, tetrahydrothiazazacycloheptenyl, dihydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl, 2-oxaspiro[4.5]decenyl, 3-oxaspiro[5.5]undecenyl, but not limited thereto. As one embodiment, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, dihydrothiaranyl, tetrahydrooxazocycloheptenyl, 2-oxaspiro[3.5]nonenyl. In one manner, it is a 5- to 8-membered partially unsaturated heterocyclic group; in another manner, it is dihydrofuranyl, dihydropyrroleyl, dihydrothiopheneyl, dihydropyranyl, tetrahydropyridyl, dihydrothiopheneyl, tetrahydrooxoheptenyl, tetrahydroazaheptenyl, tetrahydrothioheptenyl, tetrahydrooxoheptenyl, hexahydroazaheptenyl, tetrahydrothioheptenyl, dioxazol ... Dihydropyrazinyl, dihydrodithiocyclohexenyl, dihydrooxazinyl, dihydrothiazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrooxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl, dihydrodioxazinyl; as one embodiment, it is dihydropyrroleyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl; further as another embodiment, it is dihydropyranyl, tetrahydropyridyl, tetrahydrooxazinyl. As another form, it is dihydrofuranyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridyl, tetrahydrooxoheptenyl; as another form, it is dihydrofuranyl, dihydropyranyl, tetrahydrooxoheptenyl or 2-oxaspiro[3.5]nonenyl; as another form, it is dihydropyranyl; further as another form, it is tetrahydropyridyl; and as yet another form, it is tetrahydrooxoheptenyl.
When ring A is a 5- to 11-membered partially unsaturated heterocyclic group, as part of the structures of formulas (I) and (Ia)
[Chemical Formula 14-1]
middle,
The 5- to 11-membered partially unsaturated heterocyclic group condenses with a pyridazine ring at its double bond site, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 14-2]
"Aryl" is a C6-14 monocyclic to tricyclic aromatic hydrocarbon cyclic group, including bicyclic to tricyclic aromatic hydrocarbon cyclic groups formed by the condensation of its double bond with a C5-8 cyclic alkene. Examples include phenyl, naphthyl, tetrahydronaphthyl, indene, fluorenyl, etc., with phenyl being one example.
When ring A is aryl, as part of the structure of formulas (I) and (Ia)
[Chemical Formula 15-1]
middle,
The aryl benzene ring condenses with the pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 15-2]
"Heteroaryl" refers to a 5- to 6-membered aromatic hydrocarbon cyclic group containing 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen. Examples include pyrrole, furanyl, thiophene, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and tetraazinyl. In one form, it is thiophene or pyridinyl; further, in another form, it is pyridinyl; and still another form, it is thiophene.
When ring A is a heteroaryl group, [Chemical Formula 16-1] is a partial structure of formulas (I) and (Ia).
middle,
The heteroaryl group condenses with a pyridazine ring, for example, to form the following partial structures, but not limited thereto.
[Chemical Formula 16-2]
"Halogen" refers to F, Cl, Br, or I. In one sense, it is F or Cl; further, in another sense, it is F; in yet another sense, it is Cl.
"Halogenated C1-6 alkyl" refers to a straight-chain or branched C1-6 alkyl group substituted with one or more halogens. Examples include: trifluoromethyl, trifluoroethyl, trifluoropropyl, 2-fluoro-2-methylpropyl, difluoromethyl, difluoroethyl, fluoromethyl, or chloromethyl. In one manner, it is difluoroethyl, trifluoromethyl, or difluoromethyl; further, it is trifluoromethyl or difluoromethyl; in another manner, it is trifluoromethyl; and in yet another manner, it is difluoromethyl.
In this specification, "substitutable" means unsubstituted or "substituted by one or more substituents". The substitution can be at any position, as long as the hydrogen is normally present in the group.
Even if the combination is not specifically recorded, one or more methods can be combined with another method.
In this specification, "inflammatory disease and/or neurodegenerative disease" is, in one sense, an inflammatory disease and a neurodegenerative disease; further, it is an inflammatory disease; and in another sense, it is a neurodegenerative disease.
In this specification, "inflammatory disease" includes, but is not limited to, autoinflammatory diseases such as Cryopyrin-associated periodic fever syndrome (CAPS), gout, and pseudogout; and diseases such as non-alcoholic steatohepatitis (NASH). As one mode, it is an autoinflammatory disease; as another, it is CAPS; and further, it is gout. It should be noted that "Cryopyrin-associated periodic fever syndrome (CAPS)" is a disease group comprised of familial cold urticaria (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multi-organ system inflammatory diseases/infantile chronic neurocutaneous joint syndrome (NOMID/CINCA syndrome).
In this specification, "neurodegenerative diseases" refers to a group of diseases including, but not limited to, alpha-synucleinopathies such as Parkinson's disease, multiple system atrophy, and Lewy body type dementia; Alzheimer's disease; amyotrophic lateral sclerosis (ALS); and multiple sclerosis. One example is Alzheimer's disease, multiple sclerosis, and ALS; another example is multiple sclerosis. Another example is alpha-synucleinopathies; another example is Parkinson's disease; yet another example is multiple system atrophy; and yet another example is Lewy body type dementia.
In this specification, "treatment" includes both "treatment for therapeutic purposes" and "treatment for preventative purposes." "Treatment for therapeutic purposes" refers to alleviating symptoms, altering disease course, or prolonging lifespan, while "treatment for preventative purposes" refers to reducing the likelihood of developing the disease in subjects at risk. "Subjects at risk" refers to individuals with known risk factors who are more susceptible to the disease than the general population.
The compound of formula (I) or a salt thereof in this invention is shown in one of the following ways.
(1-1) Compounds of formula (I) or their salts (n and m represent the number of R1 and R2 as substituents, respectively. The same applies below).
[Chemical Formula 17]
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia) (k represents the number of R 1a as substituents. The same applies below).
[Chemical Formula 18]
(1-2) Compounds of formula (Ia) or their salts.
(1-3) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
[Chemical Formula 19]
(1-4) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy) or salts thereof.
(1-5) Compounds of formula (Ib), (Ic), (Id), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iv), (Iw), (Ix) or (Iy) or their salts.
(1-6) Compounds of formula (Ic), (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-7) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), (Ip), (Iq) or (Ir) or salts thereof.
(1-8) Compounds of formula (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or their salts.
(1-9) Compounds of formula (Ib), (Ic), (Id) or (Ie) or their salts.
Compounds of formula (Ib) (1-10) or their salts.
Compounds of formula (Ic) or their salts thereof.
Compounds of formula (Id) (1-12) or their salts.
(1-13) A compound of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) or a salt thereof.
(1-14) Compounds of formula (If), (Ig), (Ih), (Ii) or (Ij) or their salts.
(1-15) Compounds of formula (Ig), (Ih) or (Ij) or their salts.
Compounds of formula (Ig) (1-16) or their salts.
Compounds of formula (Ih) or their salts thereof.
Compounds of formula (Ij) or their salts. (1-18)
(1-19) Compounds of formula (Ik), (Im) or (In) or their salts.
Compounds of formula (Ik) or their salts thereof.
Compounds of formula (Im) or their salts thereof.
(1-22) Compounds of formula (In) or their salts.
(1-23) Compounds of formula (Io), (Ip), (Iq) or (Ir) or their salts.
Compounds of formula (Io) or their salts thereof.
Compounds of formula (Ip) (1-25) or their salts.
Compounds of formula (Iq) (1-26) or their salts.
Compounds of formula (Ir) or their salts thereof.
(1-28) Compounds of formula (Ic), (Ig), (Ih), (Ij) or (Im) or their salts.
(1-29) Compounds of formula (Ic), (Ih), (Ij) or (Im) or their salts.
(1-30) Compounds of formula (Ic) or formula (Ih) or their salts.
Compounds of formula (Ix) or their salts thereof. (1-31)
Compounds of formula (Iy) or their salts. (1-32)
(1-33) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Is), (It), (Iu), (Iv), (Iw), (Ix) or (Iy).
(1-34) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iu), (Iv), (Iw) or (Iy).
(1-35) Compounds of formula (Ih), (Ij), (Im), (Ix) or (Iy) or their salts.
(1-36) A compound or a salt thereof of formula (If), (Ig), (Ih), (Ii), (Ij), (Iv), (Iw) or (Iy).
(2-1) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-2) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 8-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-3) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-8 partially unsaturated heterocyclic group.
(2-4) Compounds with ring A being C5-8 cycloalkenyl or their salts.
(2-5) Compounds or their salts in which ring A is a 5- to 8-membered partially unsaturated heterocyclic group.
(2-6) Compounds in which ring A is a C5-8 cycloalkenyl, a 5- to 11-membered partially unsaturated heterocyclic group, an aryl or heteroaryl group, or a salt thereof. Wherein, when ring A is an aryl or heteroaryl group, formula (I) is formula (Ia), R1a are the same or different from each other, and are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl, and k is an integer from 0 to 2.
(2-7) Compounds or their salts in which ring A is a C5-8 cycloalkenyl or a 5-11 partially unsaturated heterocyclic group.
(2-8) Compounds in which ring A is aryl or heteroaryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-9) Compounds in which ring A is aryl or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-10) Compounds in which ring A is a heteroaryl group or a salt thereof. Wherein, formula (I) is formula (Ia), R 1a are the same or different from each other, and are C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl, and k is an integer from 0 to 3.
(2-11) Compounds or their salts in which ring A is a partially unsaturated heterocyclic group of 5 to 11 members.
(3-1) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo -C1-6 alkyl, or -OC3-8 cycloalkyl.
(3-2) R1 is the same or different from each other, and is a compound or a salt thereof of OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halo- C1-6 alkyl.
(4-1) R 1a are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, halogen, cyano, -OC 1-6 alkyl, -O-halo-C 1-6 alkyl, or -OC 3-8 cycloalkyl.
(4-2) R 1a are the same or different from each other, and are compounds of C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl or salts thereof.
(4-3) R 1a are the same or different from each other, and are compounds of halo- C1-6 alkyl, halogen, or -O-halo- C1-6 alkyl or salts thereof.
(4-4) R 1a is a halo- C1-6 alkyl compound or a salt thereof.
(4-5) R 1a is a halogen compound or its salt.
(4-6)R 1a is a compound of -O-halogenated C1-6 alkyl or a salt thereof.
(4-7) R 1a is a compound of C 1-6 alkyl or a salt thereof.
(4-8)R 1a is a compound of C 3-8 cycloalkyl or a salt thereof.
(4-9) R 1a is a compound of -OC 1-6 alkyl or a salt thereof.
(5-1) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-2) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, C 3-8 cycloalkyl, halogen, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-3) R 2 are the same or different from each other, and are compounds or salts thereof of C 1-6 alkyl, -C 1-6 alkylene-aryl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl.
(5-4) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C 1-6 alkylene-aryl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-5) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-6) R 2 are the same or different from each other, and are compounds of C 1-6 alkyl, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or salts thereof.
(5-7) R2 is a compound of C1-6 alkyl groups or a salt thereof.
(5-8)R 2 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(5-9)R 2 is a compound of -S(O) 2 -C 1-6 alkyl or a salt thereof.
(5-10) R2 is an oxolated compound or its salt.
(6-1)L is a compound of -NR 3- , -O- or -CR 4R 5- or a salt thereof.
(6-2)L is a compound of -NR 3- or -O- or its salt.
(6-3)L is a compound of -NR 3- or its salt.
(6-4)L is a compound of -O- or its salt.
(6-5)L is a compound of -CR4R5- or its salt.
(7-1) R 3 is a compound of H or C 1-6 alkyl or a salt thereof.
(7-2) R 3 is a compound of H or its salt.
(7-3) R 3 is a C1-6 alkyl compound or a salt thereof.
(8-1) R4 and R5 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(8-2) R4 and R5 are both compounds of H or their salts.
(8-3) R4 and R5 are both C1-6 alkyl compounds or their salts.
(9-1) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a C1-6 alkylene group ( a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups.
(9-2) R6 is a compound or a salt thereof consisting of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups), -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups), a C3- to 8-membered cycloalkyl group that may be substituted by 1 to 4 identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R11 groups.
(9-3) R6 is a compound or a salt thereof that is a C1-6 alkyl group substituted with one R7 , a -C1-6 alkylene group (a C3-8 cycloalkyl group that may be substituted with one R8 ), a -C1-6 alkylene group (a 4- to 7-membered saturated heterocyclic group), a C3-8 cycloalkyl group that may be substituted with one or two identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that may be substituted with one or two identical or different R11 groups .
(9-4) R6 is a compound or a salt thereof that can be substituted by 1 to 4 identical or different R10s of a C3-8 cycloalkyl group or a 4- to 7-membered saturated heterocyclic group that can be substituted by 1 to 4 identical or different R11s .
(9-5) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 4 identical or different R7s .
(9-6) R6 is a compound of C1-6 alkyl groups or a salt thereof that is substituted with 1 to 3 identical or different R7s .
(9-7) R6 is a compound of C1-6 alkyl group or a salt thereof that is substituted with 1 to 2 identical or different R7 groups .
(9-8) R6 is a compound of a C1-6 alkyl group substituted with one R7 or a salt thereof.
(9-9) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 4 identical or different R8 groups ) or a salt thereof.
(9-10) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 3 identical or different R8 groups ) or a salt thereof.
(9-11) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by 1 to 2 identical or different R8 groups ) or a salt thereof.
(9-12) R6 is a compound of -C1-6 alkylene- (a C3-8 cycloalkyl group that may be substituted by one R8 ) or a salt thereof.
(9-13) R 6 is a compound of -C 1-6 alkylene-C 3-8 cycloalkyl or a salt thereof.
(9-14) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 4 identical or different R9 groups ) or a salt thereof.
(9-15) R6 is a compound or a salt thereof of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 3 identical or different R9 groups).
(9-16) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by 1 to 2 identical or different R9 groups ) or a salt thereof.
(9-17) R6 is a compound of -C1-6 alkylene- (a 4- to 7-membered saturated heterocyclic group that may be substituted by one R9 ) or a salt thereof.
(9-18) R 6 is a compound of -C 1-6 alkylene-(4-7 membered saturated heterocyclic group) or a salt thereof.
(9-19) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R10s of C3-8 cycloalkyl groups.
(9-20) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R10s of C3-8 cycloalkyl groups.
(9-21) R6 is a compound or a salt thereof that can be substituted by one or two identical or different R10s of a C3-8 cycloalkyl group.
(9-22) R6 is a compound of C3-8 cycloalkyl group or a salt thereof that can be replaced by one R10 .
(9-23) R6 is a compound of C3-8 cycloalkyl or a salt thereof.
(9-24) R6 is a compound or a salt thereof that can be replaced by 1 to 4 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-25) R6 is a compound or a salt thereof that can be replaced by 1 to 3 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-26) R6 is a compound or a salt thereof that can be replaced by 1 to 2 identical or different R11 saturated heterocyclic groups of 4 to 7 members.
(9-27) R6 is a compound or a salt thereof that can be replaced by a 4- to 7-membered saturated heterocyclic group of one R11 .
(9-28) R6 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(9-29) R6 is a C1-6 alkyl group substituted with one R7 , a C3-8 cycloalkyl group substituted with one or two identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with one or two identical or different R11 groups, or a salt thereof.
(9-30) R6 is a compound or a salt thereof that can be substituted by 1 to 2 identical or different R10s , or by 1 to 2 identical or different R11s , of a C3-8 cycloalkyl group.
(9-31) R6 is a compound or a salt thereof that can be replaced by a C3-8 cycloalkyl group that is substituted by one R10 or by a 4-7 member saturated heterocyclic group that is substituted by one R11 .
(10-1) R 7 is a compound of -OR 12 , -NR 13 , R 14 , halogen or cyano, or a salt thereof.
(10-2) R 7 is a compound of -OR 12 or -NR 13 R 14 or a salt thereof.
(10-3)R 7 is a compound of -OR 12 or a salt thereof.
(10-4)R 7 is a compound of -NR 13 R 14 or a salt thereof.
(10-5)R 7 is a halogen compound or a salt thereof.
(10-6)R 7 is a cyano compound or a salt thereof.
(11-1) R8 is a C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene - NR13R14 , halogen or cyano compound or salt thereof.
(11-2) R8 is a compound of -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 or a salt thereof.
(11-3) R8 is a compound of C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , halogen, or cyano, or a salt thereof .
(11-4) R8 is a compound of -OR12 , -C1-6 alkylene- OR12 or a salt thereof.
(11-5) R 8 is a compound of -OR 12 or a salt thereof.
(11-6)R 8 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(12-1) R 9 is a compound of C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl or a salt thereof.
(12-2) R 9 is a compound or a salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(13-1) R 10 is a compound of C1-6 alkyl, halogenated C1-6 alkyl, C3-8 cycloalkyl, -OR 12 , -NR 13 R 14 , -C1-6 alkylene-OR 12 , -C1-6 alkylene-NR 13 R 14 , halogen, or cyano, or a salt thereof.
(13-2) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , halogen or cyano, or a salt thereof.
(13-3) R 10 is a C 1-6 alkyl compound or a -OR 12 compound or a salt thereof.
(13-4) R 10 is a compound of C1-6 alkyl groups or a salt thereof.
(13-5) R 10 is a compound of -OR 12 or a salt thereof.
(13-6) R 10 is a compound of -NR 13 R 14 or a salt thereof.
(13-7) R 10 is a compound of -C 1-6 alkylene-OR 12 or a salt thereof.
(13-8) R 10 is a halogen compound or a salt thereof.
(13-9) R 10 is a cyano compound or a salt thereof.
(13-10)R 10 is a compound of C1-6 alkyl, -OR 12 , -NR 13 R 14 , or cyano groups or a salt thereof.
(13-11) R 10 is a compound of C 1-6 alkyl, -OR 12 , or cyano groups or a salt thereof.
(13-12) R 10 is a compound of C 1-6 alkyl, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , or cyano, or a salt thereof.
(14-1) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , -NR 13 R 14 , -C 1-6 alkylene-OR 12 , -C 1-6 alkylene-NR 13 R 14 , halogen, cyano, oxo, -C(O)-C 1-6 alkyl, or -S(O) 2 -C 1-6 alkyl or a salt thereof.
(14-2) R 11 is a compound or salt thereof of C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O)-C 1-6 alkyl.
(14-3) R 11 is a compound of C1-6 alkyl groups or a salt thereof.
(14-4)R 11 is a compound of C3-8 cycloalkyl or a salt thereof.
(14-5) R 11 is a compound or its salt consisting of a 4- to 7-membered saturated heterocyclic group.
(14-6) R 11 is a compound of -OR 12 or a salt thereof.
(14-7) R 11 is an oxolated compound or its salt.
(14-8)R 11 is a compound of -C(O)-C 1-6 alkyl group or a salt thereof.
(14-9) R 11 is a compound or salt thereof that is C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 member saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
(14-10) R 11 is a compound of C 1-6 alkyl or -OR 12 or a salt thereof.
(14-11) R 11 is a compound of C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, -OR 12 , or -C(O)-C 1-6 alkyl or a salt thereof.
(15-1) R 12 is a compound of H or C 1-6 alkyl or a salt thereof.
(15-2) R 12 is a compound of H or its salt.
(15-3) R 12 is a compound of C1-6 alkyl groups or a salt thereof.
(16-1) R13 and R14 are the same or different from each other, and are compounds of H, C1-6 alkyl or -C(O) -C1-6 alkyl or salts thereof.
(16-2) R13 and R14 are the same or different from each other, and are H or C1-6 alkyl compounds or their salts.
(16-3) R13 and R14 are both compounds of H or their salts.
(16-4) A compound in which both R13 and R14 are H or salts thereof, or a compound in which R13 is -C(O) -C1-6 alkyl and R14 is H or salts thereof.
(16-5) R 13 is a -C(O)-C 1-6 alkyl compound, R 14 is H, or a salt thereof.
(17-1) n is an integer from 1 to 4, or a salt thereof.
(17-2) n is an integer from 1 to 3, or a salt thereof.
(17-3) A compound or its salt in which n is 1 or 2.
(17-4) Compounds or their salts in which n is 2.
(17-5) Compounds or their salts in which n is 1.
(18-1) m is an integer from 0 to 3, or a salt thereof.
(18-2)m is an integer from 0 to 2, which is a compound or its salt.
(18-3)A compound or its salt in which m is 0 or 1.
(18-4) Compounds or their salts with m = 1.
(18-5) Compounds or their salts where m is 0.
(19-1)k is an integer from 0 to 3, which is a compound or its salt.
(19-2)k is an integer from 0 to 2, which is a compound or its salt.
(19-3) Compounds or their salts in which k is 0 or 1.
(19-4) Compounds or their salts in which k is 1.
(19-5) Compounds or their salts in which k is 0.
(19-6)k is a compound or its salt where k is 1 or 2.
(20) A compound or its salt that is a combination of two or more groups described in (1-1) to (19-6) above without contradiction. Examples of such combinations are as follows, but not limited thereto.
(20-1) Compounds or salts thereof that are combinations of (1-1), (2-2), (3-1), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (17-1), (18-1), and (19-1).
(20-2) Compounds or salts thereof that are combinations of (1-2), (2-2), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-3) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-1), (5-2), (6-1), (7-1), (8-1), (9-1), (10-1), (11-1), (12-1), (13-1), (14-1), (15-1), (16-1), (18-1), and (19-1).
(20-4) Compounds or salts thereof that are combinations of (1-2), (2-6), (4-2), (5-5), (6-1), (7-2), (8-2), (9-3), (10-2), (11-3), (12-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-5) Compounds or salts thereof that are combinations of (1-2), (2-7), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-6) Compounds or salts thereof that are combinations of (1-2), (2-3), (4-3), (5-7), (6-3), (7-2), (9-30), (13-3), (14-10), (15-2), (18-3), and (19-6).
(20-7) Compounds or salts thereof that are combinations of (1-2), (2-11), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-9), (15-2), (16-4), (18-2), and (19-2).
(20-8) Compounds or salts thereof that are combinations of (1-34), (4-2), (5-5), (6-3), (7-2), (9-29), (10-2), (13-2), (14-10), (15-2), (16-4), (18-5), and (19-2).
(20-9) Compounds or salts thereof that are combinations of (1-17), (4-2), (6-3), (7-2), (9-29), (10-2), (13-11), (14-10), (15-2), (16-5), (18-5), and (19-2).
(20-10) Compounds or salts thereof that are combinations of (1-6), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-11) Compounds or salts thereof that are combinations of (1-35), (4-3), (5-7), (6-3), (7-2), (9-31), (13-5), (14-3), (15-2), (18-3), and (19-4) above.
(20-12) Compounds or salts thereof that are combinations of (1-7), (4-2), (5-4), (6-1), (7-2), (8-2), (9-3), (10-2), (11-4), (13-2), (14-2), (15-2), (16-4), (18-3), and (19-2).
(20-13) Compounds or salts thereof that are combinations of (1-28), (4-3), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-3), and (19-4) above.
(20-14) Compounds or salts thereof that are combinations of (1-11), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-15) Compounds or salts thereof that are combinations of (1-17), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-16) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-17) Compounds or salts thereof that are combinations of (1-11), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-18) Compounds or salts thereof that are combinations of (1-21), (4-4), (5-7), (6-3), (7-2), (9-22), (13-5), (15-2), (18-4), and (19-4) above.
(20-19) Compounds or salts thereof that are combinations of (1-18), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-20) Compounds or salts thereof that are combinations of (1-17), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-21) Compounds or salts thereof that are combinations of (1-16), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-22) Compounds or salts thereof that are combinations of (1-16), (4-6), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-23) Compounds or salts thereof that are combinations of (1-16), (4-5), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-24) Compounds or salts thereof that are combinations of (1-31), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-25) Compounds or salts thereof that are combinations of (1-32), (4-4), (6-3), (7-2), (9-22), (13-5), (15-2), (18-5), and (19-4) above.
(20-26) Compounds or salts thereof that are combinations of (1-17), (4-6), (6-3), (7-2), (9-27), (14-3), (18-5), and (19-4) above.
Examples of specific compounds included in this invention include compounds selected from the group consisting of compounds or salts thereof.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxetanehepteneno[4,5-d]pyridazin-1-yl-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol.
In addition, as one way of including specific compounds in the present invention, compounds selected from the group consisting of the following or their salts can be listed.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5)-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol.
Examples of specific compounds included in this invention include the following group of compounds.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
In addition, the following group of compounds can be listed as one example of specific compounds included in the present invention.
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride, and
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride.
Depending on the type of substituent, compounds of formula (I) may contain tautomers or geometric isomers. In this specification, compounds of formula (I) or their salts are sometimes described as only one form of isomer, but the present invention also includes other isomers, as well as substances obtained by isomer separation, or mixtures thereof.
Furthermore, in cases where the compound of formula (I) or its salt has an asymmetric center or axial asymmetry, enantiomers (optical isomers) based thereon may exist. The compound of formula (I) or its salt also includes any of the separated enantiomers such as (R) bodies, (S) bodies, etc., and mixtures thereof (including racemic or non-racemic mixtures). In one manner, the enantiomer is "stereochemically pure." "Stereochemically pure" means a purity that can be recognized by a person skilled in the art as substantially stereochemically pure. Alternatively, the enantiomer is a compound having a stereochemical purity of, for example, 90% ee (enantiomeric excess) or more, 95% ee or more, 98% ee or more, or 99% ee or more.
Furthermore, the present invention also includes pharmaceutically permissible prodrugs of compounds represented by formula (I). A pharmaceutically permissible prodrug is a compound having groups that can be converted to amino, hydroxyl, carboxyl, or other groups by solvent decomposition or under physiological conditions. Examples of groups forming prodrugs include those described in Prog. Med., 5, 2157-2161 (1985), or in "Development of Pharmaceuticals" (Hirokawa Shoten, 1990), Vol. 7, Molecular Design, pp. 163-198.
Furthermore, salts of compounds of formula (I) are pharmaceutically permissible salts of compounds of formula (I). Depending on the type of substituent, they may sometimes form acid addition salts or salts with bases. Specifically, examples include: acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; or with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, dibenzoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid; salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; and salts with organic bases such as methylamine, ethylamine, ethanolamine, lysine, and ornithine; and salts or ammonium salts with various amino acids and amino acid derivatives such as acetylleucine.
Furthermore, the present invention also includes various hydrates or solvates of compounds of formula (I) or salts thereof, as well as polymorphic substances.
Furthermore, this invention includes all pharmaceutically permissible compounds of formula (I) or salts thereof labeled with one or more radioactive or non-radioactive isotopes. Examples of suitable isotopes used in the isotopic labeling of the compounds of this invention include isotopes of hydrogen (e.g., 2H and 3H ), carbon (e.g., 11C , 13C , and 14C ), nitrogen (e.g., 13N and 15N ), oxygen (e.g., 15O , 17O , and 18O ), fluorine (e.g., 18F ), chlorine (e.g., 36Cl ), iodine (e.g., 123I and 125I ), phosphorus (e.g., 32P ), and sulfur (e.g., 35S ). The isotopically labeled compounds of this invention can be used for studies such as the tissue distribution of drugs and/or matrices. For example, radioactive isotopes such as tritium ( 3H ) and carbon-14 ( 14C ) are suitable for this purpose due to their ease of labeling and detection. Substitution with heavier isotopes, such as hydrogen replacing deuterium ( 2H ), can sometimes be therapeutically advantageous due to increased metabolic stability (e.g., increased in vivo half-life, reduced dosage, and fewer drug interactions). Substitution with positron-emitting isotopes ( ¹¹C , ¹⁸F , ¹⁵O , and ¹³N , etc.) can be used in positron emission tomography (PET) assays to test matrix receptor occupancy. The isotopically labeled compounds of the present invention can generally be manufactured by conventional methods known to those skilled in the art, or by using suitable isotopically labeled reagents instead of unlabeled reagents, and by employing the same preparation methods as in the examples or manufacturing examples. For example, by subjecting 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (the compound of manufacturing example 64) to a known [ 11 C] acetylation reaction (International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, Vol. 39, No. 4, pp. 287-290, 1988), a compound of example 81 in which the carbonyl carbon atom is substituted with 11 C can be obtained.
(Manufacturing method)
Compounds of formula (I) or their salts can be manufactured using various known synthetic methods based on their basic structure or the types of substituents. In this case, depending on the type of functional group, it is sometimes technically effective to replace that functional group with a suitable protecting group (a group that can be easily converted into that functional group) during the process from the starting material to the intermediate. Examples of such protecting groups include those described in "Greene's Protective Groups in Organic Synthesis" (4th edition, 2006) by Wuts (P.G.M. Wuts) and Greene (T.W. Greene), which can be appropriately selected based on their reaction conditions. In such methods, the desired compound can be obtained by introducing the protecting group, reacting, and then removing the protecting group as needed.
Furthermore, the prodrug of the compound of formula (I) can be manufactured by introducing specific groups during the process from the starting material to the intermediate, similar to the protecting group described above, or by further reacting the obtained compound of formula (I). The reaction can be carried out using methods known to those skilled in the art, such as conventional esterification, amidation, and dehydration.
The following describes representative methods for manufacturing compounds of formula (I). Each method can also be performed with reference to the appended references. It should be noted that the manufacturing methods of the present invention are not limited to the examples shown below.
The following abbreviations are sometimes used in this specification.
CN: Cyano, COMU: ({[(1-cyano-2-oxoethylidene)amino]oxy}-4-morpholinomethylene)dimethylammonium hexafluorophosphate, DMF: N,N-dimethylformamide, DMSO: dimethyl sulfoxide, DIPEA: N,N-diisopropylethylamine, EDC·HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide of hexafluorophosphate, HOBt: 1-hydroxybenzotriazole, NMP: 1-methylpyrrolidone-2-one, Me: Methyl, Oxone (registered trademark): potassium persulfate, Pd-118: [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloroisocyanurate, PdCl₂ ( PPh₃ ) ₂ PdCl₂ (dppf): [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, PdCl₂ (dppf)· CH₂Cl₂ : [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride·dichloromethane adduct, Pd₂ (dba) ₃ : (1E,4E)-1,5-diphenylpentan-1,4-dien-3-one/palladium (3:2), Pd( PPh₃ ) ₄ : tetrakis (triphenylphosphino)palladium, RuPhos Pd G₃: (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate, SPhos Pd G3: (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)methanesulfonic acid, TBS: tert-butyl(dimethyl)silyl, THF: tetrahydrofuran, Tf: trifluoromethanesulfonyl, TFA: trifluoroacetic acid, XPhos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, ODS: octadecylsilyl.
(First System)
[Chemical Formula 20]
( X1 is a halogen, Ra and Rb are both H, or Ra and Rb and the borate residues bonded to Ra and Rb form 4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane. The same applies below.)
(First step)
This step involves reacting a compound of formula (IIa) with compounds of formulas (IIIa) to (IIIc) to obtain a compound of formula (IV). The choice of steps 1 to 5 can be made depending on the type of L used as a linking group.
(Step 1-1)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIa) to obtain a compound of formula (IV) where L is -O-. In this reaction, equal amounts of the compound of formula (IIIa) and the compound of formula (IIIa), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0–190°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Examples of bases are not particularly limited and include sodium hydride, potassium tert-butoxide, sodium hydroxide, and potassium hydroxide. The presence of phase-transfer catalysts such as benzyltrimethylammonium chloride, tetrabutylammonium bromide, and 18-crown-6-ether can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-2)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in a solvent inert to the reaction or in the absence of a solvent, under cooling to reflux, preferably at 0°C to 220°C. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as sodium hydride, potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes facilitate the reaction. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-3)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . In this reaction, equal amounts of the compounds of formula (IIa) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst, a ligand, and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, such as palladium acetate and Pd₂ (dba) ₃ . Examples of ligands are not particularly limited, such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, tri-tert-butylphosphine, and XPhos. Examples of bases are not particularly limited, such as tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, and potassium tert-butoxide. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
[literature]
Journal of the American Chemical Society, 127, pp4685-4696(2005)
(Step 1-4)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIb) to obtain a compound of formula (IV) where L is -NR 3- . This step consists of a first stage that converts a compound of formula (IIa) into a compound of formula (IIb), and a second stage that converts a compound of formula (IIb) into a compound of formula (IV).
(Phase 1)
In this reaction, the compound of formula (IIa) is reacted in hydroiodic acid in the presence of a metal iodide, under cooling to reflux, preferably at room temperature to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of the metal iodide used herein are not particularly limited, and include sodium iodide, potassium iodide, etc.
(Phase Two)
In this reaction, equal amounts of compounds of formula (IIb) and (IIIb), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 190°C. Examples of catalysts used herein are not particularly limited, including copper iodide (I), copper oxide (I), copper bromide (I), copper chloride (I), and copper 2-thiophenecarboxylate (I). The presence of ligands such as proline and ethylenediamine is sometimes advantageous for facilitating the reaction. Examples of bases are not particularly limited, including tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, potassium tert-butoxide, triethylamine, and N,N-diisopropylethylamine. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Step 1-5)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIIc) to obtain a compound of formula (IV) where L is -CR4R5- . In this reaction, equal amounts of the compounds of formula (IIa) and ( IIIc ), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include copper iodide (I) and iron acetylacetone (III). Examples of solvents are not particularly limited, but include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Alternatively, this reaction can be carried out under microwave irradiation.
(Second Step)
This step involves reacting a compound of formula (IV) with a compound of formula (V) to obtain a compound of formula (I). In this reaction, equal amounts of the compounds of formula (IV) and (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 (dba) 3 , RuPhos Pd G3, SPhos Pd G3, Pd-118, etc. Examples of bases are not particularly limited and can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, potassium acetate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are also not particularly limited and can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation.
(Second system)
[Chemical Formula 21]
(R 6a is a C1-5 alkyl group substituted with 1 to 4 identical or different R 7 groups, a -C1-5 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R 8 groups), or a -C1-5 alkylene group (a 4- to 7-membered saturated heterocyclic group substituted with 1 to 4 identical or different R 9 groups). The same applies below.
This method is for preparing the following compound (Iz): in the compound of formula (I), L is -CR4R5- , R4 and R5 are both H, R6 is -CH2- (a C1-5 alkyl group substituted by 1 to 4 identical or different R7 groups), -CH2 - C1-5 alkylene- (a C3-8 cycloalkyl group substituted by 1 to 4 identical or different R8 groups), or -CH2 - C1-5 alkylene- (a 4- to 7-membered saturated heterocyclic group substituted by 1 to 4 identical or different R9 groups).
(First step)
This step involves reacting a compound of formula (IIa) with a compound of formula (IIId) to obtain a compound of formula (VI). In this reaction, equal amounts of the compound of formula (IIa) and the compound of formula (IIId), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base, preferably a copper salt, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3 , etc. Examples of bases are not particularly limited, but can include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, triethylamine, N,N-diisopropylethylamine, diisopropylamine, pyrrolidine, etc. Examples of copper salts include copper iodide (I). Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Furthermore, this reaction can also be carried out under microwave irradiation. It should be noted that this reaction can also be carried out after the compound of formula (IIa) has been converted to the compound of formula (IIb) through the first stage reaction in the first step-4 described in the first preparation method.
[literature]
Chemical Reviews, 107, pp874-922(2007)
(Second Step)
This step involves the reduction of a compound of formula (VI) to obtain a compound of formula (IVa). In this reaction, the compound of formula (VI) is reacted in the presence of a catalyst, under a hydrogen atmosphere, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 50°C, typically with stirring for 0.1 hours to 5 days. Examples of catalysts used herein are not particularly limited, but include palladium supported on carbon, palladium hydroxide, platinum oxide, etc. Examples of solvents are not particularly limited, but include alcohols such as methanol, ethanol, and 2-propanol; water, ethyl acetate, acetic acid, and mixtures thereof.
(Step 3)
This step is the same as the second step of the first preparation method, involving the reaction of the compound of formula (IVa) with the compound of formula (V) to obtain the compound of formula (Iz).
(Third System)
[Chemical Formula 22]
( Rc represents a C1-6 alkyl group, and X2 represents a halogen or -OTf. The same applies below.)
This method is for preparing a compound (Iaa) in which L is -NR 3- in the compound of formula (I).
(First step)
This step involves the cyanidation reaction of the compound of formula (VII) to obtain the compound of formula (VIII). In this reaction, equal amounts of the compound of formula (VII) and a cyanide metal, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of cyanide metals used herein are not particularly limited and include zinc cyanide, copper cyanide, sodium cyanide, potassium cyanide, etc. Examples of catalysts are not particularly limited and include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 (dppf)· CH2Cl2 , Pd2 ( dba ) 3 , etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Second Step)
This step involves the reaction of the compound of formula (VIII) with ammonia to obtain the compound of formula (IX). In this reaction, the compound of formula (VIII) and ammonia are reacted in an inert solvent under cooling to reflux, preferably at 0°C to 100°C, typically with stirring for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited, and alcohols such as methanol, ethanol, and 2-propanol can be listed. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 3)
This step involves the reaction of a compound of formula (IX) with a compound of formula (IIIb) to obtain a compound of formula (X). In this reaction, equal amounts of the compounds of formula (IX) and (IIIb), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and cyclopentanol; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. The presence of organic bases such as triethylamine and N,N-diisopropylethylamine, or inorganic bases such as potassium carbonate, sodium carbonate, and cesium carbonate, can sometimes be advantageous for facilitating the reaction. Alternatively, this reaction can also be carried out under microwave irradiation.
(Fourth step)
This step involves the reaction of a compound of formula (X) with hydrazine monohydrate to obtain compounds of formula (XIa) and/or formula (XIb). In this reaction, equal amounts of the compound of formula (X) and hydrazine monohydrate, or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 100°C, typically for 0.1 hours to 5 days. Examples of solvents used herein are not particularly limited and include alcohols such as methanol, ethanol, and 2-propanol; acetonitrile, etc. Alternatively, this reaction can be carried out under microwave irradiation.
(Step 5)
This step is the process of obtaining a compound of formula (IVb) from a compound of formula (XIa) or formula (XIb). The choice of steps 1 through 3 may be made depending on the starting material and the type of X2 .
(Step 5-1)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is -OTf. In this reaction, the compound of formula (XIa) and a trifluoromethanesulfonating agent are reacted in the presence of a base in a solvent inert to the reaction, under cooling to heating, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of trifluoromethanesulfonating agents used herein are not particularly limited, and may include trifluoromethanesulfonic anhydride, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide, etc. Examples of bases are not particularly limited, and may include sodium hydride, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, etc. Examples of solvents, without particular limitation, include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons such as dichloromethane and chloroform; water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof.
(Step 5-2)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIa) where X2 is a halogen. In this reaction, the compound of formula (XIa) and the halogenating agent are placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at 0°C to 150°C, typically for 0.1 hours to 5 days. Examples of halogenating agents used herein are not particularly limited and include phosphorus oxychloride, phosphorus tribromooxychloride, thionyl chloride, etc. Examples of solvents are not particularly limited and include ethers such as diethyl ether, THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; NMP, DMF, and mixtures thereof.
(Step 5-3)
This step involves obtaining a compound of formula (IVb) from a compound of formula (XIb) where X2 is a halogen. In this reaction, the compound of formula (XIb) and a diazotizing agent are reacted in the presence of a copper halide in a solvent inert to the reaction, under cooling to reflux, preferably at 0°C to room temperature, typically with stirring for 0.1 hours to 5 days. Examples of diazotizing agents used herein are not particularly limited, and include sodium nitrite, tert-butyl nitrite, etc. Examples of copper halides are not particularly limited, and include copper chloride (I), copper bromide (I), copper iodide (I), etc. Examples of solvents are not particularly limited, and include halogenated hydrocarbons such as dichloromethane and chloroform; acetonitrile, NMP, DMF, and mixtures thereof. The presence of hydrogen halides such as hydrochloric acid, hydrobromic acid, and hydroiodic acid can sometimes be advantageous in facilitating the reaction.
(Step Six)
This step involves reacting a compound of formula (IVb) with a compound of formula (V) to obtain a compound of formula (Iaa). In this reaction, equal amounts of the compound of formula (IVb) and the compound of formula (V), or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a catalyst and a base in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of catalysts used herein are not particularly limited, but include Pd( PPh3 ) 4 , PdCl2 ( PPh3 ) 2 , PdCl2 (dppf), PdCl2 ( dppf )· CH2Cl2 , Pd2 (dba) 3, RuPhosPdG3, etc. Examples of bases are not particularly limited, but include tripotassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium tert-butoxide, etc. Examples of solvents are not particularly limited, but can include ethers such as diethyl ether, THF, 1,4-dioxane, and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene; and water, pyridine, acetonitrile, NMP, DMF, DMSO, and mixtures thereof. Additionally, this reaction can also be carried out under microwave irradiation.
(Raw Material Synthesis-1)
[Chemical Formula 23]
( Rd represents tris( C1-6 )silyloxy or pyrrolidine-1-yl. The same applies below.)
This method involves reacting a compound of formula (XIII) with a compound of formula (XIV) to obtain a compound of formula (IIa) in which ring A is a C5-8 cycloalkenyl group or a partially unsaturated heterocyclic group of 5 to 11 members. In this reaction, equal amounts of the compounds of formula (XIII) and (XIV), or an excess of either, are used. The mixture is placed in a solvent inert to the reaction and stirred under cooling to reflux, preferably at room temperature to 150°C, typically for 0.1 hours to 5 days. The solvent used in this reaction is not particularly limited, and examples include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane and chloroform; and mixtures thereof.
(Raw Material Synthesis-2)
[Chemical Formula 24]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XV).
(First step)
This step involves the reaction of a compound of formula (XV) with hydrazine monohydrate to obtain a compound of formula (XVI). In this reaction, an excess of hydrazine monohydrate is used, and the mixture of hydrazine monohydrate and the compound of formula (XV) is stirred for 0.1 hours to 5 days in a solvent-free or solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 200°C. The solvent used in this reaction is not particularly limited, and examples include alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol; acetonitrile, DMF, NMP, DMSO, and mixtures thereof.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XVI). In this reaction, the compound of formula (XVI) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, and hydrochloric acid, sulfuric acid, acetic acid, etc. are also included. Examples of solvents used in this reaction are not particularly limited, and alcohols such as ethanol, 2-propanol, 1-butanol, and ethylene glycol are also included; water, acetonitrile, DMF, NMP, DMSO, etc., and mixtures thereof are also included.
(Step 3)
This step involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa). In this reaction, an excess of chlorinating agent is used, and the mixture of the chlorinating agent and the compound of formula (XVII) is stirred for 0.1 hours to 5 days under cooling to reflux, preferably at room temperature to 200°C. Examples of chlorinating agents used herein are not particularly limited, and include phosphorus oxychloride, thionyl chloride, etc. The addition of a small amount of DMF is sometimes advantageous in facilitating the reaction.
(Raw Material Synthesis-3)
[Chemical Formula 25]
This method is used to prepare a compound of formula (IIa) from a compound of formula (XVIII).
(First step)
This step involves the reaction of a compound of formula (XVIII) with tert-butyl hydrazine carbamate to obtain a compound of formula (XIX). In this reaction, equal amounts of the compound of formula (XVIII) and tert-butyl hydrazine carbamate, or an excess of either, are used. The mixture is stirred for 0.1 hours to 5 days in the presence of a condensing agent and a base, in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of condensing agents used herein are not particularly limited and include HATU, EDC·HCl, COMU, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Examples of bases are not particularly limited and include triethylamine, DIPEA, etc. Solvents used in this reaction are not particularly limited and include ethers such as THF, 1,4-dioxane, 1,2-dimethoxyethane, etc.; halogenated hydrocarbons such as dichloromethane, chloroform, etc.; acetonitrile, NMP, DMF, DMSO, etc., and mixtures thereof. The presence of HOBt can sometimes be advantageous in ensuring the smooth progress of a reaction.
(Second Step)
This step is the process of obtaining the compound of formula (XVII) from the compound of formula (XIX). In this reaction, the compound of formula (XIX) is stirred for 0.1 hours to 5 days in the presence of an acid in a solvent inert to the reaction, under cooling to reflux, preferably at room temperature to 150°C. Examples of acids used herein are not particularly limited, such as hydrochloric acid and sulfuric acid. Examples of solvents used in this reaction are not particularly limited, such as water, ethyl acetate, and 1,4-dioxane.
(Step 3)
This step is the same as the third step in the synthesis of raw materials -2, which involves reacting the compound of formula (XVII) with a chlorinating agent to obtain the compound of formula (XIIa).
(Other manufacturing methods)
By using the compound of formula (I) obtained by the above method as a raw material, further chemical modification reactions commonly used by those skilled in the art, such as alkylation, benzylation, esterification, amidation, acylation, sulfonation, oxidation, protection, and deprotection, can be carried out to obtain another compound of formula (I).
Compounds of formula (I) are separated and purified as free compounds, their salts, hydrates, solvates, or polymorphs. Salts of compounds of formula (I) can also be prepared by conventional salt-forming reactions. Separation and purification can be performed using common chemical operations such as extraction, fractional crystallization, and various fractional chromatography. Various isomers can be prepared by selecting appropriate starting material compounds, or they can be separated by utilizing the differences in physicochemical properties between isomers. For example, optical isomers can be obtained by general optical resolution of racemates (e.g., fractional crystallization of diastereomeric salts formed with optically active bases or acids, chromatography using chiral columns, etc.), or they can be prepared from appropriate optically active starting material compounds.
The pharmacological activity of the compound of formula (I) can be confirmed by the following tests. It should be noted that the pharmacological activity can also be confirmed by well-known modified tests.
Experimental Example 1: Inhibition of THP-1IL-1β Production
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) and ATP (Adenosine triphosphate, SIGMA, A2383) were added at final concentrations of 50 ng/mL and 5 mM, respectively, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of IL-1β was determined using ELISA (DuoSet ELISA human IL-1β, R&D Systems, DY201). IL-1β concentrations were plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoidEmax model nonlinear regression analysis.
The results are shown in Table 1. It can be confirmed that the compounds in the examples inhibit the activation of the NLRP3 inflammasome and inhibit the production of IL-1β.
[Table 1-1]
Table 1
[Table 1-2]
Table 1 (continued)
Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]> Ex <![CDATA[IC<sub>50</sub>(nM)]]>
100 4.9 108(2) 3.0 118 4.8 128 3.3
101(1) 2.0 109 1.5 119 6.0 129 86
101(2) 8.6 110 1.4 120 1.0 130 twenty two
102 5.1 111 2.9 121 8.5 131(1) 3.0
103 4.4 112 1.3 122 8.4 131(2) 79
104 3.5 113 1.2 123 47 132 95
105 8.9 114 15 I24 0.62 133 1.3
106 4.8 115 11 125 1.5 134 4.6
107 3.6 116 4.4 126 7.1 135 2.9
108(1) 27 117 130 127 5.6 136 2.2
Experimental Example 2: TNF-α Production Inhibition Test
THP-1 cells were cultured at 37°C for 2 days with 50 ng/mL PMA (phorbol myristate acetate, SIGMA, P1585) added. The culture medium was then replaced with serum-free RPMI-1640 medium, and a known concentration of the compound was added, followed by incubation at 37°C for 15 minutes. LPS (Lipopolysaccharide, SIMGA, L2880) was added at a final concentration of 50 ng/mL, and the cells were incubated at 37°C for 2 hours. The supernatant was collected, and the concentration of TNF-α was determined by ELISA (DuoSetELISA human TNF-α, R&D Systems, DY210). The TNF-α concentration was plotted against the logarithm of the compound concentration, and the IC50 value was calculated using a sigmoid Emax model nonlinear regression analysis.
It can be confirmed that Examples 1, 2(1), 3(1), 4(1), 5, 70, 73, 83, 88, 99, 111, 124 and 125, which are compounds of formula (I), showed IC50 values of more than 10 μM in this test.
Experiment 3: Rat Central Nervous System IL-1β Production Test
In male Wistar rats aged 10–14 weeks, 12.5 μg/5 μL of LPS (SIGMA, L2880) was administered intracerebrospinally under isoflurane anesthesia. Two hours later, the test compound was administered orally. One hour later, 50 μg/5 μL of BzATP (2’(3’)-O-(4-benzoylbenzoyl)adenosine 5’-triphosphate triethylammonium salt, SIGMA, B6396) was administered intracerebrospinally. Cerebrospinal fluid was recovered after 30 minutes. IL-1β p17 levels in the cerebrospinal fluid were quantified by Western blotting using an anti-IL-1β antibody (Millipore, AB1832P), and the inhibition rate relative to the solvent-administered group was calculated.
The IL-1βp17 inhibition rates relative to the solvent-administered group for Examples 1, 2 (1), 3 (1), and 124, which are compounds of formula (I), are shown in the table below. It should be noted that in the table, Dose represents the dosage of each tested compound, Ex1, Ex2 (1), Ex3 (1), and Ex124 represent Examples 1, 2 (1), 3 (1), and 124, respectively, and cases not measured are represented as NT. It can be confirmed that these compounds exhibit IL-1β inhibition.
[Table 2]
Dose Ex1 Ex2(1) Ex3(1) Ex124
0.1 mg/kg NT NT NT 55%
0.3 mg/kg -12% 81% 75% 49%
1mg/kg 74% 75% 82% 96%
3mg/kg 84% 88% 72% NT
Example 4: Evaluation of motor function in a mouse model of α-synuclein fibrils-induced neuroinflammation
In male C57BL/6J mice, 8 μg of mouse α-synuclein fibrillation protein (StressMarq Biosciences Inc., SPR-324) was administered to the left striatum. After 14–15 weeks, the test compound, suspended in 0.5% methylcellulose solution, was administered orally once daily. For the negative control group, 0.5% methylcellulose solution was administered. Motor function was evaluated using a suspension test 4 weeks after the start of administration. Mice were allowed to grasp a horizontally taut wire, fall, and then grasp again, repeating this process for 3 minutes, recording the number of falls. In this experiment, it was confirmed that specific compounds of formula (I) or their salts exhibited a beneficial effect on motor dysfunction.
Experimental Example 5: In Vitro (ex vivo) IL-1β Production Assay in Mice
Male C57BL/6J mice were administered the compound, suspended in 0.5% methylcellulose, orally once or multiple times at arbitrary doses, and blood was collected at any time afterward. LPS was added to the blood at a final concentration of 50 ng/mL, and the mice were incubated at 37°C for 3 hours. Then, ATP was added at a final concentration of 5 mM, and the mice were incubated at 37°C for 30 minutes. After centrifugation to remove blood cells, the concentration of IL-1β was determined using an ELISA method (DuoSet ELISA mouse IL-1β, R&D Systems, DY401).
Test Example 6: In Vitro Phototoxicity Test
The in vitro phototoxicity test was evaluated according to ICH S10: Guidelines for the evaluation of photosensitivity of pharmaceuticals (Drug and Food Inspection Certificate No. 0521-1) and the methods described in the OECD guideline for testing of chemicals 432: Invitro 3T3 NRU phototoxicity test, 2019. In this test, it was confirmed that the compounds of Example 1, Example 2(1), Example 3(1) and Example 124 did not have phototoxic effects.
Experimental Example 7: Safety Pharmacology Test
As a safety pharmacology study, the inhibitory effect on human Ether-a-go-go Related Gene (hereinafter referred to as hERG) channels was evaluated. The evaluation of hERG channel inhibition was performed using a modified method described in Combinatorial Chemistry & High Throughput Screening, 12, 1, 78-95 (2009). In this study, the compounds of Examples 1, 2(1), 3(1), and 124 showed IC50 values greater than 10 μM.
Based on the above results, it is expected that compounds of formula (I) or their salts may be used as highly safe pharmaceutical products for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
The compounds of formula (I) or their salts shown in Table 1 were demonstrated to inhibit IL-1β production in Example 1. Furthermore, the compounds of Examples 1, 2(1), 3(1), and 124 were also shown to inhibit IL-1β production in the central nervous system in Example 3. In addition, specific compounds of formula (I) or their salts showed improved motor function in a mouse model of α-synucleinosis induced by α-synuclein fibers, as described in Example 4. Based on these results, it is strongly expected that compounds of formula (I) or their salts can be used for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, particularly α-synucleinosis including Parkinson's disease, multiple system atrophy, and Lewy body dementia.
Furthermore, the results of Examples 6 and 7 show that the compounds of Examples 1, 2(1), 3(1), and 124 do not exhibit phototoxicity and have weak hERG channel inhibition. Based on these results, it is strongly expected that the compounds of Examples 1, 2(1), 3(1), and 124 will become highly safe pharmaceutical products.
Pharmaceutical compositions containing one or more compounds of formula (I) or their salts as active ingredients can be prepared using excipients commonly used in the art (i.e., pharmaceutical excipients or pharmaceutical carriers, etc.) and by commonly used methods.
Administration can be administered orally using tablets, pills, capsules, granules, powders, liquid preparations, etc., or via any of the following methods: intra-articular, intravenous, intramuscular, or intra-intra-articular injections, suppositories, eye drops, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalants, etc.
As a solid composition for oral administration, tablets, powders, granules, etc., can be used. In such a solid composition, one or more active ingredients may be mixed with at least one inert excipient. The composition may contain inert additives, such as lubricants or disintegrants, stabilizers, and solubilizers, according to conventional methods. Tablets, powders, granules, or pills may be coated with wax, sugar coating, or films of gastric-soluble or enteric-soluble substances as needed.
Liquid compositions intended for oral administration contain pharmaceutically permissible emulsifiers, solutions, suspensions, syrups, or elixirs, and commonly used inert diluents such as purified water or ethanol. In addition to inert diluents, the liquid composition may also contain excipients such as solubilizers, humectants, suspending agents, sweeteners, flavorings, aromatizers, and preservatives.
Injectable formulations intended for non-oral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Aqueous solvents include, for example, distilled water for injection or physiological saline. Non-aqueous solvents include, for example, alcohols such as ethanol. Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizers. They are sterilized, for example, by filtration through a bacterial trap, by combination with a bactericide, or by irradiation. Alternatively, they can be prepared as sterile solid compositions and dissolved or suspended in sterile water or sterile solvents for injection before use.
As external agents, they include ointments, plasters, creams, gels, pastes, sprays, lotions, eye drops, and eye ointments. They contain commonly used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, etc.
Inhalers or nasal inhalers, or other mucosal preparations, can be in solid, liquid, or semi-solid form and manufactured according to conventionally known methods. Known excipients may be added as appropriate, or further appropriate pH adjusters, preservatives, surfactants, lubricants, stabilizers, or thickeners may be added. Administration can be performed using a suitable inhalation or blowing device. For example, known devices or nebulizers, such as metered-dose inhalers, can be used to administer the compound alone or as a formulated mixture powder, or in combination with a pharmaceutically permissible carrier in the form of a solution or suspension. Dry powder inhalers, etc., can be used for single or multiple administration and can use dry powder or capsules containing powder. Alternatively, pressurized aerosol sprays, etc., can be used, employing a suitable propellant, such as a suitable gas like chlorofluorocarbons or carbon dioxide.
When administered orally, a daily dose of approximately 0.001 to 100 mg/kg of body weight is appropriate, preferably 0.1 to 30 mg/kg, and more preferably 0.1 to 10 mg/kg, and this dose is administered once or divided into 2 to 4 doses. When administered intravenously, a daily dose of approximately 0.0001 to 10 mg/kg of body weight is appropriate, and this dose is administered once daily or divided into multiple doses. Additionally, as a mucosal agent, approximately 0.001 to 100 mg/kg of body weight is administered once daily or divided into multiple doses. The dosage should be appropriately determined based on individual circumstances, taking into account symptoms, age, and sex.
Although the dosage form, administration site, type of excipient or additive may vary, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, or in some manner 0.01 to 50% by weight, one or more of a compound of formula (I) or a salt thereof as an active ingredient.
The compound of formula (I) can be used in combination with various therapeutic or preventative agents for diseases for which the compound of formula (I) is believed to be effective. When used in combination, the compounds can be administered simultaneously, separately and continuously, or at desired time intervals. Simultaneously administered formulations can be combination formulations or formulations prepared separately.
Example
Hereinafter, based on examples, a method for manufacturing compounds of formula (I) will be described in further detail. It should be noted that the present invention is not limited to the compounds described in the following examples. Furthermore, the manufacturing examples show a method for preparing the starting material compounds. Additionally, the method for manufacturing compounds of formula (I) is not limited to the manufacturing methods of the specific examples shown below; compounds of formula (I) can also be manufactured by combinations of these manufacturing methods or by methods obvious to those skilled in the art.
It should be noted that the starting temperatures of the DSC curves obtained under the following conditions are recorded in the table below. The DSC measurements were performed using a DSC Q2000 (manufactured by TA Instruments) at a temperature range of 25–300 °C, a heating rate of 10 °C/min, and a nitrogen flow rate of 50 mL/min. An aluminum sample pan was used, and measurements were performed without covering the sample pan. The starting temperatures of the DSC curves may vary slightly depending on the measurement conditions and should not be interpreted strictly.
Powder X-ray diffraction (XRD) was performed using an Empyrean (PANalytical) spectrometer under the following conditions: Cu bulb, 40 mA tube current, 45 kV tube voltage, 0.013° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). Alternatively, it was performed using a SmartLab (Rigaku) spectrometer under the following conditions: Cu bulb, 200 mA tube current, 45 kV tube voltage, 0.005° step size, and wavelength ranging from 2.5 to 40° diffraction angle (2θ). It should be noted that, regarding the nature of the data, the lattice spacing or overall pattern of the powder XRD pattern is important in determining the identity of the crystals. The error range of the diffraction angle (2θ (°)) in powder XRD is typically ±0.2°, but the diffraction angle and intensity vary slightly depending on the direction of crystal growth, particle size, and measurement conditions, and therefore should not be interpreted strictly.
In addition, the following abbreviations are sometimes used in the embodiments, manufacturing examples and tables described below.
The following represent the following values: PEx: Manufacturing Example Number; Ex: Example Number; PSyn: Manufacturing Example Number manufactured using the same method; Syn: Example Number manufactured using the same method; Str: Chemical Structural Formula; DAT: Physicochemical Data; EI+: m/z value in mass analysis (Electron Ionization EI, [M]+ unless otherwise specified); ESI+: m/z value in mass analysis (Ionization ESI, [M+H]+ unless otherwise specified); FAB: m/z value in mass analysis (Ionization FAB, [M+H]+ unless otherwise specified); CI: m/z value in mass analysis (Ionization CI, [M+H]+ unless otherwise specified); 1H -NMR (400MHz, CDCl3 ): δ value (ppm) of the signal in 1H -NMR of CDCl3 ; 1H -NMR (500MHz, CDCl3 ): δ value (ppm ) of the signal in 1H-NMR of CDCl3 . δ value (ppm) of the signal in 1H-NMR, 1H -NMR (400MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , 1H -NMR (500MHz, DMSO- d6 ): δ value (ppm) of the signal in 1H -NMR in DMSO- d6 , J: coupling constant, s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, br: broad peak (e.g., br s), m: multiplet, DSC 1 : temperature (initial temperature) at which the endothermic peak (decomposition point) was observed using DSC, DSC 2 : temperature (initial temperature) at which the endothermic peak (amorphous decomposition point) was observed using DSC, 2θ: diffraction angle of the peak in powder X-ray diffraction.
In the PSyn and Syn columns of the table described later, the hyphen (-) indicates that the manufacturing method is described in text form in the manufacturing example or embodiment.
In addition, for convenience, the concentration in mol/L is expressed as M. For example, 1M sodium hydroxide aqueous solution means a 1 mol/L sodium hydroxide aqueous solution.
Manufacturing Example 1
A mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (10.92 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (16.3 g), DIPEA (28 mL), and cyclopentanol (55 mL) was stirred at 160 °C for 2 days. After cooling the reaction mixture to room temperature, water/saturated sodium chloride aqueous solution (1/1) and chloroform/methanol (9/1) were added to separate the organic layer. The aqueous layer was extracted with chloroform/methanol (9/1), the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]cyclohexane-1-ol (8.24 g) as a solid.
Manufacturing Example 2
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.7 mL) were added, and the mixture was stirred at 160 °C for 44 hours. After cooling the reaction mixture to room temperature, chloroform and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, dried with anhydrous sodium sulfate, and then the solution was concentrated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 3
A mixture of 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine (1.145 g), (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (890 mg), DIPEA (2.7 mL), and NMP (15 mL) was stirred at 160 °C for 24 hours. (1R,2R)-2-aminocyclohexane-1-ol monohydrochloride (420 mg) and DIPEA (1.3 mL) were added to the reaction mixture, and the mixture was stirred at 160 °C for 20 hours. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, the organic layers were combined, and the mixture was washed with a 1/1 water/saturated sodium chloride solution and a saturated sodium chloride solution, then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate). (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohex-1-ol (36.1 mg) was obtained as a solid from the low polarity fraction, and (1R,2R)-2-[(6-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)amino]cyclohex-1-ol (504.8 mg) was obtained as an oil from the high polarity fraction.
Manufacturing Example 4
To a mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1 g) and cyclopentanol (5 mL), (1S,2R)-2-aminocyclohexyl-1-ol monohydrochloride (1.48 g) and DIPEA (1.68 mL) were added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, DIPEA (1 mL) was added, and the mixture was stirred at 160 °C for 12 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water/saturated sodium chloride aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated and dried over anhydrous sodium sulfate. After concentrating the solution, the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain a mixture (774 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol in solid form.
Manufacturing Example 5
At room temperature, a mixture of 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine (502.7 mg) and cyclopentanol (3 mL) was mixed with (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (394 mg) and DIPEA (0.393 mL), and stirred at 160 °C for 2 days under an argon atmosphere. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and saturated sodium chloride/water aqueous solution (1/1) were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetrazine-hepteno[4,5-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (57.4 mg) as an oil.
Manufacturing Example 42
A mixture of 1 g of 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione and 20 mL of methanol was mixed with 0.6 mL of 12 M hydrochloric acid and 100 mg of platinum oxide, and stirred overnight at room temperature under a hydrogen atmosphere. 20 mL of methanol and 20 mL of DMF were added to the reaction mixture, and the mixture was stirred for 1 hour under an argon atmosphere. The reaction mixture was filtered through a Celite filter, and the filtrate was concentrated under reduced pressure. Toluene was added to the residue, and the mixture was concentrated under reduced pressure. Ethyl acetate was added to the solid, and the mixture was ground. The solid was filtered off and washed with ethyl acetate to give 1.19 g of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride.
Manufacturing Example 43
A mixture of 2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione monohydrochloride (800 mg) and dichloromethane (16 mL) was mixed with DIPEA (0.250 mL), benzaldehyde (0.500 mL), and sodium triacetoxyborohydride (1.1 g) and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with chloroform/methanol (5/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione (515 mg) as a solid.
Manufacturing Example 44
A mixture of 100 mg 6-benzyl-2,3,5,6,7,8-hexahydropyrido[3,4-d]pyridazine-1,4-dione and 2 mL phosphoryl chloride was stirred at 120 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, and toluene was added, followed by further concentration under reduced pressure. Chloroform (3 mL) was added to the resulting residue, and DIPEA (1 mL) was added under ice-cold conditions. Water was added to the reaction mixture, and extraction with chloroform was performed. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 87 mg 6-benzyl-1,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine as an oil.
Manufacturing Example 45
Under a nitrogen atmosphere, sodium hydride (55%, liquid paraffin dispersion, 190 mg) was added to a mixture of 1,4-dichlorophthalazine (720 mg), 4 -hydroxy-1λ6-thiocyclohexane-1,1-dione (540 mg), and THF (14 mL) while the mixture was ice-cold. The mixture was stirred at the same temperature for 30 minutes, then heated to room temperature and stirred for 3 days. Water and ethyl acetate were added to the reaction mixture, the solid was filtered off, and washed with water and ethyl acetate to give 4-[(4-chlorophthalazine-1-yl)oxy] -1λ6 -thiocyclohexane-1,1-dione (681 mg) in solid form.
Manufacturing Example 47
In a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (100 mg) and 1,4-dioxane (3.2 mL), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane-pentaborane (350 mg), RuPhos Pd G3 (45 mg), potassium carbonate (147 mg), and water (0.64 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform and water were added, and the organic layer was separated. After concentrating the solution, the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (1R,2R)-2-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazine-1-yl}amino)cyclohexyl-1-ol (106 mg) in solid form.
Manufacturing Example 48
Under an argon atmosphere, a mixture of (1R,2R)-2-[(6-benzyl-1-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (34 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (38 mg), RuPhos Pd G3 (3 mg), potassium carbonate (38 mg), 1,4-dioxane (1 mL), and water (0.100 mL) was stirred at 130 °C for 60 minutes under microwave irradiation. Water and chloroform were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with chloroform, and the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15.6 mg) in solid form.
Manufacturing Example 63
A mixture of tert-butyl [4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]carbamate (1.38 g), dichloromethane (14 mL), and triethylamine (1.21 mL) was added to acetic anhydride (0.330 mL) and 4-dimethylaminopyridine (71 mg), and stirred overnight at room temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate), and the solid was washed with hexane/ethyl acetate (4/1) to give 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl acetate (1.24 g) in solid form.
Manufacturing Example 64
Trifluoroacetic acid (1.83 mL) was added to a mixture of 2-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}phthalazin-1-yl)-5-(trifluoromethyl)phenyl ester (1.24 g) and dichloromethane (13 mL), and the mixture was stirred overnight at room temperature. A 1 M aqueous solution of sodium hydroxide and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol/ammonia). The residue was mixed with chloroform and methanol and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the solid was washed with hexane/ethyl acetate (4/1) to give 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (607 mg) in solid form.
Manufacturing Example 65
A mixture of 2-[4-(4-aminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenol (403 mg), acetyl chloride (0.075 mL), DIPEA (0.495 mL), and dichloromethane (4 mL) was stirred at room temperature for 1 hour. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. DIPEA (0.495 mL) and acetyl chloride (0.075 mL) were added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.075 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 4 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-(4-acetaminobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl acetate (401 mg) as a solid.
Manufacturing Example 67
Under an argon atmosphere, in a mixture of 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (500 mg), (2R)-but-3-yn-2-ol (0.150 mL), and THF (8 mL), PdCl₂ ( PPh₃ ) ₂ (126 mg), copper iodide (I) (17 mg), and diisopropylamine (0.755 mL) were added under ice-cold conditions, followed by heating to room temperature and stirring for 5 hours. Water and a saturated aqueous solution of ammonium chloride were added to the reaction mixture, and the mixture was extracted with chloroform. The aqueous layer was extracted with chloroform, the organic layers were combined, dried with anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) as an oil.
Manufacturing Example 69
Platinum oxide (67 mg) was added to a mixture of (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-3-yn-2-ol (267 mg) and ethanol (6 mL), and the mixture was stirred at room temperature for 1.5 hours under a hydrogen atmosphere. Celite (registered trademark) was added to the reaction mixture and stirred. The mixture was then filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give (2R)-4-(4-chloro-6,7-dihydro-5H-cyclopentano[d]pyridazin-1-yl)but-2-ol (260 mg) as an oil.
Manufacturing Example 70
Under an argon atmosphere, a mixture of 1,4-dichloro-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.50 g), sodium iodide (3.1 g), and 57% hydroiodic acid (9 mL) was stirred at 100 °C for 30 min under microwave irradiation. The reaction mixture was cooled to room temperature, water was added, and extraction was performed with ethyl acetate. The organic layer was washed with saturated aqueous solutions of sodium bicarbonate, sodium thiosulfate, and sodium chloride, and then dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-chloro-4-iodo-6,7-dihydro-5H-cyclopentano[d]pyridazine (1.9 g) as a solid.
Manufacturing Example 72
Under an argon atmosphere, a mixture of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (100 mg), (3-aminobicyclo[1.1.1]pentan-1-yl)methanol-hydrochloride (95 mg), palladium acetate (22 mg), (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (90 mg), cesium carbonate (385 mg), and 1,4-dioxane (2 mL) was stirred at 100 °C for 24 hours. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give {3-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]bicyclo[1.1.1]pentan-1-yl}methanol (46.2 mg) in solid form.
Manufacturing Example 73
Under ice-cold conditions, 1 g of 3,6-dichloro-1,2,4,5-tetraazine was added to a mixture of tert-butyl[(3,6-dihydro-2H-pyran-4-yl)oxy]di(methyl)silane (1.42 g) and toluene (20 mL). The mixture was stirred at room temperature for 0.5 h and then at 120 °C for 16 h. After cooling the reaction mixture to room temperature, it was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (1.08 g) in solid form.
Manufacturing Example 74
Under an argon atmosphere, toluene (121 mL) and 3,6-dichloro-1,2,4,5-tetrahydrooxetrazine (6.61 g) were added to a mixture (11.67 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetrazine-4-yl)oxy]silane, and the mixture was stirred at 120 °C for 24 hours. The reaction mixture was cooled to room temperature and filtered through methanol and chloroform. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/ethyl acetate) to give 1,4-dichloro-5,6,8,9-tetrahydrooxetrazine-hepten[4,5-d]pyridazine (502.7 mg) in solid form.
Manufacturing Example 76
Hydrochloric acid (12M, 15.8 mL) was added to a mixture of 2-amino-5-cyclopropylphenol (3.50 g) and ethanol (50 mL) at -15 °C, and the mixture was stirred for 10 minutes at the same temperature. Amyl nitrite (9.6 mL) was added to the reaction mixture at -15 °C, and the mixture was stirred for 30 minutes at the same temperature. Then, a mixture of potassium iodide (50.6 g) and water (50 mL) was added dropwise at -15 °C, the mixture was heated to room temperature, and stirred for 20 hours. Ethyl acetate was added to the reaction mixture to separate the organic layer. The organic layer was washed with saturated aqueous sodium thiosulfate solution and saturated aqueous sodium chloride solution, and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-cyclopropyl-2-iodophenol (5 g) as an oil.
Manufacturing Example 77
In a mixture of 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) and 1,4-dioxane (9.2 mL), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (1.24 g), PdCl₂ (dppf) (238 mg), and potassium acetate (957 mg) were added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, PdCl₂ (dppf) (238 mg) was added, and the mixture was stirred at 100 °C for 2 hours. After cooling the reaction mixture to room temperature, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxane (620 mg) was added, and the mixture was stirred at 100 °C for 3 hours. After cooling the reaction mixture to room temperature, hexane was added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (1.98 g) as an oil.
Manufacturing Example 81
A mixture of 2.86 g of 4-bromo-3-hydroxybenzaldehyde and 30 mL of dichloromethane was added to DIPEA (2.93 mL) and 1.19 mL of chloromethyl methyl ether, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, the organic layer was separated, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde as an oil.
Manufacturing Example 83
Diethylaminosulfur trifluoride (2.2 mL) was added to a mixture of 1.35 g of 4-bromo-3-(methoxymethoxy)benzaldehyde and 20 mL of dichloromethane under ice-cold conditions. The mixture was stirred at the same temperature for 1 hour, then heated to room temperature and stirred for 3 hours. The reaction mixture was added to a mixture of ice water, sodium bicarbonate, and chloroform and stirred. The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1.3 g of 1-bromo-4-(difluoromethyl)-2-(methoxymethoxy)benzene as an oil.
Manufacturing Example 84
A mixture of 4-bromo-3-(methoxymethoxy)phenol (1.86 g), sodium dichloro(fluoro)acetate (2.43 g), and DMF (11 mL) was added dropwise to a mixture of potassium carbonate (1.65 g) and DMF (7.4 mL) at 95 °C for 1 hour, and stirred at the same temperature for 15 minutes. After cooling the reaction mixture to room temperature, potassium carbonate (1.65 g) and sodium dichloro(fluoro)acetate (2.43 g) were added, and the mixture was stirred at 95 °C for 1 hour. After cooling the reaction mixture to room temperature, ethyl acetate and water were added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with water and a saturated sodium chloride aqueous solution, and then dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-bromo-4-(difluoromethoxy)-2-(methoxymethoxy)benzene (920 mg) as an oil.
Manufacturing Example 85
Under an argon atmosphere, a mixture of 1-chloro-4-iodo-5,6,7,8-tetrahydrophthalazine (500 mg), (1R,2R)-2-amino-1-methylcyclohexane-1-ol (270 mg), copper iodide (I) (30 mg), potassium phosphate (725 mg), ethylene glycol (0.100 mL), and 1-propanol (5 mL) was stirred at 90 °C for 24 hours. After cooling the reaction mixture to room temperature, chloroform and a saturated aqueous solution of ammonium chloride were added, and the organic layer was separated. The aqueous layer was extracted with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazine-1-yl)amino]-1-methylcyclohexane-1-ol (292 mg) in solid form.
Manufacturing Example 86
Under an argon atmosphere, a mixture of ethyl 1-benzyl-5-[(trifluoromethanesulfonyl)oxy]-1,2,3,6-tetrahydropyridine-4-carboxylate (3.37 g), zinc cyanide (1.5 g), Pd(PPh 3 ) 4 (1.2 g), and DMF (42 mL) was stirred at 100 °C for 1.5 h. After cooling to room temperature, water and ethyl acetate were added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, washed with a 1/1 water/saturated sodium chloride aqueous solution and a saturated sodium chloride aqueous solution, and dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (2.04 g) as an oil.
Manufacturing Example 87
Under an argon atmosphere, a mixture of ethyl 5-[(trifluoromethanesulfonyl)oxy]-3,6-dihydro-2H-pyran-4-carboxylate (7.4 g), zinc cyanide (4.3 g), Pd(PPh 3 ) 4 (2.8 g), and DMF (74 mL) was stirred at 100 °C for 2 hours. After cooling to room temperature, ethyl acetate and water were added to the reaction mixture, and the mixture was filtered through Celite (registered trademark). After separating the two layers, the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with a 1/1 solution of water/saturated sodium chloride and dried over anhydrous sodium sulfate. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) as an oil.
Manufacturing Example 88
A mixture of ethyl 1-benzyl-5-cyano-1,2,3,6-tetrahydropyridine-4-carboxylate (930 mg) and ammonia (7 M methanol solution, 8 mL) was stirred at ice temperature for 6 hours. The reaction mixture was allowed to stand in a refrigerator for 18 hours, then heated to room temperature and stirred for 10 minutes. The reaction mixture was concentrated under reduced pressure to give 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridine-1-one (828 mg) as a solid.
Manufacturing Example 89
Ammonia (7M methanol solution, 44 mL) was added to ethyl 5-cyano-3,6-dihydro-2H-pyran-4-carboxylate (4 g) under ice-cold conditions, and the mixture was stirred at 0 °C for 3 days. The reaction mixture was concentrated under reduced pressure to give 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.261 g) as a solid.
Manufacturing Example 90
A mixture of 3-amino-5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (825 mg), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (530 mg), DIPEA (0.7 mL), and acetonitrile (20 mL) was stirred at 70 °C for 19 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (1.12 g) as a solid.
Manufacturing Example 91
A mixture of 3-amino-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (3.26 g), (1R,2R)-2-aminocyclohexyl-1-ol monohydrochloride (3.4 g), DIPEA (5.5 mL), and acetonitrile (70 mL) was stirred at 70 °C for 18 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrole-1(4H)-one (5.63 g) in solid form.
Manufacturing Example 92
A mixture of 5-benzyl-3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-c]pyridin-1-one (560 mg) and ethanol (10 mL) was mixed with hydrazine monohydrate (0.16 mL) and stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (201 mg) in solid form.
Manufacturing Example 93
Under an argon atmosphere, sodium hydride (55%, liquid paraffin dispersion, 12 mg) was added to a mixture of 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-ol (90 mg) and THF (3 mL) under ice-cold conditions, and the mixture was stirred for 20 minutes at the same temperature. 1,1,1-trifluoro-N-phenyl-N-(trifluoromethanesulfonyl)methanesulfonamide (108 mg) was added to the reaction mixture, and the mixture was stirred for 1 hour under ice-cold conditions. Water and chloroform were added to the reaction mixture, and the organic layer was separated. After extraction of the aqueous layer with chloroform, the organic layers were combined, dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then chloroform/ethyl acetate) to give 6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazine-1-yl ester (40 mg) in solid form.
Manufacturing Example 94
Sodium hydroxide (0.596 g) and benzyltriethylammonium chloride (0.922 g) were added to a mixture of (3R)-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (2 g) and dichloromethane (5 mL), and the mixture was stirred at room temperature for 30 minutes. 1,4-Dichlorophthalazine (2.37 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 24 hours. Water and dichloromethane were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (3R)-3-[(4-chlorophthalazine-1-yl)oxy]piperidine-1-carboxylic acid tert-butyl ester (0.960 g) as a solid.
Manufacturing Example 96
A mixture of (3R)-3-[(3R)-piperidin-1-carboxylic acid tert-butyl ester (960 mg) and dichloromethane (10 mL) was mixed with a solution of 1,4-dioxane hydrogen chloride (4 M, 10 mL) and stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, and then diethyl ether was added to the resulting solid and the mixture was ground. The solid was filtered off to give 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine monohydrochloride (850 mg) in solid form.
Manufacturing Example 97
Triethylamine (0.26 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (100 mg) and dichloromethane (2 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.04 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated sodium chloride aqueous solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture A). Triethylamine (0.70 mL) was added to a mixture of 1-chloro-4-{[(3R)-piperidin-3-yl]oxy}phthalazine hydrochloride (300 mg) and dichloromethane (10 mL), and the mixture was stirred at room temperature for 30 minutes. Acetyl chloride (0.10 mL) was then added, and the mixture was stirred at the same temperature for 2 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was then concentrated under reduced pressure (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-{(3R)-3-[(4-chlorophthalazin-1-yl)oxy]piperidin-1-yl}aceto-1-one (280 mg).
Manufacturing Example 98
Triethylamine (6.3 mL) was added to a mixture of oxetane (5 g) and diethyl ether (50 mL) under ice-cold conditions, followed by tert-butyldi(methyl)silane trifluoromethanesulfonate (12.3 mL), and the mixture was stirred for 10 minutes at the same temperature. Triethylamine (1.4 mL) was added to the reaction mixture, and the mixture was stirred under ice-cold conditions for 1.5 hours. Hexane and water were added to the reaction mixture, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated to give a mixture (11.7 g) of tert-butyldi(methyl)[(2,3,6,7-tetrahydrooxetane-heptene-4-yl)oxy]silane as an oil.
Manufacturing Example 99
A mixture of 500 mg of 3-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydropyrano[3,4-c]pyrrolo-1(4H)-one and 2-propanol (20 mL) was mixed with 0.300 mL of hydrazine monohydrate and stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (200 mg) in solid form.
Manufacturing Example 100
Under an argon atmosphere, sodium nitrite (80 mg) was added to a mixture of (1R,2R)-2-[(1-amino-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (198 mg), copper chloride (I) (75 mg), and hydrochloric acid (12 M, 2.5 mL) under ice-cold conditions, and the mixture was stirred for 1 hour at the same temperature. Dichloromethane (10 mL), water, and triethylamine (4.2 mL) were added to the reaction mixture under ice-cold conditions and stirred. The reaction mixture was filtered through a Celite filter and washed with dichloromethane/methanol (10/1). The organic layer was separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (170 mg) in solid form.
Manufacturing Example 101
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (131.6 mg), 10% palladium-supported carbon (containing 51% water, 84.5 mg), and methanol (3 mL) was stirred at room temperature for 4 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite filter. The filtrate was then concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (89.3 mg) as a solid.
Manufacturing Example 102
[(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.524 g) and sodium triacetoxyborohydride (2.416 g) were added to a mixture of cyclobutanone (0.640 g) and dichloromethane (25 mL) at room temperature, and the mixture was stirred for 5 hours at room temperature. The reaction mixture was injected into a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to give [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (1.940 g) as a solid.
Manufacturing Example 103
A solution of 1,4-dioxane hydrogen chloride (4M, 1.8 mL) was added to a mixture of [(3R)-1-cyclobutylpiperidin-3-yl]carbamate tert-butyl ester (225 mg) and dichloromethane (1.8 mL) with stirring at room temperature, and the mixture was stirred for 3 hours at room temperature. The reaction mixture was concentrated under reduced pressure to give (3R)-1-cyclobutylpiperidin-3-amine dihydrochloride (250 mg) as a solid.
Manufacturing Example 104
A mixture ( 393 mg ) of (1R,2R)-N1-(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)cyclohexyl-1,2-diamine and (1R,2R) -N1- (4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)cyclohexyl-1,2-diamine was added to dichloromethane (14 mL), triethylamine (0.23 mL), and di-tert-butyl dicarbonate (0.34 mL), and the mixture was stirred at room temperature for 1.5 hours. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (352 mg) of {(1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl}carbamate tert-butyl ester and {(1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl}carbamate tert-butyl ester in solid form.
Manufacturing Example 105
A solution of 1,4-dichloro-6-(triphenylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine (1.569 g) and dichloromethane (18 mL) was added to a solution of 1,4-dioxane hydrogen chloride (4 M, 6 mL), and the mixture was stirred at room temperature for 18.5 hours. The reaction mixture was filtered, the solid was washed with diethyl ether, and then dried under reduced pressure to give 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine hydrochloride (770 mg).
Manufacturing Example 106
Triethylamine (1.4 mL) and di-tert-butyl dicarbonate (1.2 mL) were added to a mixture of 1,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazine monohydrochloride (765 mg) and dichloromethane (23 mL) under ice-cold stirring, and the mixture was stirred for 17 hours while being naturally heated to room temperature. The reaction mixture was injected into water and extracted with dichloromethane. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Diethyl ether was added to the resulting solid and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give tert-butyl 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid (788 mg) as a solid. The residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 1,4-dichloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazine-6-carboxylic acid tert-butyl ester (142 mg) in solid form.
Manufacturing Example 114
A mixture of 1,4-dichloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine (700 mg) and (3R)-3-aminopiperidine-1-carboxylic acid tert-butyl ester (1.4 g) was stirred at 120 °C for 24 hours. After cooling to room temperature, the mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give a mixture (481 mg) of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester in solid form.
Manufacturing Example 116
A mixture of 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (384 mg), (1R,2R)-2-aminocyclohexyl-1-ol (426 mg), DIPEA (0.77 mL), and cyclopentanol (7.4 mL) was stirred at 145–155 °C for 18.5 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and then water and a saturated sodium chloride aqueous solution were added. Extraction was performed with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (236 mg) in solid form.
Manufacturing Example 120
A mixture of 1,4-dichloro-5,7-dihydrofurano[3,4-d]pyridazine (500 mg), (1S,3R)-3-aminocyclohexyl-1-ol monohydrochloride (795 mg), DIPEA (1.8 mL), and cyclopentanol (5 mL) was stirred at 120–130 °C for 22 hours. The reaction mixture was cooled to room temperature, injected into water, and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazine-1-yl)amino]cyclohexyl-1-ol (556 mg) as a solid.
Manufacturing Example 122
A mixture of 2,3,5,7-tetrahydrothieno[3,4-d]pyridazine-1,4-dione (78 mg) and phosphorus oxychloride (1 mL) was stirred at 98–100 °C for 2.5 h. The reaction mixture was cooled to room temperature and then poured into ice water for washing with ice water and dichloromethane. A saturated sodium bicarbonate solution was added dropwise to adjust the pH to approximately 8 while stirring at room temperature, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 1,4-dichloro-5,7-dihydrothieno[3,4-d]pyridazine (92 mg) as a solid.
Manufacturing Example 128
A mixture of (3R)-3-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester and (3R)-3-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]piperidine-1-carboxylic acid tert-butyl ester (478 mg), 2-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (680 mg), RuPhos Pd G3 (163 mg), potassium carbonate (450 mg), 1,4-dioxane (10 mL), and water (2 mL) was stirred at 100 °C for 4 hours. After cooling to room temperature, water was added to the mixture, and extraction was performed with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution and then dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and (3R)-3-({4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (200 mg) in solid form.
Manufacturing Example 134
Under an argon atmosphere, a mixture of (1S,3R)-3-[(4-chloro-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (155 mg), 2-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxane (361 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 94 mg), potassium carbonate (159 mg), 1,4-dioxane (6 mL), and water (1.4 mL) was stirred at 90–110 °C for 20 hours. The reaction mixture was cooled to room temperature, injected into water, and then filtered through a Celite (trademark) filter. The filtrate was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, then ethyl acetate/methanol) to give (1S,3R)-3-({4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (128 mg) in solid form.
Manufacturing Example 144
By the same reaction as in Manufacturing Example 74, 1,4-dichloro-5,7,8,9-tetrahydrooxetanehepten[3,4-d]pyridazine was obtained as a byproduct in solid form.
Manufacturing Example 152
Under ice-cold conditions, trifluoromethanesulfonic anhydride (0.17 mL) was added to a mixture of 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-ol (261 mg), 2,6-rutidine (0.16 mL), and dichloromethane (6 mL), and the mixture was stirred at the same temperature for 1.5 hours. Dichloromethane and water were added to the reaction mixture and stirred, and then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried with anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain 4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-1-yl ester (311 mg) in solid form.
Manufacturing Example 154
Under an argon atmosphere and with stirring at -30°C, trifluoromethanesulfonic anhydride (14.1 mL) was added dropwise to a mixture of ethyl 5,5-dimethyl-4-oxothiacyclopentane-3-carboxylate (16.169 g), DIPEA (15.3 mL), and dichloromethane (80 mL). The reaction mixture was then stirred at -45 to -15°C for 1 hour. Water was added to the reaction mixture, and the mixture was heated to room temperature and then extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (17.559 g) as an oil.
Manufacturing Example 159
Under ice-cold conditions, tert-butyl dimethyl silane trifluoromethanesulfonate (1.2 mL) was added to a mixture of (1S,2R)-2-aminocyclohexane-1-ol monohydrochloride (608 mg), dichloromethane (8 mL), and 2,6-rutidine (1.1 mL), and the mixture was stirred for 1 hour at the same temperature, followed by stirring at room temperature for 3 hours. 2,6-rutidine (0.16 mL) and tert-butyl dimethyl silane trifluoromethanesulfonate (0.3 mL) were added to the resulting mixture at room temperature, and the mixture was stirred for 20 hours at the same temperature. Dichloromethane and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture and stirred, then the two layers were separated. The aqueous layer was extracted with dichloromethane, and the combined organic layer was dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexane-1-amine (445 mg) as an oil.
Manufacturing Example 160
At room temperature, hydrochloric acid (12M, 0.5 mL) was added to a mixture of (3R)-3-({1-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (150 mg) and methanol (3 mL), and the mixture was stirred at 60 °C for 1 hour. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. Chloroform/methanol (9/1) and basic silica gel were added to the residue, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (alkaline silica, chloroform/methanol) to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (102 mg) in solid form.
Manufacturing Example 162
A mixture (113 mg) of (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol was purified by reversed-phase preparative HPLC (ODS column, 0.1% formic acid/methanol) to give (1R,2R)-2-[(1-chloro-5,7,8,9-tetrahydrooxetrazine-[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (62.4 mg) as an oil.
Manufacturing Example 163
Potassium carbonate (197.99 mg) and methyl iodide (58.10 mg) were added to a mixture of 1-chloro-N-[(3R)-piperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine dihydrochloride (110 mg) and DMF (6 mL) at 25 °C, and the mixture was stirred for 16 hours at the same temperature. The reaction mixture was added to water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. The solution was concentrated under reduced pressure to give 1-chloro-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (110 mg) as an oil.
Manufacturing Example 164
N-bromosuccinimide (23.88 g) was added to a mixture of 3-cyclopropylphenol (20 g) and chloroform (200 mL) at 0 °C, and the mixture was stirred at 15 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether) to give 2-bromo-5-cyclopropylphenol (7.7 g) as an oil.
Manufacturing Example 165
A mixture of 2,5-dihydrothiophene-3,4-dicarboxylhydrazide (127 mg) and 10% sulfuric acid (8 mL) was stirred at 115–120 °C for 1 hour. The reaction mixture was cooled to room temperature and then filtered. The filtered solid was washed with water and dried to give 2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione (94 mg) in solid form.
Manufacturing Example 166
A mixture of 308 mg of 4,6-dihydro-1H,3H-thieno[3,4-c]furan-1,3-dione, 0.96 mL of hydrazine monohydrate, and 20 mL of 2-propanol was heated to reflux at 100 °C and stirred for 14.5 h. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with 2-propanol and dried to give 2,5-dihydrothiophene-3,4-dicarboxyhydrazide (246 mg) as a solid.
Manufacturing Example 167
A mixture of 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazine-1-carboxylic acid, 9.1 mL of 1,4-dioxane hydrochloride solution, and 90 mL of ethyl acetate was stirred at 60–67 °C for 19 hours. The reaction mixture was cooled to room temperature and filtered. The filtered solid was washed with ethyl acetate and dried to give 2.717 g of 5,5-dimethyl-2,3,5,7-tetrahydrothiophene[3,4-d]pyridazine-1,4-dione in solid form.
Manufacturing Example 168
A mixture of 5.095 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid, 3.509 g of tert-butyl hydrazinocarboxylate, 10.095 g of HATU, 7.73 mL of DIPEA, and 110 mL of DMF was stirred at room temperature for 2.5 hours. Water was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 6.259 g of tert-butyl 2-[4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carbonyl]hydrazino-1-carboxylic acid as an oil.
Manufacturing Example 169
Under an argon atmosphere, a mixture of ethyl 5,5-dimethyl-4-[(trifluoromethanesulfonyl)oxy]-2,5-dihydrothiophene-3-carboxylate (15.556 g), sodium formate (9.493 g), acetic anhydride (8.8 mL), DIPEA (16.3 mL), lithium chloride (5.917 g), palladium acetate (1.045 g), and DMF (230 mL) was stirred at room temperature for 17 hours. The reaction mixture was filtered, and 10% hydrochloric acid was added to the filtrate to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol). A saturated aqueous sodium bicarbonate solution was added to the purified product, and the mixture was stirred at room temperature to adjust the pH to approximately 8, followed by washing with ethyl acetate. Under stirring at room temperature, 10% hydrochloric acid was added to the aqueous layer to adjust the pH to approximately 1, followed by extraction with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dried with anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain 9.659 g of 4-(ethoxycarbonyl)-2,2-dimethyl-2,5-dihydrothiophene-3-carboxylic acid as an oil.
Example 1
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)amino]cyclohexyl-1-ol (4.4 g), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (4.5 g), RuPhos Pd G3 (1.3 g), potassium carbonate (5.4 g), 1,4-dioxane (40 mL), and water (8 mL) was stirred at 100 °C for 2 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 3 hours. [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (965 mg) and RuPhos Pd G3 (260 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 19 hours. After cooling the reaction mixture to room temperature, water and chloroform were added to separate the organic layer. The aqueous layer was extracted with chloroform, and the combined organic layers were washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (basic and neutral silica gel, chloroform/methanol). Ethyl acetate (10 mL) and hexane (50 mL) were added to the purified product, and the mixture was stirred at room temperature for 18 hours. The solid was filtered off to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol (3.97 g) in solid form.
Example 2
In a mixture (386 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (562 mg), RuPhos PdG3 (171 mg), potassium carbonate (563 mg), and water (2.5 mL) were added, and the mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (3 mL) and hexane (12 mL) were added to the two purified products, respectively, and the mixture was stirred for 15 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (108 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (172 mg) was obtained from the high-polarity fraction.
Example 3
In a mixture (440 mg) of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1R,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (14 mL), [2-hydroxy-4-(trifluoromethoxy)phenyl]boronic acid (690 mg), RuPhosPd G3 (195 mg), potassium carbonate (643 mg), and water (2.9 mL) were added. The mixture was stirred at 100 °C for 1.5 h under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (8 mL) were added to the two purified products, respectively, and the mixture was stirred for 30 minutes. The solids were filtered off, and 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (124 mg) was obtained from the low-polarity fraction, and 2-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethoxy)phenol (242 mg) was obtained from the high-polarity fraction.
Example 4
In a mixture (380 mg) of (1S,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol and (1S,2R)-2-[(4-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol], 1,4-dioxane (12.2 mL), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (553 mg), RuPhosPd G3 (168 mg), potassium carbonate (555 mg), and water (2.4 mL) were added. The mixture was stirred at 100 °C for 1.5 hours under microwave irradiation. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1) and water were added, and the organic layer was separated. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol). Diethyl ether (2 mL) and hexane (6 mL) were added to the two purified products, respectively, and the mixture was stirred for 1 hour. The solids were filtered off, and 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (93 mg) was obtained as a solid from the low-polarity fraction, and 2-(1-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl-5-(trifluoromethyl)phenol (103 mg) was obtained from the high-polarity fraction.
Example 5
Under an argon atmosphere, RuPhos Pd G3 (17 mg) was added to a mixture of (1R,2R)-2-[(4-chloro-5,6,8,9-tetrahydrooxetane-hepteno[4,5-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (57.4 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (59.8 mg), potassium carbonate (80 mg), 1,4-dioxane (2.4 mL), and water (0.600 mL), and the mixture was stirred at 100 °C for 3 hours. RuPhos Pd G3 (16 mg) was then added to the reaction mixture, and the mixture was stirred at 100 °C for 1 hour. Subsequently, RuPhos Pd G3 (17.7 mg), 1,4-dioxane (0.800 mL), and water (0.200 mL) were added, and the mixture was stirred at 100 °C for 6 hours. After cooling the reaction mixture to room temperature, chloroform/methanol (9/1), saturated sodium chloride aqueous solution, and water were added, and the mixture was stirred at room temperature for 10 minutes. The organic layer was separated, concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, chloroform/ethyl acetate, then basic silica gel, chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxocyclohepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (9.1 mg) in solid form.
Example 70
Under an argon atmosphere, a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (150 mg), (4-chloro-2-hydroxyphenyl)boronic acid (120 mg), RuPhos Pd G3 (46 mg), potassium carbonate (150 mg), 1,4-dioxane (4 mL), and water (0.5 mL) was stirred at 100 °C for 5 hours. Then, (4-chloro-2-hydroxyphenyl)boronic acid (120 mg) and RuPhos Pd G3 (22 mg) were added to the reaction mixture, and the mixture was stirred at 100 °C for 8 hours. After cooling the reaction mixture to room temperature, basic silica gel was added, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol) to obtain a solid. Hexane/ethyl acetate (10/1) was added to the obtained solid, and the solid was filtered off to obtain 5-chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (25.2 mg) in solid form.
Example 73
A mixture of 2-(6-benzyl-4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (14 mg), formaldehyde (37% aqueous solution, 0.020 mL), 10% palladium-supported carbon (50% water content, 10 mg), and methanol (1 mL) was stirred at room temperature for 24 hours under a hydrogen atmosphere. Chloroform was added to the reaction mixture, and the mixture was filtered through a Celite (trademark) filter. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform/methanol) to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (5.6 mg) as a solid.
Example 79
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and acetyl chloride (6 mg) under ice-cold conditions and stirred at the same temperature for 2 hours. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-{1-[2,4-bis(trifluoromethyl)phenyl]-4-{[(2R)-2-hydroxypropyl]amino}-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl}ethyl-1-one (18 mg) in solid form.
Example 80
A mixture of (2R)-1-({6-benzyl-1-[2,4-bis(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-yl}amino)prop-2-ol (30 mg) and methanol (1 mL) was mixed with 10% palladium-supported carbon (50% water, 6 mg) and stirred at room temperature for 8 hours under a hydrogen atmosphere. The reaction mixture was filtered through Celite (trademark) and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and dichloromethane (1 mL) was mixed with triethylamine (0.020 mL) and methanesulfonyl chloride (8 mg) under ice-cold conditions and stirred at the same temperature for 30 minutes. Water was added to the reaction mixture, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain (2R)-1-({1-[2,4-bis(trifluoromethyl)phenyl]-6-(methanesulfonyl)-5,6,7,8-tetrahydropyridino[3,4-d]pyridazin-4-yl}amino)prop-2-ol (15 mg) in solid form.
Example 81
A mixture of 2-[4-(4-acetamidobutoxy)phthalazin-1-yl]-5-(trifluoromethyl)phenyl ester acetate (398 mg) and methanol (8 mL) was mixed with an aqueous solution of sodium hydroxide (1 M, 1.73 mL) and stirred at room temperature for 3 hours. Hydrochloric acid (1 M, 1.73 mL) and water were added to the reaction mixture, and extraction was performed with chloroform/2-propanol (4/1). The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. The solution was concentrated under reduced pressure, and the resulting solid was washed with ethyl acetate to give N-[4-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}oxy)butyl]acetamide (309 mg) in solid form.
Example 82
A solution of 1,4-dioxane hydrogen chloride (4M, 4mL) was added to a mixture of [(1R,2R)-2-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]phthalazin-1-yl}amino)cyclohexyl]tert-butyl carbamate (0.440 g) and 1,4-dioxane (10 mL) at 0 °C, and the mixture was heated to room temperature and stirred for 4 hours. A solution of 1,4-dioxane hydrogen chloride (4M, 4 mL) was added to the reaction mixture at 5 °C, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting solid was washed with diethyl ether to give 2-(4-{[(1R,2R)-2-aminocyclohexyl]amino}phthalazin-1-yl)-5-(trifluoromethyl)phenol dihydrochloride (0.375 g) in solid form.
Example 83
Hydrochloric acid (12 M, 0.060 mL) was added to a mixture of (1R,2R)-2-({4-[-4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)cyclohexane-1-ol (106 mg) and methanol (1.1 mL), and the mixture was stirred at 60 °C for 10 hours. Ethyl acetate and a saturated aqueous sodium bicarbonate solution were added to the reaction mixture to separate the organic layer, which was then extracted with ethyl acetate. The combined organic layers were washed with water and a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solution was concentrated, and the resulting residue was purified by silica gel column chromatography (using neutral silica gel, hexane/ethyl acetate, followed by basic silica gel, chloroform/methanol). Diethyl ether (1 mL) and hexane (3 mL) were added to the obtained solid, and the mixture was stirred for 15 minutes. The solid was then filtered off, thus obtaining 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol (62 mg) in solid form.
Example 88
Under an argon atmosphere, potassium carbonate (159 mg), 2-[4-[4-(difluoromethoxy)-2-(methoxymethoxy)phenyl]-4,4,5,5,5-tetramethyl-1,3,2-dioxane (564 mg), and RuPhos Pd G3 (49.3 mg) were added to a mixture of (1R,2R)-2-[(1-chloro-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)amino]cyclohexyl-1-ol (162 mg), 1,4-dioxane (2 mL), and water (0.500 mL), and the mixture was stirred at 100 °C for 1.5 h. The reaction mixture was cooled to room temperature, and methanol (2 mL) and hydrochloric acid (12 M, 0.590 mL) were added. The mixture was stirred at 60 °C for 2 h. After cooling the reaction mixture to room temperature, basic silica gel was added and the mixture was concentrated. The obtained residue was purified by silica gel column chromatography (using basic silica gel, chloroform/methanol, then neutral silica gel, chloroform/methanol). Ethyl acetate and diisopropyl ether were added to the obtained residue, and after sonication, the solid was filtered off, thus yielding 5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (46.3 mg) in solid form.
Example 90
Under ice-cold conditions, a solution of 1,4-dioxane hydrogen chloride (4M, 0.84 mL) was added to a mixture of 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazin-6(5H)-carboxylic acid tert-butyl ester (171 mg) and dichloromethane (2.6 mL), and the mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5(trifluoromethyl)phenol dihydrochloride (162 mg) as a solid.
Example 92
Under an argon atmosphere, acetyl chloride (0.041 mL) and pyridine (0.010 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (46.7 mg), dichloromethane (2 mL), and THF (1 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was then heated to room temperature, and an aqueous solution of sodium hydroxide (1 M, 1 mL) was added, and the mixture was stirred at the same temperature for 7 hours. The reaction mixture was then chilled, and hydrochloric acid (1 M, 1 mL) was added. The mixture was then heated to room temperature, and chloroform was added, and the mixture was stirred at the same temperature for 10 minutes. The organic layer was separated and concentrated. The residue was purified by silica gel column chromatography (chloroform/methanol) to obtain 1-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydropyrido[3,4-d]pyridazine-6(5H)-yl]ethyl-1-one (17.2 mg) in solid form.
Example 93
Under an argon atmosphere, methanesulfonyl chloride (0.004 mL) and DIPEA (0.039 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (18.5 mg) and dichloromethane (2 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture A). Under an argon atmosphere, methanesulfonyl chloride (0.005 mL) and DIPEA (0.048 mL) were added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (22.9 mg) and dichloromethane (3 mL) under ice-cold conditions, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous solution of sodium bicarbonate and chloroform were added to the reaction mixture, and the mixture was heated to room temperature and stirred for 5 minutes. The organic layer was separated and concentrated (as mixture B). Mixtures A and B were combined and purified by silica gel column chromatography (chloroform/methanol) to give 2-[4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-(methanesulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl]-5-(trifluoromethyl)phenol (13.8 mg) in solid form.
Example 94
Under an argon atmosphere and with ice-cold stirring, boron tribromide (17% dichloromethane solution, 2.5 mL) was added dropwise to a mixture of (1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]thiopheno[2,3-d]pyridazin-7-yl}amino)cyclohexyl-1-ol (210 mg) and dichloromethane (2.5 mL), and the mixture was stirred at 0 °C for 2 hours. A saturated aqueous solution of sodium bicarbonate and methanol were added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate), and dichloromethane was added to the purified product, followed by grinding. The precipitated solid was filtered, washed with dichloromethane, and dried under reduced pressure to obtain 2-(7-{[(1R,2R)-2-hydroxycyclohexyl]amino}thieno[2,3-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (75 mg) in solid form.
Example 95
Under ice-cold stirring, boron tribromide (0.7 mL of 17% dichloromethane solution) was added to a mixture of [(1R,2R)-2-({4-[2-methoxy-4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl}amino)cyclohexyl]carbamate tert-butyl ester (73 mg) and dichloromethane (1 mL), and the mixture was naturally heated to room temperature while stirring for 5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol) to give 2-(1-{[(1R,2R)-2-aminocyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl)-5-(trifluoromethyl)phenol (44 mg) in solid form.
Example 96
A mixture of (3R)-3-({4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydrophthalazin-1-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (194 mg), dichloromethane (4 mL), and trifluoroacetic acid (0.66 mL) was stirred at room temperature for 5.5 hours. Water was added to the reaction mixture, and the aqueous layer was washed with dichloromethane. The organic layer was extracted with 10% hydrochloric acid, and the aqueous layers were combined. Potassium carbonate and saturated sodium bicarbonate solution were added to make the mixture alkaline. The aqueous layer was extracted with dichloromethane/methanol. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. Dichloromethane and hexane were added to the resulting residue, and the mixture was ground. The precipitated solid was filtered and dried under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (80 mg) in solid form. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg) in solid form.
Example 97
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (42 mg), dichloromethane (1 mL), methanol (0.1 mL), 3-oxetane (19.9 μL), and sodium triacetoxyborohydride (68 mg) was stirred at room temperature for 5 hours. 3-oxetane (39.9 μL) and sodium triacetoxyborohydride (136 mg) were added to the reaction mixture, and the mixture was stirred at room temperature for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and extraction was performed with dichloromethane/methanol. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol) to obtain 2-(4-{[(3R)-1-(oxecyclobut-3-yl)piperidin-3-yl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (45 mg) in solid form.
Example 98
A mixture of 264 mg of 1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-carboxylic acid tert-butyl ester, dichloromethane (5 mL), and trifluoroacetic acid (0.9 mL) was stirred at room temperature for 5 hours. Under ice-cold stirring, a saturated aqueous solution of sodium bicarbonate, dichloromethane, and methanol were added to the reaction mixture. Extraction was performed with dichloromethane, and the mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Ethyl acetate was added to the resulting residue, and the mixture was ground. The precipitated solid was filtered off and dried under reduced pressure to give 72 mg of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol as a solid. The filtrate was concentrated under reduced pressure to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (21 mg) in solid form.
Example 99
Sodium triacetoxyborohydride (75 mg) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (70 mg), methanol (1.8 mL), and 37% formaldehyde aqueous solution (20 μL) under stirring at room temperature, and the mixture was stirred for 4 hours at room temperature. A saturated sodium bicarbonate aqueous solution was added to the reaction mixture, and the precipitated solid was filtered off and washed with water. The filtered solid was dried, and hexane/ethyl acetate was added and the mixture was ground. The precipitated solid was filtered off, washed with hexane, and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (35 mg) in solid form.
Example 111
Under an argon atmosphere, a mixture of (1R,2R)-2-[(4-chloro-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)amino]cyclohexyl-1-ol (236 mg), [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (342 mg), PdCl₂ (dppf)· CH₂Cl₂ ( 68 mg), potassium carbonate (229 mg), 1,4-dioxane (8 mL), and water (2 mL) was stirred at 107–112 °C for 14 hours. After cooling the reaction mixture to room temperature, [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid (171 mg) and PdCl₂ (dppf)· CH₂Cl₂ (68 mg ) were added, and the mixture was further stirred at 110–120 °C for 2 hours. The reaction mixture was then injected into a mixture of water and a saturated sodium chloride aqueous solution and extracted with ethyl acetate. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate). The purified product was dissolved in a small amount of dichloromethane, hexane was added, the precipitated solid was filtered off and dried to obtain 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (39 mg) in solid form.
Example 112
A solution of ethyl hydrochloride (4M, 4 mL) was added to a mixture of 1-[4-cyclopropyl-2-(methoxymethoxy)phenyl]-N-[(3R)-1-methylpiperidin-3-yl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazine-4-amine (250 mg) and ethyl acetate (5 mL) at 25 °C, and the mixture was stirred for 1 hour at the same temperature. After adding water and a saturated aqueous sodium bicarbonate solution to the reaction mixture, extraction was performed with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried with anhydrous sodium sulfate. After the solution was concentrated under reduced pressure, the residue was purified by reversed-phase preparative HPLC (ODS column, ammonia + ammonium bicarbonate aqueous solution/acetonitrile) to obtain 5-cyclopropyl-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (29.3 mg) in solid form.
Example 114
A mixture of (1S,3R)-3-({4-[4-[4-(difluoromethyl)-2-(methoxymethoxy)phenyl]-5,7-dihydrofurano[3,4-d]pyridazin-1-yl}amino)cyclohexyl-1-ol (122 mg), trifluoroacetic acid (0.48 mL), and dichloromethane (2 mL) was stirred at room temperature for 5 hours. While stirring the reaction mixture under ice-cold conditions, a saturated aqueous solution of sodium bicarbonate was added until the foaming subsided, followed by extraction with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol (58 mg) as a solid.
Example 117
In a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6,7-dihydro-5H-pyrrolo[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (62 mg), DIPEA (33 μL), and dichloromethane (1.6 mL), acetic anhydride (18 μL) was added while stirring under ice-cold conditions, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered, the filtered solid was washed with dichloromethane, and dried to give 1-(1-{[(1R,2R)-2-hydroxycyclohexyl]amino}-4-[2-hydroxy-4-(trifluoromethyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-d]pyridazin-6-yl)ethyl-1-one (58 mg) in solid form.
Example 124
At room temperature, a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-piperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and THF (4 mL) was added to (1H-benzotriazol-1-yl)methanol (86 mg) and sodium acetate (55 mg), and stirred for 10 minutes at the same temperature. Sodium triacetoxyborohydride (125 mg) was added to the resulting mixture, and the mixture was stirred for 1 hour at room temperature. Water and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, followed by extraction with chloroform/methanol (9/1). The organic layer was dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product, and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (72 mg) in solid form.
Example 126
A mixture of 2-(4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl-5-(trifluoromethyl)phenol (71 mg), [(1-ethoxycyclopropyl)oxy]tri(methyl)silane (72 μL), sodium cyanoborohydride (17 mg), acetic acid (16 μL), THF (1 mL), and methanol (1 mL) was stirred at 49–54 °C for 15.5 hours. The reaction mixture was cooled to room temperature, and 10% sodium hydroxide solution was added. The solution was prepared to a pH of approximately 7–8, and then extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol) to give 2-(4-{[(3R)-1-cyclopropylpiperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (15 mg) in solid form.
Example 127
Hydrochloric acid (12M, 0.5mL) was added to a mixture of 2-(4-{[(1R,2S)-2-{[tert-butyldi(methyl)silyl]oxy}cyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (60mg) and methanol (2mL) at room temperature, and the mixture was stirred for 2 hours at the same temperature. The reaction mixture was chilled, and an aqueous solution of sodium hydroxide (1M, 6mL) was added, followed by extraction with chloroform and chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to obtain 2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (25.7 mg) in solid form.
Example 128
TFA (0.5 mL) was added to a mixture of (3R)-3-({1-[2-hydroxy-4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl ester (29 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and THF (4 mL), sodium acetate (15 mg), and (1H-benzotriazol-1-yl)methanol (25 mg) were added to the residue, and the mixture was stirred for 10 minutes at room temperature. Sodium triacetoxyborohydride (36 mg) was added to the resulting mixture, and the mixture was stirred for 2 hours at room temperature. A saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride were added to the reaction mixture, and the mixture was extracted with chloroform/methanol (9/1). After neutralization with 1 M hydrochloric acid in the aqueous layer, the mixture was extracted with chloroform/methanol (9/1). The combined organic layers were dried over anhydrous magnesium sulfate, and the solution was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (basic silica gel, chloroform/methanol). Hexane/ethyl acetate was added to the purified product and the mixture was ground. The solid was filtered off and dried under reduced pressure to give 2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol (14.3 mg) in solid form.
Example 129
Oxone (registered trademark) (1.3 g) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-thiaro[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (300 mg), acetonitrile (5 mL), and water (5 mL) at 25 °C, and the mixture was stirred for 2 hours at the same temperature. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous sodium sulfate, and the solution was concentrated under reduced pressure. Acetonitrile and water were added to the residue, and the mixture was freeze-dried to give 4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-1-[2-hydroxy-4-(trifluoromethyl)phenyl]-7,8-dihydro- 6λ6 -thiaro[3,4-d]pyridazin-6,6(5H)-dione (185 mg) as a solid.
Example 132
A mixture of 2-(7,7-dimethyl-4-{[(3R)-piperidin-3-yl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (50 mg), 2,2-difluoroethyl trifluoromethanesulfonate (19 μL), triethylamine (49 μL), and ethanol (1.2 mL) was stirred at 54–62 °C for 17 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and then extracted with dichloromethane after adding water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate, then dichloromethane/methanol). The purified product was dissolved in toluene and extracted with 5% aqueous sodium hydroxide solution, water, and saturated aqueous sodium chloride solution. The aqueous layer was washed with toluene, 10% hydrochloric acid was added, and then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/hexane/methanol, then hexane/ethyl acetate) to give 2-(4-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]amino}-7,7-dimethyl-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (6 mg) in solid form.
Example 133
A solution of 1,4-dioxane hydrogen chloride (4M, 0.11 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol (150 mg) and dichloromethane (1.5 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (3 mL) was added, and the mixture was stirred at 50 °C for 48 hours. After cooling to room temperature, the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (149 mg) in crystalline form.
Example 134
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.074 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazin-1-yl)-5-(trifluoromethyl)phenol hydrochloride (103 mg) as a solid.
Example 135
A solution of 1,4-dioxane hydrogen chloride (4 M, 0.071 mL) was added to a mixture of 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl-5-(trifluoromethoxy)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred at room temperature for 120 hours. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol hydrochloride (95 mg) in crystalline form.
Example 136
A solution of 1,4-dioxane hydrogen chloride (4M, 0.147 mL) was added to a mixture of 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol (100 mg) and dichloromethane (2 mL) at room temperature, and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (2 mL) was added and stirred for 120 hours at room temperature. The mixture was chilled, and the solid was filtered off and washed with cold ethyl acetate (1 mL). The solid was dried under reduced pressure to give 5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol dihydrochloride (122 mg) as a solid.
The compounds of the manufacturing examples and embodiments shown in the table below were manufactured in the same manner as those of the manufacturing examples or embodiments described above.
[Table 3-1]
[Table 3-2]
[Table 3-3]
[Table 3-4]
[Table 3-5]
[Table 3-6]
[Table 3-7]
[Table 3-8]
[Table 3-9]
[Table 3-10]
[Table 4-1]
[Table 4-2]
[Table 4-3]
[Table 4-4]
[Table 4-5]
[Table 4-6]
[Table 4-7]
[Table 4-8]
[Table 5-1]
PEx PSyn DAT
1 - ESI+; 282.2, 284.2
2 - ESI+; 284.2, 286.1
3(1) - ESI+; 373.2, 375.2
3(2) - ES1+; 373.2, 376.2
4 - ESI+; 284.1, 286.1
5 - ESI+; 298.1, 300.2
6 1 FAB; 242.2
7 1 ESI+; 228.1, 230.1
8 1 ESI+; 333.2, 335.2
9 1 ESI+; 284.3, 286.3
10 1 ESI+; 264.3, 266.3
11 1 ESI+; 264.2, 266.2
12 1 ESI+; 264.3, 266.3
13 1 ESI+; 278.3, 280.3
14 1 ESI+; 239.1, 241.1
15 1 ESI+; 242.1, 244.0
16 1 ESI+; 228.1, 230.1
17 1 ESI+; 268.2, 270.2
18 1 ESI+; 242.2, 244.2
19 1 FAB; 377.1
20 1 FAB; 319.0
twenty one 1 FAB; 268.0
twenty two 1 ESI+; 268.1, 270.1
twenty three 1 ESI+; 296.1, 298.2
twenty four 1 ESI+; 284.2, 286.1
25(1) 1 ESI+; 284.1, 286.1
25(2) 1 ESI+; 284.I, 286.1
26 1 ESI+; 298.1, 300.1
27 1 ESI+; 282.2, 284.2
28 1 ESI+; 267.1, 269.1
29 1 ESI+; 270.1, 272.1
30 1 FAB; 254.0
31 1 FAB; 270.0
32 1 ESI+; 383.2, 385.2
33 1 FAB; 305.0
[Table 5-2]
PEx PSyn DAT
34 1 FAB; 277.0
35 1 ESI+; 284.1, 286.1
36 1 ESI+; 284.2, 286.2
37 1 ESI+; 321.3, 323.3
38 1 ESI+; 283.2, 285.2
39 1 ESI+; 293.0, 295.0
40 1 ESI+; 367.2, 369.2
41 1 ESI+; 369.3, 371.4
42 - ESI+; 168.3
43 - ESI+; 258.3
44 - ESI+; 294.3, 296.3, 298.3
45 - ESI+; 313.2
46 45 ESI+; 352.4
47 - ESI+; 450.3
48 - ESI+; 499.3
49 47 ESI+; 478.4
50 47 FAB; 503.6
51 47 ESI+; 434.3
52 47 ESI+; 470.3
53 47 ESI+; 499.2
54(1) 47 ESI+; 509.2
54(2) 47 ESI+; 509.2
55 47 ESI+; 515.2
56 47 ESI+; 445.3
57 47 ESI+; 472.3
58 47 ESI+; 436.3
59 47 ESI+; 424.4
60 47 ESI+; 523.3
61 47 ESI+; 493.5
62 47 ESI+; 495.5
63 - ESI+; 520.4
64 - ESI+; 378.2
65 - ESI+; 462.3
66 67 FAB; 236.9
67 - ESI+; 223.1, 225.1
[Table 5-3]
PEx PSyn DAT
68 69 FAB; 241.0
69 - ESI+; 227.1, 229.1
70 - ESI+; 281.0
71 70 ESI+; 295.0
72 - ESI+; 280.1, 282.1
73 - ESI+; 205.0, 207.0
74 - ESI+; 219.0, 221.0
75 73 ESI+; 304.1
76 - ESI - 259.0
77 - ESI+; 353.2 [M+Na]+
78 77 EI; 314.2
79 77 EI; 350.1
80 77 ESI+; 283.2 [M+Na]+
81 - ESI+; 245.0
82 81 EI; 302.0
83 - EI: 266.0
84 - CI; 282.9
85 - ESI+; 296.2, 298.2
86 - ESI+; 271.2
87 - ESI+; 182.1
88 - ESI+; 242.1
89 - ESI+; 153.0
90 - ESI+; 340.2
91 - ESI+; 251.2
92 - ESI+; 355.2
93 - ESI+; 487.2
94 - FAB; 364.1
95 94 FAB; 278.0
96 - FAB; 264.0
97 - FAB; 306.0
98 - CI; 229.1
99 - ESI+; 255.2
100 - ESI+; 284.1, 286.0
101 - ESI+; 409.3
102 - ESI+; 255.2
[Table 5-4]
[Table 5-5]
PEx PSyn DAT
107 72 ESI+; 281.1
108 1 ESI+; 286.1
109(1) 1 ESI+; 300.1, 302.1
109(2) 1 ESI+; 300.1, 302.1
110 1 ESI+; 324.2
111 1 ESI+; 357.0
112 1 ESI+; 369.2, 371.2
113 1 ESI+; 298.2, 300.2
114 - ESI+; 369.3
115 1 ESI+; 369.0
116 - ESI+; 286.1, 288.0
117 1 ESI+; 371.2, 373.3
118 1 <![CDATA[ESI+;377.3,379.3[M+Na]<sup>+</sup>]]>
119 1 ESI+; 270.1, 272.1
120 - ESI+; 270.1, 272.0
121 1 <![CDATA[ESI+;421.3, 423, 3[M+Na]<sup>+</sup>]]>
122 - <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm4.40(4H, s)]]>
123 44 <![CDATA[<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>)δppm1.88(6H, s)4.25(2H, s)]]>
124 47 ESI+; 540.5
125 47 ESI+; 511.4
126 47 ESI+; 483.3
127 47 ESI+; 495.3
128(1) - ESI+; 537.4
128(2) - ESI+; 537.4
129 47 ESI+; 425.2
130 47 ESI+; 435.2
131 47 ESI+; 497.3
132 47 ESI+; 481.4
133 47 ESI+; 422.3
134 - ESI+; 422.3
135 47 ESI+; 525.1
136 64 -
137 64 ESI+; 395.2
138 64 ESI+; 397.2
139 64 ESI+; 381.3
[Table 5-6]
[Table 5-7]
[Table 6-1]
[Table 6-2]
Ex Syn DAT
6 1 ESI+; 298.1
7 1 FAB; 314.3
8 1 ESI+; 406.3
9 1 ESI+; 511.2
10 1 ESI+; 439.3
11 1 ESI+; 410.3
12 1 ESI+; 390.3
13 1 ESI+; 390.4
14 1 ESI+; 390.3
15 1 ESI+; 404.2
16(1) 1 FAB; 365.1
16(2) 1 FAB; 365.0
17 1 ESI+; 368.1
18 1 ESI+; 354.2
19 1 ESI+; 394.3
20 1 FAB; 367.2
twenty one 1 ESI+; 368.2
twenty two 1 ESI+; 353.2
twenty three 1 FAB; 445.2
twenty four 1 FAB; 394.2
25 1 ESI+; 374.2, 376.1
26 1 ESI+; 354.2
27 1 ESI+; 424.2
28 1 ESI+; 370.3
29 1 ESI+; 394.2
30 1 ESI+; 360.2, 362.1
31 1 ESI+; 340.2
32 1 ESI+; 410.2
33 1 ESI+; 356.2
34 1 ESI+; 422.3
35 1 ESI+; 410.2
36 I ESI+; 356.2
[Table 6-3]
Ex Syn DAT
37 1 ESI+; 426.2
38 1 ESI+; 372.2
39 1 ESI+; 376.2, 378.2
40 1 ESI+; 406.3
41 1 ESI+; 410.3
42 1 ESI+; 410.2
43 1 ESI+; 438.3
44 1 ESI+; 424.2
45 1 ESI+; 440.2
46 1 ESI+; 370.3
47 1 ESI+; 384.3
48 1 ESI+; 408.2
49 1 ESI+; 386.3
50 1 ESI+; 393.2
51 1 ESI+; 380.3
52(1) 1 ESI+; 382.3
52(2) 1 ESI+; 382.3
53 1 ESI+; 422.3
54 1 ESI+; 438.2
55 1 ESI+; 368.3
56(1) 1 ESI+; 396.2
56(2) 1 ESI+; 396.2
57(1) 1 ESI+; 412.2
57(2) 1 ESI+; 412.2
58 1 ESI+; 384.3
59 1 FAB; 380.4
60 1 ESI+; 395.8
61 1 ESI+; 342.2
[Table 6-4]
[Table 6-5]
[Table 6-6]
[Table 6-7]
[Table 6-8]
Industrial applicability
Compounds of formula (I) or their salts have inhibitory effects on NLRP3 inflammasome activation and are expected to be used as preventive and/or therapeutic agents for inflammatory diseases and/or neurodegenerative diseases.

Claims (19)

1. A compound of formula (I) or a salt thereof,
[Chemical Formula 1]
In the formula,
Ring A is a C5-8 cycloalkenyl group, a 5-11 member partially unsaturated heterocyclic group, an aryl group, or a heteroaryl group;
R1 may be the same or different from each other, and may be OH, C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, -C1-6 alkylene-aryl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halogenated C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -, -O -, or -CR 4 R 5 -;
R3 is H or C1-6 alkyl;
R4 and R5 are the same or different from each other, and are H or C1-6 alkyl;
R6 is a C1-6 alkyl group substituted with 1 to 4 identical or different R7 groups, a -C1-6 alkylene group (a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R8 groups), a -C1-6 alkylene group (a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R9 groups), a C3-8 cycloalkyl group substituted with 1 to 4 identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted with 1 to 4 identical or different R11 groups;
R7 can be -OR12 , -NR13 , R14 , halogen, or cyano;
R8 and R10 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene- NR13R14 , halogen , or cyano ;
R9 and R11 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR12 , -NR13R14 , -C1-6 alkylene- OR12 , -C1-6 alkylene -NR13R14, halogen, cyano, oxo, -C(O)-C1-6 alkyl , or -S (O) 2 - C1-6 alkyl;
R 12 is H or C 1-6 alkyl;
R13 and R14 may be the same or different from each other, and may be H, C1-6 alkyl, or -C(O) -C1-6 alkyl;
n is an integer from 1 to 4, representing the number of R1s used as substituents;
m is an integer from 0 to 3, representing the number of R2 substituents;
In the case where ring A is aryl or heteroaryl, formula (I) is formula (Ia).
[Chemical Formula 2]
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, halogen, cyano, -OC1-6 alkyl, -O-halo- C1-6 alkyl, or -OC3-8 cycloalkyl;
k is an integer from 0 to 3, representing the number of R 1a used as substituents.
2. The compound or a salt thereof according to claim 1, wherein,
Ring A is a C5-8 cycloalkenyl group, a 5-8 membered partially unsaturated heterocyclic group, an aryl group, or a heteroaryl group;
R2 may be the same as or different from each other, and may be C1-6 alkyl, -C1-6 alkylene-aryl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, -O-halogenated C1-6 alkyl, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl.
3. The compound or a salt thereof according to claim 2, wherein formula (I) is formula (Ia).
4. The compound or a salt thereof according to claim 3, wherein,
Ring A is a C5-8 cycloalkenyl group or a 5-8 member partially unsaturated heterocyclic group.
5. The compound or a salt thereof according to claim 1, wherein,
Equation (I) is equivalent to equation (Ia).
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -, -O -, or -CR 4 R 5 -;
R3 is H;
R4 and R5 are H;
R6 is a C1-6 alkyl group substituted by one R7 , a -C1-6 alkylene group (a C3-8 cycloalkyl group that can be substituted by one R8 ), a -C1-6 alkylene group (a 4- to 7-membered saturated heterocyclic group), a C3-8 cycloalkyl group that can be substituted by one or two identical or different R10 groups , or a 4- to 7-membered saturated heterocyclic group that can be substituted by one or two identical or different R11 groups ;
R 7 is either -OR 12 or -NR 13 R 14 ;
R8 and R10 are C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene - OR12 , halogen, or cyano;
R9 and R11 are C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR12 , oxo, or -C(O) -C1-6 alkyl;
R 12 is H;
R13 and R14 are both H, or R13 is a -C(O) -C1-6 alkyl and R14 is H;
k is an integer from 0 to 2, representing the number of R 1a substituents;
m is an integer from 0 to 2, representing the number of R2 substituents.
6. The compound or a salt thereof according to claim 5, wherein,
Ring A is a C5-8 cycloalkenyl group or a 5-11 member partially unsaturated heterocyclic group;
L is -NR 3 -;
R6 is a C1-6 alkyl group substituted by one R7 , a C3-8 cycloalkyl group substituted by one or two identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted by one or two identical or different R11 groups;
R10 is a C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene - OR12 , halogen, or cyano;
R 11 is a C1-6 alkyl, halo- C1-6 alkyl, C3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O) -C1-6 alkyl.
7. The compound or a salt thereof according to claim 6, wherein,
Ring A is a C5-8 cycloalkenyl group or a 5- to 8-membered partially unsaturated heterocyclic group;
R 1a may be the same or different from each other, and may be a halo- C1-6 alkyl, halogen, or -O-halo- C1-6 alkyl;
R2 is a C1-6 alkyl group;
R6 is a C3-8 cycloalkyl group that can be substituted by 1 to 2 identical or different R10 groups, or a 4- to 7-membered saturated heterocyclic group that can be substituted by 1 to 2 identical or different R11 groups ;
R 10 is a C1-6 alkyl group or -OR 12 ;
R 11 is a C1-6 alkyl group or -OR 12 ;
k is 1 or 2, representing the number of R 1a as a substituent;
m is 0 or 1, representing the number of R2 substituents.
8. The compound or a salt thereof according to claim 1, wherein,
Equation (I) is equivalent to equation (Ia).
Ring A is a partially unsaturated heterocyclic group consisting of 5 to 11 members;
R 1a may be the same as or different from each other, and may be C1-6 alkyl, halo -C1-6 alkyl, C3-8 cycloalkyl, halogen, -OC1-6 alkyl, or -O-halo- C1-6 alkyl;
R2 may be the same or different from each other, and may be C1-6 alkyl, oxo, -C(O) -C1-6 alkyl, or -S(O) 2 - C1-6 alkyl;
L is -NR 3 -;
R3 is H;
R6 is a C1-6 alkyl group substituted by one R7 , a C3-8 cycloalkyl group substituted by one or two identical or different R10 groups, or a 4-7 member saturated heterocyclic group substituted by one or two identical or different R11 groups;
R 7 is either -OR 12 or -NR 13 R 14 ;
R10 is a C1-6 alkyl, -OR12 , -NR13R14 , -C1-6 alkylene - OR12 , halogen, or cyano;
R 11 is a C 1-6 alkyl, halo-C 1-6 alkyl, C 3-8 cycloalkyl, 4-7 membered saturated heterocyclic group, -OR 12 , oxo, or -C(O)-C 1-6 alkyl;
R 12 is H;
R13 and R14 are both H, or R13 is a -C(O) -C1-6 alkyl and R14 is H;
k is an integer from 0 to 2, representing the number of R 1a substituents;
m is an integer from 0 to 2, representing the number of R2 substituents.
9. The compound or a salt thereof according to claim 8, wherein,
Formula (I) is formula (If), (Ig), (Ih), (Ii), (Ij), (Iu), (Iv), (Iw) or (Iy),
[Chemical Formula 3]
R 11 is a C1-6 alkyl group or -OR 12 .
m is 0.
10. The compound or a salt thereof according to claim 9, wherein,
Equation (I) is equivalent to equation (Ih).
R10 is a C1-6 alkyl group, -OR12 , or cyano group.
R13 is a -C(O) -C1-6 alkyl group, and R14 is H.
11. The compound according to claim 1 or a salt thereof, wherein the compound is selected from:
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxohepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,7,8-tetrahydrophthalazine-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol
The compounds in the group.
12. The compound or a salt thereof according to claim 1, wherein the compound is selected from:
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethoxy)phenol,
2-(4-{[(1R,2S)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,6,8,9-tetrahydrooxohepteneno[4,5-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-Chloro-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol,
5-(difluoromethoxy)-2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
5-(difluoromethoxy)-2-(4-{[(3R)-1-methylpiperidin-3-yl]amino}-7,8-dihydro-5H-pyrano[3,4-d]pyridazin-1-yl)phenol,
2-(4-{[(1R,2R)-2-hydroxycyclohexyl]amino}-5,7-dihydrothieno[3,4-d]pyridazin-1-yl)-5-(trifluoromethyl)phenol, and
5-(difluoromethyl)-2-(4-{[(1R,3S)-3-hydroxycyclohexyl]amino}-5,7-dihydrofurano[3,4-d]pyridazin-1-yl)phenol
The compounds in the group.
13. A pharmaceutical composition comprising the compound of claim 1 or a salt thereof, and one or more pharmaceutically permissible excipients.
14. The pharmaceutical composition according to claim 13, wherein it is an NLRP3 inflammasome activation inhibitor.
15. The pharmaceutical composition according to claim 13, wherein it is a pharmaceutical composition for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
16. Use of the compound of claim 1 or a salt thereof in a pharmaceutical composition for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
17. Use of the compound of claim 1 or a salt thereof for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
18. The compound or a salt thereof according to claim 1, for the prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases.
19. Prevention and/or treatment of inflammatory diseases and/or neurodegenerative diseases, comprising applying an effective amount of the compound of claim 1 or a salt thereof to a subject.
HK62024101205.8A 2021-07-21 2022-07-20 Annulated pyridazine compound HK40112974A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2021-120560 2021-07-21

Publications (1)

Publication Number Publication Date
HK40112974A true HK40112974A (en) 2025-01-28

Family

ID=

Similar Documents

Publication Publication Date Title
CN118234711A (en) Cyclic pyridazine compounds
JP7675777B2 (en) Heterocyclic Compounds as Immunomodulators
TWI924849B (en) Substituted triazine compounds
CN113321654B (en) Fused pyridones as kinase inhibitors
WO2024083256A1 (en) Pan-kras degrading agent, and preparation method therefor and use thereof
CN107820496B (en) Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infections
CN105209470B (en) For treating and preventing the heteroaryl dihydro-pyrimidin of 6 hepatitis b virus infected bridgings
CN115697994B (en) Fused quinazoline derivative, preparation method thereof and application thereof in medicine
WO2023197984A1 (en) Fused ring compound, pharmaceutical composition containing same, and use of fused ring compound
CN115368383A (en) Condensed nitrogen-containing heterocyclic compound, preparation method and medical application thereof
CN106749233B (en) A class of sulfonamide derivatives and their applications
JP2025508192A (en) KIF18A inhibitor
WO2025157246A1 (en) Pyrimidine polycyclic derivative inhibitor, preparation method therefor and use thereof
CN113801114A (en) Fused bicyclic heteroaryl derivative, preparation method and application thereof in medicine
CN106565706B (en) A kind of sulfamide derivative and its application in pharmacy
WO2024090469A1 (en) Fused pyridazine derivative
WO2023041055A1 (en) Kif18a inhibitor
WO2024114787A1 (en) Amide or urea compound
TW202214631A (en) Compound as Akt kinase inhibitor
TW202220963A (en) Compounds, compositions and methods
KR20170129811A (en) A tricyclic heterocyclic compound useful as an inhibitor of TNF
WO2022166741A1 (en) Macrocyclic compound containing benzoheterocycle and acting as egfr kinase inhibitor, and pharmaceutical composition and use thereof
WO2022012593A1 (en) 5,6-dihydropyrazino[2,3-c]isoquinoline compound
WO2022028389A1 (en) Fused tricyclic derivative, preparation method therefor, and pharmaceutical use thereof
TWI894448B (en) Ctla-4 small molecule inhibitor and its application